<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Review]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[一测多评中药质量控制研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[郭东晓,林永强,林林,汪冰,徐丽华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郭东晓,林永强,林林,汪冰,徐丽华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309018&flag=1]]></guid><cfi:id>716</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[泡桐属植物的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李传厚,唐文照,高天阳,王晓静]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李传厚,唐文照,高天阳,王晓静</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309019&flag=1]]></guid><cfi:id>715</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[植物来源抗肿瘤药物药理机制、不良反应与临床应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[曹丽荣<sup>1</sup>,王鸿梅<sup>2</sup>,李军<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>曹丽荣<sup>1</sup>,王鸿梅<sup>2</sup>,李军<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309020&flag=1]]></guid><cfi:id>714</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[BRAF基因突变与肿瘤耐药]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李森朋<sup>1</sup>,张岫美<sup>1</sup>,张芮<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李森朋<sup>1</sup>,张岫美<sup>1</sup>,张芮<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308017&flag=1]]></guid><cfi:id>713</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[两面针的药理作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[韩建军,宁娜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩建军,宁娜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308018&flag=1]]></guid><cfi:id>712</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[白鲜属柠檬苦素类化合物及其生物活性的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[白媛媛,唐文照,王晓静]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>白媛媛,唐文照,王晓静</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308019&flag=1]]></guid><cfi:id>711</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基因突变小鼠培育技术研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张培彪,张苏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张培彪,张苏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308020&flag=1]]></guid><cfi:id>710</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[槲皮素的药理活性与临床应用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张志琴,朱双雪]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张志琴,朱双雪</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307009&flag=1]]></guid><cfi:id>709</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[缓释滴丸研究概况]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[胡瀚文<sup>1</sup>,张学顺<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡瀚文<sup>1</sup>,张学顺<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307010&flag=1]]></guid><cfi:id>708</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[MicroRNA作为肿瘤治疗靶点的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[杨庆华,韩向阳,张静]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨庆华,韩向阳,张静</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307011&flag=1]]></guid><cfi:id>707</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[糖尿病性骨质疏松症的发病机制与临床治疗]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[赵华,郭胜蓝,罗崇彬,朱晓洪]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵华,郭胜蓝,罗崇彬,朱晓洪</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306016&flag=1]]></guid><cfi:id>706</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[延龄草中主要化学成分的波谱特征]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[贾兰婷,杨尚军,白少岩]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>贾兰婷,杨尚军,白少岩</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306017&flag=1]]></guid><cfi:id>705</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[非PVC复合膜软包装的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[杨琳琳<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨琳琳<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306018&flag=1]]></guid><cfi:id>704</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[瓜蒌子有效成分提取方法研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[韩琳娜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩琳娜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305017&flag=1]]></guid><cfi:id>703</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于受众中心论对医药信息行为认知的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李艳<sup>1</sup>,罗集<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李艳<sup>1</sup>,罗集<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305018&flag=1]]></guid><cfi:id>702</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[口服渗透泵制剂的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[任君刚,杨硕,王立]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>任君刚,杨硕,王立</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305019&flag=1]]></guid><cfi:id>701</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[黄酮类化合物抗AD机制的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘德承<sup>1</sup>,李文德<sup>1</sup>,黄韧<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘德承<sup>1</sup>,李文德<sup>1</sup>,黄韧<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305020&flag=1]]></guid><cfi:id>700</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[菝葜化学成分与药理作用的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[钱芳芳<sup>1</sup>,张长林<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>钱芳芳<sup>1</sup>,张长林<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304021&flag=1]]></guid><cfi:id>699</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[新生儿黄疸治疗进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[谭强,韦祖巧,王宏虹]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>谭强,韦祖巧,王宏虹</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304022&flag=1]]></guid><cfi:id>698</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[山东省药品快检、监督抽验发展现状与对策]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张中湖<sup>1</sup>,高文学<sup>2</sup>,肖杰<sup>3</sup>,黄文艳<sup>3</sup>,张恒心<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张中湖<sup>1</sup>,高文学<sup>2</sup>,肖杰<sup>3</sup>,黄文艳<sup>3</sup>,张恒心<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304023&flag=1]]></guid><cfi:id>697</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[益生菌及其在药学研究中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[谢莉敏,李丹,程秀芳,刘虹,黄启亮,谷巍]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>谢莉敏,李丹,程秀芳,刘虹,黄启亮,谷巍</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304024&flag=1]]></guid><cfi:id>696</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[对药品质量定义的再探讨]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[杨菲,邵蓉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨菲,邵蓉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303022&flag=1]]></guid><cfi:id>695</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[钙离子途径介导的良性前列腺增生机制的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李卓<sup>1</sup>,柳建军<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李卓<sup>1</sup>,柳建军<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303023&flag=1]]></guid><cfi:id>694</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[毒性中药合理使用与不良反应监测探析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[丁晓梅]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>丁晓梅</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303024&flag=1]]></guid><cfi:id>693</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[降脂减肥等七类中成药非法添加西药情况研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孙晶,张中湖,王维剑]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙晶,张中湖,王维剑</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303025&flag=1]]></guid><cfi:id>692</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[纳米银抗菌活性及生物安全性研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孙倩<sup>1,2</sup>,李明春<sup>1</sup>,马守栋<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙倩<sup>1,2</sup>,李明春<sup>1</sup>,马守栋<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302016&flag=1]]></guid><cfi:id>691</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Wnt和相关信号通路交互作用在非小细胞肺癌发生发展中的作用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李玉婵,孙杰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李玉婵,孙杰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302017&flag=1]]></guid><cfi:id>690</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[唾液替代物制剂处方研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[褚志杰<sup>1</sup>,鞠建峰<sup>1</sup>,邓树海<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>褚志杰<sup>1</sup>,鞠建峰<sup>1</sup>,邓树海<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302018&flag=1]]></guid><cfi:id>689</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[指纹图谱技术在中药鉴定中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[罗格莲,郑孝勇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>罗格莲,郑孝勇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302019&flag=1]]></guid><cfi:id>688</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[抗结核药物最新进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[卢曦,杨信怡,游雪甫]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>卢曦,杨信怡,游雪甫</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301014&flag=1]]></guid><cfi:id>687</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[薤白的化学成分和药理作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[盛华刚]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>盛华刚</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301015&flag=1]]></guid><cfi:id>686</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[多烯紫杉醇纳米制剂的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[程树仓,庞鑫,翟光喜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>程树仓,庞鑫,翟光喜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301016&flag=1]]></guid><cfi:id>685</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药渣综合利用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘文伟<sup>1</sup>,刘玉璇<sup>2</sup>,赵宁<sup>1</sup>,国大亮<sup>2</sup>,张伯礼<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘文伟<sup>1</sup>,刘玉璇<sup>2</sup>,赵宁<sup>1</sup>,国大亮<sup>2</sup>,张伯礼<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301017&flag=1]]></guid><cfi:id>684</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[重组生产透明质酸技术中国专利申请分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孙永福<sup>1</sup>,郝建欣<sup>1</sup>,王凤山<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙永福<sup>1</sup>,郝建欣<sup>1</sup>,王凤山<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312012&flag=1]]></guid><cfi:id>683</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[藤茶中黄酮类成分药理作用的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[宁娜<sup>1,2</sup>,韩建军<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宁娜<sup>1,2</sup>,韩建军<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312013&flag=1]]></guid><cfi:id>682</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[影响婴儿肠道菌群构成因素的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张高娜,张建梅,谷巍]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张高娜,张建梅,谷巍</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312014&flag=1]]></guid><cfi:id>681</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[真菌感染诊断的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘东升,方海燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘东升,方海燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312015&flag=1]]></guid><cfi:id>680</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[鸸鹋油研究概述]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李亚楠<sup>1</sup>,赵宁<sup>2</sup>,刘玉璇<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李亚楠<sup>1</sup>,赵宁<sup>2</sup>,刘玉璇<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311019&flag=1]]></guid><cfi:id>679</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical composition and pharmacological activity of Cassia seed]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 0:00:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孔祥锋<sup>1,2</sup>,臧恒昌<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孔祥锋<sup>1,2</sup>,臧恒昌<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311020&flag=1]]></guid><cfi:id>678</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[岩青兰的化学成分及药理学研究综述]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[丁聪,李远辉,康恒军]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>丁聪,李远辉,康恒军</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311021&flag=1]]></guid><cfi:id>677</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复合磷酸酯酶肠溶片在肝病治疗方面的应用概述]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[杨丽,牛晓丽,王连磊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨丽,牛晓丽,王连磊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311022&flag=1]]></guid><cfi:id>676</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[P-糖蛋白与CYP450酶对千金子肠道毒性的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:59</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[段飞鹏<sup>1</sup>,王英姿<sup>1</sup>,倪健<sup>1</sup>,张超<sup>2</sup>,孙秀梅<sup>2</sup>,冯艾灵<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>段飞鹏<sup>1</sup>,王英姿<sup>1</sup>,倪健<sup>1</sup>,张超<sup>2</sup>,孙秀梅<sup>2</sup>,冯艾灵<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310017&flag=1]]></guid><cfi:id>675</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[外用温敏水凝胶基质的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈其铽,田景振]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈其铽,田景振</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310018&flag=1]]></guid><cfi:id>674</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[微丸的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:50</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王立,马维阳,王文君]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王立,马维阳,王文君</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409011&flag=1]]></guid><cfi:id>673</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[白芍的研究概况]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:50</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[巩向丹<sup>1</sup>,张叶<sup>2</sup>,刘宏明<sup>1，3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>巩向丹<sup>1</sup>,张叶<sup>2</sup>,刘宏明<sup>1，3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409012&flag=1]]></guid><cfi:id>672</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[双重修饰的主动靶向脂质体研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[蒋雯,田吉来,丁晨静,鞠安,顾宁]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>蒋雯,田吉来,丁晨静,鞠安,顾宁</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408012&flag=1]]></guid><cfi:id>671</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[透明质酸在紫杉醇新型给药系统中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[武玉敏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>武玉敏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408013&flag=1]]></guid><cfi:id>670</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[非线性药物动力学参数的计算方法研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[蔡晖<sup>1</sup>,孙春萌<sup>2</sup>,沈雁<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>蔡晖<sup>1</sup>,孙春萌<sup>2</sup>,沈雁<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407011&flag=1]]></guid><cfi:id>669</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[南极假丝酵母脂肪酶B在制备手性药物中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[矫春丽,刘学杰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>矫春丽,刘学杰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407012&flag=1]]></guid><cfi:id>668</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药全蝎的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张盼盼<sup>1</sup>,马明珠<sup>1</sup>,王集会<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张盼盼<sup>1</sup>,马明珠<sup>1</sup>,王集会<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407013&flag=1]]></guid><cfi:id>667</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Wnt信号通路在肺癌治疗方面的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[党云苗,孙杰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>党云苗,孙杰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407014&flag=1]]></guid><cfi:id>666</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[地黄药理作用和临床应用概况]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:17</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李慧芬]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李慧芬</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406013&flag=1]]></guid><cfi:id>665</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[丹参制剂高效液相色谱指纹图谱研究现状]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:17</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张珺,程月发]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张珺,程月发</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406014&flag=1]]></guid><cfi:id>664</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[泡桐属中黄酮类化合物的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[高天阳<sup>1，2</sup>,李传厚<sup>1，2</sup>,唐文照<sup>2</sup>,王晓静<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高天阳<sup>1，2</sup>,李传厚<sup>1，2</sup>,唐文照<sup>2</sup>,王晓静<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406015&flag=1]]></guid><cfi:id>663</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[盐酸阿罗洛尔临床应用研究概述]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[翟民,于长安,王孟,朱建益,郑亮]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>翟民,于长安,王孟,朱建益,郑亮</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406016&flag=1]]></guid><cfi:id>662</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on Btk inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 0:00:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[邓容,赵利枝]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>邓容,赵利枝</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406017&flag=1]]></guid><cfi:id>661</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药治疗糖尿病合并高血压的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[韩玮娜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩玮娜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405014&flag=1]]></guid><cfi:id>660</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[BMPs在中枢神经系统发育和神经保护中的作用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[周心<sup>1</sup>,官堂明<sup>2</sup>,黄韧<sup>3</sup>,李文德<sup>1,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>周心<sup>1</sup>,官堂明<sup>2</sup>,黄韧<sup>3</sup>,李文德<sup>1,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405015&flag=1]]></guid><cfi:id>659</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[矿物药鉴定之浅谈]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[林娴]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>林娴</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405016&flag=1]]></guid><cfi:id>658</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[白蛋白结合型紫杉醇的临床研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[解李丽,杨同江,张翠平,单衍强]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>解李丽,杨同江,张翠平,单衍强</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405017&flag=1]]></guid><cfi:id>657</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[外阴营养不良药物治疗进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[边瑞民,刘明华,张循格,高新富]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>边瑞民,刘明华,张循格,高新富</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405018&flag=1]]></guid><cfi:id>656</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Fat-1转基因小鼠的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[高翔,李文德]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高翔,李文德</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404010&flag=1]]></guid><cfi:id>655</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[峻下逐水中药抗白血病作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张超]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张超</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404011&flag=1]]></guid><cfi:id>654</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[大鼠动脉粥样硬化模型研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[马飞,孙洪胜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>马飞,孙洪胜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404012&flag=1]]></guid><cfi:id>653</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[类风湿性关节炎临床治疗方案的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王建明,谢书阳]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王建明,谢书阳</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404013&flag=1]]></guid><cfi:id>652</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[血液制品病毒灭活/去除方法概述]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[迟妍妍<sup>1,2</sup>,王斐<sup>1</sup>,张惠<sup>3</sup>,臧恒昌<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>迟妍妍<sup>1,2</sup>,王斐<sup>1</sup>,张惠<sup>3</sup>,臧恒昌<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404014&flag=1]]></guid><cfi:id>651</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[蜂毒素治疗肝癌的机制及相关制剂研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:01:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘淑君<sup>1</sup>,杨勇<sup>2</sup>,傅继华<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘淑君<sup>1</sup>,杨勇<sup>2</sup>,傅继华<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403013&flag=1]]></guid><cfi:id>650</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[花蕊石现代研究概况]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李慧芬]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李慧芬</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402016&flag=1]]></guid><cfi:id>649</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[阿司匹林联合氯吡格雷应用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈丹丹<sup>1,2</sup>,李晋奇<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈丹丹<sup>1,2</sup>,李晋奇<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402017&flag=1]]></guid><cfi:id>648</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[正红花油质量研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘华锋]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘华锋</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402018&flag=1]]></guid><cfi:id>647</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[微生物中氧化态硒还原酶的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王东亮<sup>1,2</sup>,毛贝蓓<sup>1</sup>,张路<sup>1,2</sup>,肖敏<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王东亮<sup>1,2</sup>,毛贝蓓<sup>1</sup>,张路<sup>1,2</sup>,肖敏<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401012&flag=1]]></guid><cfi:id>646</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[夹带剂在超临界CO2萃取中药有效成分中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孙亚伟]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙亚伟</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401013&flag=1]]></guid><cfi:id>645</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[紫草化学成分及其抗病毒、抑菌作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[曹云飞,李慧芬]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>曹云飞,李慧芬</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401014&flag=1]]></guid><cfi:id>644</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[单克隆抗体治疗肿瘤的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李红玲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李红玲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401015&flag=1]]></guid><cfi:id>643</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[肺部给药研究近况]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[凌祥,沈雁,孙春萌,涂家生]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>凌祥,沈雁,孙春萌,涂家生</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412011&flag=1]]></guid><cfi:id>642</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药治疗肝损伤的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孙铁锋<sup>1</sup>,王平<sup>2</sup>,张春莉<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙铁锋<sup>1</sup>,王平<sup>2</sup>,张春莉<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412012&flag=1]]></guid><cfi:id>641</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[京万红软膏临床应用进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张世川<sup>1</sup>,国大亮<sup>1</sup>,刘文伟<sup>2</sup>,魏雪仙<sup>1</sup>,赵宁<sup>2</sup>,刘玉璇<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张世川<sup>1</sup>,国大亮<sup>1</sup>,刘文伟<sup>2</sup>,魏雪仙<sup>1</sup>,赵宁<sup>2</sup>,刘玉璇<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412013&flag=1]]></guid><cfi:id>640</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[银杏叶提取物的研究进展与应用前景]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘秀萍<sup>1,2</sup>,臧恒昌<sup>1</sup>,于洪利<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘秀萍<sup>1,2</sup>,臧恒昌<sup>1</sup>,于洪利<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412014&flag=1]]></guid><cfi:id>639</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[老年高血压用药与进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[郑秋丽]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郑秋丽</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412015&flag=1]]></guid><cfi:id>638</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[高效液相色谱柱及其再平衡(译文)]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李奕婧<sup>1</sup>,李冰<sup>2</sup>,程春雷<sup>2</sup>,王杰<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李奕婧<sup>1</sup>,李冰<sup>2</sup>,程春雷<sup>2</sup>,王杰<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412016&flag=1]]></guid><cfi:id>637</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[表皮生长因子受体及其抑制剂的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王欣,许潇,孙瑞,刘畅,彭慧兰,马银柱,红霞,李圣男,杨阳,张帆,初颖]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王欣,许潇,孙瑞,刘畅,彭慧兰,马银柱,红霞,李圣男,杨阳,张帆,初颖</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411013&flag=1]]></guid><cfi:id>636</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[肝素类药物防治阿尔采末病的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[郝丽娜,赵孝林,吴学新]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郝丽娜,赵孝林,吴学新</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411014&flag=1]]></guid><cfi:id>635</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[脑心通胶囊联合用药情况分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王淑杰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王淑杰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411015&flag=1]]></guid><cfi:id>634</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[关于丹参及其制剂高效液相色谱指纹图谱参照物的选择研究概况]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张珺,程月发]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张珺,程月发</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411016&flag=1]]></guid><cfi:id>633</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[人血白蛋白生产及其应用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王鸣宇<sup>1,2</sup>,王斐<sup>1</sup>,臧恒昌<sup>1</sup>,张惠<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王鸣宇<sup>1,2</sup>,王斐<sup>1</sup>,臧恒昌<sup>1</sup>,张惠<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410014&flag=1]]></guid><cfi:id>632</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[马钱子的化学成分和药理作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:12</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[解宝仙<sup>1,2</sup>,唐文照<sup>2</sup>,王晓静<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>解宝仙<sup>1,2</sup>,唐文照<sup>2</sup>,王晓静<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410015&flag=1]]></guid><cfi:id>631</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我国制药机械行业的现状与发展趋势]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:12</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[郭文峰,丁晓红]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郭文峰,丁晓红</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410016&flag=1]]></guid><cfi:id>630</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[脂多糖致帕金森病动物模型研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[何欢,吴霞]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>何欢,吴霞</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509013&flag=1]]></guid><cfi:id>629</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[嵌合抗原受体T细胞治疗恶性肿瘤的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[常征,陈学武,王丽,于黎鑫]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>常征,陈学武,王丽,于黎鑫</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509014&flag=1]]></guid><cfi:id>628</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药促进益生菌生长的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘晋仙<sup>1</sup>,林永强<sup>2</sup>,汪冰<sup>2</sup>,崔伟亮<sup>2</sup>,李慧芬<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘晋仙<sup>1</sup>,林永强<sup>2</sup>,汪冰<sup>2</sup>,崔伟亮<sup>2</sup>,李慧芬<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509015&flag=1]]></guid><cfi:id>627</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[活血化瘀疗法在呼吸系统疾病中的应用探究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王妍]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王妍</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509016&flag=1]]></guid><cfi:id>626</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[左布比卡因临床应用研究概述]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张涛<sup>1,2</sup>,郑家晴<sup>1</sup>,翟民<sup>1</sup>,孟凡领<sup>1</sup>,王孟<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张涛<sup>1,2</sup>,郑家晴<sup>1</sup>,翟民<sup>1</sup>,孟凡领<sup>1</sup>,王孟<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509017&flag=1]]></guid><cfi:id>625</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药对2型糖尿病模型胰岛β细胞凋亡的保护作用及机制研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[秦定梅<sup>1</sup>,范源<sup>1</sup>,周轶平<sup>2</sup>,罗敏<sup>2</sup>,李玛琳<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>秦定梅<sup>1</sup>,范源<sup>1</sup>,周轶平<sup>2</sup>,罗敏<sup>2</sup>,李玛琳<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508012&flag=1]]></guid><cfi:id>624</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[伞形科植物多倍体育种研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王平<sup>1</sup>,赵云叶<sup>2</sup>,高燕<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王平<sup>1</sup>,赵云叶<sup>2</sup>,高燕<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508013&flag=1]]></guid><cfi:id>623</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[活血化瘀法治疗脑出血的实验研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘泰<sup>1</sup>,高玉广<sup>2</sup>,张青萍<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘泰<sup>1</sup>,高玉广<sup>2</sup>,张青萍<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508014&flag=1]]></guid><cfi:id>622</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[静脉补铁药物研究与应用进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘晋仙<sup>1</sup>,李玮涛<sup>1,2</sup>,张在忠<sup>1,2</sup>,李荣<sup>2</sup>,陈少鹏<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘晋仙<sup>1</sup>,李玮涛<sup>1,2</sup>,张在忠<sup>1,2</sup>,李荣<sup>2</sup>,陈少鹏<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508015&flag=1]]></guid><cfi:id>621</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[GLP-1受体激动剂和DPP-4抑制剂在糖尿病治疗中的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李娜,李峰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李娜,李峰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508016&flag=1]]></guid><cfi:id>620</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[金丝桃素纳米制剂的设计与发展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[田佳<sup>1</sup>,李亚楠<sup>2</sup>,沈雁<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>田佳<sup>1</sup>,李亚楠<sup>2</sup>,沈雁<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507013&flag=1]]></guid><cfi:id>619</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药柔性脂质体的制备工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[魏雪仙,张世川,刘玉璇,国大亮]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>魏雪仙,张世川,刘玉璇,国大亮</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507014&flag=1]]></guid><cfi:id>618</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药预防自然流产的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王平<sup>1</sup>,刘善新<sup>1</sup>,孙铁锋<sup>2</sup>,王杰<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王平<sup>1</sup>,刘善新<sup>1</sup>,孙铁锋<sup>2</sup>,王杰<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507015&flag=1]]></guid><cfi:id>617</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[内皮素与氧化应激]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张永田,官清华,严思敏,丁启龙]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张永田,官清华,严思敏,丁启龙</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507016&flag=1]]></guid><cfi:id>616</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[低分子肝素药理学机制及适应证研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘晋仙<sup>1</sup>,李玮涛<sup>1</sup>,张在忠<sup>2</sup>,李荣<sup>2</sup>,陈少鹏<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘晋仙<sup>1</sup>,李玮涛<sup>1</sup>,张在忠<sup>2</sup>,李荣<sup>2</sup>,陈少鹏<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507017&flag=1]]></guid><cfi:id>615</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[五没食子酰基葡萄糖治疗2型糖尿病及其并发症药效机制研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张建博<sup>1</sup>,谢雨<sup>2</sup>,杨浩然<sup>1</sup>,范源<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张建博<sup>1</sup>,谢雨<sup>2</sup>,杨浩然<sup>1</sup>,范源<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506012&flag=1]]></guid><cfi:id>614</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[p38丝裂原激活蛋白激酶在脑缺血预适应中的作用研究近况]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈炜<sup>1</sup>,刘泰<sup>1</sup>,李丹<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈炜<sup>1</sup>,刘泰<sup>1</sup>,李丹<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506013&flag=1]]></guid><cfi:id>613</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[肠道菌群与疾病的关系]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[杨异卉,李玲,黄海丽,王晨曦]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨异卉,李玲,黄海丽,王晨曦</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506014&flag=1]]></guid><cfi:id>612</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[口腔益生菌在口腔疾病防治上的研究及应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘虹,翦祎,张化朋,王丽春,张颜廷,王静]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘虹,翦祎,张化朋,王丽春,张颜廷,王静</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506015&flag=1]]></guid><cfi:id>611</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[MicroRNAs及其在NF-κB通路中的作用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[蒋艾豆,龚国清]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>蒋艾豆,龚国清</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505013&flag=1]]></guid><cfi:id>610</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[当归主要病虫害防治研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘娟娟,赵慧巧,卢年华,景明]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘娟娟,赵慧巧,卢年华,景明</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505014&flag=1]]></guid><cfi:id>609</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[田基黄成分及药理应用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[欧淑芬<sup>1</sup>,谭沛<sup>2</sup>,徐冰<sup>2</sup>,陈周全<sup>2</sup>,王永刚<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>欧淑芬<sup>1</sup>,谭沛<sup>2</sup>,徐冰<sup>2</sup>,陈周全<sup>2</sup>,王永刚<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505015&flag=1]]></guid><cfi:id>608</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[去势抵抗性前列腺癌分子信号通路的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张秀娜<sup>1</sup>,赵伟<sup>1</sup>,高晓芳<sup>1</sup>,杨勇<sup>2</sup>,季晖<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张秀娜<sup>1</sup>,赵伟<sup>1</sup>,高晓芳<sup>1</sup>,杨勇<sup>2</sup>,季晖<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504013&flag=1]]></guid><cfi:id>607</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药在肿瘤治疗中的减毒增效作用的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李娇,刘晓波]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李娇,刘晓波</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504014&flag=1]]></guid><cfi:id>606</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[壳聚糖构建细胞支架的研究现状]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孙铁峰<sup>1,2</sup>,王平<sup>2</sup>,高志惠<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙铁峰<sup>1,2</sup>,王平<sup>2</sup>,高志惠<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504015&flag=1]]></guid><cfi:id>605</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[山东省医疗器械产业发展现状及分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈洪忠,夏文龙,杨盛林]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈洪忠,夏文龙,杨盛林</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504016&flag=1]]></guid><cfi:id>604</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[雄激素及其受体在肝细胞癌中的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[赵伟<sup>1</sup>,张秀娜<sup>1</sup>,周有丽<sup>1</sup>,杨勇<sup>2</sup>,陈真<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵伟<sup>1</sup>,张秀娜<sup>1</sup>,周有丽<sup>1</sup>,杨勇<sup>2</sup>,陈真<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503013&flag=1]]></guid><cfi:id>603</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[精氨酸加压素V2受体拮抗剂托伐普坦的合成进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[彭伟,陈磊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>彭伟,陈磊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503014&flag=1]]></guid><cfi:id>602</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[次氯酸对食肉菌感染的作用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王晓琳]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王晓琳</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503015&flag=1]]></guid><cfi:id>601</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药抗辐射作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[段雅彬,姚星辰,张娟玲,李向阳]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>段雅彬,姚星辰,张娟玲,李向阳</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502010&flag=1]]></guid><cfi:id>600</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[新型中药饮片研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[牛超<sup>1</sup>,石典花<sup>2</sup>,孙立靖<sup>3</sup>,孙立立<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>牛超<sup>1</sup>,石典花<sup>2</sup>,孙立靖<sup>3</sup>,孙立立<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502011&flag=1]]></guid><cfi:id>599</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[哈士蟆治疗脓毒血症的可行性分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张娴<sup>1</sup>,盛颖<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张娴<sup>1</sup>,盛颖<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502012&flag=1]]></guid><cfi:id>598</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[降血脂药物的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[韩建军,宁娜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩建军,宁娜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501010&flag=1]]></guid><cfi:id>597</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[影响伊立替康疗效和毒性的遗传因素]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[赵仁永<sup>1,2</sup>,张蕊<sup>3</sup>,郭瑞臣<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵仁永<sup>1,2</sup>,张蕊<sup>3</sup>,郭瑞臣<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501011&flag=1]]></guid><cfi:id>596</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[马黄酊的药材来源、制备方法、质量检测与临床应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[辛义周<sup>1</sup>,赵军<sup>1</sup>,李建绪<sup>2</sup>,唐文照<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>辛义周<sup>1</sup>,赵军<sup>1</sup>,李建绪<sup>2</sup>,唐文照<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501012&flag=1]]></guid><cfi:id>595</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the treatment after resistance to first generation EGFR-TKI in patients with non-small cell lung cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Lung cancer is one of the most common malignant tumors in the world and a serious threat to human health.EGFR-TKI has become the hot topic in Non-small cell lung cancer.EGFR-TKI is the first-line treatmen on EGFR gene mutations in lung cancer,EGFR-TKI has been used for first-line therapy, second-line treatment and maintenance therapy in Non-small cell lung cancer. Although the results of EGFR-TKI for patients with Non-small cell lung cancer has been effective, with the progression of the disease,it inevitably may lead to durg resistance.In this paper,we made a review on the treatment after resistance to first generation EGFR-TKI in patients with Non-small cell lung cancer.]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DENG Wu-sheng and SUN Jie]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DENG Wu-sheng and SUN Jie</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512012&flag=1]]></guid><cfi:id>594</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the effect and mechanism of oxidative stress on vasoactive substances]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hypertension is one of the most common cardiovascular in the world and it is one of the most important risk factors for developing cardiovascular disease.It is urgent to findthe molecular mechanisms contributing to the initiation of hypertension and the new therapeutic strategy against hypertension.Vascular endothelial controls maintenance of vascular homeostasis by releasing endothelium-derived relax and constriction factor.A plethora of studies have demonstrated that the importance of oxidative stress in developing of hypertension.Oxidative stress can change the contracting and relaxing of vascular by affecting the synthesis of vasoactive substances.This review aimed to highlight oxidative stress to the endothelial function by influence of synthesis of NO,PGI<sub>2</sub>,ET-1 and TXA<sub>2</sub>.]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Wen-juan, HONG Ze, YAN Si-min and DING Qi-long]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Wen-juan, HONG Ze, YAN Si-min and DING Qi-long</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512013&flag=1]]></guid><cfi:id>593</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on drug transporter of liver and its clinical significance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[To introduce the function,distribution,and substrate characteristics of drug transporters in the liver and the effect on the treatment of drug in human body disposal process.Based on the liver drug delivery system, and the disposal of influence in the body to classify and summarize.Liver as an important organ for the metabolism and excretion of endogenous and exogenous (drug) ,except for hepatic enzymes,it also played a certain role in the process of metabolism and excretion of the drugs.The efficacy and safety of the drugs would be changed when the function of the transporters was affected.]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FU Chao<sup>1</sup> and LIU Yang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FU Chao<sup>1</sup> and LIU Yang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512014&flag=1]]></guid><cfi:id>592</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Experimental research progress on vascular cognitive impairment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[At present,great progress has been obtained the related experimental studies on treatment of vascular cognitive impairment (VCI) pathogenesis and mechanism of integrated traditional Chinese and Western medicine.According to search CNKI,Wan Fang,VIP database of nearly five years of data,take experimental study as the breakthrough point.This paper analyzed,generalized,summarized and reviewed the pathogenesis and treatment mechanism of VCI,to provide experimental basis for further prevention treatment of VCI.]]></description>
<pubDate>2016/4/25 9:06:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TAN Lulu, ZENG Peipei and LIU Tai]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TAN Lulu, ZENG Peipei and LIU Tai</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511013&flag=1]]></guid><cfi:id>591</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on <i>Sedum sarmentosum</i> Bunge]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[By reading a lot of literatures on <i>Sedum sarmentosum</i> Bunge,the research progress on its chemical constituents,pharmacological effects and clinical applications were summarized in this article,which provided scientific basis for effective development and utilization of <i>Sedum sarmentosum</i> Bunge.]]></description>
<pubDate>2016/4/25 9:06:02</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Huijuan<sup>1,2</sup>, DU Chenglin<sup>2</sup> and WANG Xiaojing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Huijuan<sup>1,2</sup>, DU Chenglin<sup>2</sup> and WANG Xiaojing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511014&flag=1]]></guid><cfi:id>590</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The current situation and analysis on off-label uses of antitumor drug]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This article collected and sorted out literatures of off-label uses of antitumor drug in recent years,and analyzed the reason,frequency and whether or not was rational use of drug.It can provide reference for antitumor medication to ensure medication safety of patients and enhance the standardized management of off-label drug use.]]></description>
<pubDate>2016/4/25 9:06:02</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GUI Lin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUI Lin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511015&flag=1]]></guid><cfi:id>589</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[诃子药理作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李斌<sup>1</sup>,李鑫<sup>2</sup>,范源<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李斌<sup>1</sup>,李鑫<sup>2</sup>,范源<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510011&flag=1]]></guid><cfi:id>588</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[活血化瘀法治疗脑出血时间窗的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘泰<sup>1</sup>,黄树斌<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘泰<sup>1</sup>,黄树斌<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510012&flag=1]]></guid><cfi:id>587</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[桥本氏甲状腺炎发病机制及治疗方法研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王平<sup>1</sup>,王建凤<sup>1</sup>,刘善新<sup>1</sup>,王杰<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王平<sup>1</sup>,王建凤<sup>1</sup>,刘善新<sup>1</sup>,王杰<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510013&flag=1]]></guid><cfi:id>586</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[以FtsZ蛋白为靶点的抗菌天然产物的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[马思提,魏国栋,刘慧,何方正]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>马思提,魏国栋,刘慧,何方正</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510014&flag=1]]></guid><cfi:id>585</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the mechanism and IR time in MCAO/IR model rats with string-fastenting method]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The MCAO/IR model in rats induced by thread embolism in middle cerebral artery is the most common used animal model in the research of ischemic brain injury.In recent years,many researches has been conducted on this animal model.This article reviewed the correlation in the time of ischemia- reperfusion(IR)and the mechanism,aimed to provide references for the selection in IR time and evaluation index in drug research and also provide some clues for the future study in MCAO/ IR model rats.]]></description>
<pubDate>2016/9/13 8:36:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Dandan<sup>1,2</sup>, XIE Xiaofang<sup>1,3</sup>, AO Hui<sup>1,3</sup> and PENG Cheng<sup>1,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Dandan<sup>1,2</sup>, XIE Xiaofang<sup>1,3</sup>, AO Hui<sup>1,3</sup> and PENG Cheng<sup>1,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609013&flag=1]]></guid><cfi:id>584</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on mechanisms of cerebral ischemia-reperfusion injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The origin and development of the cerebral ischemia-reperfusion injury is a complex pathophysiological process.Scholars have made extensive and profound studies on mechanisms of cerebral ischemia-reperfusion injury and put forward a series of theories,which laid a foundation on the pathophysiology mechanism of cerebral ischemia-reperfusion injury.This article summarized progress on mechanisms of cerebral ischemia-reperfusion injury, in order to provide the references for the treatment of cerebral ischemia-reperfusion injury.]]></description>
<pubDate>2016/9/13 8:36:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Lei<sup>1</sup>, LIU Lihua<sup>2</sup> and MA Yukui<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Lei<sup>1</sup>, LIU Lihua<sup>2</sup> and MA Yukui<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609014&flag=1]]></guid><cfi:id>583</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The influencing factors of pharmacokinetics of nifedipine oral preparation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Nifedipine is widely used for the treatment of hypertension and angina pectoris,and its clinical efficacy has been confirmed .However,there still exists difference among individuals in efficacy and safety.This article reviewed literatures about possible factors that may cause the differential of nifedipine pharmacokinetics.]]></description>
<pubDate>2016/8/8 10:12:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Xinhui<sup>1</sup>, LIU Qun<sup>2</sup>, CHU Zhijie<sup>2</sup> and GUI Ruichen<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xinhui<sup>1</sup>, LIU Qun<sup>2</sup>, CHU Zhijie<sup>2</sup> and GUI Ruichen<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608011&flag=1]]></guid><cfi:id>582</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on bioadhesive microspheres]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bioadhesive microspheres (MSs) can specifically adhere on most mucosal tissue, which can prolong the retention and release time of drugs,achieve local or systemic effect of drugs,improve bioavailability of drugs and reduce the frequency of drug administration.From this the patient compliance can be highly improved. Based on the domestic and foreign literatures, this paper introduced recent research on gastrointestinal mucoadhesive MSs,nasal mucosa adhesive MSs, oral mucoadhesive MSs and vaginal mucosa adhesive MSs.Besides,the studies and applications of cell adhesion MSs was also reviewed.]]></description>
<pubDate>2016/8/8 10:12:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Dejie<sup>1,2</sup>, ZHANG Hui<sup>1</sup>, AN Fei<sup>1,2</sup> and ZHAO Guangxi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Dejie<sup>1,2</sup>, ZHANG Hui<sup>1</sup>, AN Fei<sup>1,2</sup> and ZHAO Guangxi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608012&flag=1]]></guid><cfi:id>581</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Bergenin and its derivatives on their anti-inflammation activity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bergenin is a unique fused C-glucoside of 4-O-methylgallic acid isolated from Bergenia species,which possesses various biological activities.This article mainly focused on its anti-inflammation activity and the structural modification relating to this biological activity.]]></description>
<pubDate>2016/7/12 14:11:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DENG Lihua<sup>1</sup>, LI Yunsen<sup>2</sup> and WU Yanfen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DENG Lihua<sup>1</sup>, LI Yunsen<sup>2</sup> and WU Yanfen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607012&flag=1]]></guid><cfi:id>580</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of molecular targeted antitumor drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Malignant tumor is always a serious threat to human life,and the traditional treatment methods and treatment drugs have been far from meeting the clinical needs.In recent years,with the development of molecular biology,molecular targeted drug delivery system and targeted anticancer drugs have made breakthrough progress,which brings new hope to patients with malignant tumor.Many targeted drugs have shown great advantages in clinical trials and are approved for clinical treatment of malignant tumors,and better results have been obtained.There are also potential therapeutic agents for the treatment of malignant tumors.This paper mainly focused on the molecular targeted drug delivery system and its application in tumor treatment.]]></description>
<pubDate>2016/7/12 14:11:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FU Tingting and SONG Kai]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FU Tingting and SONG Kai</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607013&flag=1]]></guid><cfi:id>579</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of ionic liquids in pharmaceutical research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Because of the unique physical and chemical properties of Ionic liquids(ILs),ILs received more and more study and application in various fields including green chemistry,clean energy and lubricants.In recent years,the application of ILs in pharmaceutical research received more and more attentions.This paper systematically reviewed about researches and applications of ILs in pharmaceutical field,including active pharmaceutical ingredient and drug delivery system,and we explored the prospect of ILs in pharmaceutics.]]></description>
<pubDate>2016/7/12 0:00:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Yi<sup>1,2</sup>, XU Lei<sup>1,2</sup>, XU Chao<sup>1,2</sup> and JIN Xueping<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yi<sup>1,2</sup>, XU Lei<sup>1,2</sup>, XU Chao<sup>1,2</sup> and JIN Xueping<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607014&flag=1]]></guid><cfi:id>578</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on active ingredients of traditional Chinese medicines absorption kinetics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Many active ingredients of traditional Chinese medicine (TCMs) have low dissolved or low permeability characteristics, therefore insufficient consideration before formulation design will lead to decreasing bioavailability and subsequently limited efficacy.In this paper, we mainly introduced the advance progress in the study of intestinal absorption kinetics of TCMs,analyzed the influence factors of TCMs bioavailability based on intestinal physiological features and drug characteristics, and discussed new formulations in improving bioavailability of TCMs according to their biopharmaceutical properties. The purpose is to provide rationale theory so as to study the pharmacokinetics and pharmacy of TCMs normatively]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHENG Yan<sup>1</sup>, YOU Linjun<sup>2</sup>, YANG Yong<sup>2</sup> and CHEN Xijing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Yan<sup>1</sup>, YOU Linjun<sup>2</sup>, YANG Yong<sup>2</sup> and CHEN Xijing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606014&flag=1]]></guid><cfi:id>577</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The anti-tumor effects of <i>Paris Polyphylla's</i> action mechanism]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Paris polyphylla</i> is commonly used drugs of clinical traditional Chinese medicine,possesses clear hot detoxify,relieve pain and cool the frightened liver features.Nowadays,with developing of extraction technology of traditional Chinese medicine,the number of research on active constituent of <i>Paris polyphylla</i> is growing.Its action mechanism on anti-tumor effects is increasingly valued by researchers and becoming a new future research direction.]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MAN Yi<sup>1</sup>, WEI Ming<sup>2</sup> and WANG Huikai<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MAN Yi<sup>1</sup>, WEI Ming<sup>2</sup> and WANG Huikai<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606015&flag=1]]></guid><cfi:id>576</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[IKK/NF-κB signaling pathway:a potential drug target in rheumatoid arthritis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Inflammation play a critical role in the pathological process of rheumatoid arthritis.IKK/NF-κB signaling pathway have effects on the pathogenesis of rheumatoid arthritis and could provide novel treatment strategies for rheumatoid arthritis.This article summarized the role of IKK/NF-κB signal pathway in the rheumatoid arthritis and its underlying mechanism,studies of correlated drugs.]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Siying<sup>1</sup> and GONG Guoqing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Siying<sup>1</sup> and GONG Guoqing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606016&flag=1]]></guid><cfi:id>575</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of cholesterol metabolite 27-hydroxycholesterol and cancer development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Obesity rates are rising worldwide,and population data link obesity to the increased incidence of several common cancers.High cholesterol diet and the incidence of tumor are related.In recent years, studies had shown that obesity induce small molecules play a role of physiological pathology,and promote the development of cancer.Studies demonstrated that the metabolite,27-hydroxycholesterol (27-HC),can function as anestrogen,increasing the proliferation of different kinds of cancer cells.This review aimed to highlignt new method of cancer clinical treatment.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GE Yao<sup>1</sup>, HE Xiaomeng<sup>1</sup>, YANG Yong<sup>2</sup> and YU Feng<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GE Yao<sup>1</sup>, HE Xiaomeng<sup>1</sup>, YANG Yong<sup>2</sup> and YU Feng<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605010&flag=1]]></guid><cfi:id>574</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in synthesis and anti-tumor activities of combretastatin A4 derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Combretastatin A4 is an anti-tumor agent from natural extract.It can cause a collapse of blood vessels inside the tumor tissue quickly and selectively and block the blood supply,which cause ischemic necrosis of the tumor tissue as a new angiogenesis inhibitor.However,it is weak to remnants of the destruction of the tumor tissue,so it leads to the failure of chemotherapy easily.Here,the derivatives and analogues of combretastatin A4 were summarized,which was in the hope of finding a stronger inhibitor of cell proliferation,more efficient and low toxicity to lay the foundation of new anticancer drugs.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Min and TIAN Yushun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Min and TIAN Yushun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605011&flag=1]]></guid><cfi:id>573</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on the pathogenesis of sepsis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sepsis is the patients' response to severe infection with high mortality and serious impact on the quality of dailylife.Ideally,the inflammation system will eliminate the pathogen once they invade the body and restore homeostasis.But the regulating mechanism of sepsis patients are in disorder,persistent activation of neutrophil and monocyte/monocyte-macrophages,increased lymphocyte apoptosis,delayed neutrophil apoptosis and increased necrosis of cell/tissue will all affect the immune system and blood coagulation and thus impact the development of sepsis.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Yixing<sup>1</sup>, LU Ermei<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yixing<sup>1</sup>, LU Ermei<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605012&flag=1]]></guid><cfi:id>572</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on transcriptional regulation of UDP-glucuronosyltransferase and disease relativity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Glucuronidation is the most important phase Ⅱmetabolic pathways,witch is catalyzed by UDP-glucuronosyltransferases (UGTs).UGTs play a pivotal role in regulating the metabolism of numerous endogenous substrates including bilirubin, bile acid, thyroid hormones and drugs including Opioid analgesics,NSAID and so on.The research of UGT has developed rapidly in recent years.UGT and related diseases has been extensively studied.This review discussed the progress on the regulation of UGT by transcription factors and correlational study between UGT and diseases.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIE Peng, LI Tingting and JI Hui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Peng, LI Tingting and JI Hui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605013&flag=1]]></guid><cfi:id>571</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on lipid metabolism in liver and NAFLD]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Nonalcoholic fatty liver (NAFLD) refers to the risk factors besides alcohol and other explicit damage that induced liver injury,which is also a clinical and pathological syndrome with diffuse liver cell hypertrophy and hepatic steatosis bubble and so on.In recent years,the number of non-alcoholic fatty liver disease increased year by year,which had been a serious threat to human health.This article discussed the research progress of relations between hepatic lipid metabolism and nonalcoholic fatty liver from the liver lipid metabolism process.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[AN Shanshan and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>AN Shanshan and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604012&flag=1]]></guid><cfi:id>570</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on drug delivery of solid lipid nanoparticles and nanostructured lipid carriers]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Solid lipid-based nanoparticles (SLBNs) were developed as potential alternatives to other conventionaldrug delivery systems.In general,SLBNs are divided into two types:solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs).SLNs are distinguishable fromNLCs by the composition of solid particle matrix.This review provided an overview of the preparation and characterization technologies for SLBNs and using focuses on recent advances in drug delivery using SLBNs,providing the reference of SLNBs for further study.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SONG Chuanxiao<sup>1</sup>, HE Shulian<sup>2</sup>, CAO Chunfeng<sup>2</sup>, ZHANG Guofeng<sup>1,3</sup>, ZHANG Wenjun<sup>1</sup>, WANG Song<sup>1</sup> and WANG Li<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Chuanxiao<sup>1</sup>, HE Shulian<sup>2</sup>, CAO Chunfeng<sup>2</sup>, ZHANG Guofeng<sup>1,3</sup>, ZHANG Wenjun<sup>1</sup>, WANG Song<sup>1</sup> and WANG Li<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604013&flag=1]]></guid><cfi:id>569</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress and clinical applications of tumor associated macrophage]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Macrophage which surrounds tumor cells is termed tumor associated  macrophage(TAM).TAM takes part in tumor initiation,invasion,metastasis and suppression of anti-tumor immune response.The amount of TAM,to a certain degree,can predict the prognosis of cancer patients.So far,some new medicine had been used in clinical treatment targeting TAM.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Jiani, WANG Zhuo, SUN Rui and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Jiani, WANG Zhuo, SUN Rui and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604014&flag=1]]></guid><cfi:id>568</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The cultivation and responsibilities of experimental animal veterinarians under the drug GLP system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the rapid development of Chinese pharmaceutical industry,pharmaceutical non-clinical research and the work (GLP) also got rapid development, at the same time it led to the rapid development of laboratory animal science and animal experiment,the growing demand of experimental animals.Be familiar with and master experimental animal breeding management,disease prevention,diagnosis,treatment and welfare of laboratory animal veterinarians animal ethics demand is also increasing significantly.Therefore,experimental animal veterinarians in drug safety evaluation gradually highlight the importance of the laboratory.Now combine this center in aspects such as experimental animal and veterinary training experience,explore the drug GLP system functions and the cultivation of experimental animal veterinarian.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Changhua, LENG Jiawei and ZHU Qingfen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Changhua, LENG Jiawei and ZHU Qingfen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604015&flag=1]]></guid><cfi:id>567</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advance of the synthesis and pharmacology of rhein and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Rhein is one of the main components of Rhubarb.It is wildly used for the treatment of tumor,virusdiabetic nephropathy,bacterial infection and inflammatory.And it shows good clinical application value.This paper reviewed the recent studies on the synthesis and pharmacological activity of rhein and its derivatives,hoping that some useful information can be provided for the researching of rhein and its derivatives.]]></description>
<pubDate>2016/4/7 9:39:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Qiuhe<sup>1,2,3</sup>, PI Rongbiao<sup>1,2,3,4</sup> and CHEN Jingkao<sup>1,2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Qiuhe<sup>1,2,3</sup>, PI Rongbiao<sup>1,2,3,4</sup> and CHEN Jingkao<sup>1,2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603012&flag=1]]></guid><cfi:id>566</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research of pathogenesis and treatment in type 2 diabetes]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Diabetes mellitus is a chronic disease characterized by metabolic disorders and its complications,which seriously affect life quality of the patients.Due to the treatment of type 2 diabetes is based on the pathogenesis of the disease,therefore,in order to provide certain reference for personnel engaged in related research or clinical work,this article summarized the pathogenesis of type 2 diabetes and related treatment measures.]]></description>
<pubDate>2016/4/7 9:39:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Xin and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xin and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603013&flag=1]]></guid><cfi:id>565</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in main compositions and pharmacological effects of bee venom]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bee venom is a kind of active compounds secreted by the gland, which have many active ingredients like anti-inflammatory,anti-tumor,analgesic,anti-hypertensive and so on.In recent years,many scientists had been made important progress in research of the active ingredient analysis,genetic structure,pharmacological action mechanism and molecular biology of bee venom.The purpose of this article was to summarize main active ingredients of bee venom and the main pharmacological actions and provide theoretical basis for the clinical used.]]></description>
<pubDate>2016/4/7 9:39:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Bingqing and LIU Xiaobo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Bingqing and LIU Xiaobo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603014&flag=1]]></guid><cfi:id>564</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress of the signaling pathway in Sugar and lipid metabolism in hepatocyte]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Insulin plays an important role to maintain the sugar and lipid levels to internal balance in hepatocyte during health state. And glucose and lipid metabolism disorders will be presented during hepatic insulin resistance.This article focused on the effect and its mechanism of insulin on glucose and lipid metabolism of hepatocyte during health state and hepatic insulin resistance.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MA Shaoxin, HOU Shanshan and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Shaoxin, HOU Shanshan and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602011&flag=1]]></guid><cfi:id>563</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on nanoformulations of puerarin]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Puerarin has many pharmacological activities,the clinic applications of puerarin have been limited due to the poor solubility in water and low oral bioavailability.In order to improve its solubility and in vivo absorption,many novel nanoformulations have been investigated.Based on the summarized literatures,the advances in the nanoformulations of puerarin,such as nanoparticles,microemulsion and self-emulsifying drug delivery system,nanocrystal,micelles and dendrimers had been introduced.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAI Yujia<sup>1</sup> and LI Lingbing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAI Yujia<sup>1</sup> and LI Lingbing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602012&flag=1]]></guid><cfi:id>562</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Polymer hydrogels designed for protein drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Nowdays，proteins with good bioactivity and strong specificity have received widespread attention.With stimuli-responsibility of hydrogel formation,the protein drug could achieve controlled release in vivo.So The present review gives a comprehensive summary of hydrogels by synthetic cross-linked polymer and introduce the researches of thermosensitive hydrogels in detail. Finally,the problems of hydrogels for application and prospects of such hydrogels are stated]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Jia<sup>1</sup>, LI Yanan<sup>2</sup> and SHEN Yan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Jia<sup>1</sup>, LI Yanan<sup>2</sup> and SHEN Yan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602013&flag=1]]></guid><cfi:id>561</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of the tumor microenvironment and its influences on development of prostate cancer chemoresistance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Prostate cancer inevitably progresses to incurable castration-resistant prostate cancer and distant metastasis after androgen deprivation therapy.Chemotherapy is mainly used in clinical,but prostate will gradually more chemotherapeutic drug resistance.The tumor microenvironment plays an indispensable role in cancer progression,and it is closely linked to cancer resistance.The paper reviewed the tumor microenvironment and mechanisms of drug resistance in prostate cancer in order to provide an alternative strategy and new targets for prostate cancer therapy.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Xiaofang<sup>1</sup>, WU Hongxi<sup>1</sup>, ZHU Qingyi<sup>2</sup> and YANG Yong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Xiaofang<sup>1</sup>, WU Hongxi<sup>1</sup>, ZHU Qingyi<sup>2</sup> and YANG Yong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602014&flag=1]]></guid><cfi:id>560</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of TRPV1 and TRPV4 channels in ischemia/oxygen conditioning-induced cardioprotection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[TRPV channels belong to the TRP (transient receptor potential) channel,which includes TRPV1,TRPV2,TRPV3,TRPV4,TRPV5 and TRPV6,they are involved in multiple of physiological functions including sensation of pain and taste,thermoregulation.Recent studies found that TRPV1 and TRPV4 channels may participate in ischemia/oxygen conditioning-induced cardioprotection.The cardioprotective effects of TRPV1 activation during ischemic conditioning have been linked with increased CGRP,substance P and augmented ALOX expression.Furthermore,the role of TRPV4 channels in mediating preconditioning-induced preservation of vascular function in terms restoring NO and further improving EDHF-mediated endothelial relaxation has been described.In this paper,we reviewed the TRPV1 and TRPV4 channels in mediating different forms of conditioning-induced cardioprotection along with the possible mechanisms so as to provide a new therapeutic way to myocardial ischemic.]]></description>
<pubDate>2016/3/22 9:29:24</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HUANG Haiyan and ZHANG Shizhong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Haiyan and ZHANG Shizhong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601011&flag=1]]></guid><cfi:id>559</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the effect of selective COX-2 inhibitors on cardiovascular diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To review the effect of selective COX-2 inhibitors on cardiovascular diseases and their mechanisms.<b>Methods</b>  By consulting related references,the risk of cardiovascular events caused by different selective COX-2 inhibitors was compared, and the effect mechanisms of rofecoxib and celecoxib on cardiovascular system were summarized.<b>Results</b>  The research progress of selective COX-2 inhibitors and adverse cardiovascular events were comprehensively summarized.<b>Conclusion</b>  A different risk profile for COX-2 inhibitors had emerged.Compared to rofecoxib and other coxibs,celecoxib was relatively safe.Receiving celecoxib with low-dose aspirin was recommended to exhibit lower cardiovascular risk.]]></description>
<pubDate>2016/3/22 9:29:25</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Ying<sup>1</sup>, SUN Ru<sup>2</sup> and CAO Yanhua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Ying<sup>1</sup>, SUN Ru<sup>2</sup> and CAO Yanhua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601012&flag=1]]></guid><cfi:id>558</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on relationship between intracellular calcium levels and microglial activation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ca2 + is an important intracellular second messenger, which is involved in the regulation of many physiological activities of cells and tissues, including muscle contraction, metabolism, secretion and cell division.Intracellular calcium signal has extensive and complex effects on the functions of microglia cells. This article explained the effects of calcium levels in microglia cells activation according to summarize the relationship between the two,and to provide convenience for further research on the relationships between them in the future.]]></description>
<pubDate>2016/3/22 9:43:04</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DU Huihui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DU Huihui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601013&flag=1]]></guid><cfi:id>557</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The central roal of APOBEC3B in cancer development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[APOBEC3B is one member of APOBEC which is transcriptionally induced by proinflammatory cytokine and chemokine. APOBEC3B can mutate the foreign genomes (or the host Ig genes), and it plays important roles in the inherent and adaptive immunities of human organism. Furthermore, APOBCE3B can facilitate the generation of cancer-promoting viral mutants. The studies indicate that APOBEC3B is upregulated in a variety of tumor tissues, and APOBEC3B also can induce somatic mutation. So APOBEC3B plays a central role in cancer development.]]></description>
<pubDate>2016/12/29 13:59:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Jiaying<sup>1</sup>, ZHENG Yan<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Jiaying<sup>1</sup>, ZHENG Yan<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612009&flag=1]]></guid><cfi:id>556</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress and mechanism of anti-tumor peptides drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cancer is a kind of malignant disease which is a difficult problem in the world.At present,many clinical therapy and drugs are unable to avoid the drawbacks such as poor targeting, strong side effects and drug resistance.It is important to look for anti-tumor drugs which are high effective,low toxic and easily available.Peptides stand out because of their features in many kinds of anti-tumor drugs,that depends on their small molecular weight,strong targeting,high activity,low toxicity,easy to wear membrane and so on.Peptides have get extensive attention in the anti-tumor experimental study and clinical application.This paper classified anti-tumor peptides according to the mechanism and sources,respectively introduced apoptosis-promoting peptides,immunotherapied peptides,fusional peptides and other peptides,in the hope of providing reference for screening,classifying and studying anti-tumor peptide.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Shujing, LIU Huan, ZHAO Jiankai, REN Shuang, SUN Weiwei, ZHANG Wenjun, ZHANG Jianing and ZHANG Han]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Shujing, LIU Huan, ZHAO Jiankai, REN Shuang, SUN Weiwei, ZHANG Wenjun, ZHANG Jianing and ZHANG Han</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612010&flag=1]]></guid><cfi:id>555</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress on dosage form and drug delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Modern pharmaceutics have undergone a rapid development in recent years.The novel dosage form and advanced drug delivery system show expansive foreground.The developments of novel dosage form and advanced drug delivery system can achieve short-term profits,reflect products differentiations and improve the research and industrialization level of companies.With limited resources allocation,the only way for us to bridge the gap is innovation.The developments of pharmaceutics including theories and applications of novel dosage forms and advanced drug delivery systems,the latest advances on pharmaceutics, and the challenges and opportunities in the future were all reviewed in this paper.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Saiqun<sup>1</sup> and PENG Jianqing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Saiqun<sup>1</sup> and PENG Jianqing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612011&flag=1]]></guid><cfi:id>554</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances on drug impurity control and safety evaluation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a key factor affecting the safety and effectiveness of drugs, impurity has always been the focus of drug quality research and safety evaluation. This paper focused on the two aspects of drug impurity control and safety evaluation, and summarized the research status of impurity profile,impurity toxicology evaluation,impurity reference substance preparation and so on.]]></description>
<pubDate>2016/11/9 9:59:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Weijian<sup>1</sup>, LIU Fei<sup>2</sup>, NIU Chong<sup>1</sup>, XIE Jizhen<sup>2</sup>, ZHU Qingfen<sup>1</sup> and HU Defu<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Weijian<sup>1</sup>, LIU Fei<sup>2</sup>, NIU Chong<sup>1</sup>, XIE Jizhen<sup>2</sup>, ZHU Qingfen<sup>1</sup> and HU Defu<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611010&flag=1]]></guid><cfi:id>553</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress and present situation of Tibetan medicine Zuotai]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Zuotai is an ancient traditional Tibetan medicine,and it consists of mercury,sulfur,eight gold,eight ore and other raw materials.There are some heavy metals in Zuotai ,such as Hg,Au,Ag,Pb,Cu,Fe and so on.It is the main source of heavy metals in Tibetan medicine.It’s also the valuable precious material of Tibetan medicine.Modern medicine is in urgent need of in-depth study on the clinical reasonable application for it.This paper analyzed and summarized the resent progress of Zoutai,and discussed the preparation technology,chemical composition,pharmacological,pharmacokinetics,toxicology,quality standard and clinical application .]]></description>
<pubDate>2016/11/9 9:59:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Meng<sup>1</sup>, ZHOU Xuejiao<sup>1</sup> and LI Xiangyang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Meng<sup>1</sup>, ZHOU Xuejiao<sup>1</sup> and LI Xiangyang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611011&flag=1]]></guid><cfi:id>552</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Autophagy:the new therapy target of atherosclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Autophagic degradation,a process that some contents were wrapped by autophagosome,through which realize the cell metabolism and update some organelles.Autophagy is closely related to many physiological and pathological processes in atherosclerosis.In this paper,we mainly discuss the regulation of autophagy in atherosclerosis,which is under the condition of cytokines,lipid,lipopolysaccharide,advanced glycation end products and miRNA.Also describe the dual role of autophagy and its pharmacological mechanism,then summarize the relationship between autophagy and targeted drugs in atherosclerosis.Moreover,the regulation of autophagy may be as a novel target for the treatment of atherosclerosis.]]></description>
<pubDate>2016/11/9 9:59:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Xiuliang and TU Jianghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Xiuliang and TU Jianghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611012&flag=1]]></guid><cfi:id>551</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The preparation methods of hollow silica microspheres and the prospect of it as a drug carrier]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the development of the nanotechnology,hollow silica micrpspheres have a broad prospect in biochemical engineering,medicine,photology,catalysis,composite material,etc.This article reviewed the advantage of hollow silica micrpspheres as a drug carrier, summarized the preparation methods of hollow silica micrpspheres in recent years,and prospected the development of it in the field of pharmaceutical preparations.]]></description>
<pubDate>2016/10/12 14:45:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Kai<sup>1</sup> and XU Zhengxin<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Kai<sup>1</sup> and XU Zhengxin<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610011&flag=1]]></guid><cfi:id>550</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on determination technology of Chromium(Ⅲ) and Chromium(VI) and pre-treatment methods of waste water,vacant gelatin capsules,leather and cloth]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This article reviewed the research progress of determination technology of Chromium(III) and Chromium(VI) and pre-treatment methods of waste water,vacant gelatin capsules,leather and cloth. The advantage and disadvantage of several analysis methods were discussed. Some views on pre-treatment methods were brought forward.]]></description>
<pubDate>2016/10/12 14:45:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Xue, YAN Quanhong and LI Yi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xue, YAN Quanhong and LI Yi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610012&flag=1]]></guid><cfi:id>549</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of Spectrum-effect relationship in Quality control of Traditional Chinese medicine and discussions]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese medicine (TCM) is more complicate composition system,how to comprehensive control the quality of TCM has been the emphases and difficulties of study of TCM modernization.In recent years,many scholars study on the quality control of TCM.In this paper,we review the continuously growing evidence supporting the application of spectrum-effect relationship in quality control of TCM to provide reference for the internationalization of TCM.]]></description>
<pubDate>2016/10/12 14:45:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[KONG Xiaoni<sup>1</sup>, MA Jing<sup>2</sup> and SHEN Wei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KONG Xiaoni<sup>1</sup>, MA Jing<sup>2</sup> and SHEN Wei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610013&flag=1]]></guid><cfi:id>548</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of palmitoyl ascorbate in the tumor treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years,the antitumor effect of vitamin C has attracted widespread attention.However,its clinical anticancer application is compromised by the need for extremely high dose and chemical instability.In order to overcome the aforementioned limitations,researchers are committed to synthesize its derivative. Palmitoyl ascorbate as a lipophilic derivative of vitamin C shows the advantages in physicochemical properties and anticancer activity.This paper reviewed its physicochemical characteristics,anticancer activity,anticancer mechanisms and applications in the cancer treatment.The review aimed to provide useful information for the clinical application of palmitoyl ascorbate.]]></description>
<pubDate>2017/9/21 9:45:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Yue<sup>1</sup>, LU Xiaoyu<sup>1</sup>, LI Ning<sup>2</sup>, ZHAO Di<sup>1</sup>, LU Yang<sup>1</sup> and CHEN Xijing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Yue<sup>1</sup>, LU Xiaoyu<sup>1</sup>, LI Ning<sup>2</sup>, ZHAO Di<sup>1</sup>, LU Yang<sup>1</sup> and CHEN Xijing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709009&flag=1]]></guid><cfi:id>547</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the influence factors of stability and antibacterial activities of dihydromyricetin]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Dihydromyricetin is main active components of Ampelopsis grossedentata,which is rich in resources and has a wide range of pharmacological activity.It has a good application prospect.But it is less stableness and frangibility to oxidation,easily affected by many factors.This article summarized the influencing factors of stability to dihydromyricetin,and provided a basis for improving its effective use.Meanwhile,the antibacterial activity of dihydromyricetin was briefly described.]]></description>
<pubDate>2017/9/21 9:45:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HUANG Yumei, HONG Zhengshan, YANG Ke and ZENG Chunhui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Yumei, HONG Zhengshan, YANG Ke and ZENG Chunhui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709010&flag=1]]></guid><cfi:id>546</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Current situation and research progress on the nephrotoxicity of aristolochic compounds]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Aristolochic acid compounds has been found exists in various of natural drugs.It has efficacy like anti-virus and anti-inflammatory.However,the adverse reactions as strong nephrotoxicity have prevented its wider applications,while some natural drugs still widely used in market.A detailed literature review on research progress on nephrotoxicity of aristolochic acid compounds was carried out in this paper.]]></description>
<pubDate>2017/9/21 9:45:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Yimao, LI Ji and YU Feng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yimao, LI Ji and YU Feng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709011&flag=1]]></guid><cfi:id>545</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacokinetics of alkaloids in <i>Phellodendron</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The article reviewed the research on pharmacokinetics of alkaloids in phellodendron,in order to provide useful reference for dosage form design,new drug development and clinical rational use.By collecting and analyzing more than 50 articles,this paper discussed the pharmacokinetics process of the alkaloids by oral administration,including integrated absorption and transport in gastrointestinal,tissue distribution,metabolic pathway and products,different components interactions (synergistic or restriction effect) which further set up the prospects.]]></description>
<pubDate>2017/9/21 9:45:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FENG Xin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FENG Xin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709012&flag=1]]></guid><cfi:id>544</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the secondary products of <i>Eurotium</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[There are many secondary products from Eurotium.These compounds have much biological activities.This paper reviewed the compounds from Eurotium and their biological activties.]]></description>
<pubDate>2017/9/21 9:45:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yinghui<sup>1</sup> and GAO Li<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yinghui<sup>1</sup> and GAO Li<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709013&flag=1]]></guid><cfi:id>543</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The progress on mouse models of liver cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[China is a country of the highest incidence of global liver cancer and the largest number of liver cancer death,which accounts for about 55% of the world.So the study of liver cancer has been the focus of clinical and basic research in China. Animal model of liver cancer,especially the mouse liver cancer model,is an important tool to study the biological characteristics,pathogenesis,drug screening and thetherapies of liver cancer.This paper briefly reviewed the commonly used model of mouse liver cancer in recent years,and provided ideas and directions for the study of gene functions related to the occurrence of liver cancer.]]></description>
<pubDate>2017/8/30 13:48:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Juo<sup>1</sup> and LIU Huaiying<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Juo<sup>1</sup> and LIU Huaiying<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708008&flag=1]]></guid><cfi:id>542</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of multivalence glycopeptides with biological activity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The glycans attached to proteins have emerged as important biomarkers in the diagnosis of manydiseases.Protein–carbohydrate interactions typically exhibit high specificity and weak affinities toward their carbohydrate ligands,this low affinity could be solved by synthesizing the carbohydrate ligands ina multivalent manner.This review aimed to provide an overview of the most recentand exciting advances in the area of multivalent glycopeptidesand their application in glycobiology.]]></description>
<pubDate>2017/8/30 13:48:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yanyan and WU Yanfen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yanyan and WU Yanfen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708009&flag=1]]></guid><cfi:id>541</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Apoptosis and heart failure]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Apoptosis is an important physiological process of the body to maintain stability,it is regulated by genes and is an cell autonomic process.Protease is the main participant in this process, the most important of which is the cysteinyl aspartate specific proteinase (caspase) family.According to apoptosis is dependent on caspases or not,there are three pathways,death receptor pathway, mitochondrial pathway and endoplasmic reticulum pathway.There are positive and negative regulation mechanisms of cell apoptosis,which can precisely control apoptosis process.Apoptosis has very significant structural and functional consequences in the failing heart, and anti-apoptotic therapy has important clinical value in improving heart failure.]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Xinmei and ZHANG Yubin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Xinmei and ZHANG Yubin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708010&flag=1]]></guid><cfi:id>540</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on nanomedicine delivery systems in targeting atherosclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cardiovascular disease occupies the highest mortality rates in the world.Atherosclerosis (AS) is the major cause of cardiovascular disease.For traditional administration method,the concentration of drug in in the AS plaque is low,which would be difficult to implement the curative effect in plaque.As known to everyone, compared to traditional small molecule drugs,nanomedicine delivery systems possess the capacities of targeting AS plaque,triggering drug release and elevating the effective concentration of drugs in AS plaque,which would provide a potential platform and technology for diagnosis,treatment,and integration of diagnosis and treatment of AS therapy.In this paper,recently nanomedicine delivery systems for targeting AS plaque were reviewed in the angle of targeting strategy,which was aimed to provide reference to reasonable design and construct novel nanomedicine delivery systems.]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DAI Lili, SU Zhigui and ZHANG Can]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DAI Lili, SU Zhigui and ZHANG Can</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708011&flag=1]]></guid><cfi:id>539</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on preparation of small molecule kinase inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Kinase dysfunction is important in the treatment of cancer, and normal cells can tolerate the inhibition of kinases, thus providing a method for selective killing of tumor cells.All of these small molecular Kinase Inhibitor (smKIs) drugs are administered orally.The structure-activity relationship of the drug determines the low solubility of the drug, resulting in low and varible bioavailability.In this paper, the physical and chemical properties of this kind of drugs,the current progress on preparation of the commercial pharmaceutical products are reviewed, the purpose is to provide a more reasonable formulation design for smKIs drugs.]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Ting, MA Xinrong and LUO Huimin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Ting, MA Xinrong and LUO Huimin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708012&flag=1]]></guid><cfi:id>538</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Two photon protein fluorescent probes development and its application in drug research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Protein has the crucial functions in the vital phenomena and life process.Among numerous methods of protein analysis,the application of fluorescence probe in the drug screening,etc,become more extensive recently.On the basis of two photon fluorescence imaging system is a technique with high resolution,deep intact sectioning ability,a little phototoxicity,low photobleaching effect,and so on,it will be a most powerful technique for real-time imaging for protein in live cells and tissues and will be useful for new drug screening process.This review summarized the investigation and recent progresses of the protein fluorescent probes and discussed the further developing trends of two photon fluorescence protein probe in drug development.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIN Yabing, LIANG Qianying, LI Jiajun, HAN Jinliang and TIAN Yushun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIN Yabing, LIANG Qianying, LI Jiajun, HAN Jinliang and TIAN Yushun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707009&flag=1]]></guid><cfi:id>537</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of the ulcerative colitis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ulcerative colitis is a chronic and relapsing inflammatory bowel disease that is immunologically mediated.New studies indicate that various genetic abnormalities lead to overly aggressive T-cell responses to a subset of commensal enteric bacteria and in turn,injure the intestinal mucosa as the main pathogenesises.The instantaneous impact of environmental factors on mucous membrane barrier,disrupting the immune response or intestinal flora with genetic abnormalities,results in the heterogeneity of ulcerative colitis.The heterogeneity determines the diversity of its diagnosis which includes clinical assessment,endoscopic detection,histology and biology.The maintherapeutic of ulcerative colitis are aminosalicylates,immunomodulators and biologics.This paper summarized the research status of ulcerative colitis and in order to provide a new strategy for prevention,diagnosis,treatment and drug research of ulcerative colitis.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DING Dong, LI Jiani, QI Ran, LU Yuan and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Dong, LI Jiani, QI Ran, LU Yuan and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707010&flag=1]]></guid><cfi:id>536</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role of TNF-α in the mechanism of D-GalN/LPS-induced acute liver failure]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Acute liver failure (ALF),characterized by a sudden large area of inflammation and extensive hepatocyte death,is defined as a life-threatening disease.The combination of D-galactosamine (D-GalN) and lipopolysaccharide (LPS) is used to build animal models of ALF.Large amounts of research have proven that TNF-α is closely related to ALF.This article explored the role of TNF-α in the development and progression of D-GalN/LPS-induced ALF,and mainly focused on the expression of TNF-α,the pathways of induction hepatocellular apoptosis and drug intervention,which provided a new target and direction in preventing ALF.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHENG Xia, FAN Qilin, XU Lulu, ZHANG Miao and ZHANG Yubin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Xia, FAN Qilin, XU Lulu, ZHANG Miao and ZHANG Yubin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707011&flag=1]]></guid><cfi:id>535</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application progress of traditional Chinese medicine and Chinese medicine preparations in the treatment of poisoning diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Poisoning diseases are a kind of special diseases of threatening human health.Due to the rapid development of society,the deterioration of living environment,toxic substances which human exposure are increasing, the incidence rate of poisoning increases multiply daily,sopoisoning diseases had become the common topic study of emergency medicine,critical care medicine,occupation disease,toxicology,environmental medicine.In recent years,with the rapid development of emergency medicine and critical care medicine,treatment of poisoning diseases had been greatly improved,and traditional Chinese medicine and Chinese medicine preparations played an important role in the treatment of poisoning diseases.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Zhongkai, XU Xiaoyan and SONG Zhenmin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Zhongkai, XU Xiaoyan and SONG Zhenmin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707012&flag=1]]></guid><cfi:id>534</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanism of radiodermatitis and current situation of prevention and treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Radiodermatitis is a common complication of tumor radiotherapy leading to interruption or termination of radiotherapy.In recent years,there have been many new research progress for the prevention and treatment of radiodermatitis.This paper reviewed the mechanism of radiodermatitis and declared the current situation of its prevention and treatment.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QI Lulu<sup>1</sup>, WU Liang<sup>1</sup> and ZHANG Luyong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QI Lulu<sup>1</sup>, WU Liang<sup>1</sup> and ZHANG Luyong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707013&flag=1]]></guid><cfi:id>533</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the research and development of HIF-1 inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hypoxia-inducible factor (HIF) is an essential transcription factor, which mediates a hypoxic response at decreased oxygen tensions.HIF plays vital roles in tumor development and progression and meditates tumor resistance to chemotherapy and radiotherapy and is associated with poor prognosis in cancer patients.Therefore, research and development of HIF inhibitors has the potential to improve treatment efficacy.In this article, three ways of targeting HIF-1 were summarized so as to lay the foundation for the therapeutic use of HIF inhibitors.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DING Kaiqiang, TIAN Wei, ZHOU Dewang, FENG Shuang and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Kaiqiang, TIAN Wei, ZHOU Dewang, FENG Shuang and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706010&flag=1]]></guid><cfi:id>532</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in the mechanism of action of small molecular compounds on PKM2]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pyruvate kinase M2 (PKM2) may play an important role in regulating the glucolysis,proliferation and signal transduction of tumor cells.The constantly deepened researches in this field will endow the development of the new targets of anticancer drugs with bright prospect for the therapy of clinical.By the method of literature summary,the present paper,discusses the mechanism that the small molecule compounds modulate the expression regulation,inhibition and excitation of PKM2 and puts forward to be an important research direction in the anti-tumor drug screening.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Huailong<sup>1,2</sup>, YU Jiaying<sup>1,2</sup> and ZHANG Jinghong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Huailong<sup>1,2</sup>, YU Jiaying<sup>1,2</sup> and ZHANG Jinghong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706011&flag=1]]></guid><cfi:id>531</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on tumor thermo-chemotherapy based on nano-hyperthermia agents]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As hyperthermia can enhance cytotoxicity of chemotherapeutic drug significantly, the thermo-chemotherapy,combining hyperthermia and chemotherapy,could achieve desired curative effect at lower drug dose. However, the efficiency of thermo-chemotherapy is determined completely by targeting hyperthermia in tumor tissue, which is limited by traditional whole-body heating.To overcome the shortage of traditional whole-body hyperthermia, some nano hyperthermia agents, converting infrared light or magnetic energy into thermal energy efficiently, have become promising candidates on targeting hyperthermia of tumor.Especially nano hyperthermia agents can be encapsulated with chemotherapeutic drugs simultaneously to form co-delivery,which could improve the synergetic efficiency of hyperthermia and chemotherapy. Therefore, thermo-chemotherapy based on nano-hyperthermia agents has been certificated as a promising cancer treatment.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GUO Hui and XU Yue]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Hui and XU Yue</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706012&flag=1]]></guid><cfi:id>530</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The progress of modern research and authenticity of  <i>Medulla Tetrapanacis</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With <i>Chinese Pharmacopoeia</i> 2015 edition as the basis,combined with the experience of the test and reference to the relevant literature data,different characters,microscopic identification of <i>Medulla Tetrapanacis</i> and its adulterants were analyzed,the differential points are elaborated,and summarized the modern research situation of  <i>Medulla Tetrapanacis</i>,to provide technical support for future work.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Guoping and WANG Wenbing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Guoping and WANG Wenbing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706014&flag=1]]></guid><cfi:id>529</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on endoplasmic reticulum stress and inflammatory response]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A variety of cellular stresses can severely perturb endoplasmic reticulum function,which cause pathological protein misfolding and aggregation within the ER.The unfolded protein response is a three-pronged signaling axis dedicated to preserving ER homeostasis.The paper reviewed the latest research progress on the complex interplay of ER stress,inflammation,and organismal homeostasis. Inflammation is both a cause and consequence of ER stress,and identifying additional signaling convergence points would guide the development of powerful therapeutics for inflammatory diseases and other UPR-mediated disorders with inflammatory components.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Jingqi and GONG Guoqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jingqi and GONG Guoqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705009&flag=1]]></guid><cfi:id>528</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of peripheral 5- hydroxytryptamine in atherosclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Atherosclerosis (AS) is the pathological basis of a variety of cardiovascular diseases,studies have found that peripheral serotonin (5-HT) and AS are closely related.This review summarizes the role of peripheral 5-HT in the development of AS,including the promotion of macrophage-derived foam cell formation,vascular smooth muscle cell proliferation and migration,vasoconstriction,platelet aggregation and thrombosis.At the same time,this review summarized the application of sarpogrelate hydrochloride in AS treatment to provide new ideas for AS research.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHENG Ru and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Ru and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705010&flag=1]]></guid><cfi:id>527</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Strategies for treatment of Alzheimer's disease from the perspective of nano-drug delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer's disease is a serious threat to human health,mainly blood brain barrier limits the drug to reach the target and affects the treatment of Alzheimer's disease.The nano-drug delivery system for brain-targeted drug delivery offers the potential treatment and improvement for Alzheimer's disease.This article started from the pathogenesis and conventional therapeutic drugs of Alzheimer's disease,focusing from nano-drug delivery systemperspective to introduce the treatment strategies of Alzheimer's disease and summarized several typical treatment strategiesof Alzheimer's disease nano-drug delivery systems,namely,liposomes,polymer micelles,solid lipid nanoparticles and polymer nanoparticles.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Li, LIANG Shuang, LYU Jiangwei, XUE Bing and ZHANG Wenjun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Li, LIANG Shuang, LYU Jiangwei, XUE Bing and ZHANG Wenjun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705011&flag=1]]></guid><cfi:id>526</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effect of pyroptotic in gouty arthritis regulated by NLRP3 and TLR4]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pyroptotic is a strongly pro-inflammatory process of programmed cell death mediated by caspase-1.Pyroptotic,regulated by NLRP3 inflammasome and TLR4 signaling pathways together,plays an important role in the process of gout arthritis disease.This paper systematically reviewed about pyroptotic mechanism system in gouty arthritis,provided direction for the research on new drugs.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LU Guo, ZHENG Dongsen, LI Hanwen and HONG Hao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Guo, ZHENG Dongsen, LI Hanwen and HONG Hao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705012&flag=1]]></guid><cfi:id>525</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Development of study and drug treatment for herpes zoster]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Herpes zoster is an acute infectious herpes caused by varicella-zoster virus,who has the characteristic of unilateral and distributed according to nerve segment,it consists of a cluster of herpes and with neuralgia.This article summarizes the domestic and foreign related clinical literature reports from three aspects:pathogenesis,pathologic diagnosis and treatment measures,which is to provide the basis for clinical treatment.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Bin, LI Yan, BIAN Ruimin, WANG Chunwei, GAO Hang and FU Xiaoshan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Bin, LI Yan, BIAN Ruimin, WANG Chunwei, GAO Hang and FU Xiaoshan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705013&flag=1]]></guid><cfi:id>524</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of peripheral 5-hydroxytryptamine system and glucolipid metabolic balance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The peripheral 5-hydroxytryptamine（5-HT） system has a very close relationship with body glucolipid metabolic balance.In this article,four glucolipid metabolic sensitive tissues and organs of pancreas islet,liver,adipose tissue and skeletal muscle were respectively selected to review the research progress on the regulation of peripheral glucolipid metabolic by 5-HT.]]></description>
<pubDate>2017/5/2 14:32:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HOU Shanshan and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HOU Shanshan and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704009&flag=1]]></guid><cfi:id>523</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of biodegradable inorganic mesoporous nanomaterials]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In the past few years,inorganic mesoporous nanomaterials achieved great attentions by the researchers in many fields such as chemistry,material,physical and pharmacy,due to their favorable properties including large specific surface area,ordered and controllable mesopores and large specific pore volumes.Nevertheless,inferior degradable and excretive ability of inorganic mesoporous nanomaterials remains the major retard,when take future bio-clinical theranostic applications into consideration.In this review,several hot issues of inorganic mesoporous nanomaterials with their biodegradable reformatory strategies were introduced and discussed.]]></description>
<pubDate>2017/5/2 14:32:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Chengyi and HUANG Rongqin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Chengyi and HUANG Rongqin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704010&flag=1]]></guid><cfi:id>522</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Nanomaterial-induced autophagy: underlying mechanisms and functional consequences]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Autophagy,a complex catabolic pathway,is bulk degradation of cytoplasmic components through the lysosome,which provides a highly dynamic quality control mechanism to maintain cellular homeostasis,and is also a protective mechanism in response to stress.A growing body of research suggests that autophagy is also activated upon internalization of engineered nanomaterials,most likely as a protective response to what is perceived as foreign or toxic.While activation of autophagy by nanomaterials can lead to enhanced clearance,it may also be associated with activation of cell death programs.This review described the mechanisms of autophagy activation in response to naturally occurring and engineered nanomaterials and provide a comprehensive analysis of the impact of nanomaterials on the lysosome-autophagy system and their functional consequences.]]></description>
<pubDate>2017/5/2 14:32:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Fufan, CHEN Huan and ZHANG Yubin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Fufan, CHEN Huan and ZHANG Yubin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704011&flag=1]]></guid><cfi:id>521</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of pharmacokinetics study on 6-gingerol,an active component in <i>Ginger</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ginger,the root of <i>Zingiber officinale</i> Rosc.,mainly contains volatile oil, gingerols and diarylheptanoids. 6-gingerol is the main component of gingerols as well as the significant active component in Ginger. On the basis of literature study, this paper reviewed the progress of pharmacokinetics of 6-gingerol in the aspects of absorption,distribution,metabolism and excretion which aims to provide more key foundational data for clinical application.]]></description>
<pubDate>2017/5/2 14:32:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GENG Tong<sup>1,2</sup>, WU Xiaolei<sup>1,2</sup> and WANG Zhiwei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GENG Tong<sup>1,2</sup>, WU Xiaolei<sup>1,2</sup> and WANG Zhiwei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704012&flag=1]]></guid><cfi:id>520</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of IKK/NF-κB pathway in liver fibrosis and correlated drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hepatic fibrosis is the most common pathological feature in patients with chronic liver disease.Chronic liver injury can lead to inflammation and wound healing response.IKK/NF-κB is a critical signaling pathway in inflammation,so it affects the occurrence and development of liver fibrosis. It can become the target of prevention or treatment of liver fibrosis.The paper summarized the role of IKK/NF-κB pathway in liver fibrosis and studies of correlated drugs．]]></description>
<pubDate>2017/5/2 14:32:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Xiaoxia, LI Ji and YU Feng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xiaoxia, LI Ji and YU Feng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704013&flag=1]]></guid><cfi:id>519</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on thrombin binding of GPIb-Ⅸ-Ⅴ complex and related drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Thrombin,a key factor of the coagulation cascade,plays an important role on hemostasis and coagulation.Thrombin binding to platelet membrane receptor GPIb-Ⅸ-Ⅴ can mediate platelet activation and promote thrombosis.By reviewing the relevant literatures,we introduce the structure  of thrombin and GPIb-Ⅸ-Ⅴ complex and the mechanisms of its interaction.Moreover,this paper reviewed the latest study progress of novel anti-thrombotic agents targeting on thrombin or GPIb-Ⅸ-Ⅴ to provide new ideas for thrombus therapy.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CUI Shuang and GONG Guoqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Shuang and GONG Guoqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703009&flag=1]]></guid><cfi:id>518</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent research status of pharmacological action of resveratrol and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Resveratrol is a non-flavonoid polyphenol compounds that is found in many kinds of plants.It has many important functions,such as anti-tumor,anti-oxidation,regulation of blood lipids and so on,which are beneficial to human health.The paper reviewed on the research status of pharmacological action of resveratrol and its derivatives in recent years.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Jiajun, HAN Jinliang and TIAN Yushun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Jiajun, HAN Jinliang and TIAN Yushun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703010&flag=1]]></guid><cfi:id>517</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research overview of pharmacology and application development of <i>Siraitia grosvenorii</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Siraitia grosvenorii</i> is a traditional Chinese medicine.It is used more than 300 years in Guangxi folk.Modern research shows that <i>Siraitia grosvenorii</i> has a variety of pharmacological effects which is cough expectorant,antibacterial,anti-oxidation,and so on.This article reviewed the pharmacological research and product development in recent years.It provided references for further research and development of <i>Siraitia grosvenorii</i>.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Qinglian, HUANG Juan, WU Zhihui and PI Fengjuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Qinglian, HUANG Juan, WU Zhihui and PI Fengjuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703011&flag=1]]></guid><cfi:id>516</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on active constituents and pharmacological effects of <i>Salvia miltiorrhiza</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Salvia miltiorrhiza</i>,a traditional Chinese medicine,has obvious therapeutic effects on a variety of diseases.Modern medical researches have found that <i>Salvia miltiorrhiza</i> has various of effective active components,such as tanshinone,cryptotanshinone,rosmarinic acid,danshensu,salvianolic acid.It was reported that Salvia miltiorrhiza has a lot of new pharmacological effects besides the function of stimulating blood circulation for remove blood stasis,such as effect on the treatment of cardiovascular disease,liver disease,vasculitis and neurasthenia and other diseases.In this paper,we summarized the research progress on the relationship between the effective components of <i>Salvia miltiorrhiza</i> and its pharmacological activities,in order to offer certain reference to the research of <i>Salvia miltiorrhiza</i>.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIANG Xue and SHI Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Xue and SHI Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703012&flag=1]]></guid><cfi:id>515</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of CYP27A1 in tumor progression]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[CYP27A1 is a member of the cytochrome P450,and is commonly known as sterol 27-hydroxylase.This enzyme is located in many different tissues where it is found within the mitochondria.It is most prominently involved in the biosynthesis of bile acidsin both the classic and acidic pathways,thus maintaining the balance of bile acids. The other well-known function is activating vitamin D<sub>3</sub> catalytically.CYP27A1 is closely related to the formation of a variety of tumors,such as breast cancer,prostate cancer,colorectal cancer and liver cancer,etc.This article summarized the main role of CYP27A1 in the first three tumors so as to lay the foundation for the research of mechanism of tumorigenesis.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BAO Xueyang, WANG Duowei, YANG Hongbao and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BAO Xueyang, WANG Duowei, YANG Hongbao and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703013&flag=1]]></guid><cfi:id>514</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in the effect of drug metabolism on the transporters and nuclear receptors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Transporters are the proteins of transfer function in all organs of human and play important roles in drug absorption,distribution,metabolism and excretion. Nuclear receptors are intracellular ligand-activated transcription factors, activate the ligands affect metabolic enzymes and transporter expression and activity, which affects drug metabolism in the body.The article reviewed the research progress of a few important members of the transporters and nuclear receptors and the effect of drug metabolism.]]></description>
<pubDate>2017/3/28 14:39:38</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Xuejiao<sup>1</sup>, DUAN Yabin<sup>2</sup>, ZHANG Juanling<sup>1</sup> and LI Xiangyang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Xuejiao<sup>1</sup>, DUAN Yabin<sup>2</sup>, ZHANG Juanling<sup>1</sup> and LI Xiangyang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702009&flag=1]]></guid><cfi:id>513</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of targeted therapy for chronic myeloid leukemia with Bcr-Abl<sup>T315I</sup> mutation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chronic Myeloid Leukemia (CML) is a self-renewing hematopoietic stem cell malignancy.The advent of the first-generation tyrosine kinase inhibitor—Imatinib has brought the gospel to the CML patients.However,resistance to Imatinib remains a major challenge,especially the Bcr-Abl<sup>T315I</sup> mutations that with the highest resistance.Fortunately,there are many of therapies targeting T315I mutations having been reported,including the currently marketed Ponatinib.This review focused on the research progress of targeted therapies of T315I mutation in recent years.]]></description>
<pubDate>2017/3/28 14:39:38</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHENG Yan<sup>1</sup>, LI Jiaying<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Yan<sup>1</sup>, LI Jiaying<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702010&flag=1]]></guid><cfi:id>512</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on molecular mechanism of fever]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fever is a systemic reaction triggered by infective or noninfectious conditions,which causes an increase in body temperature by raising the body temperature setting point.Although fever as a defense mechanism of the conclusion is full of controversy,it is certain that fever is the main clinical symptoms of disease,infection,inflammation,poisoning and other diseases,and fever is one of the earliest alarm signal.Therefore,it has an critical significance for the development of antipyretics with broad prospects to know the basic mechanism of fever at the molecular level.]]></description>
<pubDate>2017/3/28 14:39:38</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SONG Yangyang, REN Yi, JI Hui and GONG Xiaojian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Yangyang, REN Yi, JI Hui and GONG Xiaojian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702011&flag=1]]></guid><cfi:id>511</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on formulations of curcumin by oral administration]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Curcumin has many bioactivities, its application in clinic has been limited due to poor water solubility,biotransformation in the process of absorption in the intestinal tract and low oral bioavailability.It has been a study hot to enhance the oral absorption of curcuminwith modern preparation technology.This review introduced the progress in the oral formulation of curcumin based on the recently reported literature.]]></description>
<pubDate>2017/3/28 14:39:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIANG Minghua<sup>1</sup> and ZHAI Guangxi<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIANG Minghua<sup>1</sup> and ZHAI Guangxi<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702012&flag=1]]></guid><cfi:id>510</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Coating technology and its application in oral solid controlled-release preparations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This review explored the coating materials and coating methods that commonly used in oral solid controlled release formulations according to domestic and foreign literatures.Reasonable choice of coating materials and coating methods can effectively improve the stability of controlled release formulations,which can enhance the therapeutic effect of the drugs.]]></description>
<pubDate>2017/3/28 14:39:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Li, LIU Huashi, ZHANG Wenjun and LIANG Shuang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Li, LIU Huashi, ZHANG Wenjun and LIANG Shuang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702013&flag=1]]></guid><cfi:id>509</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress  of FcγRs on the develepment and treatment of immune disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Leukocyte immunoglobulin G receptors (FcγR) belong to the immunoglobulin superfamily,have potent effector functions to the specificity of IgG,and serve as a link between the humoral and cellular immunity.The specific region of IgG binding to FcγRwill induce a series of cell specific immunoreaction. Furthermore,FcγR polymorphisms influence the efficacy of cellular responses,and have been associated withimmunity relateddiseases and diseases severity.Studies also suggest that FcγRs influence effectiveness of immunotherapy (monoclonal antibody and intravenous immunoglobulins).Similarly,FcγRs play a role in the microbial infections.This review will summarize the relationship of FcγRsand immunological diseases,and discuss its potential clinical relevance.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Xiaomeng<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Xiaomeng<sup>1</sup>, YANG Yong<sup>2</sup> and CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701010&flag=1]]></guid><cfi:id>508</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and recent application of molecularly imprinted monoliths for HPLC]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Combining with the molecularly imprinted polymers (MIP) and monolithic columns,imprinted monoliths have several advantages,such as high selectivity,low cost,good physical and chemical stability,high versatility and improved mass-transfer kinetics.Recently imprinted monoliths are regarded to be one of the promising approaches to prepare the high performance material as the chromatography stationary phase in analytical chemistry.In this paper, we mainly reviewed various new synthetic technologies and strategies for imprinted monoliths and displayed the latest applications of imprinted monoliths in separation or determination of drugs.Some thoughts on perspectives of imprinted monoliths are also expressed.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WEI Zehui<sup>1</sup>, MU Lina<sup>2</sup>, CHEN Yuxin<sup>3</sup> and LI Feifei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Zehui<sup>1</sup>, MU Lina<sup>2</sup>, CHEN Yuxin<sup>3</sup> and LI Feifei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701011&flag=1]]></guid><cfi:id>507</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The relationship between Vascular activities of prostaglandins and cardiovascular diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Prostaglandins are endogenous compounds with wide biological activities.Most tissues and cells of mammal can synthesize PGs.In normal physiological condition,endothelial cells release various substances to control the balance of vascular tone including endothelium-derived relaxing factor (EDRF) and endothelium-derived contracting factors (EDCF),such as PGI<sub>2</sub> and TXA<sub>2</sub>.Accumulating evidence indicates that PGs not only can affect the vascular system but also implicated in cardiovascular diseases with the changing PGs.This review summarized PGs and their effect on vascular activities,and briefly summarized the change of the concentration of PGs in cardiovascular diseases.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DAI Yuanyuan, CHEN Xuezhuo, CUI Yajiao and DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DAI Yuanyuan, CHEN Xuezhuo, CUI Yajiao and DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701012&flag=1]]></guid><cfi:id>506</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The research situation of sustained-release formulation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sustained-release formulation (SRP) as a forefront type of pharmaceutical preparations has been widely studied and applied.SRP has an important role in applications because of their sustained drug release,long-lasting efficacy and less side effects.SRP shows great efficacies in prolonging the drug retention time,decreasing the frequency of medication and enhancing patients compliance.At present,the sustained-release preparations were used to improve traditional medicine dosage forms and develop new drugs.After a review of the related literatures,this essay summarized the research and application progress of sustained-release preparations.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Ping and QUAN Jishan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Ping and QUAN Jishan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701013&flag=1]]></guid><cfi:id>505</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Synthesis and application of 4-(tri-fluoromothexy) benzenamine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper introduced the physical and chemical properties of fluorinated intermediates,reaction mechanism,the latest application and development trend of scientific research.4-trifluoro methoxy aniline as a representative of fluorinated intermediates compound synthesis process route of research and the actual research and development application,and introduced a new synthesis methods on developing trifluoro methoxy aniline synthesis of ideas,so that more concise and easy to understand fluoride compounds and its downstream products,4-trifluoro methoxy aniline for scholars made a detailed summary and induction,also for the optimization of the process and new technology research of grope for the way.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Hailong, LIU Jingjing and LIU Guo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Hailong, LIU Jingjing and LIU Guo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701014&flag=1]]></guid><cfi:id>504</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of drug-loaded nanoparticles in dry powder inhalations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The causes of the lack of commercial application of nanoparticles in dry powder inhalations was analyzed,and compared the advantages of conventional DPIs;The formation mechanism and preparation method of the two kinds of dry powder inhaler which are nanoparticles carrier complex and large diameter hollow nanoparticles aggregates were introduced.Due to the inhalation with dispersion performance and excellent performance of the dry lung deposition of nanoparticles,and also has the unique properties of nanoparticles as drug carrier,which has a strong advantage and wide development space in dry powder inhalations.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QU Jing<sup>1</sup>, ZHANG Tong<sup>1</sup> and YANG Xiaobo<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QU Jing<sup>1</sup>, ZHANG Tong<sup>1</sup> and YANG Xiaobo<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712010&flag=1]]></guid><cfi:id>503</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of stress on the immune microenvironment and the immunotherapy of tumor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Stress is a constellation of events,initiated by astressor that precipitates a reaction in thebrain which,inturn,activatesphysiologic systems in the body.The physiologic stress response results in the releaseof neurotransmitters and hormones asthe brain’s messengers to the body.Many researches have proved that stress can affect immune system in manyways.Tumor immunity plays an important role in the therapy of tumor and tumor development and progression.This review focused on the researches how stress affects the immune microenvironments of tumor and its immunotherapy.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Dandan and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Dandan and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712011&flag=1]]></guid><cfi:id>502</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the relationship between osteopontin and calcium oxalate stones]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Urinary tract stones are common and multiple diseases of the urinary tract surgery, the rates of its incidence and recurrence after treatment have increased year by year and have centralization trends, which is in the first place in the urology department of hospitalized patients.More than 70 percent of the urinary calculi are calcium oxalate (CaOx) stones,which related to the thermodynamics (supersaturation) and kinetics (nucleation,growth and aggregation) properties of CaOx crystals.Osteopontin is a secretory phosphorylated glycoprotein,widely distributed in a variety of tissues and cells,it also closely related to the formation of CaOx stone.In this paper,the functional structure of OPN and its relationship with CaOx stone were briefly described, which provided theoretical guidance for more understanding of OPN anti-calculus mechanism.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QIN Shiting, YIN Xijing and YANG Ke]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIN Shiting, YIN Xijing and YANG Ke</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712012&flag=1]]></guid><cfi:id>501</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research of the relationship between NLRP3 inflammasome and metabolic syndrome]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As the research goes on,the link between inflammation and metabolic syndromeisbecoming increasingly evident.Chronic inflammationplays an important roleonthe onset and development of metabolic syndrome.Many inflammatory cytokines are involved in the development of metabolic diseases. Among them,interleukin (IL)-1β is known to contribute to the inflammatory response in various metabolic diseases.NLRP3 inflammasome is aprotein complex that activates interleukin-1β family cytokine.Many studies have implicated the activation of theNLRP3 inflammasome ina variety of diseasesincluding hypertension, atherosclerosis,obesity, and type 2diabetes.This review summarized these developments anddiscuss their implications for a better understanding of inflammation in metabolic syndrome.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIN Na, QU Jia, ZHOU Jifang and DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Na, QU Jia, ZHOU Jifang and DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712013&flag=1]]></guid><cfi:id>500</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on in vitro antibacterial activities of some kinds of damp dispersing herbs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This review summarized the in vitro antibacterial activity of damp dispersing herbs,including <i>Pogostemon cablin</i>(Blanco) Benth.,<i>Magnolia officinalis</i> Rehd. et Wils., <i>Atractylodes Lancea</i>(Thunb.) DC., <i>Amomum tsao-ko Crevost et Lemarie</i>, <i>Alpinia katsumadai Hayata</i>,<i>Amomum kravanh</i> Pierre ex Gagnep.,<i>Eupatorium fortunei Turcz</i>.and <i>Amomum villosumLour</i>.,etc.The mechanism and antibacterial composition for inhibiting pathogenic bacteria and pathogensweredescribed by recent literature, which could be used to facilitate further study of the damp dispersing herbs.]]></description>
<pubDate>2017/12/7 15:02:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Lan, PENG Cheng, YAN Peiao, LI Yunxia and ZHANG Ruoqi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Lan, PENG Cheng, YAN Peiao, LI Yunxia and ZHANG Ruoqi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711010&flag=1]]></guid><cfi:id>499</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on neuroprotective effects of honokiol]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Honokiol,a poly-phenolic compound,extracted from the Chinese medicinal herb <i>Magnolia grandiflora</i>,possesses multiple activities including anti-inflammatory,antimicrobial, anticancer and antioxidant.In recent years, it has been found that honokiol has obvious protective effect on the nervous system.Honokiol has been reported to cross the blood brain barrier, suggesting it can be a powerful therapeutic compound against a broad spectrum of neurological disorders. This review summarized the neuroprotective effects and mechanisms of honokiol to provide a reference for further research.]]></description>
<pubDate>2017/12/7 15:02:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHENG Anqi, LIU Wentao, ZHANG Yan and ZHANG Guangqin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHENG Anqi, LIU Wentao, ZHANG Yan and ZHANG Guangqin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711011&flag=1]]></guid><cfi:id>498</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application progress of hot melt extrusion technology in pharmaceutical preparations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper reviews the advantages and processes and equipment of hot melt extrusion technology as a novel pharmaceutical preparation technology, as well as many applications of hot melt extrusion technology in pharmaceutical preparations, and prospects for the application of the technology.]]></description>
<pubDate>2017/12/7 15:02:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Shuo, WANG Li, ZHANG Wenjun and LIANG Shuang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Shuo, WANG Li, ZHANG Wenjun and LIANG Shuang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711012&flag=1]]></guid><cfi:id>497</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the research and development of inflammatory mechanism in diabetic wound]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chronic wounds,a serious complication of diabetes,are refractory or even incurable.It not only reduces the quality of life of patients,but also aggravates the burden of the patients.In diabetes,wound healing is disturbed by a sustained amplified inflammatory response,in which the number and function of neutrophils are abnormal,the functions and phenotypes of macrophages are disordered,and the inflammatory complex is activated.In this article,the related inflammatory mechanisms of diabetic wound were reviewed so as to provide information for the drug development of diabetic wounds.]]></description>
<pubDate>2017/12/7 15:02:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIANG Pengjun, JI Hui, GU Ming, KANG Ruijuan and GONG Xiaojian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIANG Pengjun, JI Hui, GU Ming, KANG Ruijuan and GONG Xiaojian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711013&flag=1]]></guid><cfi:id>496</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of <i>Abrus mollis</i> Hance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Abrus mollis</i> Hance is used as Chinese folk herbal medicine for treatment of a variety of diseases.This paper reviewed the research on chemical composition,pharmacological activity and quality analysis of this natural resource,which provided reference for the development of its research.]]></description>
<pubDate>2017/12/7 15:02:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YAN Qianru and WU Weikui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Qianru and WU Weikui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711014&flag=1]]></guid><cfi:id>495</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in antitumoral strategies with combination drug therapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Combination drug therapy has gradually become the focus of cancer treatment in recent years. It can minimize the side effects of chemotherapeutics as well as increase its antitumor effects via playing synergistic antitumor effect of drug.In this review, relevant recent researches of combination drug therapy for cancer treatment were reviewed,including antibody-drug conjugate,multidrug resistance reversal agents joint antineoplastic,gene therapy joint antineoplastic and photodynamic therapy joint antineoplastic,so as to provide theoretical references for the design and application of combination drug therapy.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TANG Baoqiang, YU Yinglan, TU Jiasheng and SUN Chunmeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TANG Baoqiang, YU Yinglan, TU Jiasheng and SUN Chunmeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710010&flag=1]]></guid><cfi:id>494</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Denosumab is the first marketed product of anti-Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) monoclonal antibody for the treatment of osteoporosis and other bone diseases.The clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis was reviewed in this article.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Yijia, LUO Liping<sup>1</sup> and LIU Yanzhi<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yijia, LUO Liping<sup>1</sup> and LIU Yanzhi<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710011&flag=1]]></guid><cfi:id>493</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the methods of micronucleus assay]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Micronucleus (MN) assay as an examination for genetic toxicity evaluation has been widely used in drugs,cosmetics,health food and other fields.The assay could sensitively reflect the damage of genetic toxicity to the chromosome.With the development of detection technology and the application of new methods,the detection methods of micronucleus were more and more diverse.This review focused on the current technology of micronucleus detection, and provided references for the application of micronucleus detection technology.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QU Jiansong<sup>1</sup>, YUAN Jingqing<sup>2</sup>, ZHAO Yanxia<sup>1</sup>, FAN Zhiyun<sup>1</sup> and ZHU Qingfen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QU Jiansong<sup>1</sup>, YUAN Jingqing<sup>2</sup>, ZHAO Yanxia<sup>1</sup>, FAN Zhiyun<sup>1</sup> and ZHU Qingfen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710012&flag=1]]></guid><cfi:id>492</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of carbon electrodes in pharmaceutical analysis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Due to the wide potential window, low background current, high stability as well as low passivatable surface,carbon-material electrodes have been widely used in many fields such as electrocatalysis, electrosynthesis, and electrochemical analysis, especially in pharmaceutical analysis and determination. This paper summarized the type, preparation, characterization and application in pharmaceutical analysis of various carbon-material electrodes and their chemically modified electrodes. This paper also made a prospect of these electrodes.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIA Wenting, LYU Jiangwei, WANG Xin, ZHAO Youcheng, LU Qinyi and HUA Zhuomeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIA Wenting, LYU Jiangwei, WANG Xin, ZHAO Youcheng, LU Qinyi and HUA Zhuomeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710013&flag=1]]></guid><cfi:id>491</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Drug delivery systems of tumor necrosis factor-related apoptosis-inducing ligand in tumor therapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of tumor necrosis factor family, which specifically binds to death receptor 4 or death receptor 5 overexpressed on the cell membrane surface of tumor cells, thus inducing cell apoptosis while sparing normal cells.Therefore,it has become one of the promising protein drug in tumor therapy.However,TRAIL exihits poor stability and bioavailability in vivo,which strongly limits the clinical application. In order to potentiate beneficial properties of TRAIL,and avoid these disadvantages,drug carries were discovered,which emerging as a new strategy for TRAIL delivery.This review provided a brief overview of the recent advances in drug delivery of TRAIL.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Anwei, JU Caoyun and ZHANG Can]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Anwei, JU Caoyun and ZHANG Can</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809009&flag=1]]></guid><cfi:id>490</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmacokinetic research progress of six active ingredients from <i>Salvia miltiorrhiza</i> and <i>Panax notoginseng</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Salvia miltiorrhiza</i> and <i>Panax notoginseng</i> are Chinese medicinal materials with long history.Consulting the related literatures at domestic and abroad in recent years,the article summarized the chemical composition and pharmacokinetics including pharmacokinetic parameters and metabolic products of <i>Salvia miltiorrhiza</i> and <i>Panax notoginseng</i>,and provided reference for the further development of <i>Salvia miltiorrhiza</i> and <i>Panax notoginseng</i>.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIA Tainqian, LI Xinghuan, REN Li and SUN Jing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIA Tainqian, LI Xinghuan, REN Li and SUN Jing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809010&flag=1]]></guid><cfi:id>489</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on amphiphilic chitosan derivatives in drug delivery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chitosan (CS) is a natural alkaline polysaccharide with a rich source,exhibiting good biocompatibility and biodegradability,but poor solubility limits its application in the field of medicine.In order to overcome its shortcomings, amphiphilic chemical modification of CS is carried out;by selecting different hydrophilic and hydrophobic groups,amphiphilic chitosan derivatives (ACSs) were designed and synthesized.ACSs are easily self-assembled into amphiphilic chitosan nanocarriers (ACNs) in water,which are widely used in the delivery of multiple drugs to increase drug solubility,stability,reduce drug toxicity,as well as improve bioavailability.In this work,the synthesis methods of ACSs and their applications in drug delivery systems were reviewed.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Chunli, JU Caoyun and ZHANG Can]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Chunli, JU Caoyun and ZHANG Can</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809011&flag=1]]></guid><cfi:id>488</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of content uniformity in preparations of Chinese materia medica]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Content uniformity of traditional Chinese medicine（TCM） preparations is a weak link in the quality control of TCM. In recent years, new progress has been made in the research of TCM.In this paper,the content uniformity of the related components of Chinese medicinal preparation containing chemicals or not was reviewed,in order to improve the quality control level of TCM preparations.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YAN Qianru and WU Weikui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Qianru and WU Weikui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809012&flag=1]]></guid><cfi:id>487</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of controlled release formulations for pulmonary delivery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years,the targeted pulmonary delivery has received increasing attention,with the merit of direct drug deposition at the diseased site,lack of first pass metabolism and good compliance of patients.However,it is strictly challenged in many different ways such as the efficient clearance mechanisms,frequent dosing and clinical medication safety problem.This review covered these controlled release formulations for the clinical application of pulmonary delivery, based on lung clearance mechanisms.]]></description>
<pubDate>2018/8/27 10:55:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LU Yayuan<sup>1</sup>, ZHAO Di<sup>1</sup>, LI Ning<sup>1</sup>, LU Shan<sup>2</sup> and CHEN Xijing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Yayuan<sup>1</sup>, ZHAO Di<sup>1</sup>, LI Ning<sup>1</sup>, LU Shan<sup>2</sup> and CHEN Xijing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808010&flag=1]]></guid><cfi:id>486</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research profile of <i>Scutellaria baicalensis</i> Georgi for Alzheimer disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer’s disease(AD) is a neurodegenerative disease with cognitive dysfunction.The main pathological features of the disease are the SP, the NFT and the loss of neurons.The mechanism of the disease is complex,and there is no effective treatment.The main active ingredient of <i>Scutellaria baicalensis</i> Georgi is flavonoids,which has good effect on inflammation,oxidation,tumor and immune regulation,and it can be used as an anti-AD drug.Many study show that the active ingredient of <i>Scutellaria baicalensis</i> Georgi can resist AD related inflammation,oxidative stress,neurotoxicity and protect the neurons,thus improving the pathological condition of AD model,reversing their cognitive dysfunction,and providing new idea for the treatment of AD.In this paper,the mechanism of <i>Scutellaria baicalensis</i> Georgi ainst AD is discussed on the pathogenesis of AD.]]></description>
<pubDate>2018/8/27 10:55:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QIN Lixia<sup>1,2</sup>, WU Qian<sup>1,2</sup> and XU Shijun<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIN Lixia<sup>1,2</sup>, WU Qian<sup>1,2</sup> and XU Shijun<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808011&flag=1]]></guid><cfi:id>485</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on neuroprotective mechanisms of key proteins related to vascular cognitive impairment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Vascular cognitive impairment was mainly caused by cognitive impairment of cerebrovascular disease,the occurrence and development of which are closely related to the survival of neurons.A variety of classical signaling pathways and related proteins play an important role in the prevention and treatment of vascular cognitive disorders in promoting synaptogenesis and axonal growth,inhibiting apoptosis,repairing oxidative DNA damage and responding to oxidative stress,respectively.This article provides an overview of the neuroprotective mechanisms of key proteins in some signaling pathways and some other related proteins to vascular cognitive impairment.]]></description>
<pubDate>2018/8/27 10:55:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HU Ruiyun and CHEN Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Ruiyun and CHEN Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808012&flag=1]]></guid><cfi:id>484</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacological effect and clinical application of <i>Eucommia ulmoides</i> leaves]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Eucommia ulmoides</i> leaves is a dry leaf of <i>Eucommia ulmoides</i> and special edible and medicinal plant resource in China.<i>Eucommia ulmoides</i> leaves are rich in active components and pharmacological effects. It has antioxidant,blood pressure reduction,blood lipids reduction,blood sugar reduction, anti-osteoporosis,anti-fatigue,anti-bacterial and many other functions,currently used to treat hypertension, hyperlipidemia, hyperglycemia, tocolysis and osteoporosis.The paper introduced the recent progress pharmacological effects of <i>Eucommia ulmoides</i> leaves and its clinical application, to provide references for the further development of <i>Eucommia ulmoides</i> leaves.]]></description>
<pubDate>2018/8/27 10:55:11</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZENG Qiao<sup>1,2</sup> and WEI Chengbo<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZENG Qiao<sup>1,2</sup> and WEI Chengbo<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808013&flag=1]]></guid><cfi:id>483</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The mechanism of Notch signaling pathway in cerebral ischemia injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Notch receptors regulate cell proliferation,differentiation,synaptic plasticity and neurons ageing through binding to different ligands. Notch signaling pathway plays an important role in cell growth and development.The Notch signaling pathway can be activated by ischemic injury. The activated Notch signaling pathway plays an important role in the repair of post-ischemic damage by regulating the apoptosis of neurons, the inflammatory response of immune cells, angiogenesis and neurogenesis. This paper explored the mechanism of Notch signaling pathway in details in cerebral ischemic injury, which lays the foundation for the treatment of cerebral ischemic.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIA Nian, XU Dan, HOU Kai, CHEN Shijie and LI Yunman]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIA Nian, XU Dan, HOU Kai, CHEN Shijie and LI Yunman</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807010&flag=1]]></guid><cfi:id>482</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the anti-tumor activity of bergenin and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bergenin is a natural secondary metabolite extracted from the rhizomes,barks or leaves of various plants,which possesses various biological activities.In recent years,there have been many researches on the structural modification of it.This article mainly focused on its anti-tumor activity and the structural modification relating to this biological activity．]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Meng, NIU Youhong and WU Yanfen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Meng, NIU Youhong and WU Yanfen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807011&flag=1]]></guid><cfi:id>481</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the preparation method of oral film]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a novel and convenient oral administration method,oral film possessed many advantages compared with the traditional formulation,which has attracted more and more attention from researchersand pharmaceutical companies.In this paper,we mainly focused on the development of the preparation technology of oral film,including solvent casting,hot-melt extrusion,electrospinning and 3D printing.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Hui, HE Dongsheng, LI Yanan and TU Jiasheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Hui, HE Dongsheng, LI Yanan and TU Jiasheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807012&flag=1]]></guid><cfi:id>480</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of polyethylene glycol modified small lipids in micellar drug delievery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Lipids had been widely applied to the research about drug delivery carriers on account of its no toxicity,no immunogenicity and good biocompatibility.Polyethylene glycol (PEG) modified lipids can self-assemble into micelles in water due to its amphiphilicity.And these polymers have the characteristics of increasing aqueous solubility and stability of hydrophobic compounds, improving the pharmacokinetic behavior and therapeutic effect. PEGylated lipids will be promising carriers in nano-drug delivery systems. In this paper, the applications of PEGylated small lipids in micellar delivery systems were summarized, including PEGylated phospholipids, cholesterol and fatty acids.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LU Xiaoyu<sup>1</sup>, FANG Min<sup>1</sup>, LI Ning<sup>2</sup>, LU Shan<sup>3</sup> and CHEN Xijing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Xiaoyu<sup>1</sup>, FANG Min<sup>1</sup>, LI Ning<sup>2</sup>, LU Shan<sup>3</sup> and CHEN Xijing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807013&flag=1]]></guid><cfi:id>479</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of in-situ gel for ocular drug delivery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In-situ ophthalmic gel shows unique features and advantages，and it can effectively enhance bioavailability of the drug.In this paper,the classification and characteristics of in-situ ophthalmic gel were introduced in detail,and relevant literatures at home and abroad in recent years were summarized in recent years.As a new type of preparation,the in-situ ophthalmic gel has a wide application prospect.There would be more and more attention and research in the area of eye administration.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Tong<sup>1</sup>, XU Weina<sup>2,3</sup> and LI Qiuhua<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Tong<sup>1</sup>, XU Weina<sup>2,3</sup> and LI Qiuhua<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807014&flag=1]]></guid><cfi:id>478</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advance on <i>Corydalis saxicola</i> Bunting]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Corydalis saxicola</i> Bunting as a traditional Chinese medicine has extensive pharmacological effects such as hepatoprotective,anti-oxidant,antibacterial,anti-inflammatory and even anti-tumor activities.It is clinically used to treat acute chronic hepatitis,viral hepatitis,hyperbilirubinemia,hepatoma and adjuvant therapy for other cancers.The active components of <i>Corydalis saxicola</i> Bunting are the total alkaloid,which are complex and diverse.In this paper,the chemical composition analysis,pharmacological action,clinical application and pharmacokinetics of <i>Corydalis saxicola</i> Bunting were reviewed,hoping to provide references for its development and further research.]]></description>
<pubDate>2018/7/6 16:37:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Jiaojiao, QIU Zhixia, LIU Qiuyan and HUANG Fang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Jiaojiao, QIU Zhixia, LIU Qiuyan and HUANG Fang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806010&flag=1]]></guid><cfi:id>477</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances on human physiology and pharmacokinetic of hypoxia in plateau]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To briefly review the research progress of human physiology and pharmacokinetics of high altitude hypoxia in recent years,and to provide reasonable guidance for clinical rational drug use,avoiding adverse reactions and individualized drug use.<b>Methods</b>  41 literatures at home and abroad were reviewed. From the aspects of human physiology and pharmacokinetics, the effects of hypoxic environment on the body were summarized.<b>Results and Conclusion</b>  Plateau has the characteristics of low oxygen, low pressure, high cold, strong radiation, large temperature difference between day and night, among which the hypoxia caused by hypoxia causes severe physiological pressure on the human body. Plateau-induced hypobaric hypoxia can cause abnormal oxygen concentration in cells, affecting the body's drug metabolism and pharmacokinetic (PK) characteristics. The change in pharmacokinetic parameters of most research drugs is mainly manifested by a significant decrease in CL, t<sub>1/2</sub>. The MRT was significantly prolonged and V<sub>d</sub> was decreased in the acute hypoxic group.]]></description>
<pubDate>2018/7/6 16:37:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[NIAN Yongqiong<sup>1</sup>, XIN Yuanyao<sup>1</sup>, ZHOU Xuejiao<sup>1</sup> and LI Xiangyang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIAN Yongqiong<sup>1</sup>, XIN Yuanyao<sup>1</sup>, ZHOU Xuejiao<sup>1</sup> and LI Xiangyang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806011&flag=1]]></guid><cfi:id>476</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of heat-clearing drugs in treating diabetic complications]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Diabetic patients often suffer from various complications of diabetes, including diabetic nephropathy, diabetic encephalopathy,diabetic heart disease and diabetic ophthalmopathy under the influence of persistent hyperglycemia.These complications have become the leading cause of death and disability in diabetic patients, Chinese medicine plays an important role in the treatment of diabetic complications.Chinese medicine theory that heat toxicity is one of the important factors in the occurrence of diabetic complications,mainly because of late diabetes, organs dysfunction, qi organs and organs purging dysfunction,causing stasis phlegm dampness, as time goes by heat toxicity. In response to this pathogenesis,Chinese medicine in the treatment of diabetic complications,the treatment of detoxification to take more,widely used in traditional Chinese medicine,so this article around the heat in recent years,the treatment of diabetic complications in the clinical application and basic research to do a review.]]></description>
<pubDate>2018/7/6 16:37:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YIN Rifeng<sup>1</sup>, WEI Yueyin<sup>1</sup>, XIE Xiaoqin<sup>1</sup>, XIA Xing<sup>2</sup> and LI Yuqing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YIN Rifeng<sup>1</sup>, WEI Yueyin<sup>1</sup>, XIE Xiaoqin<sup>1</sup>, XIA Xing<sup>2</sup> and LI Yuqing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806012&flag=1]]></guid><cfi:id>475</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on biological function of BRPF proteins and its inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bromodomain and PHD finger containing (BRPF) proteins function as epigenetic readers that specifically recognize acetylated lysine on histone tails to facilitate the transcription of target genes.This review summarized our understanding of how BRPF proteins recognize and bind for acetyl-lysine marks,the importance of acetylated histone recognition for their biological functions and the development of inhibitors of BRPF bromodomains.]]></description>
<pubDate>2018/7/6 16:37:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yong, JIAO Yu and TANG Weifang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yong, JIAO Yu and TANG Weifang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806013&flag=1]]></guid><cfi:id>474</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of mesoporous silicon materials for improving bioavailability of insoluble drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Mesoporous silica as a popular inorganic mesoporous carrier material recently is suitable for loading insoluble drugs at amorphous state due to its uniform pore, good thermal stability and biocompatibility.The reasons for low oral bioavailability of insoluble drugs were analyzed by reviewing the relevant literature at home and abroad,and the latest research progress of mesoporous silica carrier material for improving bioavailability of insoluble drugs were also concluded.This provided reference for design and preparation of mesoporous silica carrier materials with specific structure and characterization for improving bioavailability of insoluble drugs in clinical application.]]></description>
<pubDate>2018/7/6 16:37:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LYU Jiangwei, SHUN Han, WEI Yanqing, ZHANG Wenjun, REN Jungang and LYU Chunyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Jiangwei, SHUN Han, WEI Yanqing, ZHANG Wenjun, REN Jungang and LYU Chunyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806014&flag=1]]></guid><cfi:id>473</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of microRNAs regulating cardiac fibrosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cardiac fibrosis is a common pathological process in many clinical heart diseases such as heart failure, arrhythmia and diabetic cardiomyopathy. MicroRNAs (miRNAs) are a group of non-coding RNA composed of 16-22 nucleotides that regulate gene expression and play important roles in many biological processes.In recent years,a large number of studies have shown that miRNA plays an important role in the process of cardiac fibrosis.In this review,we mainly summarized the research progress of some microRNAs involved in the regulation of cardiac fibrosis.]]></description>
<pubDate>2018/6/13 9:41:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Yan, LIU Tingting, FENG Kai, XU Haonan and TANG Yiqun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Yan, LIU Tingting, FENG Kai, XU Haonan and TANG Yiqun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805009&flag=1]]></guid><cfi:id>472</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Classification and research progress on phenylethanoid glycosides]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[By reading a large number of relevant literature,research progress on phenylethanoid glycosides were summarized.Plant sources were integrated in year-by-year order and classified according to the number of glycosyl groups,the pharmacological activity was summarized according to the structure characteristics,which can provide scientific basis for effective development and utilization of plants of phenylethanoid glycosides.]]></description>
<pubDate>2018/6/13 9:41:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XUE Jing<sup>1,2</sup>, WANG Ying'ai<sup>1,2</sup>, JIA Xianhui<sup>2</sup>, DU Chenglin<sup>2</sup> and TANG Wenzhao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XUE Jing<sup>1,2</sup>, WANG Ying'ai<sup>1,2</sup>, JIA Xianhui<sup>2</sup>, DU Chenglin<sup>2</sup> and TANG Wenzhao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805010&flag=1]]></guid><cfi:id>471</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Regulation of Akt in cardiovascular diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The mammalian serine/threonine Akt kinases (protein kinase B or PKB) comprises three closely related isoforms Akt1,Akt2 and Akt3 (or PKBα/β/γ respectively).Akt/PKB is a key master regulator of a wide range of physiological functions including proliferation,survival,growth,and migration and invasion.Akt activation has been implicated in both normal and disease processes,including in development and metabolism,as well as cancer and cardiovascular disease.Akt promotes cell survival via Bcl-2 and Bcl-x activities.Inhibition of Foxo3 and GSK3β by Akt also increases cell survival.Akt stimulates cell proliferation and migration through NO and MMPs.Akt also increases VEGF secretion and mediates eNOS phosphorylation.Therefore,Akt may play an important role in many cardiovascular pathological processes.This review summarised recent studies of Akt in cardiac hypertrophy,atherosclerosis,vascular remodelling and aneurysm formation,in order to provide a comprehensive overview of Akt function in vascular disease.]]></description>
<pubDate>2018/6/13 9:41:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Fan, YE Junmei and ZHANG Yubin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Fan, YE Junmei and ZHANG Yubin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805011&flag=1]]></guid><cfi:id>470</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Relationship between quality of <b>Lonicera japonica</b> Thunb.and influencing factors of origin]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Origin is an important part of the quality formation of <i>Lonicera japonica</i> Thunb.It has obvious effect on the content of chlorogenic acid and luteolin.In order to provide some references for controlling the quality of <i>Lonicera japonica</i> Thunb. and improving the clinical efficacy,this paper summarizes the influences of the factors such as regionalism,germplasm resources,field management,harvesting and processing on the quality of <i>Lonicera japonica</i> Thunb.]]></description>
<pubDate>2018/6/13 9:41:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Mingling and WANG Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Mingling and WANG Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805012&flag=1]]></guid><cfi:id>469</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role of estrogen receptors in central nervous system diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Estrogen receptors, including nuclear receptors and membrane receptors, exert transcriptional regulatory functions through genomic and non-genomic effects, respectively. Estrogen receptors are expressed in the hypothalamus, hippocampus, amygdala and cortex of the brain and play a role in synaptic plasticity, learning and memory, cognition and neuroprotection. This review summarized the structure, classification, and roles of estrogen receptors in a variety of central nervous system diseases, including Alzheimer's disease, Parkinson’s disease, schizophrenia, and cerebral ischemia.]]></description>
<pubDate>2018/5/23 17:07:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Xuejiao, JI Hui, TANG Susu and OU Yu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xuejiao, JI Hui, TANG Susu and OU Yu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804010&flag=1]]></guid><cfi:id>468</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in molecular mechanism of PI3K/AKT/mTOR pathway in inflammation related diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Inflammation is a response that an organism use it to resolve infection,tissue injury or other cellular stress,and to restore tissue function through repair mechanisms.Multiple signaling pathways are activated during the onset of inflammation,including the NF-kappa B pathway,the JAK/STAT pathway,the MAPK pathway,and the PI3K/Akt/mTOR pathway.This review summarized the molecular mechanism of PI3K/Akt/mTOR pathway in inflammatory related diseases in recent years,and provided a theoretical basis for developing PI3K/Akt/mTOR targeted drugs.]]></description>
<pubDate>2018/5/23 17:07:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JI Yingying and GONG Guoqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JI Yingying and GONG Guoqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804011&flag=1]]></guid><cfi:id>467</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances in the chemical constituents and biological activities of <i>Athyrium multidentatum</i> (Doll.) Ching]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Athyrium multidentatum</i> (Doll.) Ching is a species in pteridophyte belonging to Athyriaceae.It has been used in folk medicine for anti-hypertension,clearing heat and removing toxicity and expelling parasite etc.In this paper,the progress on chemical compositions and pharmacological activities of <i>Athyrium multidentatum</i> (Doll.) Ching was reviewed to provide a reference for the exploitation of the medicinal resource.A total of 32 compositions including 9 polyphenols,7 flavonoids,3 steroides and other 6 compounds were identified.]]></description>
<pubDate>2018/5/23 17:07:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MU Jie, SHENG Jiwen, JING Liang, LIU Dongmei, YAN Han and WANG Jin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MU Jie, SHENG Jiwen, JING Liang, LIU Dongmei, YAN Han and WANG Jin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804012&flag=1]]></guid><cfi:id>466</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical constituents and pharmacological effects of stems of <i>Daphne genkwa</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The <i>Daphne genkwa</i> is usually used in traditional Chinese medicine. There have been a lot of reports on chemical ingredients and pharmacological activities of flower buds, roots, and leaves of <i>Daphne genkwa</i>, respectively. However, there were less relative researches its stems which exhibited good medicinal values.This article summarized literatures of stems of <i>Daphne genkwa</i>, systematically discussed its chemical components and pharmacological effects, and provided a reference for the research of stems of <i>Daphne genkwa</i>.]]></description>
<pubDate>2018/5/23 17:07:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Peilin, LIN Yongqiang and GUO Dongxiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Peilin, LIN Yongqiang and GUO Dongxiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804013&flag=1]]></guid><cfi:id>465</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of relationship between serotonin and insulin resistance-related diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the relationship between serotonin and insulin resistance -related diseases.<b>Methods</b>  Using PubMed, CNKI retrieval related literature and related books to summarize.<b>Results</b>  Serotonin is closely related to insulin resistance in liver, adipose tissue and skeletal muscle.<b>Conclusion</b>  Upstream and downstream of serotonin related synthetases and receptors are very likely to become therapeutic targets of insulin resistance-related diseases.]]></description>
<pubDate>2018/4/19 15:28:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Guangli and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Guangli and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803009&flag=1]]></guid><cfi:id>464</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent progress on correlation between fingerprints and pharmacodynamics of traditional Chinese medicines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The efficacy and safety of traditional Chinese medicine (TCM) are directly depend on its quality. According to the complex ingredients of TCM, it is very important to promote the development of traditional Chinese medicine by elucidating the therapeutic basis and establishing the quality standard to reflect the internal quality of traditional Chinese medicine. In this paper, we reviewed and summarized the recent researches of spectrum-effect relationship of traditional Chinese medicine, including the multidimensional fingerprint, pharmacodynamics and data processing technology in spectrum-effect relationship of traditional Chinese medicine.It could provide thoughts and advices for the further study of Spectrum-effect relationship of traditional Chinese medicine.]]></description>
<pubDate>2018/4/19 15:28:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DIAO Jiayin<sup>1</sup>, XU Can<sup>1</sup>, WANG Shumei<sup>1,2</sup> and CHEN Lei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DIAO Jiayin<sup>1</sup>, XU Can<sup>1</sup>, WANG Shumei<sup>1,2</sup> and CHEN Lei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803010&flag=1]]></guid><cfi:id>463</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Role of bile acid nuclear receptor FXR in cholestasis and related pharmacotherapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In physiological conditions, bile is dynamically balanced by the enterohepatic circulation in the humans, whereas bile synthesis dysfunction or bile flow disturbance can cause cholestasis.One of the important component of bile is bile acid and nuclear receptors such as Farnesoid X receptor (Farnesoid X receptor,FXR) can regulate the process of bile acid synthesis,transport and metabolism through the regulation of bile acid metabolic enzymes,synthetic enzymes and bile acid transporters.FXR is one of the targets on the treatment of cholestasis.In addition to the listed drugs such as Obeticholic acid,some traditional Chinese medicines with hepatic protection and choleretic effects could also regulate FXR.This review discussed the role of FXR in cholestasis and the progress on the therapeutic drugs of FXR as target for the treatment of cholestatic.]]></description>
<pubDate>2018/4/19 15:28:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XU Lijie<sup>1</sup>, JIANG Sida<sup>2</sup>, JI Hui<sup>1</sup>, LI Tingting<sup>1</sup> and HU Qinghua<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Lijie<sup>1</sup>, JIANG Sida<sup>2</sup>, JI Hui<sup>1</sup>, LI Tingting<sup>1</sup> and HU Qinghua<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803011&flag=1]]></guid><cfi:id>462</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of methods for protein content determination in recombinant protein drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[How to realize the accurate quantification of protein drugs has been an important topic in the quality control of biotechnological drugs. In this paper, the methods of protein content determination are systematically divided into three categories : standard quantitative method,colorimetric analysis method and ultraviolet absorption method, and each method is discussed seperately about how to achieve accurate quantification. In addition, a method for the determination of protein content in antibody-drug conjugates was proposed,which provided a reference for the accurate determination of protein content in this recombinant protein drug.]]></description>
<pubDate>2018/4/19 15:28:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QU Yaocheng and YAO Xuejing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QU Yaocheng and YAO Xuejing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803012&flag=1]]></guid><cfi:id>461</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Regulation mechanism of autophagy in vascular endothelial cells and its effects on cardiovascular diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Autophagy in endothelial cells plays important roles in several kinds of cardiovascular diseases such as hypertension,thrombosis,atherosclerosis and so on.These cardiovascular diseases can be depressed by modulating autophagy in vascular endothelial cells.This paper mainly reviewed signal pathways and factors involving in regulating autophagy in vascular endothelial cells and its effects on cardiovascular diseases. In order to provide new ideas for prevention and treatment of cardiovascular diseases.]]></description>
<pubDate>2018/3/26 15:43:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Qian and GONG Guoqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Qian and GONG Guoqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802010&flag=1]]></guid><cfi:id>460</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the comparative studies of the sonodynamic activities of sonosensitizers]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sonodynamic therapy is a promising approach to tumor therapy. The development of sonosensitizer is a key problem in SDT research. It is an important way to design and develop the sonosensitizer with good sonodynamic activity by comparative studing on their sonodynamic activities. In this paper, the comparative studing progress of various kinds of sonosensitizers were summarized. It was hoped to provide research ideas for the design and development of new sonosensitizers with good sonodynamic activity and suitable for clinical application.]]></description>
<pubDate>2018/3/26 15:43:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Lingling<sup>1</sup>, XU Mingling<sup>1</sup>, LIU Bin<sup>1</sup>, WANG Xiaofang<sup>1</sup>, HE Lingling<sup>2</sup> and WANG Xin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Lingling<sup>1</sup>, XU Mingling<sup>1</sup>, LIU Bin<sup>1</sup>, WANG Xiaofang<sup>1</sup>, HE Lingling<sup>2</sup> and WANG Xin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802011&flag=1]]></guid><cfi:id>459</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in pharmacotherapy for the advanced hepatocellular carcinoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hepatocellular carcinoma (HCC) is the sixth common primary tumor.and the third cause of cancer-related death worldwide.Despite the spread of HCC,its treatment is still a hard challenge, due to high rate of late diagnosis and to lack of therapeutic options for advanced disease. In fact radical surgery and liver transplantation, the most radical therapeutic approaches, are indicated only in case of early diagnosis.Systemic therapy is particularly important for patients with advanced HCC,including targeted agent therapy and chemotherapy,with sorafenib as the only standard treatment available.In this review,we discussed the current situation and progress of systemic therapies for the advanced HCC．]]></description>
<pubDate>2018/3/26 15:43:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CUI Tingting and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Tingting and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802012&flag=1]]></guid><cfi:id>458</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanism and clinical application of Donkey-hide Gelatin Mixture on hematological system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Donkey-hide Gelatin Mixture is the compound preparations of traditional Chinese medicine containing of gelatin,red ginseng,prepared radix rehmanniae,ecte,which has the effects of benefiting qi and nourishing blood.In this paper,we reviewed the mechanism and clinical application of Donkey-hide Gelatin Mixture on hematological system in the past 10 years,which provided the basis of the further study of Donkey-hide Gelatin Mixture.]]></description>
<pubDate>2018/3/26 15:43:50</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Min, LIU Li, ZHANG Shouyuan, KONG Xianguo, ZHOU Yan, SUN Yangen, ZHANG Lu and LI Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Min, LIU Li, ZHANG Shouyuan, KONG Xianguo, ZHOU Yan, SUN Yangen, ZHANG Lu and LI Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802013&flag=1]]></guid><cfi:id>457</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Detection of host cells residual DNA in biological drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, the bio-drugs have striking effects on kinds of diseases and a rising proportion in drug market. Then the bio-safety problem of bio-drugs is put on the agenda gradually. The host cell residual DNA is potentially dangerous due to the transmission possibility of tumor or virus-related genes, so most national drug regulatory authorities have strict control of it. At the same time, the national pharmacopoeia has also provided several kinds of classical methods for host cells residual DNA detection. The best method is real-time quantitative PCR currently, because of its specificity, high sensitivity, fast and high throughput. The article briefly introduced the limits of residual DNA detection issued by several national regulatory authorities, and then summarized and compared the existing common detection methods.]]></description>
<pubDate>2018/3/26 15:43:50</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIA Huiyan and YAO Xuejing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIA Huiyan and YAO Xuejing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802014&flag=1]]></guid><cfi:id>456</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in domestic listed Chinese patent medicine for cancer adjuvant treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[74 papers after 2010 were systematically reviewed and summarized through survey database. Experiment research and clinical application of domestic listed Chinese patent medicine in cancer adjuvant treatment field were summarized.It was helpful for developing new Chinese patent medicine for cancer adjuvant treatment.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Ye<sup>1,2</sup>, LI Zhou<sup>1</sup>, GAO Hao<sup>2</sup>, LI Wenjia<sup>1</sup> and QIAN Zhengming<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Ye<sup>1,2</sup>, LI Zhou<sup>1</sup>, GAO Hao<sup>2</sup>, LI Wenjia<sup>1</sup> and QIAN Zhengming<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801009&flag=1]]></guid><cfi:id>455</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in research methods of polysaccharide chromatography fingerprint]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The bioactivity of polysaccharide is related to its compositional monosaccharide,structure and molecular mass distribution.That’s why the fingerprint plays an important role in the quality control of polysaccharide.It is large molecular mass,complex structure and not being detected by UV that makes it hard to build the fingerprint.This review summarized the research methods of polysaccharide chromatography fingerprint,including compositional analysis and molecular mass distribution.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Beibei and LU Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Beibei and LU Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801010&flag=1]]></guid><cfi:id>454</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of nano drug delivery systems in volatile oil of traditional Chinese medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese medicine volatile oil are widely known for their biological properties and are extensively used in medicine for promoting health, as well as preventing and treating different diseases. However, their physicochemical characteristics, such as high volatility, low water solubility and stability, together with the side effects associated with their use have limited their application in medicine. Therefore, attempts have been made to preserve them through encapsulation in nano drug delivery systems such as nanoparticles,nanoemulsion,microemulsion, liposomes.This review presented recent systematic studies on their nano drug delivery systems,and summarized the characteristics and problems of each nano drug delivery systems,in order to provide some beneficial thoughts in further developing new products of traditional Chinese medicine volatile oils.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Bo<sup>1</sup>, ZHOU Yang<sup>1</sup>, WANG Fuling<sup>1</sup>, CHENG Bingchen<sup>2</sup>, JIANG Weixin<sup>1</sup>, ZHANG Yanhui<sup>1</sup> and ZHAO Wei<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Bo<sup>1</sup>, ZHOU Yang<sup>1</sup>, WANG Fuling<sup>1</sup>, CHENG Bingchen<sup>2</sup>, JIANG Weixin<sup>1</sup>, ZHANG Yanhui<sup>1</sup> and ZHAO Wei<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801011&flag=1]]></guid><cfi:id>453</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of origin and developmental differentiation of hepatic macrophage]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Macrophages exist in all tissues and show functional diversity. Macrophages are important components of cells in the liver and are essential for maintaining homeostasis or rapid response to liver damage.Studies have shown that the mature macrophages in tissue are derived from embryonic development.Macrophages contain heterogeneous subsets. Kupffer cell is a group of cells that have a self-sustaining function in the liver,distinct from monocyte-derived macrophages. Different environmental signals determine the differentiation direction and function of macrophages in liver. In this review, we focused on the origin,classification and differentiation of macrophages in the liver, and briefly introduce its functions.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BAI Yang and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BAI Yang and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801012&flag=1]]></guid><cfi:id>452</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of chitosan nanoparticles and its application in medical field]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chitosan has attracted much attention due to its excellent physical and chemical properties and biological activity, and nanomaterials have shown good prospects in biomedical field. In this paper, the preparation method of chitosan nanoparticles was introduced, and the application of chitosan nanoparticles in medicine was reviewed. Finally, the prospect of chitosan nanomaterials in biomedical application was put forward.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Gaorong<sup>1</sup>, OUYANG Qianqian<sup>1</sup>, LI Sidong<sup>1</sup>, HUANG Na<sup>1</sup>, CHEN Fajin<sup>1</sup>, LI Puwang<sup>2</sup> and LUO Rongqiong<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Gaorong<sup>1</sup>, OUYANG Qianqian<sup>1</sup>, LI Sidong<sup>1</sup>, HUANG Na<sup>1</sup>, CHEN Fajin<sup>1</sup>, LI Puwang<sup>2</sup> and LUO Rongqiong<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801013&flag=1]]></guid><cfi:id>451</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of myeloid-derived suppressor cells involved in tumor microenvironment immunosuppression]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The tumorigenesis, development and metastasis of tumors are closely related to their microenvironment.Tumor cells can modify their environment through autocrine and paracrine to maintain their survival and development.Tumor immunosuppression is an important feature of tumor microenvironment.More and more studies show that Myeloid-derived suppressor cells (MDSCs) play an important role in tumor microenvironment immunosuppression.This article reviewed the research progress of MDSCs involved in tumor microenvironment immunosuppression,so as to lay the foundation for further understanding and targeting tumor immunosuppression.]]></description>
<pubDate>2019/1/14 14:42:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LU Yuan, ZHAO Sen and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Yuan, ZHAO Sen and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812008&flag=1]]></guid><cfi:id>450</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Tanreqing Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese medicine injections have become more and more widely used,and have become a hot field in current drug research.Tanreqing Injection is one of the most widely used Chinese medicine injections in the respiratory system.Research on its prescription composition,quality control,pharmacological effects,clinical application and safety is constantly improving.Through the retrieval and analysis of the related literatures of Tanreqing injection,the research progress of Tanreqing Injection was reviewed from the above aspects, in order to provide reference for the in-depth study and clinical application of Tanreqing Injection.]]></description>
<pubDate>2019/1/14 14:42:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[REN Hongyao<sup>1</sup>, LIU Weiguo<sup>1</sup>, SONG Xiaoling<sup>2</sup> and LIU Fengqin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>REN Hongyao<sup>1</sup>, LIU Weiguo<sup>1</sup>, SONG Xiaoling<sup>2</sup> and LIU Fengqin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812009&flag=1]]></guid><cfi:id>449</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on <i>in vivo</i> models of fungal biofilm]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[During infection,fungi frequently transition to a biofilm lifestyle.Fungal cells in a biofilm lifestyle are distinct from the planktonic cells.Infections caused by fungal biofilm are particularly difficult to eradicate.Therefore, the discovery of novel strategies to treat fungal biofilms is of great interest.Animal biofilm models in vivo can better take into account the host immune system and are indispensable for the study of medical device related infection.<i>Candida albicans</i> was used as the research object in this paper.The aim of this review was to describe the five different <i>in vivo</i> biofilm models developed for fungal biofilm study,as well as the operating process,application, advantages and disadvantages of these models.]]></description>
<pubDate>2019/1/14 14:42:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Ming<sup>1,2</sup>, GU Wenrui<sup>3</sup> and SUN Shujuan<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Ming<sup>1,2</sup>, GU Wenrui<sup>3</sup> and SUN Shujuan<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812010&flag=1]]></guid><cfi:id>448</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Relationship between endothelial nitric oxide synthase and metabolic syndrome]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years,metabolic syndrome has been a focus of concern among the general public.The main feature of metabolic syndrome is the aggregation of various cardiovascular metabolic risk factors.Its key pathophysiological mechanisms involve hypertension,atherosclerosis,type II diabetes,insulin resistance,and so on.Recent studies have shown that endothelial nitric oxide synthase is involved in pathological processes such as hypertension,atherosclerosis,type 2 diabetes,and insulin resistance.This article summarized the relationship between nitric oxide synthase and metabolic syndrome in order to provide a reference for research.]]></description>
<pubDate>2019/1/14 14:42:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Jifang, LYU Ge and DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Jifang, LYU Ge and DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812011&flag=1]]></guid><cfi:id>447</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Applications of rheology in hot melt extrusion processes of pharmaceutical manufacturing]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[:Hot melt extrusion is a novel technique in the field of pharmaceutical manufacturing with numerous advantages.The article aimed to give an overview to hot melt extrusion technique,the basics of rheology,applications of rheology and common problems in processing.]]></description>
<pubDate>2019/1/14 14:42:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Jie, DI Donghua and WANG Da]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Jie, DI Donghua and WANG Da</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812012&flag=1]]></guid><cfi:id>446</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Strategies for method development of hydrophilic interaction liquid chromatography (HILIC) and application in platinum drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hydrophilic interaction liquid chromatography have solved chromatographic separation problems of polar compounds such as platinum drugs.The application of Hydrophilic interaction liquid chromatography is increasingly widely in pharmaceutical analysis as well as pharmacokinetic study.How to complete the method development of hydrophilic interaction liquid chromatography is an important problem for researchers.However,few references are available.This paper summarized the method development of polar compounds by hydrophilic interaction liquid chromatography in pharmacokinetic studies,including selection of stationary phase,selection of mobile phase,optimization of pH and elution gradient,and application in platinum drugs.]]></description>
<pubDate>2018/12/3 10:00:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QIN Zhiying, REN Guanghui, TAN Yanan, WANG Yonghan, ZHAO Di, LI Ning, LU Yang and CHEN Xijing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIN Zhiying, REN Guanghui, TAN Yanan, WANG Yonghan, ZHAO Di, LI Ning, LU Yang and CHEN Xijing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811009&flag=1]]></guid><cfi:id>445</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacological effects of Secoiridoid glycosides]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Secoiridoid glycosides are a class of natural active molecules with the functions of hepatoprotection, decreasing blood glucose, regulating blood lipid, anti-inflammatory, anti-tumor and neuroprotective effect. This article reviewed the pharmacological effects of gentiopicroside, sweroside and swertiamarin, in order to lay a foundation for the further research and development of secoiridoid glycosides.]]></description>
<pubDate>2018/12/3 10:00:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Huijuan<sup>1</sup>, LI Ju<sup>2</sup>, MA Xiaohui<sup>2</sup> and LI Yunman<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Huijuan<sup>1</sup>, LI Ju<sup>2</sup>, MA Xiaohui<sup>2</sup> and LI Yunman<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811010&flag=1]]></guid><cfi:id>444</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New research progress on pharmacological effects of <i>Curcumae Rhizoma</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Curcumae Rhizoma</i> is a traditional Chinese medicine.It is widely distributed throughout our country and widely used in folk.Its chemical composition mainly is volatile oils and curcuminoid,polysaccharides,sterols,phenolic acids,alkaloids and so on.Modern pharmacological studies have shown that it has anti-tumor,anti-platelet aggregation,antithrombus,regulating blood lipid,antiatherogenic,anti-tissue fibrosis,anti-inflammatory,analgesic,anti-bacteria,antiviral,hypoglycemic,anti-oxidant and other pharmacological effects.This paper review summarizes the new research progress on pharmacological effects <i>Curcumae Rhizoma</i> in recent years,in order to provide reference for the further research progress and development of <i>Curcumae Rhizoma</i>.]]></description>
<pubDate>2018/12/3 10:00:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Xiaojun<sup>1,2</sup>, WEI Jie<sup>1,2</sup>, SU Hua<sup>1,2</sup>, YAN Kejian<sup>1,2</sup> and NONG Yunkai<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Xiaojun<sup>1,2</sup>, WEI Jie<sup>1,2</sup>, SU Hua<sup>1,2</sup>, YAN Kejian<sup>1,2</sup> and NONG Yunkai<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811011&flag=1]]></guid><cfi:id>443</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacokinetic of andrographolide and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Andrographolide is a natural diterpenoid lactone compound with labdane skeleton，isolated from Andrographis paniculate（Burm）Nees. It is one of the main effective components of it. In recent years，many of its derivatives are superior to the prototype drugs in solubility，and have been used as the main components of some Chinese medicines on clinic. In this paper，the pharmacokinetics of andrographolide and its derivatives were reviewed，and the development and utilization of this natural active ingredient were provided.]]></description>
<pubDate>2018/12/3 10:00:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Ling<sup>1,2</sup>, WANG Kai<sup>1</sup>, DING Liqin<sup>2</sup>, QIAO Miao<sup>1,2</sup>, HOU Wenbin<sup>3</sup> and QIU Feng<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Ling<sup>1,2</sup>, WANG Kai<sup>1</sup>, DING Liqin<sup>2</sup>, QIAO Miao<sup>1,2</sup>, HOU Wenbin<sup>3</sup> and QIU Feng<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811012&flag=1]]></guid><cfi:id>442</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The evolution and modern research of <i>Fructus Viticis</i> and its processed products]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Fructus viticis</i> as simple <i>Vitex trifolia</i> or <i>Vitex trifolia</i> dry ripe fruit.Beginning in Shennong book of materia medica as a top grade, is a commonly used traditional Chinese medicine (TCM), All editions of Chinese pharmacopoeia are accepted, It has the effect of removing wind heat and removing head. In this paper, Historical records of ancient books, processing history and modern research on <i>Fructus viticis</i> and its processed products were reviewed.]]></description>
<pubDate>2018/12/3 10:00:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Zuocheng<sup>1</sup>, CHANG Ruilian<sup>2</sup> and ZHANG Guiju<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Zuocheng<sup>1</sup>, CHANG Ruilian<sup>2</sup> and ZHANG Guiju<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811013&flag=1]]></guid><cfi:id>441</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of β-cyclodextrins and its derivatives as active pharmaceutical ingredients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[β-Cyclodextrins are cyclic oligosaccharides that have a lipophilic cavity and a hydrophilic external surface.β-Cyclodextrins have the ability to encapulate hydrophobic molecule such as cholesterol,sphingolipids intracellularly,and promote the efflux of cholesterol and other lipids from the cell,finally regulate the homeostasis of cholesterol and other lipids.In recent years,researches on pharmacodynamics of β-cyclodextrins as well as their derivatives that have been used as active pharmaceutical ingredient for Niemann-Pick Type C disease,Alzheimer's disease,hypoxic-ischemic encephalopathy,atherosclerosis,cancer and other diseases have made some progress.This article summarized the research progress of β-cyclodextrins as well as their derivatives used as active pharmaceutical ingredient in various diseases,and aimed to provide reference for the advancement of β-cyclodextrin as well as their derivatives in the clinical research of various diseases through regulating lipid homeostasis.]]></description>
<pubDate>2018/10/18 9:58:38</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Yan, SU Zhigui and ZHANG Can]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yan, SU Zhigui and ZHANG Can</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810009&flag=1]]></guid><cfi:id>440</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of natural flavonoids in prevention and treatment of diabetic nephropathy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Diabetic nephropathy (DN) is a serious complication of diabetes and its pathogenesis is complex and diverse. Modern pharmacological studies have shown that natural flavonoids have a variety of potential medicinal value, the prevention and treatment of DN is one of them.The mechanism of anti-DN activity of flavonoids is a comprehensive result of a variety of physiological activities, including anti-oxidative stress and elimination of free radicals,anti-inflammatory, to improve blood glucose and lipid disorders, anti-apoptosis, regulating vasodilation and improving hemodynamic abnormalities to achieve.This paper reviewed the various roles of flavonoids in the prevention and treatment of DN and related mechanisms, and hoped to provide a reference for the development of drugs for the prevention and treatment of DN.]]></description>
<pubDate>2018/10/18 9:58:38</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WEN Jingyu, CHEN Jun, LIU Kunling, LU Na, LI Qiuhui and LI Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEN Jingyu, CHEN Jun, LIU Kunling, LU Na, LI Qiuhui and LI Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810010&flag=1]]></guid><cfi:id>439</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on application of functionalized nanoparticles in brain targeted drug delivery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The existence of the blood-brain barrier results in the drug failing to reach the target site effectively and exerting a great influence on the development and progress of the nervous system drug.Nanotechnology has been proven to be an effective tool for brain-targeted therapy,especially in brain tumors and neurodegenerative diseases.The functionalized nanoparticles improve drug compliance through surface modification and the like, and on the basis of the original treatment of the drug,achieve more precise targeting and high efficiency of aggregation at the target site and play a therapeutic role.This paper reviewed the functional nanoparticles and their functionalization strategies,as well as the advantage and application in diagnosis and treatment of brain diseases.This review provided a reference for the study of the treatment of brain disease.]]></description>
<pubDate>2018/10/18 9:58:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Wenjun, XIN Xuewei, LI Hong, YUE Changlin, ZHU Dongya, SONG Chunxiao and WANG Shujing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Wenjun, XIN Xuewei, LI Hong, YUE Changlin, ZHU Dongya, SONG Chunxiao and WANG Shujing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810011&flag=1]]></guid><cfi:id>438</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of relationship between NAFLD and T2DM]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Non Alcoholic fatty liver disease(NAFLD) is currently the most commom chronic liver disease in the world, encompassing various pathological abnormalities ranging from simple steatosis,steatoheptitis,to hepatic fibrosis and cirrhosis.The association between NAFLD and Type 2 Diabetes Mellitus (T2DM) is strong and conplex,given that the prevalence of NAFLD is particularly high in individuals with Type 2 Diabetes Mellitus.In this review,we focused on the mechanisms and relationships of NAFLD and T2DM in order to deep the understanding of both and provide guidance for their clinical treatment.]]></description>
<pubDate>2018/10/18 9:58:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Haiwei and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Haiwei and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810012&flag=1]]></guid><cfi:id>437</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on paclitaxel nanoformulation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Paclitaxel is a microtubule-binding compound that is clinically used for the treatment of breast cancer, ovarian cancer, and so on.The low solubility of paclitaxel leads to many problems for the clinical application.Nanocarriers have unique advantages in drug delivery, including improving drug solubility, increasing drug circulation time, targeting delivery to tumor sites, reducing systemic toxicity, and so on.This review summarized the research progress of paclitaxel nanopreparations in recent year for further research of paclitaxel.]]></description>
<pubDate>2018/10/18 9:58:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[AN Fei, LIU Dejie and LENG Jiawei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>AN Fei, LIU Dejie and LENG Jiawei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810013&flag=1]]></guid><cfi:id>436</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[脂毒性诱导的非酒精性脂肪性肝炎的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 16:10:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李晨,闪雪纯,傅继华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李晨,闪雪纯,傅继华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909007&flag=1]]></guid><cfi:id>435</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the application of polymer PEG-PLGA in nano drug delivery systems]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 0:00:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张文君<sup>1,2,3</sup>,王晴<sup>1</sup>,吴梦婷<sup>1</sup>,吕江维<sup>1</sup>,吕春艳<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张文君<sup>1,2,3</sup>,王晴<sup>1</sup>,吴梦婷<sup>1</sup>,吕江维<sup>1</sup>,吕春艳<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909008&flag=1]]></guid><cfi:id>434</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药致肾毒性研究进展及临床预防策略]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 16:10:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张琳<sup>1</sup>,韩欣汝<sup>2</sup>,臧恒昌<sup>3</sup>,刘伟<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张琳<sup>1</sup>,韩欣汝<sup>2</sup>,臧恒昌<sup>3</sup>,刘伟<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909009&flag=1]]></guid><cfi:id>433</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[蛋白酶激活受体拮抗剂在抗血小板领域的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 16:10:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李杉杉,朱雄]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李杉杉,朱雄</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909010&flag=1]]></guid><cfi:id>432</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanism and drug research of AMPK and PPARs in type 2 diabetes mellitus]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Type 2 diabetes mellitus (T2DM) is a major epidemic worldwide which features insulin resistance and decreased insulin secretion from pancreatic β cells,causing disorders of glycolipid metabolism.The pathogenesis of the disease is multifactorial. AMPK and PPARs,as key regulators of metabolic processes in the body,contribute significantly to the balance of glycolipid metabolism.This article focuses on the mechanism of the above-mentioned regulators in the development of T2DM and the therapeutical effect and mechanism of corresponding drugs,in order to provide reference for the development of T2DM drugs.]]></description>
<pubDate>2019/8/30 17:59:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DING Jie and FU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Jie and FU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908010&flag=1]]></guid><cfi:id>431</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Metabolic reprogramming of macrophages and its functional effects]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Macrophages are derived from bone marrow stem cells and are an important innate immune cell that is present in all tissues and has functional diversity,such as phagocytosis, antigen presentation, and so on.Macrophages also play an important role in monitoring and regulating the local microenvironment. Metabolic reprogramming is a general term for metabolic abnormalities, including metabolically related products, enzymes, and metabolic pathways. Metabolic abnormalities are the main factors leading to changes in the local microenvironment. This paper focuses on the effects of metabolic reprogramming on the plasticity and function of macrophages.]]></description>
<pubDate>2019/8/30 17:59:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Xue and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Xue and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908011&flag=1]]></guid><cfi:id>430</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Drugs of promoting liver regeneration and their mechanisms]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Liver is a highly regenerative organ in mammals.As such,injury to liver results in stimulation of quiescent hepatocytes to reenter the cell cycle,resulting in liver regeneration and restoration of liver function.Yet,hepatic regenerative responses are not always successful because liver injury sometimes results in progressive damage that leads to severe liver failure.For patients with cirrhosis or cancer after their partial hepatectomy,it is of great clinical significance to find drugs and methods that can both protect liver function and improve liver regeneration.This article reviews the drugs that promote liver regeneration and their mechanisms, aiming to provide new insights for the development of effective medication.]]></description>
<pubDate>2019/8/30 17:59:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Jingting<sup>1</sup> and WU Xiaoming<sup>2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Jingting<sup>1</sup> and WU Xiaoming<sup>2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908012&flag=1]]></guid><cfi:id>429</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on novel drug delivery systems of Irinotecan]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Irinotecan is a camptothecin derivative belonging to the topoisomerase I inhibitors,which has broad-spectrum antitumor activities.In clinical applications both single drug treatment and multiple chemotherapy of irinotecan have achieved good therapeutic effects.However, disadvantages of irinotecan,such as short half-life and poor biocompatibility have limited its widely clinical use.Novel drug delivery systems which with high bioavailability and low side effects have become the focus in recent years.The article summarized the research progress of irinotecan on the new drug carriers,such as nanoparticles,liposomes and microspheres.]]></description>
<pubDate>2019/8/30 17:59:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUI Jiying, GAO Cong and DOU Mingjin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUI Jiying, GAO Cong and DOU Mingjin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908013&flag=1]]></guid><cfi:id>428</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in the study of the pleomorphic adenoma gene zinc finger protein family in tumor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a nuclear protein transcriptional regulator, the pleomorphic adenoma gene (PLAG) zinc finger protein family regulate the expression of many important genes in the body. Pleomorphic adenoma gene 1 (PLAG1)，Pleomorphic adenoma gene-like 1(PLAGL1) and Pleomorphic adenoma gene-like 2(PLAGL2) belong to the zinc finger protein gene family. In recent years, great progress has been made in the structure, function and mechanism of the PLAG family members,and it has been found that this family members is associated with the development of various tumors.The research progress of structure and transcription mechanism of the PLAG family and its relationship with various tumors were reviewed in this paper.It provided a theoretical basis for the PLAG family members as a new target for tumor therapy.]]></description>
<pubDate>2019/7/26 10:27:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHENG Shufang, HU Weiwei, YANG Yong and CHEN Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Shufang, HU Weiwei, YANG Yong and CHEN Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907009&flag=1]]></guid><cfi:id>427</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Role of IL-6/gp130 in rheumatoid arthritis: Study progress from mechanism to clinical transformation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Interleukin-6 (IL-6) is involved in development of chronic inflammation,autoantibody production and vascular permeability changes. It is one of the most highly expressed inflammatory mediators during the onset of rheumatoid arthritis and has become a target for drug therapy. Different sources of IL-6 can mediate JAK-STAT, ERK-MAPK and PI3K-AKT through classic-signaling or trans-signaling or cluster-signaling transduction pathway by binding to IL-6Rα and gp130. Intracellular signal transduction causes inflammation. Targeted drugs against IL-6/gp130 have been gradually developed, but there are still many adverse reactions and side effects. Thus targeted drug delivery or local treatment of rheumatoid arthritis are favored. This article summarized the current development and application of drugs targeting IL-6 and its receptors in the treatment of rheumatoid arthritis, discussed the advantages of new drug delivery systems in the treatment of rheumatoid arthritis, expecting to provide new ideas for developing new drugs for treatment of rheumatoid arthritis.]]></description>
<pubDate>2019/7/26 10:27:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Jinwen<sup>1</sup>, ZHANG Ying<sup>2</sup> and TIAN Jilai<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Jinwen<sup>1</sup>, ZHANG Ying<sup>2</sup> and TIAN Jilai<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907010&flag=1]]></guid><cfi:id>426</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on quality control of active components in different medicinal parts of <i>Trichosanthes kirilowii</i> Maxim.]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Trichosanthis Semen</i>,<i>Trichosanthis Pericarpium</i>,<i>Trichosanthis Fructus</i>,<i>Trichosanthis Radix</i> are various medicinal parts of <i>Trichosanthes kirilowii</i> Maxim.The current pharmacopoeia is too simple to control their quality scientifically and reasonably although they are traditional chinese medicinal materials.We reviewed the research on the safety and efficient parts of <i>Trichosanthis Semen</i>,<i>Trichosanthis Pericarpium</i>,<i>Trichosanthis Fructus</i> as well as <i>Trichosanthis Radix</i>.In order to provide scientific and comprehensive standards for different medicinal parts of <i>Trichosanthes kirilowii</i> Maxim.,we proposed suggestions on the basis of the existing problems.]]></description>
<pubDate>2019/7/26 10:27:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MU Xiangrong, LIN Lin, JIAO Yang and LIN Yongqiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MU Xiangrong, LIN Lin, JIAO Yang and LIN Yongqiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907011&flag=1]]></guid><cfi:id>425</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of traditional Chinese medicine pillls]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pills, as an ancient dosage form, are still in use today. At present, modern research on pills is becoming one of the hotspots in the development of traditional Chinese medicine. This paper reviews the development of excipients, preparation processes and quality control of pills in production in recent years. Some ideas and suggestions on the inheritance, improvement, development and innovation of pills are provided.]]></description>
<pubDate>2019/7/26 10:27:48</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Haiyan<sup>1</sup>, CAI Chenglong<sup>2</sup>, DU Qingwei<sup>2</sup>, ZHANG Cuicui<sup>2</sup>, FU Jialei<sup>3</sup>, SUN Dandan<sup>3</sup> and YAN Suesheng<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Haiyan<sup>1</sup>, CAI Chenglong<sup>2</sup>, DU Qingwei<sup>2</sup>, ZHANG Cuicui<sup>2</sup>, FU Jialei<sup>3</sup>, SUN Dandan<sup>3</sup> and YAN Suesheng<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907012&flag=1]]></guid><cfi:id>424</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of selective estrogen receptor regulators on AD]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Estrogen can improve learning and cognitive function and prevent Alzheimer's disease, but the increasing incidence of reproductive system cancers such as breast cancer and endometrial cancer limits its clinical application. Selective estrogen receptor regulators are a class of non-steroidal ligands that selectively bind to estrogen receptors and act as estrogen-like agents. Because of their specificity to tissue receptor selection, SERMs can reduce the side effects of estrogen therapy. This article reviewed the possible mechanisms of neuroprotective effects of SERMs in recent years.]]></description>
<pubDate>2019/6/27 10:49:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[REN Xiaoqian, TANG Susu and HONG Hao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>REN Xiaoqian, TANG Susu and HONG Hao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906008&flag=1]]></guid><cfi:id>423</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the mechanism of NK cells in liver disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Natural killer (NK) cells are the main congenital lymphocyte subsets, which mainly mediate anti-tumor and anti-viral responses, and have the ability to rapidly kill cells that have pathological or viral infections. This article reviews the important role of NK cells in liver disease and put forward a prospect for the treatment of liver disease.]]></description>
<pubDate>2019/6/27 10:49:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Yan and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yan and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906009&flag=1]]></guid><cfi:id>422</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the Role of Mena and TES Proteins in Tumor Invasion and Metastasis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Mena protein is one of the Ena/VASP family proteins, which plays an important role in the formation and extension of cell pseudopods and cell movement. TES is a cell adhesion molecule, which inhibits the migration and invasion of cancer cells in vitro. Recent studies have shown that the formation and extension of pseudopods and cell adhesion are the main factors affecting the migration and invasion of cancer cells. In this paper, the effects of the interaction between Mena and TES proteins on the pseudopods, cell motility and cell adhesion of cancer cells were discussed to elucidate the migration and invasion of Mena and TES in cancer cells. The role and molecular mechanism in the process provide new therapeutic target strategies and ideas for cancer metastasis patients.]]></description>
<pubDate>2019/6/27 10:49:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QI Xuexiu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QI Xuexiu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906010&flag=1]]></guid><cfi:id>421</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of intestinal flora and brain-intestinal-kidney axis in chronic kidney disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the increasing incidence of chronic kidney disease (CKD), it has become a major global public health problem. According to the latest Global Nephrology Health Report released by the 2017 World Kidney Congress, one out of every 10 people worldwide has kidney disease. In recent years, there has been increasing evidence of intestinal flora imbalance and impaired intestinal barrier function in CKD patients, and CKD patients have a higher risk of dementia and cognitive impairment than non-CKD patients. This article reviews the role of intestinal flora and brain-intestinal-kidney axis in chronic kidney disease, and hopes to delay the progression of chronic kidney disease and its complications by regulating the intestinal flora as a target.]]></description>
<pubDate>2019/6/27 10:49:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Xiuxiu, LI Qing, CAO Tengli and CHEN Dingding]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xiuxiu, LI Qing, CAO Tengli and CHEN Dingding</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906011&flag=1]]></guid><cfi:id>420</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on nanoformulations of ursolic acid]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ursolic acid (UA) is a pentacyclic triterpenoid compound with various biological activities such as liver protection,anti-inflammatory and anti-cancer.It has a wide range of pharmacological activities.However,lower water solubility and bioavailability limit its clinical application.Therefore, the development of new dosage forms to improve the bioavailability of ursolic acid has become an important part of ursolic acid research.Nanocarriers are widely used to improve the water solubility of drugs,improve drug efficacy,and prolong drug action time.This paper summarized the related researches on ursolic acid nano-preparations from domestic and abroad,including liposomes,micelles,nanoparticles,nanosuspensions and nanoemulsions,which will provide necessary ideas and references for the future research.]]></description>
<pubDate>2019/6/27 10:49:43</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FANG Min<sup>1,2</sup>, LI Jiaming<sup>2</sup>, LI Ning<sup>3</sup>, ZHAO Di<sup>2</sup>, CHEN Xijing<sup>2</sup> and ZHANG Guangqin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FANG Min<sup>1,2</sup>, LI Jiaming<sup>2</sup>, LI Ning<sup>3</sup>, ZHAO Di<sup>2</sup>, CHEN Xijing<sup>2</sup> and ZHANG Guangqin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906012&flag=1]]></guid><cfi:id>419</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The relationship of cancer-associated pathways and biomarkers of venous thrombosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cancer patients have an increased risk of venous thromboembolism (VTE). In this review, we summarize common and cancer type–specific pathways of VTE in cancer patients. Increased levels of leukocytes, platelets, and tissue factor–positive (TF+) microvesicles (MVs) are all potential factors that alone or in combination increase cancer-associated thrombosis.In different types of cancer, leukocytosis, thrombocytosis, neutrophils, soluble P-selectin, PAI-1, TF + MV are all associated with VTE.A better understanding of the pathways that increase VTE in cancer patients may lead to the development of new therapies to reduce the morbidity and mortality associated with thrombosis.]]></description>
<pubDate>2019/6/3 16:05:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIANG Minrui and GONG Guoqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Minrui and GONG Guoqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905008&flag=1]]></guid><cfi:id>418</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the effect of radiation on cytochrome P450]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the progress of science, nuclear energy and nuclear technology have been widely used in medical, energy, military, food processing and other aspects of national defense and national life. Potential radiation injuries include cancer patients receiving radiation therapy, radiation-related workers and people living in Plateau areas. Under radiation, a series of physiological changes, some of which are pathological changes, affect the absorption, distribution, metabolism and excretion of drugs in the body, resulting in changes in pharmacokinetic characteristics. Focusing on the individualized medication of these populations has gradually become the focus of research in medical and pharmaceutical research.The effects of ionizing and non ionizing radiation on cytochrome P450 were reviewed in this paper.]]></description>
<pubDate>2019/6/3 16:05:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIN Yuanyao, NIAN Yongqiong and LI Xiangyang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIN Yuanyao, NIAN Yongqiong and LI Xiangyang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905009&flag=1]]></guid><cfi:id>417</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[ROS regulation of FOXO activity and its expression]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Forkhead box,class O(FOXO) is an important regulator of various intracellular processes in-vitro and in vivo. It regulates energy metabolism, oxidative stress response, redox signaling pathway, cell cycle progression, apoptosis, etc. Reactive oxygen species(ROS) modulates activation of FOXO and protein content at multiple levels. On one hand, ROS regulates the protein expression through p53,miRNA, HuR. whereas, on the other hand, ROS also modifies FOXO activation and stabilization, through phosphorylation, acetylation. In addition, ROS may also modulate FOXO protein activation by affecting FOXO transcriptional coactivators.Under several pathological conditions associated with oxidative stress, activation of FOXO exceeds that leads to various diseases,such as diabetes and cancer.. In this review, we will discussed on the effects of ROS on FOXO activity and its expression. This will further clarify the pathogenesis of the disease and provide ideas for the development of new drugs.]]></description>
<pubDate>2019/6/3 16:05:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LYU Ge, ZHOU Jifang, YANG Jie and DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Ge, ZHOU Jifang, YANG Jie and DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905010&flag=1]]></guid><cfi:id>416</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the analgesic effect of poppy, <i>Rhizoma Corydalis</i> and <i>Corydalis saxicola</i> Bunting]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pain is the fifth vital sign of the human, which is a kind of self-protection and a warning to harmful stimuli. Although opioids have significant adverse reactions and addiction, they are still the main treatment for severe acute and chronic pain. This paper sorted out the analgesic plants of <i>Papaver somniferum</i> L., <i>Corydalis yanhusuo<i/> W. T. Wang and <i>Corydalis saxicola<i/> Bunting in the <i>Papaveraceae</i>, and reviews them from ancient books, main active ingredients, pharmacological effects and clinical studies in order to more scientifically discover analgesia.]]></description>
<pubDate>2019/6/3 16:05:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XUE Chu, LIU Sixue and HUANG Fang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XUE Chu, LIU Sixue and HUANG Fang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905011&flag=1]]></guid><cfi:id>415</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The current situation and sustainable exploitation and utilization of traditional Chinese medicine resources]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This article briefly introduced the research progress of  traditional Chinese medicine resources’  present situation and traditional Chinese medicine resources’ sustainable exploitation and utilization.After analyzed domestic literature in the past years, we summarized the basic situation of the traditional Chinese medicine resources’ sustainable exploitation and utilization from 3 aspects:expanding the drug source,perfecting the relevant regulations of the drug development and production,applying the new technology.Now，the new technologies for sustainable exploitation and utilization of traditional Chinese medicine resources include tissue culture technology, gene engineering, enzyme engineering, biosynthesis technology and so on.The application of these new technologies has far-reaching significance for the sustainable development of traditional Chinese medicine resources.]]></description>
<pubDate>2019/6/3 16:05:49</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GUO Mingxing, FU Chunsheng and CHEN Yahui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Mingxing, FU Chunsheng and CHEN Yahui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905012&flag=1]]></guid><cfi:id>414</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in research on the function of purinergic receptor P2Y in immune inflammation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[P2Y receptor (P2YRs) is a kind of G protein coupled receptor (GPCRs) activated by extracellular nucleotides, belonging to purine receptor family.The physiological activators of P2Y receptors include dinucleotide or triphosphate nucleotide purine and pyrimidine, such as ATP, ADP, UTP, UDP, nucleotide sugar and dinucleotide.P2Y receptor is widely expressed in tissue and plays an important role in immune response. In recent years, P2Y receptor has shown great potential as a drug target in inflammation, cancer, cardiovascular and neurodegenerative diseases, and the study of P2Y receptor is of great significance for the further development of new drugs. In this paper, the classification, structure, pharmacological properties of P2Y receptor and potential drugs targeted at P2Y receptor are reviewed.]]></description>
<pubDate>2019/5/10 16:54:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Hanwen, JI Hui and HU Qinghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Hanwen, JI Hui and HU Qinghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904008&flag=1]]></guid><cfi:id>413</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of magnetic drug carriers in antitumor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The magnetic carrier carrying anticancer drugs is targeted to the target area by the action of external magnetic field, which increases the drug concentration of the target tissue and effectively reduces the toxic side effects.Magnetic drug carrier has the advantages of targeting, slow release and controlled release, and has become a new carrier system commonly used in tumor targeted therapy.This paper reviewed the application of magnetic drug carrier magnetic nanoparticles, magnetic liposomes and magnetic microspheres in the treatment and diagnosis of tumors.]]></description>
<pubDate>2019/5/10 16:54:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MA Lixia and YU Lan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Lixia and YU Lan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904009&flag=1]]></guid><cfi:id>412</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on hepatoprotective effects of <i>Schisandra chinensis</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Schisandra chinensis</i> is a commonly used traditional nourishing Chinese medicine.It possesses the effects of calming the heart and tranquilizing the mind and is mainly used for treatment of dysphoria and palpitation, insomnia and dreamful sleep due to the lack of spirit preservation.In recent years,a great deal of domestic and international research had been carried out on the hepatoprotective effects of <i>Schisandra chinensis</i>.In this paper,the hepatoprotective effects of <i>Schisandra chinensis</i> were summarized and elaborated to provide a theoretical reference for the clinical research and development of hepatoprotective drugs.]]></description>
<pubDate>2019/5/10 16:54:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HU Di<sup>1,2,3</sup>, WEI Guowei<sup>1,2,3</sup> and QU Zhongyuan<sup>1,2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Di<sup>1,2,3</sup>, WEI Guowei<sup>1,2,3</sup> and QU Zhongyuan<sup>1,2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904010&flag=1]]></guid><cfi:id>411</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The chemical constitutes and biological activities of <i>Xanthium</i> L in Xinjiang]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Fructus Xanthii</i> is an important Chinese traditional medicine.<i>Xanthium sibiricum</i> Part and three invasive species of <i>Xanthium</i>:<i>Xanthium spinosum</i> Linn,<i>Xanthium italicum</i> Moretti and <i>Xanthium mongolicum</i> Kitag are distributed in Xinjiang Uygur Autonomous region. Due to the strong competition and huge biomass, the invasive species always misused as counterfeits. Chemical constitutes of three invasive species and their biological activities were reviewed according to recent studies.This review revealed the chemical basis and provided the guidance for the advanced development of the plant resources.]]></description>
<pubDate>2019/5/10 16:54:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[PAN Le<sup>1</sup>, HE Yuan<sup>1</sup>, LEI Dongyu<sup>2</sup> and JIN Lu<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>PAN Le<sup>1</sup>, HE Yuan<sup>1</sup>, LEI Dongyu<sup>2</sup> and JIN Lu<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904011&flag=1]]></guid><cfi:id>410</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the chemical constituents and biological activities of <i>Ceriops</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Ceriops</i> is a kind of plant of mangroves family. Due to its special habitat, it can produce some bioactive metabolites, which have strong physiological functions and medicinal effect, and thus with potential value for human health and disease prevention. This article aimed at reviewing the recent papers on chemical constitutes and biological actions and expecting further research and utilization of <i>Ceriops</i>.]]></description>
<pubDate>2019/5/10 16:54:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Li<sup>1</sup> and ZHENG Jing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Li<sup>1</sup> and ZHENG Jing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904012&flag=1]]></guid><cfi:id>409</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in methods of clinical diagnosis for drug-induced liver injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Drug-induced liver injury (DILI) is a wide range of adverse drug reactions that can eventually lead to acute liver failure. At present, DILI has gradually become a global public medical problem that cannot be ignored. Its incidence rate is on the rise and it is the most common reason for withdrawing approved drugs from the market. To identify DILI early and stop the offending drug as soon as possible can prevent further damage. Therefore, clinical diagnosis is the key to timely treat DILI. In this article,the diagnostic methods of clinical DILI were reviewed to provide new insights and references for the treatment of DILI.]]></description>
<pubDate>2019/4/12 10:55:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MA Bailing, LU Wu, TIAN Jiangwei and YU Boyang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Bailing, LU Wu, TIAN Jiangwei and YU Boyang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903008&flag=1]]></guid><cfi:id>408</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on absorption of <i>Polygonum multiflorum</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a traditional Chinese medicine, <i>Polygonum multiflorum</i> (PM) is widely used in clinical practice and plays an important role in the treatment of diseases. Clinically, PM are mainly oral administration, and the effect of the drug is based on that the chemical components are absorbed into the body and interact with the body. Therefore, it is significant to study the absorption mechanism of PM.In this paper, the absorption kinetics of the main components of PM were summarized, and it was expected to provide a reference for the evaluation of the bioavailability of PM, improve the dosage form, and improve the efficacy.]]></description>
<pubDate>2019/4/12 10:55:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Yimeng, QUAN Yunyun and LI Yunxia]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Yimeng, QUAN Yunyun and LI Yunxia</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903009&flag=1]]></guid><cfi:id>407</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of fibrinogen related drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fibrinogen is an important substance in the process of blood coagulation and thrombosis. High fibrinogen is a vital risk factor for various thrombotic diseases and is considered a marker of disease status in the clinic. Fibrinogen and platelet glycoprotein IIb/IIIa receptors are vital targets for drug research in thrombotic diseases. Therefore, this paper will review the mechanism of fibrinogen-induced thrombosis and the progress of related drugs.]]></description>
<pubDate>2019/4/12 10:55:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HUANG Jin, YIN Xiaojian and HUANG Fang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Jin, YIN Xiaojian and HUANG Fang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903010&flag=1]]></guid><cfi:id>406</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of polysaccharide iron complex in the treatment of renal anemia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The main cause of renal anemia is erythropoietin deficiency,and the lack of iron affects erythropoiesis.Polysaccharide iron complex is an oral iron supplement with small side effects and good stability,and has good bioavailability,which can effectively improve the hemoglobin level of anemia patients.This paper reviewed the structural properties,mechanism of action,clinical application status and progress of polysaccharide iron complexes.]]></description>
<pubDate>2019/4/12 10:55:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GUO Caijie, WANG Hui, CHEN Jiejun and ZHANG Cong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Caijie, WANG Hui, CHEN Jiejun and ZHANG Cong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903011&flag=1]]></guid><cfi:id>405</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on regulatory mechanisms of cholesterol 7α-hydroxylase in cholestasis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cholestasis is an abnormal accumulation of bile acids caused by various causes, and the clinical manifestations are jaundice or macular tumors. Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme which catalyzes the synthesis of bile acids from cholesterol. Its activity is closely related to the amount of bile acid synthesis. FXR-mediated FXR/SHP signaling pathway and FXR/FGF19/FGFR4 signaling pathway, and PXR-mediated signaling pathway are important CYP7A1 regulatory pathways in vivo. The above signaling pathways regulate the synthesis of bile acids by regulating the activity of CYP7A1，thus maintain the internal balance of bile acids.This review introduced the research progress of regulatory mechanisms of CYP7A1 in cholestasis in recent years, and provided references for exploring the targets of clinical treatment of cholestasis.]]></description>
<pubDate>2019/3/29 12:07:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Huitao and LIN Yining]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Huitao and LIN Yining</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902008&flag=1]]></guid><cfi:id>404</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in detoxification of mycotoxins]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Mycotoxins are ubiquitous in feeds, grains,foods,and Chinese herbal medicine,which are harmful to human and animal health.According to the removal mechanism,the removal method of mycotoxins is mainly divided into physical detoxification,chemical detoxification,and biological detoxification.This paper summarized the methods for removing mycotoxins at this stage.]]></description>
<pubDate>2019/3/29 12:07:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Xuejie<sup>1,2</sup>, AN Na<sup>1</sup>, GAO Yixuan<sup>1,2</sup>, XU Hao<sup>1,2</sup> and GUO Yifei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xuejie<sup>1,2</sup>, AN Na<sup>1</sup>, GAO Yixuan<sup>1,2</sup>, XU Hao<sup>1,2</sup> and GUO Yifei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902009&flag=1]]></guid><cfi:id>403</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the treatments of keloids]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Keloids are characterized clinically by post-surgical recurrence and have been a big challenge for the world.Nowadays no entirely satisfactory method currently exists.Their pathogenesis remains unclear in despite of considerable research to unravel this phenomenon. The main progress of therapies was reviewed as follows.]]></description>
<pubDate>2019/3/29 12:07:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Meiting, OUYANG Qianqian and LI Sidong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Meiting, OUYANG Qianqian and LI Sidong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902010&flag=1]]></guid><cfi:id>402</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress about antitumor activity and mechanism of natural polypeptides]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tumor is one of the major diseases that seriously threaten human health.At present,radiotherapy and chemotherapy are the main treatment of tumor,but its side effects are large and the drug resistance is strong.Antitumor peptides are mainly divided into natural peptides,artificial modified peptides and synthetic peptides.Natural antitumor active peptides are active material which was accumulated in the adaptation to environment for years in animals and plants.Its molecular weight is small,its side effects are few, its activity is high, and its source is widespread.At present,many natural peptides have been found to act on tumor cells,tumor vascular cells and immune cells through a variety of mechanisms to achieve better anti-tumor activity which has good prospects for research and development.This article combined the related research at home and abroad, summarized the source of active peptide, mechanism and research status of it.Then we hope to provide references for finding more natural antitumor peptides.]]></description>
<pubDate>2019/3/29 12:07:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MA Lin, WANG Shujing, SUN Weiwei, ZHOU Xiaoxiao, ZHENG Yan, GAO Wei and LIU Wenjie]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Lin, WANG Shujing, SUN Weiwei, ZHOU Xiaoxiao, ZHENG Yan, GAO Wei and LIU Wenjie</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902011&flag=1]]></guid><cfi:id>401</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of anti-inflammatory properties of luteolin]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Luteolin is a natural flavonoid,which possesses a wide spectrum of pharmacological actions.Plants that is aboundant with luteolin have been used to treat inflammation-related diseases because luteolin have strong anti-inflammatory activity.In this review,we summarized the progress of recent studies on the anti-inflammatory mechanisms of luteolin.]]></description>
<pubDate>2019/3/29 12:07:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Qian and WU Guanzhong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Qian and WU Guanzhong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902012&flag=1]]></guid><cfi:id>400</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in molecular mechanism of adhesion molecules in the regulation of EMT and cancer cell stemness]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Changes in cell adhesion and motility are considered key elements in determining the development of invasive and metastatic tumors.Co-opting the epithelial-to-mesenchymal transition (EMT) process,which is known to occur during embryonic development,and the associated changes in cell adhesion properties in cancer cells are considered major routes for tumor progression.More recent in vivo studies in tumor tissues and circulating tumor cell clusters suggest a stepwise EMT process rather than an “all-or-none” transition during tumor progression.This review summarized the molecular mechanisms underlying the changes in cell adhesion and adhesion-mediated signaling and their relationships to the partial EMT states and the acquisition of stemness traits by cancer cells.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Dewang and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Dewang and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901009&flag=1]]></guid><cfi:id>399</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on active components and modern pharmacological action of various drugs in Dedu Honghua-7 Powder]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The main active ingredients extracted from Deduhonghua-7 powder each group were obtained: flavonoids,polysaccharide,alkaloids and saponins,As well as the modern pharmacological effects of these ingredients.The research progress of the prescription in the aspects of protecting liver, promoting gallbladder function,resisting liver fibrosis,preventing and treating fatty liver, regulating immunity, resisting oxidation and the like was summarized. the active ingredients and the same and different effects of the prescription were compared,and the activity of the prescription was enhanced or complemented each other after being formed, so as to provide theoretical basis for guiding clinical medication and further research and development.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CAO Ruizhen, BAI Liang, XU Yanan, YU Lili and ZHANG Chunlan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAO Ruizhen, BAI Liang, XU Yanan, YU Lili and ZHANG Chunlan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901010&flag=1]]></guid><cfi:id>398</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of MG53 in heart diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Mitsugumin 53 (MG53),also known as Trim72 (Tripartite Motif Protein 72),is a member of the multifunctional TRIM family,which is mainly distributed in heart and skeletal muscle.MG53 protein is a membrane repairing protein,which can be used as one of the key components of mechanical repair of the muscular membrane.The main function of MG53 is to maintain the integrity of cells and the normal function of cells.In recent years,many studies have shown that MG53 plays an critical role in the development of various heart diseases such as atrial fibrillation,ischemic heart disease and diabetic heart disease.Therefore,further understanding of physiological and pathological mechanism of MG53 can provide an effective target in the clinical treatment of heart disease.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Tingting, WEI Yanchun, FENG Kai and TANG Yiqun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Tingting, WEI Yanchun, FENG Kai and TANG Yiqun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901011&flag=1]]></guid><cfi:id>397</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on extraction,purification and activity of betaine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Betaine can be used as a penetrant and methyl source to help maintain liver,heart and kidney health.In this paper,the main preparation process,determination methods and activity research of natural betaine were reviewed.This provided basis for the study of betaine preparation process and application of clinical betaine,which will help to expand the application of betaine.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIANG Meichen and ZHANG Dejun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Meichen and ZHANG Dejun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901012&flag=1]]></guid><cfi:id>396</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the model and signaling pathways of acute liver injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Liver has the function of synthesis, detoxify, antioxidant activity, etc. Meanwhile it is liable to be attacked by free radical and some drugs.Liver diseases have always been the center of clinical researcher, while acute liver injury is the initiating condition of almost all liver diseases with diverse pathogenesis. There have been many kinds of animal models simulating different injury types, following with three signaling pathway associated with acute liver injury. Here we sketched four common animal models, among which are CCl4, D-GalN/LPS, APAP and alcohol, and introduced the roles of three signaling pathways, Keap1-Nrf2, TLR4 and NLRP3, in the development and progression of acute liver injury.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YUE Shuwen and CHEN Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUE Shuwen and CHEN Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901013&flag=1]]></guid><cfi:id>395</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[脑缺血再灌注损伤中关键蛋白的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[孟文静,陈真]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孟文静,陈真</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912007&flag=1]]></guid><cfi:id>394</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[高原低氧条件下的肠道菌群与药物代谢]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘贵琴<sup>1</sup>,李向阳<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘贵琴<sup>1</sup>,李向阳<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912008&flag=1]]></guid><cfi:id>393</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[相关基因多态性的沙坦类药物药代动力学研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[宋忠金,周静,李宁,赵娣,陈西敬]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宋忠金,周静,李宁,赵娣,陈西敬</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912009&flag=1]]></guid><cfi:id>392</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药现场鉴定技术研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[胡晓宇,杨馨玥,姚金剑,陈雪,都景晓,辛杰,张波,陈敏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡晓宇,杨馨玥,姚金剑,陈雪,都景晓,辛杰,张波,陈敏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912010&flag=1]]></guid><cfi:id>391</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of a Tibetan medicine - <i>Biebersteinia heterostemon</i> Maxim]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Biebersteinia heterostemon</i> Maxim for the oxen seedlings B.heterostemon plant,is a traditional Tibetan medicine.It is mainly distributed in Gansu,Qinghai,Ningxia six pan shanxi slope,northwest Sichuan (Norge) and other areas of China.In recent years,the research on the active ingredients of <i>B.heterostemon</i> has proved that it has analgesia,anti-inflammatory,antioxidant,sedative anti-spasm,hypoglycemic and other effects.This paper summarized the research of <i>B.heterostemon</i>, and discussed the chemical composition,pharmacology,toxicology and quality standards,and it provides a scientific basis for <i>B. heterostemon</i>，further development.]]></description>
<pubDate>2019/12/2 15:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yuemin, LIU Na, KOU Liang, LIU Xuefeng, LUO Huiying and JING Ming]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yuemin, LIU Na, KOU Liang, LIU Xuefeng, LUO Huiying and JING Ming</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911008&flag=1]]></guid><cfi:id>390</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in studies on biomolecular and application in Molecular Biochromatography of Traditional Chinese medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Molecular bio-chromatography technology with good reproducibility and high analysis speed is developed based on the principle of molecular specific recognition,which is extensively applied in screening research of pharmacodyamic material basis of traditional Chinese medicine.This paper briefly reviewed the bio-macromolecules such as plasma protein,receptor,enzyme which were commonly used in molecular biochromatography and the application in traditional Chinese medicine research,including screening active compounds, drug interaction research, and quality control methods,which also provide reference for molecular biochromatography application.]]></description>
<pubDate>2019/12/2 15:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Jueling<sup>1,2</sup>, AN Qi<sup>1</sup>, CHEN Su'e<sup>1</sup>, ZHAO Longshan<sup>3</sup> and LIU Liangliang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Jueling<sup>1,2</sup>, AN Qi<sup>1</sup>, CHEN Su'e<sup>1</sup>, ZHAO Longshan<sup>3</sup> and LIU Liangliang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911009&flag=1]]></guid><cfi:id>389</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in the determination of organic carboxylic acids by derivatization HPLC/MS]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Directly quantitative determination of carboxylic acid compounds in body fluid by LC-MS analysis is still an issue.Recent studies have shown that chemical derivatization mass spectrometry is an important method to solve this problem.In this paper,recent studies on the determination of trace carboxylic acids by this method are reviewed,and the derivative reagents and chemical reactions used are summarized.]]></description>
<pubDate>2019/12/2 15:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Chenxi, LU Aiyu, XUE Yangrui, SUN Yinzhe, JIANG Xuan, XU Fengguo and JIAO Yu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Chenxi, LU Aiyu, XUE Yangrui, SUN Yinzhe, JIANG Xuan, XU Fengguo and JIAO Yu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911010&flag=1]]></guid><cfi:id>388</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Development of polyethyleneimine as non-viral gene vectors in structural modification]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Polyethylenimine (PEI), as one of the most classic non-viral gene vectors, has received great attention in the field of gene delivery due to its high transfection efficiency,but its toxicity limits the application of PEI. This paper reviewed the development of different structural modifications of PEI, such as polysaccharide modified PEI, PEG modified PEI,low molecular PEI derivatives,to potentially reduce cytotoxicity without significantly sacrificing transfection efficiency.]]></description>
<pubDate>2019/12/2 15:14:04</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIN Hao, HE Dongsheng and TU Jiasheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Hao, HE Dongsheng and TU Jiasheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911011&flag=1]]></guid><cfi:id>387</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[靶向表皮生长因子受体的抗肿瘤治疗研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/15 9:11:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王名雪<sup>1</sup>,李壮林<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王名雪<sup>1</sup>,李壮林<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910007&flag=1]]></guid><cfi:id>386</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[清热药抗呼吸道合胞病毒的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/15 9:11:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[马元荣<sup>1,2,3</sup>,孙铁锋<sup>3</sup>,王平<sup>3,4</sup>,杜海涛<sup>1</sup>,张恒龙<sup>5</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>马元荣<sup>1,2,3</sup>,孙铁锋<sup>3</sup>,王平<sup>3,4</sup>,杜海涛<sup>1</sup>,张恒龙<sup>5</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910008&flag=1]]></guid><cfi:id>385</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[三氮唑类α-葡萄糖苷酶抑制剂研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/15 9:11:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张子沛,薛婉莹,熊德彩,吴艳芬]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张子沛,薛婉莹,熊德彩,吴艳芬</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910009&flag=1]]></guid><cfi:id>384</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[海洋生物海绵中溴吡咯生物碱的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/15 9:11:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[高荔]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高荔</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910010&flag=1]]></guid><cfi:id>383</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances on adverse reactions and toxic side effects of oral antithrombotic drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Oral antithrombotic agents are widely used clinically to prevent and treat thromboembolic diseases, including antiplatelet drugs and anticoagulant drugs. Their application provides convenient and effective treatment for patients with thrombosis, but their adverse reactions such as intracranial hemorrhage, gastrointestinal bleeding, liver and kidney damage are increasingly prominent, which limit their clinical ability. In this paper, we reviewed the recent clinical research on the adverse reactions of oral antithrombotic agents and the related progress of their toxic and side effects mechanisms, so as to provide some clues and references for the possible rational use of oral antithrombotic agents and the development of new drugs.]]></description>
<pubDate>2020/9/30 14:34:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Qianliu<sup>1,2</sup>, LIU Yuankai<sup>1,2</sup>, ZHANG Yuanyuan<sup>1,2</sup>, KOU Junping<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Qianliu<sup>1,2</sup>, LIU Yuankai<sup>1,2</sup>, ZHANG Yuanyuan<sup>1,2</sup>, KOU Junping<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009007&flag=1]]></guid><cfi:id>382</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Development of CAR-T and difficulties in the treatment of solid tumor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the development of tumor research, novel therapies have occurred, including immunotherapy. One of the most promising therapies is Chimeric Antigen Receptor T cell therapy (CAR-T). It has achieved the great breakthroughs in the treatment of hematological malignancy, but not in solid tumor. This article discussed the development of CAR-T and the difficulties encountered in the treatment of solid tumor.]]></description>
<pubDate>2020/9/30 14:34:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MA Jinyan, YANG Yong, WANG Yun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Jinyan, YANG Yong, WANG Yun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009008&flag=1]]></guid><cfi:id>381</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in pharmacology of cynomolgus monkeys in animal models of chronic diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the growth of the aging population, the incidence of chronic diseases among the elderly is getting higher and higher. However, chronic diseases, as a kind of insidious disease with a long course and complex etiology, bring certain troubles to clinical treatment. Therefore, finding an experimental animal pathological model similar to human to conduct preclinical research is the basis of overcoming this disease. As non-human primates, cynomolgus monkeys are very similar to human beings in structure, physiology and metabolism. The organism's response to biological pathogens is similar to that of humans. With a long life cycle and biological characteristics very similar to human characteristics, it is an ideal model for the observation and study of chronic diseases, and also one of the most ideal experimental animals in the laboratory pharmacology research. In this paper, we review the experimental research and application of cynomolgus monkeys in animal models of chronic liver disease, lung disease and cardiovascular disease in recent years.]]></description>
<pubDate>2020/9/30 14:34:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Shaofeng, WANG He, ZHAO Xiangpei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Shaofeng, WANG He, ZHAO Xiangpei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009009&flag=1]]></guid><cfi:id>380</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of autophagy in liver fibrosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Liver fibrosis is a dynamic process along with accumulation of extra intercellular matrix resulting from various pathogenic factors. Hepatic stellate cell activation is the central link of liver fibrosis. Autophagy, a critical lysosomal pathway, reveals a broad and complex role in various metabolic processes of liver. Autophagy in different type of cells plays an opposite role, in macrophages, hepatocytes and endothelial cells autophagy limits the release of inflammatory cytokines and inhibits inflammation injury to inhibit liver fibrosis. However, autophagy in Hepatic stellate cells upregulates development of liver fibrosis by regulating oxidative stress, endoplasmic reticulum stress, lipid metabolism and so on. This article reviewed the role of autophagy in liver fibrosis, which provided a better theoretical basis for the development of drugs to delay and reverse liver fibrosis.]]></description>
<pubDate>2020/9/30 14:34:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Liu, LI Min, WANG Xiaoping, QIANG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Liu, LI Min, WANG Xiaoping, QIANG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009010&flag=1]]></guid><cfi:id>379</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recruitment and differentiation of macrophages in intestinal homeostasis and inflammation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Monocytes have plasticity in the blood circulation system. In intestinal homeostasis, monocytes enter the intestinal mucosa and differentiate into resident macrophages. Resident macrophages secret some anti-inflammatory factors to maintain intestinal homeostasis. When intestinal inflammation occurs, monocytes enter the intestinal mucosa and differentiate into immature macrophages, which secret pro-inflammatory factors and chemokines to promote the development of inflammation. Based on this theory, we can develop drugs that target the recruitment and differentiation process of macrophages for treatment of IBD. In this article, we described the recruitment and differentiation process of macrophages in colon tissues, and reviewed the research progress of drugs which targeted macrophages in IBD.]]></description>
<pubDate>2020/8/26 16:19:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIN Yanting and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Yanting and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008008&flag=1]]></guid><cfi:id>378</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Potassium ion channels – a new target for analgesic drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pain is a common clinical disease, which directly affects people's daily life, but its mechanism is not very clear. In recent years, it has been found that potassium channel plays an important role in regulating pain, and it is considered to be a new target for the treatment of pain. This paper mainly summarized the types of potassium channels and the role of each subtype in pain, as well as the research progress of potassium channel opener as pain treatment drugs.]]></description>
<pubDate>2020/8/26 16:19:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HONG Jiangru<sup>1</sup>, QIU Jie<sup>1</sup>, XU Xiuqi<sup>1</sup>, LIU Wentao<sup>2</sup> and ZHANG Guangqin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HONG Jiangru<sup>1</sup>, QIU Jie<sup>1</sup>, XU Xiuqi<sup>1</sup>, LIU Wentao<sup>2</sup> and ZHANG Guangqin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008009&flag=1]]></guid><cfi:id>377</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of intestinal flora to chronic hepatitis B patient]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the influence of intestinal flora to chronic hepatitis B patient.<b>Methods</b>  Through searching, sorting out and analyzing literature review in recent 20 years at home and abroad, the research profile on the influence of intestinal flora to chronic hepatitis B patient were studied.<b>Results</b>  Intestinal flora of chronic hepatitis B patient was less than one of normal person. Intestinal flora and disease interact in a very complex way.<b>Conclusion</b>  Delaying the progression of liver disease by supplementing with probiotics or by transplanting faecal bacteria should become a new focus.]]></description>
<pubDate>2020/8/26 16:19:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Guangyu<sup>1</sup>, WANG Honghong<sup>2</sup>, SU Hua<sup>3</sup> and JIANG Jin<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Guangyu<sup>1</sup>, WANG Honghong<sup>2</sup>, SU Hua<sup>3</sup> and JIANG Jin<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008010&flag=1]]></guid><cfi:id>376</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Potential Application of Vesicle Carrier Formulations in Treating Skin Diseases in Transdermal Drug Delivery System]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper reviewed the composition,characteristics of liposome,transfersomes,ethosomes and niosomes,and their applications in the treatment of several skin diseases in transdermal drug delivery system, providing suggestions for future research.]]></description>
<pubDate>2020/8/26 16:19:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Shuo, ZHANG Wenjun and WANG Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Shuo, ZHANG Wenjun and WANG Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008011&flag=1]]></guid><cfi:id>375</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of supercritical fluid chromatography in pharmaceutical analysis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Supercritical fluid chromatography(SFC) is a kind of chromatogram that uses supercritical fluid as mobile phase and relies on the solvation ability of mobile phase for separation and analysis.As a powerful complement to gas chromatography(GC) and liquid chromatography(LC), SFC has shown fast separation speed, high efficiency and environmental protection in separation and analysis multiple substances, which has widely prospect in application. This review provides a summary of the applications of supercritical fluid chromatography in analysis and separation of chiral drugs, natural products, metabolites and impurity detection according to the articles mainly published in CNKI, Science Direct and Pub Med databases in recent years, and it also puts forward some thoughts for further research.]]></description>
<pubDate>2020/8/26 16:19:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHU Lin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Lin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008012&flag=1]]></guid><cfi:id>374</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on neutrophil extracellular traps and related immune-inflammatory diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Neutrophils are the most abundant type of immune effector cells in the human innate immune system. They exert their immune functions mainly through phagocytosis, oxidative stress, and the formation of neutrophil extracellular traps (NETs). However, excessive NETs may also cause tissue damage and participate in the pathological process of the disease, especially in inflammatory diseases or autoimmune diseases. This article mainly focuses on the formation and regulation of NETs, the pathological process of NETs involved in immune inflammatory diseases, and summarizes the existing small molecule compounds that interfere with the formation of NETs and the drugs that may play a role in treating diseases by regulating the production of NETs.]]></description>
<pubDate>2020/7/31 15:58:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Chunxiao and HU Qinghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Chunxiao and HU Qinghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007009&flag=1]]></guid><cfi:id>373</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Gut microbes-new target for atherosclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As the largest microbial community system in the body, the changes of microbial composition and abundance in the intestinal tract are closely related to the health of the body. Risk factors for atherosclerosis (old age, obesity, eating habits, etc.) induce intestinal ecological imbalance.And changes in intestinal microbial metabolites (short-chain fatty acids,trimethylamine-N-oxide, etc.) induce atherosclerosis Occurrence and development. This article reviews the role of intestinal microorganisms and their metabolites in atherosclerosis and the research progress of intestinal targeted therapy and intervention.]]></description>
<pubDate>2020/7/31 15:58:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Qing<sup>1</sup>, WANG Hao<sup>1</sup>, ZHANG Xiuxiu<sup>2</sup> and CHEN Dingding<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Qing<sup>1</sup>, WANG Hao<sup>1</sup>, ZHANG Xiuxiu<sup>2</sup> and CHEN Dingding<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007010&flag=1]]></guid><cfi:id>372</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on GSDMD-mediated pyroptosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pyroptosis is a new programmed cell death. Its morphological characteristics,molecular mechanism are significantly different from other progammed cell death. As a hottest research, researchers found that it has a deep relationship between many diseases. Current studies have confirmed that GSDMD plays an important role in pyroptosis. The study on the relationship between GSDMD and pyroptosis and the mechanism of pyroptosis can help to find the connection with diseases, which provides new ideas for the treatment and target.]]></description>
<pubDate>2020/7/31 15:58:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YE Shumin and HU Qinghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YE Shumin and HU Qinghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007011&flag=1]]></guid><cfi:id>371</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of UPLC-MS/MS for pesticide residues analysis in Chinese medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ultra high performance liquid mass spectrometry (UPLC-MS/MS) is a new technology with a wide range of applications. In this paper, the application of this technology at present were systematically reviewed and the response methods of matrix effect were summarized and discussed according to the research of domestic and foreign scholars using UPLC-MS/MS for the detection of agricultural residues in traditional Chinese medicine . In order to provide some suggestions of the follow-up research and application of UPLC-MS/MS in the field of agricultural residue analysis of traditional Chinese medicine and looks ahead its application prospect.]]></description>
<pubDate>2020/7/31 15:58:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Qian<sup>1</sup>, LIN Lin<sup>2</sup>, GUO Dongxiao<sup>2</sup> and LIN Yongqiang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Qian<sup>1</sup>, LIN Lin<sup>2</sup>, GUO Dongxiao<sup>2</sup> and LIN Yongqiang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007012&flag=1]]></guid><cfi:id>370</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the current situation of chinese medicine drink tablet industry and countermeasure stois]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[There are many problems in modern Chinese medicine tablets, especially the quality of drink tablets. The quality of Chinese medicine tablets is inextricably linked to clinical efficacy. The healthy development of Chinese medicine tablets has a decisive impact on the future development of the whole Chinese medicine industry. Based on this, this paper analyzes the problems existing in the Chinese medicine tablet industry and puts forward corresponding countermeasures to provide reference for the further development of the Chinese medicine drink tablet industry.]]></description>
<pubDate>2020/7/3 13:44:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Shujuan<sup>1,2</sup>, WANG Linyan<sup>3</sup>, ZHANG Yugui<sup>1,2</sup>, XIN Erdan<sup>1,2</sup>, NIU Jiangtao<sup>1,2</sup>, SI Xinlei<sup>1,2</sup>, LI Donghui<sup>1,2</sup>, WU Hongwei<sup>1,2</sup> and LI Yuefeng<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Shujuan<sup>1,2</sup>, WANG Linyan<sup>3</sup>, ZHANG Yugui<sup>1,2</sup>, XIN Erdan<sup>1,2</sup>, NIU Jiangtao<sup>1,2</sup>, SI Xinlei<sup>1,2</sup>, LI Donghui<sup>1,2</sup>, WU Hongwei<sup>1,2</sup> and LI Yuefeng<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006007&flag=1]]></guid><cfi:id>369</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The main pathogenic factors of irritable bowel syndrome and traditional Chinese medicine treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Irritable Bowel Syndrome (IBS) is a chronic recurrent functional gastrointestinal disease. The pathophysiology of IBS is not fully understood, and its pathogenesis is multifactorial. IBS has many pathogenic factors. These factors may not all exist in every patient, but they all play an important role in the pathogenesis of IBS. The typical clinical manifestation of IBS is discomfort or abdominal pain due to changes in the form of defecation. The timely diagnosis of IBS is essential, so treatments that relieve symptoms (diarrhea, constipation, pain) can be introduced. This article has compiled all the possible pathogenic factors of IBS in the existing research, provided more ideas for the researchers to study new targets for the treatment of IBS, and summarized the syndromes of IBS in the diagnosis of traditional Chinese medicine, and summarized traditional Chinese medicine treatment of IBS.]]></description>
<pubDate>2020/7/3 13:44:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WEI Jinyao<sup>1</sup>, CHENG Jun<sup>2</sup> and HUANG Fang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Jinyao<sup>1</sup>, CHENG Jun<sup>2</sup> and HUANG Fang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006008&flag=1]]></guid><cfi:id>368</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Tranexamic acid in treatment of melasma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Melasma is a common acquired pigmentary disorder marked by irregular hyperpigmented macules or patches. Traditional topical therapies including hydroquinone, tretinoin and so on. however , there are many side effects. Tranexamic acid is a plasmin inhibitor, a synthetic derivative of the amino acid lysine. It is approved by the US Food and Drug Administration for treatment of menorrhagia and to prevent hemorrhage.Tranexamic acid has consistently been reported as an effective treatment of melasma, it exerts its effect by inhibiting plasminogen activator. A literature search was performed using PubMed, Web of Science, CNKI, ScienceDirect database systematic reviews. We summarized and analyzed the pharmacological study and clinical study of tranexamic acid in the treatment of melasma, and we provide a reference for the clinical application of tranexamic acid in the treatment of melasma.]]></description>
<pubDate>2020/7/3 13:44:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Xue<sup>1,2</sup>, ZHAO Xiaoyu<sup>2</sup>, ZHOU Zequan<sup>2</sup>, XING Mengzhen<sup>2</sup>, GAO Yunhua<sup>2</sup>, ZHAO Lichun<sup>1</sup> and ZHANG Suohui<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xue<sup>1,2</sup>, ZHAO Xiaoyu<sup>2</sup>, ZHOU Zequan<sup>2</sup>, XING Mengzhen<sup>2</sup>, GAO Yunhua<sup>2</sup>, ZHAO Lichun<sup>1</sup> and ZHANG Suohui<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006009&flag=1]]></guid><cfi:id>367</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on a kind of Tibetan medicated bath Wuweiganlu]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Wuweiganlu is a Kind of classic Tibetan Medicated Bath, which is used to treat many illnesses classified as ‘Long’ diseases, such as rheumatoid arthritis. The basic formula of Wuweiganlu includes <i>Rhododendron</i>, <i>Juniperus</i>, <i>Ephedra</i>, <i>Myricaria</i> and <i>Artemisia</i>, but the exact origin of these herbs remains controversial. The use of Wuweiganlu is flexible as it allows changes in herb composition based on basic formula according to different diseases. What’s more, Wuweiganlu shows variety pharmacological activities, which suggests high value in future research.]]></description>
<pubDate>2020/7/3 13:44:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Changyue and LU Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Changyue and LU Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006010&flag=1]]></guid><cfi:id>366</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in research on the dual roles of <i>Psoralea corylifolia</i> and its active components in liver injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Although traditional Chinese medicine (TCM) <i>Psoralea corylifolia</i> is a traditional kidney-reinforcing drug, it has the effect of promoting liver function, regulating discharge the liver Qi, improve the qi flow, resistance against disease and detoxification due to it nourishing the Liver and Kidney. It has a wide range of clinical applications. Modern pharmacological studies have confirmed that <i>Psoralea corylifolia</i> and some of its active components are a "double-edged sword" that not only protects against liver damage but also causes liver damage. This paper reviews the dual effects of Chinese medicine <i>Psoralea corylifolia</i> and its active components on the liver and provides references for its further development and utilization.]]></description>
<pubDate>2020/7/3 13:44:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BAO Juan, ZHUO Shaoyuan, LIANG Meiting, XIE Huan, MA Mengying, GAN Siling and FENG Na]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BAO Juan, ZHUO Shaoyuan, LIANG Meiting, XIE Huan, MA Mengying, GAN Siling and FENG Na</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006011&flag=1]]></guid><cfi:id>365</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the hepatoprotective effect and mechanism of Chinese medicine on liver injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Liver injury, a threat to human health, is induced by chemicals, drugs, alcohol, and other factors, deteriorating to liver cirrhosis and liver cancer. And traditional Chinese medicine with the strengths of multi-target, and low toxicity were received more attention.This article reviewed the pathogenesis of chemical liver injury, immunological liver injury, drug induced-liver injury and alcoholic liver injury, and the pharmacological mechanism of traditional Chinese medicine in liver injury in recent years, providing a theoretical basis for the further treatment on liver injury．]]></description>
<pubDate>2020/5/28 11:25:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHENG Rongyao and LI Tingting]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Rongyao and LI Tingting</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005008&flag=1]]></guid><cfi:id>364</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of pharmacological activity of resveratrol]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Resveratrol is a non-ketone polyphenolic compound containing a stilbene structure.It is present in many common medicinal plants and has various pharmacological activities such as antitumor, antioxidation, antibacterial and cardiovascular protection. In this paper, the research progress of pharmacological activities of resveratrol in recent years was reviewed, which provided a basis for further development and utilization of resveratrol.]]></description>
<pubDate>2020/5/28 11:25:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Xu, LI Fenglu, XING Xiaoyi, YANG Wenqiang, WANG Zhen and YU Xiuling]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Xu, LI Fenglu, XING Xiaoyi, YANG Wenqiang, WANG Zhen and YU Xiuling</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005009&flag=1]]></guid><cfi:id>363</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of targeted liposomes]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the deep research on liposomes,research on targeted liposomes has also made great progress.Targeting liposomes is an ideal pharmaceutical carrier with the advantages of high targeting,low toxicity and long-term sustained release.In recent years, targeting liposomes has become a research hotspot of tumor targeted therapy. In this paper,we focused on the classification, advantages and disadvantages of targeted liposomes, and reviewed the research progress of targeting liposomes.It would provide a reference for further research on liposomes.]]></description>
<pubDate>2020/5/28 11:25:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Guilan<sup>1,2</sup>, LI Wenjun<sup>1</sup> and WANG Chunhua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Guilan<sup>1,2</sup>, LI Wenjun<sup>1</sup> and WANG Chunhua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005010&flag=1]]></guid><cfi:id>362</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Etiology of chronic prostatitis and research progress on the treatment of traditional Chinese medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chronic prostatitis/chronic pelvic pain syndromes(CP/CPPS) is a complex and comprehensive disease that occurs in adult males. It has been the focus of scholars at home and abroad. In recent years, there are many researches and clinical reports about the cause of the disease.However,there is still no conclusion.The multi-component and multi-target of traditional Chinese medicine has played an important role in its treatment, and its research is very necessary. This article reviewed the etiology of CP/CPPS and the effect of traditional Chinese medicine treatment, which may provide a reasonable basis for further research and treatment of CP/CPPS.]]></description>
<pubDate>2020/5/28 11:25:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CUI Xingxing and YU Feng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Xingxing and YU Feng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005011&flag=1]]></guid><cfi:id>361</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacological effects of Borneol and Borneol ester]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Borneol has been used as adjuvant medicine in China for thousands of years.Modern pharmacological studies have shown that borneol can protect the central nervous system,improve the function of learning and memory,promote permeability,inhibit bacteria and fight inflammation.However,the application of borneol is limited by its high volatility,irritability to gastric mucosa and reproductive toxicity.Therefore, many current studies have used the prodrug principle to synthesize borneol ester with natural active molecules or proprietary drugs, and found that borneol ester is lower toxicity and more effective than that of borneol. At the same time borneol ester exerted other new functions, such as cardiovascular protection, treatment of Alzheimer's disease, tumor cell inhibition and so on. Further studies are needed to develop borneol ester for clinic usage.]]></description>
<pubDate>2020/5/6 16:00:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Yufeng<sup>1</sup>, ZHU Zeyu<sup>2</sup>, CHEN Jingnan<sup>3</sup>, PI Jiakai<sup>3</sup> and WEI Yuchen<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Yufeng<sup>1</sup>, ZHU Zeyu<sup>2</sup>, CHEN Jingnan<sup>3</sup>, PI Jiakai<sup>3</sup> and WEI Yuchen<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004007&flag=1]]></guid><cfi:id>360</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role and mechanism of natural products on GSH in preventing and treating of liver diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Glutathione (GSH) is the most abundant non-protein thiol in mammals, which has powerful functions of anti-oxidation, detoxification, regulating apoptosis and immunity. In many liver diseases, the homeostasis of GSH is disrupted by impaired synthesis and transport pathway or by excessive consumption. The destruction of GSH homeostasis in the liver will not only produce ROS to oxidate proteins, DNA and lipids, but also affect various signal pathways involved in metabolism, proliferation and so on. These will lead to the pathogenesis of various liver diseases. Flavonoids and other natural products have a good role in the prevention and treatment of liver diseases. This review introduced the role of GSH in liver diseases and the mechanism of drug intervention, providing new ideas for the prevention and treatment of liver diseases.]]></description>
<pubDate>2020/5/6 16:00:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Jie, DING Yaxue, ZONG Yixuan and DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Jie, DING Yaxue, ZONG Yixuan and DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004008&flag=1]]></guid><cfi:id>359</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Resource utilization situation and development trend of <i>Paeoniae Radix Alba</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper mainly introduces four aspects of the <i>Paeoniae Radix Alba</i>,including  historical traceability, the current status of resource utilization (planting area distribution, planting area and yield,export trade,domestic supply and demand),the main problems and future development trends and prospects.This paper also systematically summarized the scale development and production processing of <i>Paeoniae Radix Alba</i> in recent years and pointed out the problems of processing technology and technical equipment upgrade during the process of planting and processing.Moreover,the future development has been discussed to provide a theoretical basis for the future industrial development of <i>Paeoniae Radix Alba</i>.]]></description>
<pubDate>2020/5/6 16:00:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HAN Jinlong<sup>1</sup>, TIAN Beijing<sup>1</sup>, SHEN Chenggang<sup>1</sup>, NI Dapeng<sup>1</sup>, WANG Xianchang<sup>1</sup>, XIE Xinjing<sup>2</sup> and WANG Zhifen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Jinlong<sup>1</sup>, TIAN Beijing<sup>1</sup>, SHEN Chenggang<sup>1</sup>, NI Dapeng<sup>1</sup>, WANG Xianchang<sup>1</sup>, XIE Xinjing<sup>2</sup> and WANG Zhifen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004009&flag=1]]></guid><cfi:id>358</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on preparation of hyaluronic acid]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hyaluronic acid is a kind of acidic mucopolysaccharide, which has excellent physiological functions, such as moisturizing, lubricating and promoting wound healing. It has high commercial value and is widely used in pharmaceutical, cosmetic products and cosmetology This paper summarizes the development and recent research hotspots of production of hyaluronic acid, methods for determination of hyaluronan molecular weight, and looks forward to the development trend of it.]]></description>
<pubDate>2020/5/6 16:00:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QU Xiaomei<sup>1</sup>, GUO Daliang<sup>1</sup>, LIU Yang<sup>1</sup>, ZHAO Yu<sup>2</sup> and LIU Yuxuan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QU Xiaomei<sup>1</sup>, GUO Daliang<sup>1</sup>, LIU Yang<sup>1</sup>, ZHAO Yu<sup>2</sup> and LIU Yuxuan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004010&flag=1]]></guid><cfi:id>357</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[星形胶质细胞-神经元相互作用与抑郁症]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/4/20 13:55:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘思敏,洪浩]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘思敏,洪浩</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003009&flag=1]]></guid><cfi:id>356</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[同物异名植物盆架树化学成分及药理活性研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/4/20 13:55:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[尤钰琳<sup>1</sup>,孙雪明<sup>2</sup>,李菲菲<sup>1</sup>,王姝麒<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>尤钰琳<sup>1</sup>,孙雪明<sup>2</sup>,李菲菲<sup>1</sup>,王姝麒<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003010&flag=1]]></guid><cfi:id>355</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[布鲁顿酪氨酸激酶（BTK）信号通路与疾病]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/4/20 13:55:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈潇,龚国清]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈潇,龚国清</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003011&flag=1]]></guid><cfi:id>354</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[青心酮在医药领域的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/4/20 13:55:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[曲梅,孙娜,崔艳茹,吕玉涵,段煜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>曲梅,孙娜,崔艳茹,吕玉涵,段煜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003012&flag=1]]></guid><cfi:id>353</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[线粒体功能障碍与阿尔茨海默病发病的相关性研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 14:28:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[胡钰慧,何玲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡钰慧,何玲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002009&flag=1]]></guid><cfi:id>352</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我国抗菌中药的研发投入和专利成果分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 14:28:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[袁月梅,姚美村,白丽红]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>袁月梅,姚美村,白丽红</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002010&flag=1]]></guid><cfi:id>351</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[阿卡波糖药理研究进展及其临床应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 14:28:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[程鹏<sup>1</sup>,李玉慧<sup>1</sup>,郭瑞臣<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>程鹏<sup>1</sup>,李玉慧<sup>1</sup>,郭瑞臣<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002011&flag=1]]></guid><cfi:id>350</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[韦伯潘力氏小体及其内容物对血栓形成的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 14:28:10</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王芳磊,龚国清]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王芳磊,龚国清</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002012&flag=1]]></guid><cfi:id>349</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[以蛋白翻译后修饰的视角探究脂肪肝的发病机制]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:26</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张嘉洸,盛亮]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张嘉洸,盛亮</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001007&flag=1]]></guid><cfi:id>348</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[银杏叶提取物对神经退行性疾病的作用机制及研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:26</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张徽,王淑静,袁天宇,杨骄,代民言,张琦,金成斌]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张徽,王淑静,袁天宇,杨骄,代民言,张琦,金成斌</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001008&flag=1]]></guid><cfi:id>347</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[二氢吡啶类钙拮抗剂药物基因组学的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[魏加莉,周静,李宁,赵娣,陈西敬]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>魏加莉,周静,李宁,赵娣,陈西敬</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001009&flag=1]]></guid><cfi:id>346</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[抗风湿性关节炎的中药及作用机制研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘婷<sup>1,2</sup>,张斗胜<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘婷<sup>1,2</sup>,张斗胜<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001010&flag=1]]></guid><cfi:id>345</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[IL-7及IL-15在肿瘤免疫疗法中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[聂文冰,尹鸿萍]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>聂文冰,尹鸿萍</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001011&flag=1]]></guid><cfi:id>344</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent research progress on the antioxidant activity of <i>Glycyrrhiza</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202012008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a common Chinese medicine, <i>Glycyrrhiza</i> is widely used in clinical practice. As a natural antioxidant, its antioxidant activity has attracted more and more attention. In order to provide reference for further study and clinical application of <i>Glycyrrhiza</i> antioxidation, this paper reviewed the relative literatures at home and abroad in recent years.]]></description>
<pubDate>2021/1/12 9:35:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Nianhong<sup>1</sup>, HUA Min<sup>2</sup>, DAI Yanpeng<sup>1</sup>, SHI Dianhua<sup>1</sup>, ZHOU Qian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Nianhong<sup>1</sup>, HUA Min<sup>2</sup>, DAI Yanpeng<sup>1</sup>, SHI Dianhua<sup>1</sup>, ZHOU Qian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202012008&flag=1]]></guid><cfi:id>343</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacological effects and structural modification of celastrol]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202012009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Celastrol is one of the active ingredients in <i>Tripterygium wilfordil</i> Hook.f. It is a natural friedelane pentacyclic triterpene which possesses a variety of pharmacological activities. Natural products as well as their derivatives serve as important sources in discovery of new bioactive agents. Therefore, many studies via synthesizing the derivatives of celastrol to find some more bioactive candidate compounds have been carried out. In this paper, the recent research progress of pharmacological activity and structural modification of celastrol are critically reviewed, which is of great significance for its further pharmacological research, providing valuable guidance for the synthesis of new high-efficiency and low-toxicity celastrol derivatives.]]></description>
<pubDate>2021/1/12 9:35:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Hailan, XU Shaohua, XU Wei, SHA Mei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Hailan, XU Shaohua, XU Wei, SHA Mei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202012009&flag=1]]></guid><cfi:id>342</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[近年来，社区获得性肺炎成为最为常见的肺部感染，发病群体极为广泛，造成严重的健康威胁。本文对抗菌药物细菌耐药性、药物递送系统（DDS）在肺部感染治疗方面的优势和研究难点等研究进行归纳和总结，简要介绍了抗菌药物在肺部治疗的现状，针对肺部感染的药物递送，特别是针对铜绿假单胞菌（PA）感染，讨论了目前肺部递送抗菌药物载体的研究进展及DDS与肺部生物屏障的相互作用，以期为解决抗菌药物治疗方面面临的重大问题和克服肺部生物学屏障、提高药物在感染病灶的生物利用度提供一种新的思路。]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years,community-acquired pneumonia has become the most common lung infection, with a very wide range of disease groups, posing a serious health threat. This article summarizes studies on antibacterial drug resistance, drug delivery system advantages and research difficulties in the treatment of lung infections, and briefly introduces the current status of antibacterial drugs in lung treatment.Drug delivery for lung infections, Especially for Pseudomonas aeruginosa (PA) infection, the current research progress of antibacterial drug delivery in the lungs and the interaction between DDS and the biological barrier of the lungs are discussed in order to solve the major problems faced by antibacterial drugs and overcome the lung It can provide a new way of thinking about the biological barrier and improve the bioavailability of drugs in infected lesions.]]></description>
<pubDate>2020/12/7 15:11:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李楠，刘畅，刘洪斌]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李楠，刘畅，刘洪斌</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011010&flag=1]]></guid><cfi:id>341</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Design of traditional Chinese Medicine granule based on Classical prescription]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[It is one of the hot spots in the second development of traditional Chinese medicine compound preparation. As one of the important carriers of its inheritance and innovation, the traditional Chinese medicine compound granule has the characteristics of quick effect and easy to take.In view of the complex composition of traditional Chinese medicine, the research is not deep,the quality is not easy to control and so on, this paper from the basic properties of drugs, combined with the current new drug research and development model,put forward the design principle of compound granule of traditional Chinese medicine,in order to return to the classic,inheritance and innovation thought to study the source of medicinal materials,processing and preparation process system.]]></description>
<pubDate>2020/12/7 15:11:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李鑫，闫影，孙志伟，张文君]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李鑫，闫影，孙志伟，张文君</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011011&flag=1]]></guid><cfi:id>340</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Latest research progresss in biomarkers of heart failure]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Heart failure is a complex clinical syndrome with high incidence rate and mortality worldwide. Good biomarkers are helpful for risk stratification and prognosis assessment. At present, natriuretic peptide is the only biomarker to be entered into the guidelines of heart failure.In recent years,a variety of biomarkers related to the pathological process of heart failure have emerged one after another, which are related to fibrosis,myocardial cell injury,matrix remodeling and so on.These biomarkers have certain value for screening and differentiation of heart failure, disease risk stratification and prognosis evaluation. This paper summarized and analyzed these biomarkers.]]></description>
<pubDate>2020/12/7 15:11:54</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[贾雪<sup>1,2</sup>，王相阳<sup>2</sup>，马晓慧<sup>2</sup>，阿基业<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>贾雪<sup>1,2</sup>，王相阳<sup>2</sup>，马晓慧<sup>2</sup>，阿基业<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011012&flag=1]]></guid><cfi:id>339</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on drug action pathways and targets for treating polycystic ovary syndrome]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Polycystic ovary syndrome( PCOS) is a common reproductive endocrine disorders in gynecology．Its pathogenesis is complex, including factors such as reproduction, endocrine, metabolism and psychology.The pathogenesis of polycystic ovary syndrome is still unknown. Women with polycystic ovary syndrome are at higher risk for cardiovascular disease, osteoporosis, and cancer, which has a significant impact on women's health and quality of life. This article introduced the pathways and targets for improving and treating polycystic ovary syndrome, in order to find better drugs to improve the patient's quality of life.]]></description>
<pubDate>2020/11/13 13:56:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HU Jie, HUANG Fang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Jie, HUANG Fang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010008&flag=1]]></guid><cfi:id>338</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in pharmacological study of Xiaochaihu Granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Xiaochaihu Granules (XCHG) has the functions of inducing sweat to dispel heat and protecting injured liver and stomach. In this paper, based on the existing pharmacological researches and clinical practices, the protective effects of XCHG, such as antiviral actions, antipyretic effects, anti-inflammation, immune regulation, liver and stomach protection, and reducing hormone side effects, were systematically reviewed to provide helpful reference for the XCHG’s further research and development.]]></description>
<pubDate>2020/11/13 13:56:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BI Cong<sup>1</sup>, ZHENG Ruwen<sup>1</sup>, JIANG Zhiqiang<sup>1</sup>, ZHANG Junhua<sup>1</sup>, HE Yixi<sup>1</sup>, WU Hao<sup>2</sup>, YAO Hongliang<sup>3</sup>, WANG Yonggang, LIU Hong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BI Cong<sup>1</sup>, ZHENG Ruwen<sup>1</sup>, JIANG Zhiqiang<sup>1</sup>, ZHANG Junhua<sup>1</sup>, HE Yixi<sup>1</sup>, WU Hao<sup>2</sup>, YAO Hongliang<sup>3</sup>, WANG Yonggang, LIU Hong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010009&flag=1]]></guid><cfi:id>337</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress on the construction of animal cirrhosis models]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cirrhosis is the final pathological histology result of liver fibrosis. Along the development of liver fibrosis, pseudolobuli is formed at first, then tissues of liver will deform and become hard, finally result to cirrhosis. It’s of great significance to build suitable cirrhosis models for the experience accumulation and clinical treatment. Unfortunately, a perfect example so far is not constructed based on the performance of existing models. Herein we summarize the merits and drawbacks of these cirrhosis models, which will be helpful to develop better animal cirrhosis models and clinic treatment of cirrhosis in the future.]]></description>
<pubDate>2020/11/13 13:56:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Song, NI Desheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Song, NI Desheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010010&flag=1]]></guid><cfi:id>336</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on traditional Chinese Herbal Paste]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese herbal paste prescription has a long history,definite therapeutic effect and is more widely used in clinic. The application of paste prescription is not limited to curing diseases, modern application pays more attention to health care.This paper is to summarize the historical source, clinical application, pharmacological research and quality control of the formula, looking into the future of the paste,and putting forward my own opinions on the production process, quality control and clinical application of the paste.in the hope of providing some reference for the development of the paste prescription.]]></description>
<pubDate>2020/11/13 13:56:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Ziyan<sup>1</sup>, GUO Daliang<sup>1</sup>, LIU Yang<sup>1</sup>, ZHAO Yu<sup>2</sup>, LIU Yuxuan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Ziyan<sup>1</sup>, GUO Daliang<sup>1</sup>, LIU Yang<sup>1</sup>, ZHAO Yu<sup>2</sup>, LIU Yuxuan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010011&flag=1]]></guid><cfi:id>335</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Stem cell therapy in autism spectrum disorders]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Autism spectrum disorders (ASD) are a group of heterogeneous neurodevelopmental disorders characterized by a wide range of cognitive, emotional, and neurobehavioral abnormalities, social interaction and communication dysfunctions, restricted interests, and repetitive and stereotypic verbal and nonverbal behaviors.Presently, the worldwide incidence is 12 per 1000 children. Despite its increasing rate, currently autism remains untreatable.Stem cells could exert a positive effect in ASDs through the following mechanisms:stimulation of repair in the damaged tissue, synthesizing and releasing anti-inflammatory cytokines and survival-promoting growth factors; integrating into existing neural and synaptic network, and restoring plasticity. The paracrine mechanisms of MSCs show interesting potential in ASD treatment.]]></description>
<pubDate>2020/11/13 13:56:47</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHANG Zheng, JI Ruilian, ZHANG Jie, LIU Sujing, WANG Lihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHANG Zheng, JI Ruilian, ZHANG Jie, LIU Sujing, WANG Lihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010012&flag=1]]></guid><cfi:id>334</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[色氨酸代谢与肾脏基本互作研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/10/22 16:02:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[谭蓓，张尊建，许风国，张培]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>谭蓓，张尊建，许风国，张培</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109009&flag=1]]></guid><cfi:id>333</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[DOT1L，治疗骨关节炎的新靶点]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/10/22 16:02:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[逯爱梅<sup>1</sup>，孙水<sup>2</sup>，于辰曦<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>逯爱梅<sup>1</sup>，孙水<sup>2</sup>，于辰曦<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109010&flag=1]]></guid><cfi:id>332</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[肝缺血再灌注在不同阶段的损伤机制和临床治疗策略]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/10/22 16:02:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[杜施嘉<sup>1</sup>，吴红茜<sup>2</sup>，史广江<sup>2</sup>，杨勇<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杜施嘉<sup>1</sup>，吴红茜<sup>2</sup>，史广江<sup>2</sup>，杨勇<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109011&flag=1]]></guid><cfi:id>331</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[菊苣酸的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/10/22 16:02:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王红<sup>1</sup>，冯帅<sup>1</sup>，史磊<sup>1</sup>，田新<sup>1</sup>，李峰<sup>1</sup>，李鹏<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王红<sup>1</sup>，冯帅<sup>1</sup>，史磊<sup>1</sup>，田新<sup>1</sup>，李峰<sup>1</sup>，李鹏<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109012&flag=1]]></guid><cfi:id>330</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[P2Y6在心血管疾病中的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/10/22 16:02:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张倩，胡庆华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张倩，胡庆华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109013&flag=1]]></guid><cfi:id>329</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[核桃分心木的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/9/9 11:28:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[曾诗榆，苏薇薇，王永刚]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>曾诗榆，苏薇薇，王永刚</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108009&flag=1]]></guid><cfi:id>328</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[比率型电化学传感器构建策略的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/9/9 11:28:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[杜敏<sup>1</sup>，郑雅妮<sup>2</sup>，戴乐天<sup>3</sup>，周学敏<sup>2</sup>，洪俊丽<sup>2</sup>，杨杰<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杜敏<sup>1</sup>，郑雅妮<sup>2</sup>，戴乐天<sup>3</sup>，周学敏<sup>2</sup>，洪俊丽<sup>2</sup>，杨杰<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108010&flag=1]]></guid><cfi:id>327</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中缝正中核的功能研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/9/9 11:28:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[韩晓蒙，洪浩，唐苏苏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩晓蒙，洪浩，唐苏苏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108011&flag=1]]></guid><cfi:id>326</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Viability PCR在活性微生物检测领域的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/9/9 11:28:13</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[姜大勇，解恒杰，伊廷存，徐立清，霍胜楠，程祥龙]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>姜大勇，解恒杰，伊廷存，徐立清，霍胜楠，程祥龙</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108012&flag=1]]></guid><cfi:id>325</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of gelatin-based bioink in pharmaceutical research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the current advancement of the bioprinting technique, in vitro models established by bioprinting have attracted great attention in the new drug screening and toxicity evaluation. As a novel tissue engineering technique, the most important part of bioprinting is the bioink, which is a mixture of biomaterials loaded with different cells. The gelatin-based bioinks have been widely used to print the three-dimension in vitro models for drug research and development, which showed obvious advantages compared with the two-dimension model. This article reviews gelatin and its derivatives-based bioinks which have been used for drug screening and toxicity evaluation. The prospect of new gelatin-based bioinks is discussed.]]></description>
<pubDate>2021/8/16 15:40:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Jungen<sup>1,2</sup>, ZHANG Lei<sup>3</sup>, HE Yuanzi<sup>1,2</sup>, ZHANG Junying<sup>4</sup>, WU Chunyong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Jungen<sup>1,2</sup>, ZHANG Lei<sup>3</sup>, HE Yuanzi<sup>1,2</sup>, ZHANG Junying<sup>4</sup>, WU Chunyong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107009&flag=1]]></guid><cfi:id>324</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in the treatment of Alzheimer's disease with traditional Chinese Medicine for promoting blood circulation and removing stasis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer's disease (AD) is a degenerative disease of central nervous system which is characterized by hyperphosphorylation of tau protein and senile plaques caused by deposition of beta amyloid. According to traditional Chinese medicine theory, AD is a chronic pathophysiological process, not a single organ disease caused by a single factor, but caused by the interaction of qi, blood, phlegm, depression, blood stasis and other diseases caused by internal injury of seven emotions, long illness and exhaustion, and old body deficiency. Chinese medicine treatment of AD drug research in recent years has made certain progress, especially herbs for promoting blood circulation to remove blood stasis play important roles. In this paper, AD treatment for promoting blood circulation to remove blood stasis drugs were summarized as follows, and the roles of promoting blood circulation to remove blood stasis drugs in the treatment of AD were expected.]]></description>
<pubDate>2021/8/16 15:40:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Yuhang, LAN Jiangchun, ZHANG Xiaoyu, YAN Liwen, ZHENG Huimin, HE Shan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Yuhang, LAN Jiangchun, ZHANG Xiaoyu, YAN Liwen, ZHENG Huimin, HE Shan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107010&flag=1]]></guid><cfi:id>323</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances on improving effects of traditional Chinese medicine in multiple organ dysfunction syndrome]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Multiple organ dysfunction syndrome (MODS) is a common condition, with a large number of etiologies and acomplicated treatment. At present, a single treatment method cannot achieve an effective treatment clinically for MODS. Traditional Chinese medicine has the characteristics of holistic concept and syndrome differentiation, and has the advantages of multi-target and multi-step treatment for MODS. This article reviewed the research progress of Traditional Chinese medicines in the prevention and treatment of MODS reported by Chinese and foreign journals in the past five years, which included following aspects such as intervention of inflammatory response, intervention of tissue ischemia-reperfusion injury, intervention of intestinal barrier function destruction, intervention of microcirculation disorders and other aspects.]]></description>
<pubDate>2021/8/16 15:40:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Zhuo, GONG Shuaishuai, REN Yuchuan, KOU Junping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Zhuo, GONG Shuaishuai, REN Yuchuan, KOU Junping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107011&flag=1]]></guid><cfi:id>322</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of high performance liquid chromatography / mass spectrometry in protein detection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the development of science, mass spectrometry has developed from a powerful tool for the analysis of molecular weight and structure of organic compounds to an indispensable technology for the analysis of biological macromolecules. In recent years, the combination of high performance liquid chromatography and mass spectrometry (HPLC-MS), which has strong separation ability, is developing rapidly. It has the advantages of high sensitivity, high resolution and strong specificity. It has been widely used in analysis of food, drug, biological samples and so on. In this paper, we reviewed the proteomics and qualitative and quantitative analysis of proteins by HPLC-MS.]]></description>
<pubDate>2021/8/16 15:40:09</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Jiayin, AN Yang, SU Jun, DU Guangguang, WANG Jia, DONG Qinghai, LIU Jihua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Jiayin, AN Yang, SU Jun, DU Guangguang, WANG Jia, DONG Qinghai, LIU Jihua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107012&flag=1]]></guid><cfi:id>321</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[抗衰老中药的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[郑心怡，马国]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郑心怡，马国</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106009&flag=1]]></guid><cfi:id>320</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[瞬时受体电位离子通道与银屑病]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[钟尤，马玉香，强磊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>钟尤，马玉香，强磊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106010&flag=1]]></guid><cfi:id>319</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[水飞蓟素的药理学研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王伊宁，张甜甜，李玮萱，乔子桐，张纯刚]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王伊宁，张甜甜，李玮萱，乔子桐，张纯刚</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106011&flag=1]]></guid><cfi:id>318</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[嘌呤受体信号通路在肺部疾病中的作用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[黄麒，胡庆华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>黄麒，胡庆华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106012&flag=1]]></guid><cfi:id>317</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Interaction between intestinal flora and bile acids in nonalcoholic fatty liver disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Nonalcoholic fatty liver disease (NAFLD) is a global disease, and its incidence rate is rising yearly. Research showed that intestinal flora plays a significant role in metabolism and immunity, and bile acid is the key signal factor regulating blood glucose, blood lipid and energy metabolism. As vital roles of the gut-liver axis, both of them are closely related to the occurrence and development of NAFLD. To clarify the complex relationship between intestinal flora and bile acids in NAFLD is a crux clue for the treatment of NAFLD. Therefore, this article reviewed the interaction between intestinal flora and bile acids in NAFLD, hoping to provide reference for the treatment of NAFLD.]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Ping, LIN Yining]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Ping, LIN Yining</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105007&flag=1]]></guid><cfi:id>316</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the effects of monocyte/macrophage autophagy in liver diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The immune function of liver is crucial to maintain the homeostasis of the whole body. In a pathological state, macrophages from various sources in liver play different roles, affecting the normal function of liver. Numerous studies indicated that almost functions of macrophages are closely related to autophagy, such as differentiation and polarization of macrophage, release of cytokines and inflammatory response. It is current hotspot to research the role of macrophage autophagy in liver diseases, and it has gradually become a potential target for the prevention and therapy of liver diseases. This paper reviewed the effect of monocyte/macrophage autophagy in liver disease.]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Min, SHEN Qin, WANG Xiaoping, QIANG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Min, SHEN Qin, WANG Xiaoping, QIANG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105008&flag=1]]></guid><cfi:id>315</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent Advances of the Berberrubine pharmacological action and structural]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Berberrubine as a natural drug, have varieties of pharmacological activities. Many investigations have been many reported on the synthesis and biological activities of berberrubine.This paper have summarized the anti-cancer,anti-inflammation,anti-nervous system disease,anti-cardiovascular disease,anti-fungus and anti-diabetes of berberrubine.At the same time,the structure modification were also summarized,which provides a reference for its reasonable development and utilization.]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QI Fei, WANG Guosheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QI Fei, WANG Guosheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105009&flag=1]]></guid><cfi:id>314</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on model and signaling pathways of vascular dementia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Vascular dementia is a severe cognitive impairment syndrome caused by ischemic stroke, hemorrhagic stroke and cerebrovascular disease causing hypoperfusion in the brain region.Vascular dementia can be prevented because preventive measures such as control of vascular risk factors, antiplatelet therapy and anticoagulation therapy have been established for pathogenic cerebrovascular diseases,but there is no symptomatic treatment for vascular dementia.Understanding its basic mechanism and model is very important for the treatment of vascular dementia.This article describes some animal models of vascular dementia,and briefly introduces current research on its pathogenesis,providing a reference for the treatment and medication of vascular dementia.]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Xining, CHEN Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xining, CHEN Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105010&flag=1]]></guid><cfi:id>313</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on Identification of Rhubarb Based on Rhapontin Detection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Rhubarb is one of the most widely used traditional Chinese medicines. As recorded in Chinese pharmacopoeia (2015th edition), there are about 153 kinds of Chinese traditional compound medicine which contain rhubarb. However, the falsifies of rhubarb influence clinical application seriously. Rhapontin, an important identification marker, is used for the identification of crude drug of rhubarb, Jiuweigantai capsule, Sanhuang tablets and Chiho capsule as recorded in Chinese pharmacopoeia. However, it is still insufficient for so many agents.What’s more,the detection methods vary from the different amount of rhubarb and different preparations. In this paper, several detection methods of rhapontin were summarized based on domestic and foreign literatures in the past 20 years, which provided valuable references for further researches on the identification of rhubarb.]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Xue<sup>1</sup>, XIN Jie<sup>1,2</sup>, WANG Zhen<sup>1,2</sup>, ZHANG Bo<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Xue<sup>1</sup>, XIN Jie<sup>1,2</sup>, WANG Zhen<sup>1,2</sup>, ZHANG Bo<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105011&flag=1]]></guid><cfi:id>312</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[藏药湿生扁蕾的配伍研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[现代藏药在预防和治疗多种疾病中发挥了不可替代的重要作用,而各种药物配伍使用更好地发挥药物治疗作用。近年来针对藏药湿生扁蕾的配伍运用愈加广泛,广大的植物药学研究工作者对藏药湿生扁蕾的配伍方面进行了研究。本文主要收集了近年来关于藏药湿生扁蕾配伍研究的相关文献,对其临床配伍应用研究成果和理论研究成果进行分析整理为湿生扁蕾的临床应用和研究提供了参考。]]></description>
<pubDate>2021/5/25 19:40:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yuemin, BO Shuangqin, JING Ming]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yuemin, BO Shuangqin, JING Ming</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104009&flag=1]]></guid><cfi:id>311</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on nuclear G protein-coupled receptors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In classical pharmacology, G protein-coupled receptors are characterized to initiate signal transduction through their activation on the cell surface as a cell response to extracellular stimuli.However,nuclear GPCRs (nGPCRs) have been found with particular features differed from plasma membrane GPCRs (mGPCRs) such as origins,functions,signaling pathways and patterns of action.This article summarized the current research progress on nGPCRs,with a purpose to providing new ideas and strategies for drug development targeting GPCRs.]]></description>
<pubDate>2021/5/25 19:40:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[KE Xuan, HONG Hao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KE Xuan, HONG Hao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104010&flag=1]]></guid><cfi:id>310</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of gene drug pulmonary delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Various lung diseases such as asthma, emphysema,cystic fibrosis,lung virus infection and lung cancer have severely affected human health.Gene therapy has opened up a new therapeutic approach for the treatment of lung diseases.However,because naked therapeutic genes are easily degraded and have poor targeting ability,a safe and effective delivery system is needed.This article will discuss the drug delivery barriers and feasible methods for gene drug delivery to the lungs in vivo.]]></description>
<pubDate>2021/5/25 19:40:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Yue<sup>1</sup>, SUN Jingxin<sup>1</sup>, JIN Guangyu<sup>2</sup>, JIN Yong<sup>1</sup>, SUN Dandan<sup>1</sup>, QUAN Jishan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yue<sup>1</sup>, SUN Jingxin<sup>1</sup>, JIN Guangyu<sup>2</sup>, JIN Yong<sup>1</sup>, SUN Dandan<sup>1</sup>, QUAN Jishan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104011&flag=1]]></guid><cfi:id>309</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[抗幽门螺杆菌的用药研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[幽门螺杆菌(<i>Helicobacter pylori</i>, Hp) 感染不仅与胃炎、消化性溃疡、胃癌等消化系统疾病关系密切，还与缺血性心脑血管疾病、脑出血、糖尿病等多种非消化系统疾病有关。目前用于根除幽门螺杆菌感染的药物主要有质子泵抑制剂、抗生素、铋剂、益生菌及中药等。然而，面对我国基数庞大的感染人口，幽门螺杆菌的根除率却在逐年下降，因此越来越多的联合用药方案被应用于临床治疗。本文将从抗幽门螺杆菌药物、联合用药方案以及药物相互作用等方面进行综述。]]></description>
<pubDate>2021/5/25 19:40:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Yang<sup>1</sup>, ZHU Junbo<sup>1</sup>, LI Xiangyang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Yang<sup>1</sup>, ZHU Junbo<sup>1</sup>, LI Xiangyang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104012&flag=1]]></guid><cfi:id>308</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of the anti-inflammatory and immunomodulatory effects of hydrogen sulfide]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hydrogen sulfide (H2S) is a gaseous signaling molecule with multiple bioactivities,such as anti-oxidation,regulation of cell cycle,pro-apoptosis,anti-inflammation and immune modulation,etc.Several compounds, termed as H2S donors,release H2S directly or indirectly to play protective and therapeutic effects on cardiovascular diseases,autoimmune diseases,neurodegenerative diseases, diabetes, cancers and many other diseases.This review mainly summarized the research advances of H2S and its donors in anti-inflammation and immunomodulation.]]></description>
<pubDate>2021/5/25 19:40:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Yajing, DAI Yue]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yajing, DAI Yue</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104013&flag=1]]></guid><cfi:id>307</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application progress of drug crystal forms in drug research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Drug crystal determines the safety, clinical effectiveness and quality control of drugs, which has become a hot issue in the field of pharmaceutical research at home and abroad.In the research process of drug crystal form,the use of efficient crystal form preparation methods to obtain the ideal drug crystal form is an important part of drug research and development.It is very important to take appropriate crystal form detection method to accurately detect and evaluate crystal form drug to ensure the quality of drug preparation.Although the polymorphism of the drug restricts the clinical application of the drug,it also makes the clinical application of the drug more selective. In this paper,the preparation methods,evaluation methods and clinical application of drug polymorphic forms are reviewed, which can provide reference for the research and development of drug polymorphic forms.]]></description>
<pubDate>2021/5/25 19:40:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Wenjun, LI Donghui, LYU Chunyan, CHEN Yonglin, LI Xiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Wenjun, LI Donghui, LYU Chunyan, CHEN Yonglin, LI Xiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104014&flag=1]]></guid><cfi:id>306</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of hypoxia-inducible factor-1/2 in hepatocellular carcinoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world with high morbidity. At present, the clinical treatments of liver cancer are very limited. Although only Sorafenib and Lenvatinib are approved as first-line systemic treatments, which are available for advanced unresectable hepatocellular carcinoma, they still fail to provide a significant survival benefit to patients.  Therefore, it is particularly urgent to find new therapeutic targets.  A large number of studies indicated that hypoxia is an important feature of solid tumors, and under hypoxic conditions, tumors initiate a series of inducing factors to adapt to this environment. Hypoxia inducible factors (HIFs) family is one of the inducing factors that plays a core regulatory role.  It has been reported that HIFs were involved in the occurrence and development of hepatocellular carcinoma, and there is a significant correlation with clinical prognosis. Therefore, the development of therapeutic targets based on HIFs has become a key spot in HCC therapy.  This article briefly reviewed the role of HIF-1α and HIF-2α , two major members of the HIFs family, in hepatocellular carcinoma, and provides new strategies for the research and treatment of HCC.]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GUO Haixin, HU Weiwei, YANG Yong, CHEN Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Haixin, HU Weiwei, YANG Yong, CHEN Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103009&flag=1]]></guid><cfi:id>305</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[藏药湿生扁蕾抗纤维化的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[年来广大的药学工作者对藏药湿生扁蕾抗纤维化方面进行了很多研究，表明藏药湿生扁蕾中的化学成分在抗结肠纤维化、抗肺纤维化、抗肝纤维化三个方面有显著疗效。本文收集了近几年来关于藏药湿生扁蕾的文献，对藏药湿生扁蕾关于抗纤维化方面研究的文献进行整理和分析，并系统阐述了藏药湿生扁蕾抗纤维化的研究进展。]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BO Shuangqin, Jingming]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BO Shuangqin, Jingming</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103010&flag=1]]></guid><cfi:id>304</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the role of fibroblasts in skin wound repair]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Skin is the largest organ which protects the human body from external disturbances. Damaged skin may result in impaired body function or even death. Various acute and chronic skin injuries significantly affect the quality of patients’ life. It is very important to investigate the specific molecular mechanism of skin wound repair in medical research.Fibroblasts exist in most organs and are responsible for the production and turnover of extracellular matrix (ECM) molecules. It has been reported that fibroblasts change their phenotype during the tissue repair, which can increase the production and contraction of extracellular matrix at the injury site. Fibroblasts in the skin exist in the dermis. When skin is damaged, fibroblasts and their activated forms, myofibroblasts, participate in skin wound repair to a certain extent. On the one hand, fibroblasts are involved in the formation of granulation tissue at the early stage. On the other hand, myofibroblasts have effect on pathological scar formation after wound healing.]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Wenshu, XU Yujiao, ZHUO Yating, LIU Yunyao, QIANG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Wenshu, XU Yujiao, ZHUO Yating, LIU Yunyao, QIANG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103011&flag=1]]></guid><cfi:id>303</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The application of SPR in drug research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The surface plasma resonance (SPR)technology has been widely applied in the field drug research.Through the study of the principle of surface plasmon resonance technology, this article reviewed the main role of surface plasmon resonance technology in biomedical research, and in the application of various of diseases, and the technology development trend and prospect in the future.]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHENG Xiyan, LIU Yunyao, JIA Xirong, DONG Meng, LI Xurui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Xiyan, LIU Yunyao, JIA Xirong, DONG Meng, LI Xurui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103012&flag=1]]></guid><cfi:id>302</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Overview of research on ursodeoxycholic acid]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ursodeoxycholic acid is used as a treatment for gallstones 、cholestatic cirrhosis and other diseases,which has the important features include gallbladder, protecting liver cells and immune regulation.The advances in the pharmacological effects and mechanism of ursodeoxycholic acid were reviewed, guidanced for clinical applications and drug development in the further.]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YOU Meigui<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YOU Meigui<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103013&flag=1]]></guid><cfi:id>301</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress of Tibetan Medicine on Cerebral Ischemic Diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cerebral ischemic disease is one of the main diseases that endanger human health.The pathogenesis of cerebral ischemic injury includes energy metabolism disorders, metabolic acidosis,Ca<sup>2+</sup> overload, excitatory amino acid secretion,increased free radical production,inflammatory response,apoptosis and autophagy.The characteristics of Tibetan medicine are special,and the composition of Tibetan medicine is complex,the processing technology and the method of taking it are unique,making Tibetan medicine have great therapeutic potential for cerebral ischemic diseases.This article reviews the pathogenesis of cerebral ischemic disease and the research progress of Tibetan medicine in the treatment of cerebral ischemic disease,providing a theoretical basis for the treatment of cerebral ischemic disease by Tibetan medicine.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Qian<sup>1</sup>, YANG Jianxin<sup>1</sup>, LIU Guiqin<sup>2</sup>, LI Xiangyang<sup>1,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Qian<sup>1</sup>, YANG Jianxin<sup>1</sup>, LIU Guiqin<sup>2</sup>, LI Xiangyang<sup>1,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102008&flag=1]]></guid><cfi:id>300</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Overview of pharmacological activities of aspirin derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Aspirin, with a variety of pharmacological activities,is one of the typical conventional drugs with new use. In recent years, its derivatives were obtained via modifying and transforming its structure in order to enhance its activities and deduce its side effects. In this paper, 30 aspirin derivatives were summarized in the synthetic routes and pharmacological activities. The pharmacological activities of 30 aspirin derivatives mainly focus on antipyretic analgesia, anti-inflammatory, anti-osteoporosis, prevention and treatment of cardiovascular and cerebrovascular diseases,anti-tumor activities and so on. It can provide reference for related research and application.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Dinghao, XING Zhihua, LI Xingyang, WANG Qiqi, BAO Ran, CHENG Meichi, ZHANG Fengyang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Dinghao, XING Zhihua, LI Xingyang, WANG Qiqi, BAO Ran, CHENG Meichi, ZHANG Fengyang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102009&flag=1]]></guid><cfi:id>299</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Prospects of development of TCM injection and suggestions for re-evaluation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to get rid of the dilemma of traditional Chinese medicine (TCM) injections and promote its clinical safe application and real development, the contents of TCM injections were sorted and discussed to come up with the suggestions on reevaluation of TCM injections, such as definition modification, prescription source analysis, pharmacodynamics and the interpretation of adverse reaction mechanism, the determination of TCM markers, the improvement of quality standards and the specification of instruction guides, etc. ,which were carried out by systematic literature collation and analysis, based on the main document retrieval tools such as CNKI, Vip, Wanfang and other databases , through the subject words "TCM injection" including "prospects of development" or "review", "adverse reactions","allergic reactions", "safety evaluation", "safety re-evaluation", "clinical application" and so on, combing with relevant laws and regulations promulgated by authoritative departments.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Yijing, LI Xiaodong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Yijing, LI Xiaodong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102010&flag=1]]></guid><cfi:id>298</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in removal of heavy metals from amino acid and peptide materials]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Heavy metals are currently one of the "carcinogenic, teratogenic and mutagenic" pollutants with great biotoxicity. It is the consistent goal of researchers to find a method for the removal of heavy metals with high removal rate,good biological safety and no secondary pollution.Because the adsorption method has simple operation, high efficiency, environmental protection, economic savings gradually recognized according to the characteristics of the activated carbon, cellulose,such as adsorption material is widely used,adsorption materials,nano magnetic iron oxide and other new adsorption materials arises at the historic moment,it is applied in the medical field of amino acids for hydroxyl,carboxyl,amino,thiol groups with the characteristics of heavy metal ion chelating has obvious advantage in removal of heavy metals, but not yet there are research results of the literature in this field to sum up, therefore, this article mainly from the current existing amino acid type, effect of polymer and the mechanism of action of removing heavy metal were reviewed, It provides reference for the removal of heavy metals in aqueous solution and traditional Chinese medicine solution in the future.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Xueqing<sup>1</sup>, ZHANG Xuejie<sup>2</sup>, SHEN Yiping<sup>2</sup>, HUANG Tiantian<sup>3</sup>, GUO Yifei<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Xueqing<sup>1</sup>, ZHANG Xuejie<sup>2</sup>, SHEN Yiping<sup>2</sup>, HUANG Tiantian<sup>3</sup>, GUO Yifei<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102011&flag=1]]></guid><cfi:id>297</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in the mechanism of SIRT1 improving diabetic vascular endothelial function]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Vascular endothelial dysfunction is the initiating factor and main pathophysiological basis of diabetic vascular complications,and it is an early sign of diabetic vascular disease.The ultimate goal of clinical treatment of diabetes is to prevent diabetic vascular disease, so improving vascular endothelial dysfunction is an important target for the treatment of diabetes.A large number of studies have shown that SIRT1 is closely related to high glucose induced endothelial injury and can improve the function of vascular endothelial cells by resisting inflammation,oxidation,and senility.This article will briefly summarized the mechanism of SIRT1 improving vascular endothelial function.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LEI Yongfang<sup>1,2</sup>, NIE Xuekun<sup>2</sup>, LIN Minhua<sup>2</sup>, WANG Yujia<sup>2</sup>, CHEN Zichun<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LEI Yongfang<sup>1,2</sup>, NIE Xuekun<sup>2</sup>, LIN Minhua<sup>2</sup>, WANG Yujia<sup>2</sup>, CHEN Zichun<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102012&flag=1]]></guid><cfi:id>296</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on amino acid metabolism regulation and tumor immunity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Warburg's major discovery in aerobic glycolysis established that metabolic reprogramming is the primary feature of cancer. In the process of tumorigenesis and tumor development, it is often accompanied by abnormal metabolism of sugars, lipids and amino acids. Many tumors use the flexibility of their metabolism to redistribute nutrients to their advantage and thus get away from immune surveillance. Previous studies on tumor metabolism mainly focused on glucose metabolism. In recent years, the contribution of amino acid metabolism to tumor development has gradually been paid more attention. Amino acids, as essential nutrients for the survival of all cells in the body, their metabolic processes are also inextricably linked to tumor development. This paper reviews the role of several types of amino acids in tumorigenesis and tumor immunity.]]></description>
<pubDate>2021/3/1 14:21:04</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Xingyi, WANG Xu, ZHOU Tao, YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Xingyi, WANG Xu, ZHOU Tao, YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101007&flag=1]]></guid><cfi:id>295</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of PD⁃1/PD-L1 pathway in melanoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Programmed cell death 1 (PD-1) and its ligand (PD-L1) are a pair of co-stimulatory molecules, PD-1/PD-L1 pathway play an important role in the processes of production,development and escape.Activating the PD-1/PD-L1 pathway can inhibit tumor-specific T cell activity.It has been proved that PD-1 activation contributes to tumor immune escape and PD-1/PD-L1 inhibitors can enhance immune response,inhibit the growth of tumor cells.In recent years,great achievements have been got in melanoma about PD-1/PD-L1 inhibitors. This article reviewed the expression of PD-1/PD-L1 in melanoma and the clinical application of PD-1/PD-L1 inhibitors.Moreover,we further discussed the clinical application prospect and adverse reactions of PD-1/PD-L1 inhibitors.]]></description>
<pubDate>2021/3/1 14:21:04</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Huazhu, LIU Xiaobo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Huazhu, LIU Xiaobo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101008&flag=1]]></guid><cfi:id>294</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical constituents and pharmacological action of <i>Dendrobium</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The research progress of <i>Dendrobium</i> chemical composition and pharmacological action was reviewed, which provided theoretical reference for the rational development and clinical application of <i>Dendrobium</i>.<b>Methods</b>  Based on "<i>Dendrobium</i>" and other key words, the literature about chemical composition, pharmacological action and processing technology of <i>Dendrobium</i> in recent ten years was inquired in the database of CNKI, PubMed and so on, and representative literature were selected for review.<b>Results</b>  The chemical components of <i>Dendrobium</i> are complex, mainly including polysaccharides, alkaloids, flavonoids, phenanthrene, benzenes, volatile oils, amino acids and trace elements, etc. It has the pharmacological activities of anti-oxidation, anti uric acid, anti-tumor, anti fatigue, hypoglycemia, immune regulation, etc.<b>Conclusions</b>  With the further study of active components and pharmacological effects, <i>Dendrobium</i> will have a broad application prospect in medicine, health care and other aspects.]]></description>
<pubDate>2021/3/1 14:21:04</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TAO Zexin<sup>1</sup>, LU Ningshu<sup>2</sup>, WU Xiaoqian<sup>2</sup>, HUANG Yuke<sup>3</sup>, XIAO Yuxiao<sup>3</sup>, WANG Xing<sup>2,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TAO Zexin<sup>1</sup>, LU Ningshu<sup>2</sup>, WU Xiaoqian<sup>2</sup>, HUANG Yuke<sup>3</sup>, XIAO Yuxiao<sup>3</sup>, WANG Xing<sup>2,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101009&flag=1]]></guid><cfi:id>293</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of removing cholesterol crystals for anti-atherosclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Atherosclerosis is the leading cause of cardiovascular and cerebrovascular diseases,which is characterized by the formation of plaque under aortic endothelium. The present of cholesterol crystals in plaque could aggravate the inflammatory, destabilize and rupture plaque,ultimately leading to acute cardiovascular and cerebrovascular events.Thereby,removal of cholesterol crystals in atherosclerotic plaque would promote atherosclerosis regression.In this review,we summarized the formation and characteristic of cholesterol crystals in atherosclerotic lesions,the impact of cholesterol crystals on atherosclerosis progression, and the strategies of inhibiting or removing cholesterol crystals for anti-atherosclerosis.This review would provide theoretical basis and reference for the development of anti-atherosclerosis drugs based on the target of cholesterol crystals.]]></description>
<pubDate>2021/3/1 14:21:04</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MO Rui<sup>1</sup>, CHEN Song<sup>2</sup>, SU Zhigui<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MO Rui<sup>1</sup>, CHEN Song<sup>2</sup>, SU Zhigui<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101010&flag=1]]></guid><cfi:id>292</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[肾结石形成的自噬机制及中草药防治研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/31 9:04:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李雨君，李森华，杨柯]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李雨君，李森华，杨柯</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112011&flag=1]]></guid><cfi:id>291</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[靶向神经酰胺生成途径的阿尔茨海默病治疗药物研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/31 9:04:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[金泳增，何玲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>金泳增，何玲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112012&flag=1]]></guid><cfi:id>290</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[功能化介孔二氧化硅在肿瘤诊疗一体化的应用进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/31 9:04:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王美琪<sup>1</sup>，吕春艳<sup>1,2</sup>，高雪艳<sup>1</sup>，张文君<sup>1,2</sup>，崔闻宇<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王美琪<sup>1</sup>，吕春艳<sup>1,2</sup>，高雪艳<sup>1</sup>，张文君<sup>1,2</sup>，崔闻宇<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112013&flag=1]]></guid><cfi:id>289</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[成纤维细胞生长因子在炎症性疾病中的作用及临床应用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/31 9:04:44</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[吴林菱，李娴静，冯爽，杨勇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>吴林菱，李娴静，冯爽，杨勇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112014&flag=1]]></guid><cfi:id>288</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[聚合物微针载药系统研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Yi, SONG Ting, CHEN Wenlin, LI Hailiang, LU Aiyu, ZHANG Junying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Yi, SONG Ting, CHEN Wenlin, LI Hailiang, LU Aiyu, ZHANG Junying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111010&flag=1]]></guid><cfi:id>287</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[丹酚酸B的药理作用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WEI Xiyu, YANG Ting, LIU Houru, SUN Yue, ZHANG Zhenzhen, LI Wei, YU Dehong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Xiyu, YANG Ting, LIU Houru, SUN Yue, ZHANG Zhenzhen, LI Wei, YU Dehong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111011&flag=1]]></guid><cfi:id>286</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[靶向EGFR治疗非小细胞肺癌的小分子研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIANG Xiaoyun, LI Mengling, YANG Yang, LI Jiaying, YANG Jingya, XU Fang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Xiaoyun, LI Mengling, YANG Yang, LI Jiaying, YANG Jingya, XU Fang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111012&flag=1]]></guid><cfi:id>285</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[钠钾ATP酶与肿瘤研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG YE<sup>1</sup>, LI Xianjing<sup>1</sup>, YANG Yong<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG YE<sup>1</sup>, LI Xianjing<sup>1</sup>, YANG Yong<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111013&flag=1]]></guid><cfi:id>284</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on nuclear transport mechanism of tumor-associated proteins]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The nuclear transport of signal molecules is the basis of many signal transduction pathways. The occurrence and development of tumors are often related to the abnormal subcellular localization of a variety of signal proteins. Therefore, elucidating the nuclear transport mechanism of tumor-related proteins is essential for studying the pathogenesis of tumors and developing new therapies. This article introduces the basic components of the nuclear transport system and reviews the nuclear transport mechanisms of many important tumor-related proteins.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Yixin<sup>1</sup>, DAI Peiying<sup>2</sup>, YANG Yong<sup>3</sup>, CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yixin<sup>1</sup>, DAI Peiying<sup>2</sup>, YANG Yong<sup>3</sup>, CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110010&flag=1]]></guid><cfi:id>283</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[eview of pharmacological effects, metabolism and quality control of <i>Eclipta prostrata</i> L. and its chemical components]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ecliptae Herba, the dry aerial part of <i>Eclipta prostrata</i> L. (Family asteraceae). As a traditional medicinal plant, it has been widely used in clinical all over the world. Based on the literature published in recent years, this paper reviewed the progress in the researches of pharmacological effects, metabolism and quality control of <i>Eclipta prostrata</i> L. and its chemical components, in order to provide reference for the study of clinical application and quality control of <i>Ecliptae Herba</i>.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIANG Guangyang<sup>1,2</sup>, LI Shukun<sup>3</sup>, DENG Yi<sup>4</sup>, YIN Jun<sup>1</sup>, CHEN Wansheng<sup>2,4</sup>, CHEN Junfeng<sup>2</sup>, ZHANG Feng<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Guangyang<sup>1,2</sup>, LI Shukun<sup>3</sup>, DENG Yi<sup>4</sup>, YIN Jun<sup>1</sup>, CHEN Wansheng<sup>2,4</sup>, CHEN Junfeng<sup>2</sup>, ZHANG Feng<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110011&flag=1]]></guid><cfi:id>282</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of three-dimensional models in prediction of drug-induced hepatotoxicity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hepatotoxicity is a common side effect during drug treatment, and also the main reason for the failure of clinical trials and the withdrawal of drugs from the market. Therefore, it is crucial to develop an in vitro model that could effectively identify the drug hepatotoxicity for the new drug research and development. However, traditional hepatocyte models are limited due to the loss of the specific liver functions during two-dimensional (2D) culture, thus failing to accurately evaluate the hepatotoxicity. The emerging three-dimensional (3D) culture technology provides benefits for the in vitro assemble of hepatocytes by simulating the physiological microenvironment. Therefore, 3D hepatocytes could exhibit in vivo-like phenotypes and reactions to drug toxicity and have great potential in the evaluation of hepatotoxicity.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Yuanzi<sup>1,2</sup>, ZHANG Lei<sup>3</sup>, WU Chunyong<sup>1,2</sup>, ZHANG Junying<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Yuanzi<sup>1,2</sup>, ZHANG Lei<sup>3</sup>, WU Chunyong<sup>1,2</sup>, ZHANG Junying<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110012&flag=1]]></guid><cfi:id>281</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on the substance basis and mechanism of <i>Trichosanthis Radix</i> in the treatment of diabetes mellitus]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Trichosanthis Radix</i> is from the radix of Trichosanthes kirilowii Maxim. and Trichosanthes rosthornii Harms. It has many pharmacological effects such as clearing heat, reducing fire, producing saliva, quenching thirst, and so on. And it is an important traditional Chinese medicine in the treatment of diabetes. However, prescription and Chinese patent medicine are the major form for treating diabetes. It seems difficult for new drugs development. In this paper, we summarized the research progress on the substance basis and mechanism of <i>Trichosanthis Radix</i> in the treatment of diabetes mellitus in order to provide reference for new drug development.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Jing<sup>1</sup>, JIANG Jie<sup>1</sup>, LI Xinpeng<sup>2</sup>, CHEN Min<sup>2</sup>, ZHANG Bo<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jing<sup>1</sup>, JIANG Jie<sup>1</sup>, LI Xinpeng<sup>2</sup>, CHEN Min<sup>2</sup>, ZHANG Bo<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110013&flag=1]]></guid><cfi:id>280</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the pathogenesis of drug-induced liver injury caused by different drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Drug-induced liver injury(DILI) is caused by drugs or their metabolites or excipients, which is one of the common adverse drug reactions in clinical practice. DILI has a high incidence in China, second only to viral hepatitis and fatty liver disease. DILI is a leading cause of liver failure in Europe and the United States. Although people have long been aware of the harm of drug-induced liver injury, due to its complex etiology, non-specific clinical manifestations and weak specificity of diagnostic markers, patients with drug-induced liver injury often cannot be diagnosed in time and eventually develop liver failure or even death. More than 1 100 drugs are known to cause liver damage to varying degrees. Therefore, this paper reviewed the pathogenesis of drug-induced liver injury from the perspective of etiology, hoping to give readers a more comprehensive and in-depth understanding of DILI.]]></description>
<pubDate>2022/10/10 9:39:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHEN Qin, WANG Xiaoping, QIANG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHEN Qin, WANG Xiaoping, QIANG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209007&flag=1]]></guid><cfi:id>279</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in preparation and biological activity of sialic acid]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sialic acid is a α-ketoacid containing 9 carbons, Sialic acid has a variety of biological activities because of its different location and form, such as anti-tumor, anti-inflammation, antivirus, promoting nerve development. Combined with the research at home and abroad in recent years, the preparation methods and biological activity of sialic acid were reviewed in order to further study sialic acid.]]></description>
<pubDate>2022/10/10 9:39:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Menghua<sup>1</sup>, LIN Xiaoxian<sup>2,3</sup>, JU Mengmeng<sup>2,3</sup>, YIN Jialu<sup>2,3</sup>, WANG Dongliang<sup>2,3</sup>, WANG Shuqi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Menghua<sup>1</sup>, LIN Xiaoxian<sup>2,3</sup>, JU Mengmeng<sup>2,3</sup>, YIN Jialu<sup>2,3</sup>, WANG Dongliang<sup>2,3</sup>, WANG Shuqi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209008&flag=1]]></guid><cfi:id>278</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of xanthine oxidase inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Xanthine oxidoreductase (XOD) is a highly versatile flavinase, which is ubiquitous in different species and tissues. Gout is due to the metabolic disorder of uric acid in the body, which leads to the high level of uric acid and affects the normal operation of the body. Inhibition of XOD can reduce the level of uric acid and play the role of anti hyperuricemia. Nowadays, the most effective drug for the treatment of gout and hyperuricemia is XOD inhibitor. This paper summarized the pharmacological effects and clinical applications of XOD inhibitors, and summarized the XOD inhibitors that have been on the market and in the development stage in recent years, and reviewed the latest progress of XOD inhibitors.]]></description>
<pubDate>2022/10/10 9:39:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Tianshu<sup>1</sup>, HU Weifeng<sup>2</sup>, XIAO Yuxiao<sup>1</sup>, SU Xiaoyu<sup>1</sup>, LI Jiaqi<sup>1</sup>, JIA Yuhan<sup>1</sup>, WANG Xing<sup>1,3</sup>, CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Tianshu<sup>1</sup>, HU Weifeng<sup>2</sup>, XIAO Yuxiao<sup>1</sup>, SU Xiaoyu<sup>1</sup>, LI Jiaqi<sup>1</sup>, JIA Yuhan<sup>1</sup>, WANG Xing<sup>1,3</sup>, CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209009&flag=1]]></guid><cfi:id>277</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ ｏｎ ｃｈｅｍｉｃａｌ ｃｏｎｓｔｉｔｕｅｎｔｓ ｏｆ <i>Ｃｉｎｎａｍｏｍｕｍ</i> ｐｌａｎｔｓ]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Cinnamomum</i> plants are of important value in urban greening, medicine and food fields.These plants contain various kinds of chemical compounds, including volatile oil, diterpenoids, liganans, flavonoids, alkaloids, and so on. These compounds exhibit a wide range of pharmacological activities including antioxidant, antimicrobial, anti-inflammatory, anticancer, antidiabetic, wound healing, anti-HIV, antidepressant and Immunosuppressive activities. The main compounds are volatile oil, diterpenoids, flavonoids and lignans. This paper summarized the research results of chemical composition of <i>Cinnamomum</i> plants, in order to provide reference for further development of <i>Cinnamomum</i> plants.]]></description>
<pubDate>2022/10/10 9:39:46</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Shan, ZHANG Xueli, WANG Jiating, WANG Zhen, ZHOU Jinchuan, ZHANG Haijuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Shan, ZHANG Xueli, WANG Jiating, WANG Zhen, ZHOU Jinchuan, ZHANG Haijuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209010&flag=1]]></guid><cfi:id>276</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Advances in Chronic Stress Promoting Tumor Metastasis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tumor metastasis is an important part of the malignant development of tumors, and it is also the main reason for the failure of poor tumor prognosis. At present, there are many theories about the causes of tumor metastasis. However the relevant treatment are very limited, so it is particularly urgent to discover new targets of tumor metastasis. A large number of clinical studies have shown that chronic stress is an important reason for promoting tumor development. Therefore, the analysis of the mechanism related to tumor metastasis from the starting point of chronic stress has become the main trend of current research. In this paper, we briefly review the current research reporting chronic stress-regulated tumor metastasis, and evaluate the current treatment methods, providing new ideas for tumor treatment.]]></description>
<pubDate>2022/9/5 13:24:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Chen, LIU Boyang, HU Weiwei, YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Chen, LIU Boyang, HU Weiwei, YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208008&flag=1]]></guid><cfi:id>275</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the gut-organ axis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The gut interacts with multiple organs via neural, immune and endocrine pathways, which is called the gut-organ axis. And gut microbiota plays an important role in the gut-organ axis. Based on this theory, we can treat diseases about the intestine and associated organs by targeting the gut-organ axis. This article reviewed the research progress of the gut-brain axis, the gut-liver axis, the gut-lung axis, the gut-heart axis, the gut-skin axis and the gut-adipose axis.]]></description>
<pubDate>2022/9/5 13:24:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CUI Xinmeng, GAO Xinghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Xinmeng, GAO Xinghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208009&flag=1]]></guid><cfi:id>274</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of thrombolytic therapy for acute ischemic stroke]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Stroke is one of the important causes of death and disability among adults in our country. It has the characteristics of high morbidity, recurrence, disability and mortality. At present, early thrombolysis is a widely recognized and effective main treatment modality. The thrombolytic drug recombinant tissue plasminogen activator (rt-PA) is the only ischemic stroke drug approved by the FDA, but it has many limitations in clinical use. In recent years, clinical research on thrombolytic therapy has developed rapidly. This article summarized the thrombolytic therapy of acute ischemic stroke (AIS) in order to provide ideas for the drug treatment of AIS.]]></description>
<pubDate>2022/9/5 13:24:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Xi<sup>1</sup>, YOU Meigui<sup>1,2</sup>, TIAN Hua<sup>1,2</sup>, CHEN Xiaoyi<sup>1</sup>, LIN Min<sup>1</sup>, LAN Xingpeng<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Xi<sup>1</sup>, YOU Meigui<sup>1,2</sup>, TIAN Hua<sup>1,2</sup>, CHEN Xiaoyi<sup>1</sup>, LIN Min<sup>1</sup>, LAN Xingpeng<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208010&flag=1]]></guid><cfi:id>273</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role and mechanism of lipoic acid in the prevention and treatment of liver diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Lipoic acid is a powerful mitochondrial coenzymes with antioxidant stress, anti-inflammatory, detoxification and hypolipidemic effects. The liver is an important organ involved in human metabolism. Liver diseases seriously affect human life and health. This review introduced the role of lipoic acid in various liver diseases,and systematically elucidated the therapeutic mechanism of lipoic acid to provide ideas for the application of lipoic acid in various liver diseases.]]></description>
<pubDate>2022/9/5 13:24:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZONG Yixuan, DING Yaxue, LONG Tao, ZHANG Huidan, MENG Lu, DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZONG Yixuan, DING Yaxue, LONG Tao, ZHANG Huidan, MENG Lu, DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208011&flag=1]]></guid><cfi:id>272</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in clinical application and dosage form of nifedipine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the extension of clinical application time of drugs and the deepening of drug and disease research, many old drugs have been found new uses and applied in clinic, which greatly saves R & D time and cost. Nifedipine, a calcium channel blocker, is a common drug for the treatment of cardiovascular diseases such as hypertension and angina pectoris. In recent years, it has been found new uses which broadened its clinical application.This article will briefly introduce the research progress of various clinical uses and different dosage forms of nifedipine.]]></description>
<pubDate>2022/9/5 13:24:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Zhijing<sup>1</sup>, QIN Huaiguo<sup>2</sup>, CHANG Gang<sup>2</sup>, YAN Dong<sup>2</sup>, HUANG Cuiping<sup>2</sup>, ZHAI Guangxi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Zhijing<sup>1</sup>, QIN Huaiguo<sup>2</sup>, CHANG Gang<sup>2</sup>, YAN Dong<sup>2</sup>, HUANG Cuiping<sup>2</sup>, ZHAI Guangxi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208012&flag=1]]></guid><cfi:id>271</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on biomarkers of transporters]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Drug transporters mediated the absorption, distribution and metabolism of drugs, and their extensive substrate specificity is one of the main factors leading to drug interactions. As substrates of transporters, biomarkers can reflect the function of transporter proteins through the changes of their own concentration, which is highly significant in pharmacology. The study of biomarkers helps to uncover transporter-mediated drug interactions. This article reviewed representative biomarkers of liver and kidney transporters, and discussed the significance, limitations and future directions of biomarkers in predicting transporter involved drug interactions.]]></description>
<pubDate>2022/8/3 16:00:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Jiaxin, LIN Yining]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jiaxin, LIN Yining</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207010&flag=1]]></guid><cfi:id>270</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of endoplasmic reticulum stress and autophagy in skeletal muscle regeneration]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Satellite cell-mediated regeneration and repair is essential for the restoration of intact muscle function after injury. In a variety of pathophysiological processes, the unfolded protein response (UPR) and autophagy induced by endoplasmic reticulum stress (ERS) can remove accumulated dysfunctional proteins, both of which are important mechanisms for maintaining cell homeostasis. In recent years, more and more studies have found that ERS and autophagy are activated during skeletal muscle regeneration, and play an important regulatory role in the process of muscle regeneration, which is essential for the repair of injured muscles. This paper mainly reviewed the research progress of the role of ERS and autophagy in muscle regeneration in recent years, and aims to provide a theoretical basis for therapeutic strategies to improve skeletal muscle regeneration by regulating endoplasmic reticulum stress and autophagy.]]></description>
<pubDate>2022/8/3 16:00:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Chunjie, JIANG Zhenzhou]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Chunjie, JIANG Zhenzhou</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207011&flag=1]]></guid><cfi:id>269</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New clinical progress of inhaled preparations and related devices for children asthma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Inhaled preparation refers to the liquid or solid preparation.The raw drug dissolves or disperses in a suitable medium, enters the lung in the form of vapor or aerosol, and has local or systemic effects. The inhalation device is that disperses the drug into small droplets and acts on the lung. This paper introduces the children asthma’s types and clinical efficacy of atomized inhalation drugs, and the principle, characteristics ,and clinical applications of inhalation devices, to provide references for medical staff, medicine, and preparation companies.]]></description>
<pubDate>2022/8/3 16:00:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI You, WU Jiliang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI You, WU Jiliang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207012&flag=1]]></guid><cfi:id>268</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Compound liquorice Buccal Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Compound licorice tablets are a dosage form reform based on compound licorice tablets, which has been improved to contain tablets, making them a new dosage form with suitable taste and stable quality.Mainly has the effect of cough, phlegm, anti-inflammatory, through clinical observation confirmed that the effect of compound licorice tablets containing cough phlegm is better than Compound liquorice tablets.In this article, through the analysis of relevant literature, from the pharmacological action, clinical curative effect, preparation technology, quality control, four aspects summarized the research progress of compound licorice buccal tablet and progress,, and systematically expounds the research progress of compound licorice tablets, which provides a further basis for its rational application in clinical practice.]]></description>
<pubDate>2022/8/3 16:00:56</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XU Jie<sup>1</sup>, LIU Xuefeng<sup>1</sup>, JING Ming<sup>1</sup>, ZHU Yingbu<sup>2</sup>, LI Zongmin<sup>2</sup>, TENG Dong<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Jie<sup>1</sup>, LIU Xuefeng<sup>1</sup>, JING Ming<sup>1</sup>, ZHU Yingbu<sup>2</sup>, LI Zongmin<sup>2</sup>, TENG Dong<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207013&flag=1]]></guid><cfi:id>267</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of regulation of UDP-glucuronosyltransferases and herb-drug interaction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The glucuronidation reaction catalyzed by uridine diphosphate glucuronyltransferases (UGT) is the most important metabolic reaction in phase II metabolism，which plays a role in maintaining the homeostasis of endogenous compounds such as bilirubin and bile acids and disposal process of exogenous compounds such as drug and carcinogens.The expression and enzymatic activities of UGTs are regulated by multidimensional mechanisms and various factors. An in-depth study of its regulatory network and herb-drug interactions mediated by UGT provides guidance for safer and more effective clinical use of herb. Therefore, this article summarized the molecular regulation mechanisms of UGT such as epigenetic modifications, transcriptional level, and posttranslational modification, as well as UGT-mediated herb-drug interactions.]]></description>
<pubDate>2022/7/19 16:37:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Nan<sup>1</sup>, LI Tingting<sup>2</sup>, CHEN Xijing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Nan<sup>1</sup>, LI Tingting<sup>2</sup>, CHEN Xijing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206010&flag=1]]></guid><cfi:id>266</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of related substances of Atomoxetine Hydrochloride based on its impurity profile]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The impurity profile of Atomoxetine hydrochloride was comprehensively explored according to the synthetic route and possible degradation pathway. And on this basis, the domestic and foreign research progress of related substances of atomoxetine hydrochloride was summarized with different analytical schemes, starting from the impurity profile idea and the structure of impurities, in order to resolve the difficult separation of isomers. The comprehensive and reliable technical support for the quality control of atomoxetine hydrochloride and its preparation was provided in order to ensure the safety of drug use for children.]]></description>
<pubDate>2022/7/19 16:37:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Shuying<sup>1,2</sup>, NI Zhiwei<sup>2</sup>, ZHANG Qing<sup>2</sup>, LU Dafeng<sup>2</sup>, ZANG Shuchao<sup>2</sup>, WANG Yuling<sup>2</sup>, ZHAI Guangxi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Shuying<sup>1,2</sup>, NI Zhiwei<sup>2</sup>, ZHANG Qing<sup>2</sup>, LU Dafeng<sup>2</sup>, ZANG Shuchao<sup>2</sup>, WANG Yuling<sup>2</sup>, ZHAI Guangxi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206011&flag=1]]></guid><cfi:id>265</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on ion channels in diabetic cardiomyopathy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Diabetic cardiomyopathy is a serious public health problem, which patients' hearts will change in function and structure. The potassium channel, sodium channel, calcium channel and TRPM7 channel in the heart are closely related to the disease, and this review analyzed the relevant heart ion channels to understand their potential role in the pathophysiology and pathogenesis of diabetic cardiomyopathy.]]></description>
<pubDate>2022/7/19 16:37:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Qianru, TANG Yiqun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Qianru, TANG Yiqun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206012&flag=1]]></guid><cfi:id>264</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The progress of concomitant administration of haloperidol with other drugs in the treatment of tic disorders and schizophrenia in children]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Haloperidol is a typical antipsychotic drug used to treat the symptoms of behavioral impulse and anxiety caused by mental diseases. However, the total effective rate of using haloperidol alone is low. The concomitant administration of haloperidol with other drugs often has better efficacy and safety to treat mental diseases. The paper reviewed the important progress and discussed the the advantages of haloperidol concomitant administration in the treatment of tic disorder and schizophrenia in children, so as to provide basis for clinical medication.]]></description>
<pubDate>2022/7/19 16:37:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LYU Hongyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Hongyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206013&flag=1]]></guid><cfi:id>263</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in physico-chemical properties and toxicological-pharmacological activities of embelin]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To master the physico-chemical properties,toxicological and pharmacological effects of Embelin. To provide theoretical basis for the anti-breast cancer efficacy study of Embelin.<b>Methods</b>  Refer to relevant literature domestic and foreign research, by concluded, analyzed and summed of embelin- related articles.<b>Results</b>  The Embelin extracted and purified from rattan vine is weakly acidic and can be obtained by IR,UV, HPLC and TLC. The toxicity of embelin on heart, liver, kidney and other organs in mice was weak.It has anti-inflammatory and anti-tumor pharmacological effects, but it has certain neurotoxicity. <b>Conclusion</b>  Embelin has low toxicity and good effects. It is significant to study the anti-inflammatory and anti - tumor effects of Embelin.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SU Hua<sup>1</sup>, LIU Guo<sup>2</sup>, ZENG Xianbiao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SU Hua<sup>1</sup>, LIU Guo<sup>2</sup>, ZENG Xianbiao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205008&flag=1]]></guid><cfi:id>262</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study of fluconazole prophylaxis for invasive candidiasis in preterm infant]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the change of China's family planning policy, the birth rate of preterm infants continues to rise. Invasive candidiasis (IC) is an important cause of disability and death of preterm infants due to poor immune function.In recent years, low-dose fluconazole has been tried to prevent IC in preterm infants, but the safety and efficacy remain controversial. In this paper, the status of resistance of Candida, the antibacterial activity, PK/PD characteristics of fluconazole and the effectiveness and safety of IC prevention were reviewed, providing reference for clinical application.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Honghong<sup>1,2,3</sup>, HE Jing<sup>1</sup>, YU Qiao'ai<sup>4</sup>, JIANG Yongjiang<sup>5</sup>, HUANG Yuling<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Honghong<sup>1,2,3</sup>, HE Jing<sup>1</sup>, YU Qiao'ai<sup>4</sup>, JIANG Yongjiang<sup>5</sup>, HUANG Yuling<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205009&flag=1]]></guid><cfi:id>261</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on tumor-associated macrophages involved in the mechanism of bevacizumab resistance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bevacizumab is an anti-tumor angiogenesis drug approved by the FDA. With the deepening of treatment, the emergence of its drug resistance has a significant impact on clinical treatment. Therefore, clarifying the mechanism of drug resistance, delaying and overcoming drug resistance can improve the clinical efficacy of bevacizumab and effectively prolong the survival period of cancer patients. During the treatment of bevacizumab, macrophages are recruited into tumor tissues and further transformed into tumor-associated macrophages promotes the occurrence and development of tumors. This article reviewed the current research status of tumor-associated macrophages involved in bevacizumab resistance, aiming to systematically clarify the role of tumor-associated macrophages in tumor proliferation, invasion and metastasis, and provided theoretical support for the use of effective means to alleviate or eliminate bevacizumab resistance.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HU Yajie<sup>1,2</sup>, HAN Tian<sup>2</sup>, LU Tao<sup>2</sup>, HU Qinghua<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Yajie<sup>1,2</sup>, HAN Tian<sup>2</sup>, LU Tao<sup>2</sup>, HU Qinghua<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205010&flag=1]]></guid><cfi:id>260</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical constituents of <i>Allium fistulosum</i>, a medicinal and edible plant]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Allium Fistulosum</i>, a medicinal and edible plant, has complex chemical constituents, which are mainly composed of flavonoids, steroidal saponins and sulfur-containing compounds. It can eliminate nitrite, inhibit the proliferation of tumor cells, reduce Blood Lipid, prevent and cure steatosis. In this paper, the chemical constituents and pharmacological activities of <i>Allium Fistulosum</i> in recent years were reviewed to provide basis for its further development and utilization.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Ying<sup>1</sup>, YU Bing<sup>2</sup>, YANG Shangjun<sup>1</sup>, GAO Dehai<sup>2</sup>, MU Yanling<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Ying<sup>1</sup>, YU Bing<sup>2</sup>, YANG Shangjun<sup>1</sup>, GAO Dehai<sup>2</sup>, MU Yanling<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205011&flag=1]]></guid><cfi:id>259</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of melatonin on children's clinic application]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Melatonin is one of the neuroamine hormones secreted by human and mammalian pineal gland, which has the clinical effect of improving sleep quality and overcoming sleep disorders. Due to the specific use requirements of melatonin in clinical application population, its clinical application and research development in children are slow. Not all diseases affecting children's sleep problems could be treated with melatonin or adjuvant therapy with melatonin. The paper summarized the domestic application and progress of melatonin on children's clinical application and research, so as to provide guidance and experience for its clinical medication.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LYU Hongyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Hongyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205012&flag=1]]></guid><cfi:id>258</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of curcumin against gastric cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Curcumin(CCN) is a polyphenolic compound extracted from the plant turmeric, and is the main active ingredient of turmeric.Curcumin has significant pharmacological effects, including a strong anti-gastric cancer effect that has been discovered in recent years. The mechanisms of action of curcumin anti-gastric cancer mainly includes inhibition of proliferation and invasion, induction of apoptosis and reversal of chemical drug resistance.This paper elaborates its mechanism of action at the cellular level through different signaling pathways.Due to the poor water solubility and low oral availability of curcumin, the dosage form of curcumin is usually optimized clinically to improve the efficiency.]]></description>
<pubDate>2022/5/10 10:37:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Lin, WANG Jinwei, YIN Li, BAO Ziwei, YING Xixiang, ZHANG Chungang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Lin, WANG Jinwei, YIN Li, BAO Ziwei, YING Xixiang, ZHANG Chungang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204008&flag=1]]></guid><cfi:id>257</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role of uric acid in the formation of non-alcoholic fatty liver disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As one of the most common chronic liver diseases in the world, nonalcoholic fatty liver disease (NAFLD) has always been a research hotspot. NAFLD is closely related to obesity and related metabolic disorders. Hyperuricemia or high serum uric acid levels are common metabolic abnormalities that occur in obese people. Epidemiological studies have confirmed that serum uric acid levels are significantly related to non-alcoholic fatty liver, while xanthine oxidase (XO) is a key enzyme that controls uric acid synthesis. This article focused on reviewing the role of uric acid and the rate-limiting enzyme XO in the formation of NAFLD. We also expounded the relationship between uric acid and metabolic syndrome (MS) related diseases, such as insulin resistance, diabetes, and hyperlipidemia. Finally, the application of XO inhibitors in the treatment of various diseases is introduced.]]></description>
<pubDate>2022/5/10 10:37:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DING Yaxue, ZONG Yixuan, MENG Lu, ZHANG Huidan, DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Yaxue, ZONG Yixuan, MENG Lu, ZHANG Huidan, DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204009&flag=1]]></guid><cfi:id>256</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of NMDA receptor and NMDA receptor inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[NMDA receptor is an ionotropic glutamate receptor, which plays a key role in the excitatory synaptic transmission, plasticity and excitotoxicity of the central nervous system, and It is closely related to the body's memory, learning and emotions. This article provides a detailed overview of the structure,distribution and activation of NMDA receptor and their physiological activities, introduces and summarizes the NMDA receptor antagonists that have been studied more at present, and provides information basis for NMDA receptor related research.]]></description>
<pubDate>2022/5/10 10:37:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YE Yuying, LUO Yangwen, YU Pei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YE Yuying, LUO Yangwen, YU Pei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204010&flag=1]]></guid><cfi:id>255</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Regulation of analgesic active components in natural products on TRPV1 channel]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Transient receptor potential vanilloid 1(TRPV1) is a nonselective cationic channel, mainly expressed in sensory neurons, which can be activated by capsaicin, thermal stimulation, proton, etc. TRPV1 is strongly associated with pain and plays an important role in inflammatory pain, neuropathic pain, cancer pain and other pain. It is a promising molecular target for the development of new analgesics. In recent years, different chemical types of natural products have been found to regulate TRPV1 channels. The paper summarized the analgesic effect of natural products on TRPV1 channel.]]></description>
<pubDate>2022/5/10 10:37:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XU Xiuqi<sup>1</sup>, LI Guang<sup>2</sup>, ZHANG Guangqin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Xiuqi<sup>1</sup>, LI Guang<sup>2</sup>, ZHANG Guangqin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204011&flag=1]]></guid><cfi:id>254</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on the relationship between uremic encephalopathy and vascular endothelial dysfunction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cardiovascular and cerebrovascular diseases are the most common complications of chronic kidney disease and the main cause of death of patients with end-stage renal disease. A large number of studies have shown that uremic encephalopathy is related to uremic hormone accumulation, oxidative stress, inflammation and other factors. The damage of cerebral vascular endothelium caused by uremic toxin and the destruction of blood-brain barrier function are one of the pathological causes of uremic encephalopathy. Therefore, repairing cerebral vascular endothelium can be used as a therapeutic strategy for the prevention and treatment of this disease. This paper reviews the relationship between uremic encephalopathy and vascular endothelium caused by chronic kidney disease, hoping to provide a treatment strategy for uremic encephalopathy.]]></description>
<pubDate>2022/5/10 10:37:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Ruijie, WANG Hao, CHEN Dingding]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Ruijie, WANG Hao, CHEN Dingding</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204012&flag=1]]></guid><cfi:id>253</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Natural products in the prevention and treatment of non-melanoma skin cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ultraviolet B radiation is a major contributor to non-melanoma skin cancer. UVB not only directly penetrates skin and causes DNA damage, but also leads to harmful reactions related to oxidative stress, inflammation and immunity, which promotes the occurrence and development of non-melanoma skin cancer. Therefore, drugs targeted non-melanoma skin cancer in UVB radiation have a considerable prospect. In recent years, a number of natural products have been identified that they show potential for the prevention and treatment of UVB-induced non-melanoma skin cancer. In this paper, the specific research progress of natural products in the treatment of non-melanoma skin cancer was reviewed.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHUO Yating, PI Peiling, CUI Yingyue, LIU Yunyao, QIANG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHUO Yating, PI Peiling, CUI Yingyue, LIU Yunyao, QIANG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203009&flag=1]]></guid><cfi:id>252</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on Protective effect and Mechanism of <i>Gentiana macrophylla Pall</i>. on Cerebral Ischemia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Gentiana macrophylla Pall</i>. has a variety of active ingredients, which have the effects of anti-inflammatory, anti-oxidative stress, anti-apoptosis and other effects. It is a high-frequency drug used by traditional Chinese medicine in the treatment of ischemic stroke. This paper reviewed the protective effect and mechanism of <i>Gentiana macrophylla Pall</i>. on ischemic stroke, providing a theoretical basis for <i>Gentiana macrophylla Pall</i>. and its preparations in the treatment of ischemic stroke.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LUO Shuping, ZHANG Yuqin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LUO Shuping, ZHANG Yuqin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203010&flag=1]]></guid><cfi:id>251</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on anti-tumor effect of panax notoginseng saponins]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Panax notoginseng</i> saponins（PNS）are the main active components of Panax notoginseng，which have pharmacological effects such as vasodilation，inhibit platelet aggregation，reducing blood lipid，anti-inflammation，anti-oxidation and so on. Following the deeper investigation, recent studies have shown that PNS has a multi-target anti-tumor activity. It can directly kill tumor cells, inhibit tumor cell growth or metastasis, induce tumor cell apoptosis and differentiation, reverse multidrug resistance,and enhance and stimulate immunity.PNS showed a strong inhibitory effect on leukemia，multiple myeloma,gastric cancer,liver cancer,pancreatic cancer,colon cancer,breast cancer,cervical cancer,endometrial cancer,melanoma,lung cancer,prostate cancer and glioma. This article through review the domestic related literature in recent years，the anti-tumor effect of panax notoginseng saponins were summarized，so as to provide reference for the further research and application.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GONG Weiliang, ZHUANG Haitao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GONG Weiliang, ZHUANG Haitao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203011&flag=1]]></guid><cfi:id>250</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of nanotechnology in traditional Chinese medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the rapid development of science and technology, nanotechnology has been brought into our life step by step. The field of traditional Chinese medicine are being guided, developed and polished by nanotechnology with its flourishing. The specific characteristics of Nano traditional Chinese medicine in aspects as size, shape, and materials can effectively reduce the drug toxicity and improve the efficacy. Nanotechnology can also be applied to the analysis of traditional Chinese medicine to enhance the sensitivity of medical tests and shorten the test time. This paper systematically elaborated the application progress of nanotechnology in traditional Chinese medicine, analyzed the problems encountered by nanotechnology in improving the application of traditional Chinese medicine, discussed the solutions to the problems, and envisions the research directions in the future.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Tao<sup>1</sup>, ZHANG Wenjun<sup>1</sup>, ZHANG Guofeng<sup>2</sup>, CHEN Wei<sup>1</sup>, ZHANG Hanwen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Tao<sup>1</sup>, ZHANG Wenjun<sup>1</sup>, ZHANG Guofeng<sup>2</sup>, CHEN Wei<sup>1</sup>, ZHANG Hanwen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203012&flag=1]]></guid><cfi:id>249</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of pharmacokinetic software simulation technology in the field of pharmacy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Physiologically-based pharmacokinetic software simulation technology is conducted by in silico software to build a model which can simulate the physiological or pathological environment of the organism, and to predict the pharmacokinetic behavior (absorption, distribution, metabolism, and excretion) of the drug. This review outlines the common functional modules of the PBPK model and their applications in drug research, including early development and new formulation studies, food efficacy, drug interactions, childhood drug research, inhalation formulation development, and generic drug conformity assessment. It also briefly introduces the characteristics of commonly used commercial PBPK softwares. What’s more, the current challenges of the PBPK model are discussed, including the scope of application of the model and the criteria for evaluating the accuracy of the model.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Di<sup>1</sup>, ZHANG Juan<sup>2</sup>, LI Rui<sup>1</sup>, LI Pan<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Di<sup>1</sup>, ZHANG Juan<sup>2</sup>, LI Rui<sup>1</sup>, LI Pan<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203013&flag=1]]></guid><cfi:id>248</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research and recent progress of rectal drug delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Oral administration is the preferred route of conventional drug therapy due to its simple and convenient form of administration. However, Rectal administration can be a safe alternative for those who cannot take oral drugs for fasting or other reasons and have poor medication compliance. Mucosal surfaces of rectal are rich in blood supply, providing rapid drug transportation to the local or systemic circulation therapy and avoiding degradation by first-pass hepatic metabolism, prevent gastric acid and enzyme to the destruction of drugs, reduce the stimulation of drugs to the stomach. However, its utilisation has been relatively low in recent years due to the lack of proven pharmacokinetic studies and the high dependence on drug delivery devices, as well as the potential for patient discomfort due to the specific site of administration. This article reviews the characteristics and advantages of rectal drug delivery, discusses the factors affecting the absorption of it, introduces the types of common drug delivery devices, novel rectal dosage form and prospects its research progress to provide theoretical basis and reference for the development of rectal drug delivery preparations.]]></description>
<pubDate>2022/3/16 16:00:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Chunhui<sup>1,2</sup>, HAN Xiaolu<sup>2</sup>, LI Meng<sup>2</sup>, WANG Zengming<sup>2</sup>, LI Chunmei<sup>1</sup>, WANG Xiangtao<sup>1</sup>, ZHENG Aiping<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Chunhui<sup>1,2</sup>, HAN Xiaolu<sup>2</sup>, LI Meng<sup>2</sup>, WANG Zengming<sup>2</sup>, LI Chunmei<sup>1</sup>, WANG Xiangtao<sup>1</sup>, ZHENG Aiping<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202009&flag=1]]></guid><cfi:id>247</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of signal pathways related to the pathogenesis of uric acid nephropathy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Uric acid nephropathy is renal damage caused by hyperuricemia due to excessive production or reduced excretion of uric acid, commonly known as gout nephropathy. Uric acid nephropathy can be induced by multiple signaling pathways and inflammatory factors activated v by high uric acid levels. In this review, "Uric acid", "nephropathy", "Uric acid nephropathy" and other keywords were used to search the literatures about the signaling pathways related to the pathogenesis of Uric acid nephropathy in the recent ten years from the databases such as CNKI and PubMed, and representative literatures were selected for an integrated review. By studying the pathogenesis of uric acid nephropathy and the progress of related signaling pathways, this paper integrated the specific mechanism of the pathogenesis of uric acid nephropathy, and provided a new treatment method for the treatment of uric acid nephropathy based on the role of multiple signaling pathways.]]></description>
<pubDate>2022/3/16 16:00:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Tianshu<sup>1</sup>, XIAO Yuxiao<sup>1</sup>, SU Xiaoyu<sup>1</sup>, LI Jiaqi<sup>1</sup>, CHEN Jiajia<sup>2</sup>, HU Weifeng<sup>3</sup>, JIA Yuhan<sup>1</sup>, WANG Xing<sup>1,4</sup>, CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Tianshu<sup>1</sup>, XIAO Yuxiao<sup>1</sup>, SU Xiaoyu<sup>1</sup>, LI Jiaqi<sup>1</sup>, CHEN Jiajia<sup>2</sup>, HU Weifeng<sup>3</sup>, JIA Yuhan<sup>1</sup>, WANG Xing<sup>1,4</sup>, CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202010&flag=1]]></guid><cfi:id>246</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on cardiovascular activities of berberine hydrochloride]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Berberine is one of isoquinoline alkaloids, which exists in plants such as Coptis chinensis and Phellodendron chinense. Its hydrochloride named Berberine hydrochloride is commonly used in clinic with many cardiovascular pharmacological effects such as cardiotonic, anti-arrhythmic, endothelial protection, myocardial protection, blood pressure reduction, anti-atherosclerosis, diabetic cardiovascular disease treatment, etc. It is a potential cardiovascular disease treatment drug. In this paper, by searching the PubMed database, the cardiovascular pharmacology researches of Berberine hydrochloride are reviewed.]]></description>
<pubDate>2022/3/16 16:00:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIN Qingwei<sup>1</sup>, LI Peibo<sup>1</sup>, WU Hao<sup>1</sup>, PENG Wei<sup>1</sup>, ZHONG Hualin<sup>1</sup>, SU Weiwei<sup>1</sup>, CHENG Chunlei<sup>2</sup>, WANG Yonggang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Qingwei<sup>1</sup>, LI Peibo<sup>1</sup>, WU Hao<sup>1</sup>, PENG Wei<sup>1</sup>, ZHONG Hualin<sup>1</sup>, SU Weiwei<sup>1</sup>, CHENG Chunlei<sup>2</sup>, WANG Yonggang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202011&flag=1]]></guid><cfi:id>245</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The overview of techniques of AD drug developments targeting tau protein]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer’s disease (AD) is a neurodegenerative disease with memory and recognition defects and anxiety. The senile plaque formed by amyloid β-protein (Aβ) and neurofibrillary tangles containing tau protein are the main pathological characteristics. Tau hypothesis is one of the most accepted AD mechanisms. As most potential drugs targeting Aβ failed in clinical trials recently, tau protein attracts much more attention. Based on the recent studies on AD drug developments, this review summarizes the models and techniques used in molecular, cellular, mouse, and computational researches. We further evaluate the advantages and disadvantages of each model and prospect the future directions.]]></description>
<pubDate>2022/3/16 16:00:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHONG Suyue, TAN Qiulong, YAO Xuanbao, YANG Jiaying, XIAO Shifeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHONG Suyue, TAN Qiulong, YAO Xuanbao, YANG Jiaying, XIAO Shifeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202012&flag=1]]></guid><cfi:id>244</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The specific role of glycans in tumor metastasis, immune regulation and treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Glycan and glycosylation is essential for regulating cell function, abnormal glycosylation modification and changes in glycan content or composition can accelerate the malignant transformation of cancer cells, promote tumor metastasis, participate in the regulation of the organism's anti-tumor immune response, which ultimately promotes tumor development. To understand the occurrence and development of tumors, studying tumor-related glycosylation and abnormal glycans expression is of great significance. Therefore, this essay aims to clarify the relationship between glycosylation and tumor development and summarize the latest related glycosylation treatment strategies, which will provide new ideas and approaches for tumor treatment.]]></description>
<pubDate>2022/2/23 16:42:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[NIE Biyao<sup>1</sup>, DAI Peiying<sup>2</sup>, YANG Yong<sup>3</sup>, WANG Chen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIE Biyao<sup>1</sup>, DAI Peiying<sup>2</sup>, YANG Yong<sup>3</sup>, WANG Chen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201008&flag=1]]></guid><cfi:id>243</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on the mechanism of quercetin on Alzheimer's disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer's disease is the most common neurodegenerative disease in the elderly. Due to the accelerated aging of the world population, the incidence rate of AD continues to grow. The research on the neuroprotective effect of Chinese herbal medicine or Chinese medicine extract is increasing. Quercetin is a kind of flavonoid compound, which can protect neurons from oxidative damage, reduce lipid peroxidation and inhibit the formation of amyloid precursor.This article reviewed the new progress in the source, kinetics, and mechanism of action of quercetin on Alzheimer's disease, and deeply elaborated the molecular mechanism of quercetin on Alzheimer's disease.]]></description>
<pubDate>2022/2/23 16:42:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Liying<sup>1</sup>, KONG Jian<sup>2</sup>, GUAN Qingyan<sup>1</sup>, YANG Xiaoyun<sup>3</sup>, YANG Xiao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Liying<sup>1</sup>, KONG Jian<sup>2</sup>, GUAN Qingyan<sup>1</sup>, YANG Xiaoyun<sup>3</sup>, YANG Xiao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201009&flag=1]]></guid><cfi:id>242</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of lung-gut axis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The lung and gut are not anatomically related, but show close relationship in the clinic. This phenomenon is named as the lung-gut axis. It has been recognized that lung and gut can influence each other by multiple ways, such as host microbiota, mucosal immunity, and neuroendocrine network. This paper reviewed the understanding of the lung-gut axis and the research advances.]]></description>
<pubDate>2022/2/23 16:42:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Wenjie, DAI Yue]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Wenjie, DAI Yue</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201010&flag=1]]></guid><cfi:id>241</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advance on the stems and leaves of <i>Panax notoginseng</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The stems and leaves of <i>Panax notoginseng</i> (SLPN) are the by-product of <i>P. notoginseng</i>. Modern research showed that SLPN contains a variety of active components and nutrients, such as saponins, flavonoids, vitamins, amino acids and so on. SLPN has various pharmacological function, including anti-anxiety, anti-depression, anti-osteoporosis, anti-diabetes, anti-cancer, anti-aging, anti-obesity and others. Up till now, there have been many reports about the chemical compounds of SLPN. Although the chemical composition of <i>Panax notoginseng</i> has already been extensively studied, most researchers focus on the pharmacological activity of total <i>Panax notoginseng</i> saponins, and only very few studies discuss relevant pharmacological mechanisms. This paper provides a summary of the chemical composition and pharmacological function of SLPN, as a source of theoretical reference for future development and utilization of <i>Panax notoginseng</i> by-products, as well as a scientific basis to ensure effective use of these by-products.]]></description>
<pubDate>2022/2/23 16:42:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHI Pingping, PAN Jun, LI Hong, LIU Xiuwei, JIN Pengcheng, WU Xinyi, TIAN Hao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHI Pingping, PAN Jun, LI Hong, LIU Xiuwei, JIN Pengcheng, WU Xinyi, TIAN Hao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201011&flag=1]]></guid><cfi:id>240</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Ｓｔｕｄｙ ｏｎ ｔｈｅ ｒｅｌａｔｉｏｎｓｈｉｐ ｂｅｔｗｅｅｎ ｍａｔｅｒｉａｌ ａｔｔｒｉｂｕｔｅｓ ａｎｄ ｌｕｂｒｉｃａｔｉｏｎ ｐｅｒｆｏｒｍａｎｃｅ ｏｆ ｍａｇｎｅｓｉｕｍ ｓｔｅａｒａｔｅ ａｎｄ ｆｌａｖｏｒ]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Intestinal epithelium is the "first line of defense" against the entry of external pathogens, and its quickly self-renewal is pivotal for maintaining intestinal physical barrier and homeostasis. This self-renewal process relies on the intestinal stem cells (ISCs) at the bottom of the crypt and is regulated by a complex signal network within the ISCs niche. However, the source of environmental signals and how they regulate the fate of ISCs remain unclear. Recent researches showed that immune cells like T cells, innate lymphocyte cells (ILCs), dendritic cells (DCs) and macrophages play a key role in regulating ISCs fate. The paper reviewed the latest literature on immune cells regulation of ISCs, in order to better understand the intestinal homeostasis and provide insights for the treatment of intestinal epithelial barrier diseases.]]></description>
<pubDate>2023/1/17 13:57:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SONG Lijuan, WANG Yun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Lijuan, WANG Yun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212007&flag=1]]></guid><cfi:id>239</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacological action and new dosage forms of paeoniflorin]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Paeoniflorin is a monoterpene glycoside compound with remarkable hepatoprotective activity. However, the poor lipid solubility of paeoniflorin leads to low bioavailability and slow onset of action, which limits its wide application. Therefore, the research and development of new dosage forms of paeoniflorin to improve the bioavailability and drug efficacy is a hotspot of current research. Based on this, this article synthesizes relevant domestic and foreign literatures, and performs a comprehensive and collated review of the research on the hepatoprotective pharmacological effects and new dosage forms of paeoniflorin, with a view to providing theoretical basis and ideas for the application and new dosage forms development reference.]]></description>
<pubDate>2023/1/17 13:57:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YUAN Tengteng<sup>1,2,3</sup>, WANG Lei<sup>1,2</sup>, TANG Yanan<sup>1,2,3</sup>, HU Zihan<sup>1,2,3</sup>, DU Jiaojiao<sup>1,2,3</sup>, WANG Rulin<sup>1,2</sup>, ZHANG Caiyun<sup>1,2,3</sup>, CHEN Weidong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Tengteng<sup>1,2,3</sup>, WANG Lei<sup>1,2</sup>, TANG Yanan<sup>1,2,3</sup>, HU Zihan<sup>1,2,3</sup>, DU Jiaojiao<sup>1,2,3</sup>, WANG Rulin<sup>1,2</sup>, ZHANG Caiyun<sup>1,2,3</sup>, CHEN Weidong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212008&flag=1]]></guid><cfi:id>238</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in targeting pancreatic cancer-associated fibroblasts]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pancreatic cancer-associated fibroblasts (PCAFs), one of the most abundant stroma cell types in pancreatic cancer, are the key inducers of fibrotic and desmoplastic microenvironment. PCAFs also promote tumor proliferation and metastasis by intensive and diverse crosstalk with pancreatic cancer cells as well as immune cells, and play an important role in the resistance against chemo-, radio- and immunotherapies. Therefore, PCAFs has become a popular target in pancreatic cancer treatment. In this review, based on the origin, characteristic and biological function of PCAFs, advances in therapeutic drugs and potential targeted delivery strategies against PCAFs were reviewed and analyzed, in the hope of providing new ideas for further improving the therapeutic outcome against pancreatic cancer.]]></description>
<pubDate>2023/1/17 13:57:59</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TONG Yuqing, YANG Mengnan, CUI Meirong, YIN Tingjie]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TONG Yuqing, YANG Mengnan, CUI Meirong, YIN Tingjie</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212009&flag=1]]></guid><cfi:id>237</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on formation and application of glycyrrhizin-based hydrogel]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Natural small-molecule gelators can spontaneously form gels in solution with certain response to external environmental stimuli, and have favorable biological activities and biocompatibility, therefore show huge potential development and utilization value in multi-fields. However, natural small-molecule gelators have been rarely discovered and systematically studied in both fundamental and applied research area. Glycyrrhizin，a typical gelator, has been widely used in pharmaceutics, food, chemical engineering and other fields due to its unique physicochemical properties and biological activities. Particularly, glycyrrhizin is an excellent emulsion-gel matrix or sustained/controlled carrier. The present review summarized mechanism study and application progress of glycyrrhizin hydrogel to provide references for further exploring the application approaches of glycyrrhizin-related gels in biomedical field.]]></description>
<pubDate>2023/1/17 13:57:59</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Lirong<sup>1</sup>, DONG Zhi<sup>1</sup>, YANG Yuerui<sup>1</sup>, REN Zhixian<sup>1</sup>, REN Hongli<sup>1</sup>, LIU Chen<sup>1</sup>, WANG Wenping<sup>1,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Lirong<sup>1</sup>, DONG Zhi<sup>1</sup>, YANG Yuerui<sup>1</sup>, REN Zhixian<sup>1</sup>, REN Hongli<sup>1</sup>, LIU Chen<sup>1</sup>, WANG Wenping<sup>1,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212010&flag=1]]></guid><cfi:id>236</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in the preprocessing and detection of DNA adductomics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[DNA adduct is a kind of DNA damage formed by the covalent combination of electrophilic substances and DNA. The unrepaired DNA damage might increase the risk of cancer. Liquid chromatography-mass spectrometry with high sensitivity and selectivity has been the most used method for the detection of DNA adducts. Multiple known or unknown DNA adducts could be detected and identified from the complex biological matrix with DNA adductomic technology, which could deepen the understanding of the toxicity of genotoxic substances. Although the sample pretreatment, detection technology and data processing have been optimized, DNA adductomic analysis still faces great challenges.]]></description>
<pubDate>2023/1/17 13:57:59</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Xinran<sup>1,2</sup>, SUN Tong<sup>3</sup>, GUO Na<sup>4</sup>, ZHANG Junying<sup>5</sup>, WU Chunyong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xinran<sup>1,2</sup>, SUN Tong<sup>3</sup>, GUO Na<sup>4</sup>, ZHANG Junying<sup>5</sup>, WU Chunyong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212011&flag=1]]></guid><cfi:id>235</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Coagulation factor Ⅻ: a new target for antithrombotic drug]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[People's health is under serious threat with the incidence of thrombotic diseases increasing year by year. Most of the drugs currently commonly used to treat thrombosis are associated with bleeding risks. Each factor in the clotting pathway has been developed to varying degrees in order to find effective antithrombotic therapeutic targets that can avoid bleeding. Among these factors, coagulation factor Ⅻ (FⅫ) stands out because numerous studies have shown that blocking FⅫ's function prevents thrombosis without causing spontaneous bleeding. Therefore, with the theme of FⅫ as a new target of antithrombotic drugs, this paper reviewed the role of FⅫ in thrombosis and its research progress as a target of antithrombotic drugs.]]></description>
<pubDate>2022/12/12 13:59:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Xinping, LIAN Qi, YU Boyang, LIU Jihua, LIU Xiufeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Xinping, LIAN Qi, YU Boyang, LIU Jihua, LIU Xiufeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211008&flag=1]]></guid><cfi:id>234</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of nano hydroxyapatite and its application in unstable drug delivery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hydroxyapatite is the main component of inorganic substance in natural bone tissue, which has good biocompatibility, affinity and biodegradation. Widely used in bone tissue replacement materials, plastic and plastic surgery materials, is a non-toxic, non-carcinogenic, no side effects of bioactive materials. In recent years, new drug delivery vectors based on nanometer hydroxyapatite particles have been active in the field of pharmaceutics research. Therefore, the common preparation methods and application of nanometer hydroxyapatite materials in drug delivery system in recent years were summarized in this paper.]]></description>
<pubDate>2022/12/12 13:59:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Dan<sup>1</sup>, WANG Qiang<sup>2,3</sup>, FAN Xingjun<sup>1</sup>, GAO Junxia<sup>2</sup>, YU Fengbo<sup>1,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Dan<sup>1</sup>, WANG Qiang<sup>2,3</sup>, FAN Xingjun<sup>1</sup>, GAO Junxia<sup>2</sup>, YU Fengbo<sup>1,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211009&flag=1]]></guid><cfi:id>233</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role of inflammation caused by STING in cardiovascular diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Stimulator of interferon genes(STING) is a key protein mediating immune defense in innate immune response. In addition, STING involves in multiorgan inflammation, which is activated indirectly by free DNA via DNA sensor and activates IRF3 or NF-κB, upregulating the level of inflammatory factor. In recent years, it has be[1]en disclosed that inflammatory response mediated by STING promotes the progression of cardiovascular diseases. Therefore, the study of the role of inflammation caused by STING in cardiovascular diseases can provide a new therapeutic target for cardiovascular diseases.]]></description>
<pubDate>2022/12/12 13:59:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[NIE Xiaoyan, WANG Lintao, HE Chaoyong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIE Xiaoyan, WANG Lintao, HE Chaoyong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211010&flag=1]]></guid><cfi:id>232</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Textual research on the homology of Huajuhong both as medicine and as food]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Huajuhong is a genuine medicinal material in Huazhou, a city in West Guangdong province. The current Chinese Pharmacopoeia stipulates that it is the dry outer peel of immature or nearly mature fruits of <i>Citrus grandis</i> ' tomentosa ' or <i>Citrus grandis</i> (L.) Osbeck. This paper reviews the literatures related to Huajuhong in the published editions of Chinese Pharmacopoeia, relevant laws and regulations and Emerson database, analyzes them, and studies their medicine and food homology. It is concluded that the application of Huajuhong has a long history. The "Huajuhong" in Ejiao Yinzi recipe of Puji recipes is the earliest accurate literature record that uses "Huajuhong" as the name. According to the literatures, "Huajuhong" has appeared as a normal drug name for at least 600 years; Huajuhong is a kind of Chinese medicinal material and with high safety and a wide variety of health benefits that can be used both as medicine and as food.]]></description>
<pubDate>2022/12/12 13:59:58</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Yonggang, WU Hao, LI Peibo, PENG Wei, SU Weiwei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Yonggang, WU Hao, LI Peibo, PENG Wei, SU Weiwei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211011&flag=1]]></guid><cfi:id>231</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Reasrch progress on concomitant administration of oxcarbazepine with other drugs in the treatment of epilepsy and trigeminal neuralgia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Oxcarbazepine is a typical antiepileptic drug used to treat epilepsy and trigeminal neuralgia. Oxcarbazepine is well tolerated and has broad prospects in combination therapy. The paper reviewed the progress and discussed the advantages of oxcarbazepine concomitant administration in the treatment of epilepsy and trigeminal neuralgia, so as to provide research data and relevant support basis for clinical medication.]]></description>
<pubDate>2022/12/12 13:59:59</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LYU Hongyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Hongyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211012&flag=1]]></guid><cfi:id>230</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on nanomedicine overcoming tumor multidrug resistance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[For cancer treatment, multidrug resistance (MDR) is an important obstacle. The excellent functions of nanomedicine, such as targeting and co-delivery of drugs, make it a good carrier of overcoming MDR. This paper introduces main mechanisms of MDR, focusing on the design of nanomedicine to overcome MDR with the guidance of inhibiting efflux, inducing programmed cell death,and reversing multidrug resistance by targeting tumor micro-environment. This paper provides reference for the treatment of drug-resistant tumors.]]></description>
<pubDate>2022/11/11 10:33:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[KUANG Zheng, QIN Chao, YANG Lei, YIN Lifang, HAN Xiaopeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KUANG Zheng, QIN Chao, YANG Lei, YIN Lifang, HAN Xiaopeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210008&flag=1]]></guid><cfi:id>229</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of curcuminoids]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Curcumin, as the main active component of the traditional Chinese medicine turmeric, shows good application prospects for inflammation, tumors, metabolic diseases and neurological diseases, and its clinical application is limited due to its low bioavailability. The structural modification around curcumin has always been of interest to pharmacologists. This article reviews the research progress of curcuminoids in the past five years, and provides references for the development of curcumin drugs.]]></description>
<pubDate>2022/11/11 10:33:32</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Zongyi, PENG Mingli]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Zongyi, PENG Mingli</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210009&flag=1]]></guid><cfi:id>228</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on key proteins in vascular cognitive impairment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Vascular cognitive impairment refers to cognitive impairment caused by various cerebrovascular diseases, ranging from mild cognitive impairment to vascular dementia. VCI usually affects the advanced functions of the brain, especially in the areas of executive function and memory. With the gradual increase in the incidence of vascular cognitive impairment, in recent years, research on the pathogenesis of vascular cognitive impairment is also deepening. This article reviewed the key target proteins of vascular cognitive impairment, and provides references for the treatment and medication of vascular cognitive impairment.]]></description>
<pubDate>2022/11/11 10:33:32</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TAN Xiaoyun, CHEN Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TAN Xiaoyun, CHEN Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210010&flag=1]]></guid><cfi:id>227</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Sijunzi Decoction and its modified recipes in the treatment of non-small cell lung cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sijunzi Decoction is a classical prescription of Jianpi and Yiqi，and also commonly used in the clinical treatment of malignant tumor. In recent years，clinical and experimental studies have found that Sijunzi Decoction and its modified recipes have anti-small cell lung cancer effect. In clinical research，Sijunzi Decoction and its modified recipes can improve clinical efficacy，improve the quality of life，improve the immune function and reduce the adverse reactions caused by chemotherapy in the treatment of non-small cell lung cancer. In experimental research，it can inhibit the growth of lung cancer cells，promote the apoptosis of lung cancer cells，inhibit the metastasis of lung cancer cells，regulate the immune function, regulate the microenvironment of lung cancer，and alleviate the cachexia of lung cancer. This paper reviewed the progress in the clinical study and experimental research of Sijunzi Decoction and its modified recipes for the treatment of non-small cell lung cancer,to provide some reference and ideas for clinical treatment in the future.]]></description>
<pubDate>2022/11/11 10:33:32</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yucai, WANG Yongfeng, ZHAO Lijiang, ZHUANG Haitao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yucai, WANG Yongfeng, ZHAO Lijiang, ZHUANG Haitao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210011&flag=1]]></guid><cfi:id>226</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[肿瘤中干细胞样T细胞的调控研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈玉梅<sup>1</sup>，杨勇<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈玉梅<sup>1</sup>，杨勇<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309010&flag=1]]></guid><cfi:id>225</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[阿霉素在纳米递送系统中联合用药的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李江<sup>1</sup>，史雄喜<sup>1</sup>，刘佳慧<sup>1</sup>，陈建明<sup>1</sup>，武鑫<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李江<sup>1</sup>，史雄喜<sup>1</sup>，刘佳慧<sup>1</sup>，陈建明<sup>1</sup>，武鑫<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309011&flag=1]]></guid><cfi:id>224</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[芎芍胶囊治疗动脉粥样硬化作用机制的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈利捷<sup>1,2</sup>，金宇<sup>2</sup>，陈启庭<sup>2</sup>，许贵鹏<sup>2</sup>，张淼<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈利捷<sup>1,2</sup>，金宇<sup>2</sup>，陈启庭<sup>2</sup>，许贵鹏<sup>2</sup>，张淼<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309012&flag=1]]></guid><cfi:id>223</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[FoxO转录因子参与糖尿病心肌病脂代谢研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[唐睿，汤依群]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>唐睿，汤依群</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309013&flag=1]]></guid><cfi:id>222</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[不同种属来源肝素组成与结构分析方法研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘晋仙<sup>1</sup>，李玮涛<sup>1,2</sup>，柳晓芳<sup>2</sup>，王秀萍<sup>2</sup>，张中志<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘晋仙<sup>1</sup>，李玮涛<sup>1,2</sup>，柳晓芳<sup>2</sup>，王秀萍<sup>2</sup>，张中志<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309014&flag=1]]></guid><cfi:id>221</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the pharmacological mechanism of <i>Ginkgo biloba</i> leaves]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Ginkgo biloba</i> is a multi-functional economic tree with medicinal and ornamental value. The rich metabolic components in Ginkgo biloba contribute to the material basis of medicinal value. Hundreds of chemical constituents with significant pharmacological activities from leaves mainly includes flavonoids and their glycosides, terpene trilactones (TTL), phenylpropanoids and polyphenols, alkylphenolic acids, others etc. which can improve blood circulation in the heart and brain, protect the nervous system to improve memory and cognitive, regulating metabolic, antioxidant, anti-inflammatory and antitumor activity etc. The pharmacological activities of <i>Ginkgo biloba</i> extracts have been summarized clearly until now, but there is still a lack of reviews on the molecular target and pharmacological mechanisms of these compounds. This paper firstly classified the chemical structures of these compounds that exert the above effects, and then reviewed the molecular mechanisms of their effects according to their medical activities, and mapped the profile of pharmacology based on their molecular targets, so as to provide guidance for the development of new drugs and the use of combined clinical drug.]]></description>
<pubDate>2023/9/11 16:16:02</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MENG Jie, WANG Guolin, LU Yibin, HAI Mengyue, WU Yunfei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MENG Jie, WANG Guolin, LU Yibin, HAI Mengyue, WU Yunfei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308010&flag=1]]></guid><cfi:id>220</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on risk factors for colorectal cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Colorectal cancer(CRC) is one of the most common gastrointestinal malignancies in the world, and its morbidity and mortality rank the third. It is a global public problem threatening human health seriously. With the development of economy, the change of lifestyle and diet structure, the incidence of CRC has been on the rise in recent years. Although the current clinical treatment for CRC has made some progress, CRC is usually diagnosed at a later stage, so the treatment effect is not very good. The occurrence of CRC is closely related to genetics, lifestyle, diet, environment and other factors. Therefore, this paper summarizes the risk factors affecting the incidence of CRC, in order to provide a theoretical basis for the early prevention and treatment of CRC.]]></description>
<pubDate>2023/9/11 16:16:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SU Yali<sup>1</sup>, CAO Qiuhua<sup>2</sup>, GAO Xinghua<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SU Yali<sup>1</sup>, CAO Qiuhua<sup>2</sup>, GAO Xinghua<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308011&flag=1]]></guid><cfi:id>219</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress of research on the effect of Fucoidan on gut microflora and chronic renal failure]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fucoidan have become a research hotspot because of their antioxidant, anti-inflammatory and anti-coagulant effects. The incidence of chronic renal failure (CRF) has been increasing year by year in recent years. Studies on the gut-renal axis have revealed a bidirectional regulation between the gut microflora (GM) and CRF, and the ability of GM to regulate the health of the body by balancing homeostasis has become a potential target for the treatment of CRF. Fucoidan are used as a microbial regulator to interfere with GM dysregulation and thus control the CRF process, preventing potential risk factors for accelerated renal failure. Therefore, this paper investigates the effects of Fucoidan on GM and CRF and the mechanism of bidirectional regulation of GM and CRF, and provides research directions and ideas for the subsequent development and utilization of Fucoidan.]]></description>
<pubDate>2023/9/11 16:16:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HUANG Yayu<sup>1,2</sup>, LIN Mini<sup>1,2</sup>, CAI Shuyun<sup>1,2</sup>, YAN Guangyu<sup>3</sup>, CHEN Weizhu<sup>2</sup>, ZHANG Yiping<sup>1,2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Yayu<sup>1,2</sup>, LIN Mini<sup>1,2</sup>, CAI Shuyun<sup>1,2</sup>, YAN Guangyu<sup>3</sup>, CHEN Weizhu<sup>2</sup>, ZHANG Yiping<sup>1,2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308012&flag=1]]></guid><cfi:id>218</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the chemical constituents，pharmacological effects and the prediction and analysis of Q-marker of <i>Melicope pteleifolia</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Melicope pteleifolia</i> mainly contains alkaloids, flavonoids, benzopyrans and tryptamines chemical components, as well as a small amount of acetophenone, volatile oil and other chemical. It has anti-inflammatory and analgesic effects, bacteriostatic and antiviral effects, blood glucose and lipid regulation, anti-tumor, liver protection and antioxidant effects and other pharmacological activities. By summarizing and sorting out the existing literature at home and abroad,this study summarizes and expounds the chemical components and pharmacological effects of <i>Melicope pteleifolia</i>, and combines the concept of quality markers to predict and analyze the quality markers of <i>Melicope pteleifolia</i> in the aspects of plant affinity, chemical component specificity, correlation with traditional drug efficacy, and component measurability, different origins and processing methods, in order to provide a reference for further development and utilization of <i>Melicope pteleifolia</i> and improve its quality evaluation system, etc.]]></description>
<pubDate>2023/9/11 16:16:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHENG Yanwei<sup>1,2,3</sup>, NAN Huiling<sup>1,3,4</sup>, LIN Qinghua<sup>1,3,4</sup>, LIN Ning<sup>1,3,4</sup>, LI Xuejian<sup>1,2</sup>, CHEN Qing<sup>1,2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Yanwei<sup>1,2,3</sup>, NAN Huiling<sup>1,3,4</sup>, LIN Qinghua<sup>1,3,4</sup>, LIN Ning<sup>1,3,4</sup>, LI Xuejian<sup>1,2</sup>, CHEN Qing<sup>1,2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308013&flag=1]]></guid><cfi:id>217</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of glucose and lipid metabolic <i>in vitro</i> models]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The dynamic balance between glucose metabolism and lipid metabolism, which are the two basic metabolisms of the body, is essential to maintain homeostasis of the body. At present, the disorders of glucose and lipid metabolism such as diabetes, overweight and obesity seriously endanger public health security. Due to the complex pathogenesis, the development of therapeutic drugs is in urgent need of appropriate glucose and lipid metabolism models. In addition, the infinite proliferation of tumor cells under suitable conditions is mainly achieved through the interconversion of glycolysis and oxidative phosphorylation (OXPHOS). Therefore, the study of glucose and lipid metabolic models is also of great significance for tumor therapy. In vitro 3D models can simulate cell-cell and cell-extracellular matrix interactions, which are more closely related to the in vivo environment than 2D models. And the similarity between 3D models and in vivo condition can be further enhanced by multicellular coculture. Currently, cellular spheroids and organ chips are the main 3D models for in vitro studies of glucose and lipid metabolism, which play an important role in the study of glucose and lipid metabolism mechanisms and drug screening. However, the ability of glucose and lipid metabolic capacity of these two models still lags behind that of the in vivo level and still faces major challenges.]]></description>
<pubDate>2023/9/11 16:16:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHUANG Ken<sup>1</sup>, GUO Na<sup>2</sup>, LIAO Wenjun<sup>1</sup>, YUAN Hua<sup>3</sup>, SUN Tong<sup>1</sup>, WU Chunyong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHUANG Ken<sup>1</sup>, GUO Na<sup>2</sup>, LIAO Wenjun<sup>1</sup>, YUAN Hua<sup>3</sup>, SUN Tong<sup>1</sup>, WU Chunyong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308014&flag=1]]></guid><cfi:id>216</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on regulation of lipid metabolism by intestinal flora in obesity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Obesity is a global health problem associated with a variety of metabolic disorders. Intestinal flora is considered as an important contributor to the occurrence and development of obesity and obesity-related metabolic diseases. The role of intestinal flora in obesity and related metabolic diseases has attracted more and more attention in the past decades. Intestinal flora has been considered as a potential therapeutic target for obesity. Intestinal flora gets involved in host lipid metabolism and the underlying mechanism is complex. To provide ideas for the prevention and treatment of obesity and related diseases, this article reviewed the representative species in the occurrence and development of obesity and summarized the research progress of the potential mechanism of intestinal flora in the regulation of lipid metabolism.]]></description>
<pubDate>2023/8/14 11:14:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XU Jiaqi, LIN Yining]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Jiaqi, LIN Yining</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307011&flag=1]]></guid><cfi:id>215</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New progress in studies on chemical constituents and pharmacological action of leaves of <i>Acanthopanax senticosus</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a traditional medicinal material, <i>Acanthopanax senticosus</i> leaves have been widely used in modern chemical research, medical research and daily diet. The saponins, flavonoids, amino acids, phenolic acids, organic acids and other chemical components that have been identified ,and have been shown pharmacological effects and drug effects, such as nervous system protection, sedative and hypnotic effects, hypoglycemic and lipid-lowering effects, antioxidant effects and anti-inflammatory effects, respectively. In this paper, the chemical constituents and pharmacological effects of leaves of Acanthopanax senticosus were summarized in order to provide scientific basis for further exploration of the application prospect of leaves of <i>Acanthopanax senticosus</i> in the future.]]></description>
<pubDate>2023/8/14 11:14:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Qiang<sup>1</sup>, ZHANG Ruobing<sup>1</sup>, YANG Yuhe<sup>2</sup>, TIAN Bing<sup>1</sup>, LI Wenlan<sup>1</sup>, LI Chenxue<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Qiang<sup>1</sup>, ZHANG Ruobing<sup>1</sup>, YANG Yuhe<sup>2</sup>, TIAN Bing<sup>1</sup>, LI Wenlan<sup>1</sup>, LI Chenxue<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307012&flag=1]]></guid><cfi:id>214</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of <i>Achyranthes aspera</i>——traditional uses, chemical constituents and pharmacological activities]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Achyranthes aspera</i> is a commonly used folk medicine with a long history of application. This paper summarized the traditional uses, chemical compositions and pharmacological activities of <i>Achyranthes aspera</i> according to the domestic and foreign literature in recent years. The results showed that the traditional application of <i>Achyranthes aspera</i> at home and abroad was relatively extensive, and the leaves, juice, seeds, roots and other parts had medical records. The main chemical components were triterpenoids and their saponins, sterones, alkaloids and organic acids. It has many pharmacological activities, such as antioxidant, anti-tumor, antibacterial, anti-virus and anti-infection, anti-convulsion, anti-anxiety, anti-depression and neuroprotection, liver and gastrointestinal protection, immune regulation, anti-fertility activity, hypoglycemic and hypolipidemic activity. It is a plant with good development prospects. This review hopes to provide a reference for further research, development and utilization of <i>Achyranthes aspera</i>.]]></description>
<pubDate>2023/8/14 11:14:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BI Wu, SUN Hui, DING Ye, LI Wenli]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BI Wu, SUN Hui, DING Ye, LI Wenli</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307013&flag=1]]></guid><cfi:id>213</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[ASICs —— a new target for the drugs of neurological-related diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Acid sensing ion channels (ASICs) are proton-gated cation channels, which are activated by H+. Recent studies showed that ASICs participate in the pathological process of neurological-related diseases such as epilepsy, inflammatory pain and ischemic brain injury. ASICs is a new target for the drugs of neurological-related diseases. In this review, we concluded the regulatory role of ASICs in neurological-related diseases and the latest progress of research on drugs acting on ASICs.]]></description>
<pubDate>2023/8/14 11:14:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YUAN Ziqi<sup>1</sup>, MU Lurong<sup>1</sup>, LI Guang<sup>2</sup>, ZHANG Guangqin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Ziqi<sup>1</sup>, MU Lurong<sup>1</sup>, LI Guang<sup>2</sup>, ZHANG Guangqin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307014&flag=1]]></guid><cfi:id>212</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Antiobesity effect of Berberine and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Obesity is a chronic metabolic disease caused by the imbalance of long-term energy intake and consumption, which is closely related to the abnormal proliferation and hypertrophy of adipose tissue. Inhibition of the proliferation and differentiation of preadipocytes is also a way to inhibit obesity. In recent years, Berberine (BBR) has been found to inhibit the proliferation and differentiation of adipocytes and lipid accumulation, and affect the process of adipocyte differentiation through PI3K-AKT, Ucp1, AMPK, AMPk-pgC1α axis. This review describes the effects of BBR on adipocyte proliferation differentiation, lipid accumulation, and adipogenic heat production, providing new insights into intervention strategies for how BBR can help prevent and manage obesity through adipogenic heat production.]]></description>
<pubDate>2023/8/14 11:14:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QIU Fanghong<sup>1</sup>, ZHANG Guiju<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIU Fanghong<sup>1</sup>, ZHANG Guiju<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307015&flag=1]]></guid><cfi:id>211</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of TRPM7 in heart diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[TRPM7 is a bifunctional membrane protein with ion channel and protein kinase activities, which is widely expressed among tissues and implicated in a variety of cellular functions. In recent years, many studies have shown that TRPM7 channel plays a critical role in the development of various heart diseases such as cardiac fibrosis, ischemic heart disease and diabetic heart disease. Therefore, further understanding of physiological and pathological mechanism of TRPM7 can provide an effective target in the clinical treatment of heart disease.]]></description>
<pubDate>2023/7/25 13:23:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XU Ying, TANG Yiqun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Ying, TANG Yiqun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306008&flag=1]]></guid><cfi:id>210</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application value of HMGB1-TLR4 signaling pathway and its regulator in anti-hepatic fibrosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The pathophysiological mechanism of hepatic fibrosis (HF) is extremely complex.Up to now,there is no ideal medicine and methodology in hepatic fibrosis treatment.Based on the analysis of the structure,related factors (TNF-α,IL-1β,IL-6, etc.) and the functions (regulation of NF-κB,activation of MAPK, etc.) of HMGB1-TLR4,it can be inferred that HMGB1-TLR4 aggravates the symptoms of HF by activating HSC,MAPK as well as promoting the release of a pro-inflammatory factor of NF-κB.Accordingly,the regulation of the high mobility group protein (HMGB1) -Toll-like receptor 4 (TLR4) signaling pathway is critical in alleviating the occurrence and development of HF.Although the anti-HF effects among the applications of existing HMGB1-TLR4 regulators has not met clinical expectations yet,such as TLR4 antibody,NF-κB inhibitor,Chaiqi Yigan Decoction,Chines herbal medicine Sancao Granule(SCG),Astragalus root,etc.using HMGB1-TLR4 signaling pathway as the pathway and screening for anti-HF lead compounds especially Chinese medicine with complementary effects of multi-component and multi-target sites still remains to be the target of future research.]]></description>
<pubDate>2023/7/25 13:23:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZENG Huahua, MA Min, SUN Yujie, HU Jiamin, HUANG Debin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZENG Huahua, MA Min, SUN Yujie, HU Jiamin, HUANG Debin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306009&flag=1]]></guid><cfi:id>209</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on traditional uses, coumarins, pharmacological activities, and toxicology of <i>Angelica</i> L.]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Angelica</i> L., a genus in the Apiales family, about 110 species have been found in the world. As traditional medicinal plants, many kinds of <i>Angelica</i> L. have the medicinal value of dispelling wind and dehumidifying, enriching blood and promoting blood circulation. As one of the main effective ingredients of <i>Angelica</i> L., coumarins are the main material basis of efficacy. Therefore, this paper systematically reviewed the research progress on traditional uses, coumarins, pharmacological activities, and toxicology of <i>Angelica</i> L., analyzed the current research situation of <i>Angelica</i> L., and provided scientific basis and direction for the future development, utilization and further research of <i>Angelica</i> L.]]></description>
<pubDate>2023/7/25 13:23:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Yanghai<sup>1</sup>, LIU Lu<sup>2</sup>, ZHAO Bonian<sup>2</sup>, GAO Yan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Yanghai<sup>1</sup>, LIU Lu<sup>2</sup>, ZHAO Bonian<sup>2</sup>, GAO Yan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306010&flag=1]]></guid><cfi:id>208</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in the treatment of Bcl-2 inhibitor Venetoclax in B-cell lymphoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bcl-2 protein is a key protein in regulating cell apoptosis, which is highly expressed in many hematological malignancies and plays an anti-apoptotic role. Venetoclax is the first highly selective bcl-2 inhibitor. Its first indication in the world is chronic lymphocytic leukemia (CLL), and clinical studies have been extended to a variety of B-cell lymphoma, myelodysplastic syndrome (MDS) and other hematological tumors. This review reviewed the therapeutic progress of venetoclax in B-cell lymphoma.]]></description>
<pubDate>2023/7/25 13:23:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[PAN Yu, CHEN Weiwei, LIU Nan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>PAN Yu, CHEN Weiwei, LIU Nan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306011&flag=1]]></guid><cfi:id>207</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Role of TRPM7 in diabetic myocardial fibrosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Diabetic cardiomyopathy (DCM) is a cardiovascular complication after diabetes mellitus (DM) develops to a certain stage. Fibrosis is one of the important pathological reconstruction, which mainly involving cardiac fibroblasts (CFs). TRPM7 (Transient receptor potential mela statin-subfamily member 7) is a membrane protein with dual structure of cation channel and protein kinase, which is constitutively expressed in cardiac fibroblasts. TRPM7 plays an important role in the pathological process of diabetic cardiac fibrosis. It can impact the development of diabetic cardiac fibrosis by influencing expression of transforming growth factor β1(TGF-β1), activation of renin-angiotensin-aldosterone system (RAAS), signal transduction of Ca2+ and metabolization of Mg2+. This article discussed the extensive and important role of TRPM7 in diabetic cardiac fibrosis, and pays attention to its potential as a therapeutic target to reduce fibrosis.]]></description>
<pubDate>2023/6/26 13:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIANG Yifeng, TANG Yiqun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Yifeng, TANG Yiqun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305007&flag=1]]></guid><cfi:id>206</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Huoxiang Zhengqi series preparation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide a theoretical basis for the secondary development of Huoxiang Zhengqi series preparations and provide reference for the quality control standard of Huoxiang Zhengqi formula.<b>Methods</b>  With "Huoxiang Zhengqi" and "pharmacological action" as the key words, relevant literature was reviewed through VIP, Wanfang, CNKI, PubMed and other databases, and the formulation, quality control, clinical application and pharmacological action of Huoxiang Zhengqi were summarized.<b>Results</b> This article analyzed and summarized the related literature of a series of preparations, discussed the prescription derivation, quality control, pharmacological action and clinical application of Huoxiang Zhengqi recipe, and explains its shortcomings in the mechanism of action and the reform of dosage form.<b>Conclusion</b>  The modern pharmacological mechanism of Huoxiang Zhengqi series preparations needs to be improved urgently, and the scientificity and safety in clinical application still need to be solved.]]></description>
<pubDate>2023/6/26 13:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Wanying<sup>1</sup>, LIU Meng<sup>1</sup>, TAO Xiaoqian<sup>1</sup>, CHENG Lan<sup>1</sup>, ZHANG Chungang<sup>1,2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Wanying<sup>1</sup>, LIU Meng<sup>1</sup>, TAO Xiaoqian<sup>1</sup>, CHENG Lan<sup>1</sup>, ZHANG Chungang<sup>1,2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305008&flag=1]]></guid><cfi:id>205</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Antioxidant effects of silymarin in chronic diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Silymarin has been widely used as a hepatoprotective agent in various liver diseases, and its hepatoprotective effect seems to be attributed to its powerful antioxidant, anti-inflammatory and anti-lipid deposition effects. More and more studies have shown that silymarin has a good therapeutic effect on chronic diseases caused by oxidative stress, such as cardiovascular disease, metabolic syndrome, neurodegenerative disease, cancer and complications. This article reviews the research on the therapeutic pathways of silymarin for chronic diseases in the past five years, focusing on the damage mechanism of chronic diseases and oxidative stress and the key role played by the antioxidant capacity of silymarin, in order to provide ideas for the clinical use of silymarin.]]></description>
<pubDate>2023/6/26 13:41:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LONG Tao, ZHANG Huidan, MENG Lu, ZONG Yixuan, DING Yaxue, DING Qilong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LONG Tao, ZHANG Huidan, MENG Lu, ZONG Yixuan, DING Yaxue, DING Qilong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305009&flag=1]]></guid><cfi:id>204</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on identification and quality evaluation of <i>Hirudo</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide reference for further improving the authenticity identification and quality evaluation method of hirudo and ensuring the safety and effectiveness of clinical medication of hirudo. <b>Methods</b>  Research papers published from January 2000 to August 2022 were searched in databases such as CNKI, VIP, Wanfang Data, PubMed, Science Direct and Web of Science using hirudo, identification, and quality evaluation as key words. And the literature review was conducted with the theme of “authenticity identification” and “quality evaluation”. <b>Results</b>  The identification methods of hirudo include character identification, physical and chemical identification, molecular identification, protein electrophoresis and capillary electrophoresis. Among them, molecular identification and protein electrophoresis identification are objective, accurate and widely used. The quality evaluation methods are abundant, including antithrombin evaluation method, high performance liquid chromatography, protein electrophoresis method, infrared spectroscopy analysis, gas chromatography-mass spectrometry technology, fingerprint technology, etc. <b>Conclusion</b>  Molecular identification is the most accurate identification method of hirudo, which can be applied in both Chinese medicinal materials and Chinese patent medicine. Since the pharmacodynamic substances are not very clear, the biological evaluation technology based on antithrombin evaluation method and the fingerprint technology based on macro evaluation have more advantages in quality evaluation.]]></description>
<pubDate>2023/6/26 13:41:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JI Shuqi<sup>1</sup>, ZHANG Huiting<sup>1</sup>, WANG Mengxuan<sup>1</sup>, GONG Yujie<sup>1</sup>, WANG Yiying<sup>1</sup>, LIU Yujiao<sup>1</sup>, DONG Hongjing<sup>2</sup>, ZHANG Bo<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JI Shuqi<sup>1</sup>, ZHANG Huiting<sup>1</sup>, WANG Mengxuan<sup>1</sup>, GONG Yujie<sup>1</sup>, WANG Yiying<sup>1</sup>, LIU Yujiao<sup>1</sup>, DONG Hongjing<sup>2</sup>, ZHANG Bo<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305010&flag=1]]></guid><cfi:id>203</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanism of vascular smooth muscle cell phenotypic transformation  in neointimal hyperplasia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Vascular neointimal hyperplasia is the pathological basis of cardiovascular diseases including atherosclerosis and restenosis after angioplasty. Vascular smooth muscle cells (VSMCs) are highly plastic and can undergo phenotypic switch under many pathological conditions, which is characterized by conversion of VSMCs from contractile to synthetic phenotype. Studies have shown that phenotypic transformation of VSMCs promotes proliferation and migration, thereby participating in the formation of vascular intima. In this review, we summarized the molecular mechanisms underlying phenotypic transformation of VSMCs that affect neointimal hyperplasia development and progression. It provides theoretical basis for the prevention and therapy of vascular remodeling diseases.]]></description>
<pubDate>2023/5/31 10:08:17</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Danmei<sup>1,2</sup>, HE Lu<sup>1,2</sup>, HE Chaoyong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Danmei<sup>1,2</sup>, HE Lu<sup>1,2</sup>, HE Chaoyong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304009&flag=1]]></guid><cfi:id>202</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of essential oil of Chinese herbal medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The essential oil of Chinese herbal medicine is a volatile oily liquid with a certain smell extracted from Chinese herbal medicine. The essential oil of Chinese herbal medicine has small molecules, strong penetration, antibacterial, antioxidant, anti-inflammatory and analgesic effects, and is widely used. In this paper, the application of essential oil of Chinese herbal medicine in medicine, food, agriculture, aquaculture and clothing industry was reviewed, providing basis for the development and utilization of essential oil of Chinese herbal medicine.]]></description>
<pubDate>2023/5/31 10:08:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHENG Qi, QU Yang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Qi, QU Yang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304010&flag=1]]></guid><cfi:id>201</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[CC chemokines and psoriasis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Psoriasis is an immune-mediated autoimmune skin disease. It is mainly characterized by excessive thickening and abnormal differentiation of the epidermis, accompanied by a systemic inflammatory response. The pathogenesis of psoriasis is accompanied by the infiltration of a large number of immune cells. These inflammatory cells and their released cytokines play an important role in the occurrence and development of psoriasis. At present, a large number of studies have suggested that there are a variety of CC chemokines in the skin of psoriatic lesions. They actively participate in the recruitment and activation of T lymphocytes, macrophages and neutrophils in the psoriasis inflammation site. Psoriasis in the inflammatory cycle. Therefore, understanding the role of CC chemokines and their receptors in psoriasis will contribute to the exploration of the pathogenesis of psoriasis and provide new ideas for the development of therapeutic targets for psoriasis. This review introduced the CC chemokines reported to be associated with psoriasis, and discussed their possible roles in the pathogenesis of psoriasis.]]></description>
<pubDate>2023/5/31 10:08:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHEN Xin, WANG Xiaoping, QIANG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHEN Xin, WANG Xiaoping, QIANG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304011&flag=1]]></guid><cfi:id>200</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical constituents and pharmacological effects of twigs of <i>Morus</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The twigs of <i>Morus alba</i> L.is a commonly used traditional Chinese medicine. It is rich in compound types. It mainly contains isopentenyl flavones, alkaloids, coumarins, stilbene, and triterpenes. It also contains amino acids, organic acids, volatile oils, and many other ingredients. Modern pharmacological studies have shown that it has analgesia, anti-inflammatory, hypoglycemic, and antioxidant activities. The article summarizes the relevant literature, summarizes the main chemical components, pharmacological effects and clinical applications in mulberry twigs, and provides references for its further the development of quality control and utilization.]]></description>
<pubDate>2023/5/31 10:08:18</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIANG Huiliang<sup>1,2</sup>, TIAN Mengyin<sup>1</sup>, YUE Jianan<sup>1</sup>, LI Zhen<sup>1,2</sup>, ZANG Hengchang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIANG Huiliang<sup>1,2</sup>, TIAN Mengyin<sup>1</sup>, YUE Jianan<sup>1</sup>, LI Zhen<sup>1,2</sup>, ZANG Hengchang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304012&flag=1]]></guid><cfi:id>199</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the separable microneedles]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The separable microneedle is a type of dissolving microneedle. The needle tip and backing can be quickly separated after being applied to the skin, which effectively reduces the wearing time of the microneedles and improves the drug delivery efficiency. It is a new type of transdermal drug delivery system and it has become a research hotspot in recent years. At present, various forms of separable microneedles have been developed, and in vitro and in vivo studies have confirmed that separable microneedles have broad application prospects. This paper summarizes the characteristics and classification of the current separable microneedles, in order to provide a reference for the subsequent development and application of separable microneedles.]]></description>
<pubDate>2023/5/25 8:59:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SONG Ting, CHEN Wenlin, LU Aiyu, LI Hailiang, ZHANG Junying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Ting, CHEN Wenlin, LU Aiyu, LI Hailiang, ZHANG Junying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303009&flag=1]]></guid><cfi:id>198</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of ultrasound-targeted microbubble destruction for acute myocardial infarction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the change of people's living habits and dietary structure, the incidence of acute myocardial infarction (AMI) is increasing year by year. How to effectively reduce myocardial necrosis and salvage ischemic myocardium is an important goal of clinical research, however, it is difficult to effectively salvage myocardial cells and avoid adverse events with the routinely applied surgical and pharmacological treatments in clinical practice. With the development of microbubble technology,ultrasound-targeted microbubble destruction (UTMD) as a safe and effective targeted delivery system is expected to be an effective tool for the treatment of acute myocardial infarction in the future. The article reviewed the mechanism of action and progress in the application of UTMD in the treatment of AMI.]]></description>
<pubDate>2023/5/25 8:59:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Lizhou<sup>1,2</sup>, TAN Jiayu<sup>2</sup>, WANG Haiyan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Lizhou<sup>1,2</sup>, TAN Jiayu<sup>2</sup>, WANG Haiyan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303010&flag=1]]></guid><cfi:id>197</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on  innate immune signaling pathways represented by STING in psoriasis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Psoriasis regards as a type of complicated immune disorder with versatile external and internal pathological triggers, of which mechanism remains unclear. Currently, the well-known dominant pathway is IL-23/Th17 axis, along with other participated compartments, such as antiviral patterns, pro-/pre-inflammatory cytokines, and molecules involved in antigen presentation. Amongst all, numerous autoantigens or pathogens inevitably invade and exist in the psoriatic lesion environment. They trigger PRR (pattern recognition receptors), such as STING, TLR, RIG1 and according downstream transcription factors (e.g. NF-κB and IRF), which eventually accelerate psoriasis progress. This review summarized the mechanisms of action of different pattern recognition receptors in innate immune signaling pathways in psoriasis progress for further development of therapeutics.]]></description>
<pubDate>2023/5/25 8:59:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Xiangzheng, ZHANG Tingting, HE Yuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xiangzheng, ZHANG Tingting, HE Yuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303011&flag=1]]></guid><cfi:id>196</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Fenofibrate preparation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fenofibrate belongs to the fibrate class of hypolipidemic drugs, and is one of the first-choice drugs for lowering triglycerides, with a high clinical usage rate. Since fenofibrate is insoluble in water and difficult to be absorbed, it leads to low bioavailability and reduced efficacy of the drug. To solve this problem, different types of formulations have emerged. This article reviews the research progress of fenofibrate formulations, in order to provide ideas for the further development of its formulations.]]></description>
<pubDate>2023/5/25 8:59:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FENG Qiaoqiao, ZHANG Tianyou, LIU Rong, SONG Kai, MING Yi, HU Jingfeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FENG Qiaoqiao, ZHANG Tianyou, LIU Rong, SONG Kai, MING Yi, HU Jingfeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303012&flag=1]]></guid><cfi:id>195</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of adenosine in tumor development, immune regulation and treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cancer has been evaluated as mitochondrial metabolic disease, and tumor cells mainly produce energy through anaerobic glycolysis. Adenosine metabolic pathways are the main targets of current attention. These metabolic pathways usually occur in the process of tumorigenesis and play a key role in tumor immune escape and immunosuppression. Therefore, the adenosine metabolic pathway has been regarded as an essential factor affecting the effectiveness of tumor immunotherapy and has become a crucial target for anti-tumor therapeutic strategies. Therefore, this essay aimed to clarify the specific roles of adenosine molecules in tumor progression, immune regulation, and immunotherapy, which will provide new ideas and approaches for anti-tumor treatment.]]></description>
<pubDate>2023/4/21 10:23:02</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LYU Kaiyan<sup>1</sup>, DUAN Jingjing<sup>1</sup>, YANG Yong<sup>2</sup>, DAI Beiying<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Kaiyan<sup>1</sup>, DUAN Jingjing<sup>1</sup>, YANG Yong<sup>2</sup>, DAI Beiying<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302009&flag=1]]></guid><cfi:id>194</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Role of injury-associated molecular pattern HMGB1 in prostatic inflammation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[High mobility group protein 1(HMGB1), as a key regulatory molecule of inflammatory response, plays a pro-inflammatory role through its downstream receptors such as RAGE and TLR. Prostatic inflammation provides an immune microenvironment for the development of early prostate diseases. It can promote prostatic proliferation by acting on prostatic epithelial cells, and also can act on immune cells in the prostatic interstitium, such as macrophages and dendritic cells, thus promotes the secretion of pro-inflammatory factors such as IL-6 and TNF-α from immune cells. HMGB1 levels rise is closely related to prostate hyperplasia and prostate cancer, but how it regulates the prostate gland inflammation in the development is still not fully clarified. This review summarized the potential function of HMGB1 and its related downstream receptor in prostate associated diseases and provide a reference for the transformation therapy of prostatitis and prostate cancer-related immune diseases.]]></description>
<pubDate>2023/4/21 10:23:02</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Xiaoqing, ZHAOU Xiaohui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Xiaoqing, ZHAOU Xiaohui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302010&flag=1]]></guid><cfi:id>193</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of solid self-microemulsion drug delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a new drug delivery system, solid self-microemulsion drug delivery system can significantly improve the oral bioavailability of insoluble drugs by combining the advantages of both microemulsion liquid and solid preparation. With various excipients prescription design and coating technology, it can achieve different drug delivery by controlling the drug release rate and completing the targeted drug delivery. The investigation on solid self-microemulsion drug delivery system is significant due to its wide application prospect. The application of solid self-microemulsion carrier, solidification technology and new application of solid self-microemulsion preparation were summarized in this paper, which provided a reference for the study of solid self-microemulsion technology to improve the release of insoluble drugs.]]></description>
<pubDate>2023/4/21 10:23:02</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIN Kexin, LYU Jiangwei, BEN Yuwen, ZHANG Kaili, PAN Shuyu, LIU Jiaxuan, CHEN Wei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIN Kexin, LYU Jiangwei, BEN Yuwen, ZHANG Kaili, PAN Shuyu, LIU Jiaxuan, CHEN Wei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302011&flag=1]]></guid><cfi:id>192</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Overview of the application of new green solvents in the extraction of traditional Chinese medicines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[It is of great significance to improve the extraction rate of active components of traditional Chinese medicine in clinical application. The choice of extraction solvent is one of the important factors affecting the extraction rate. Green solvents include ionic liquid, low eutectic solvent and natural low eutectic solvent. As the extraction solvent of traditional Chinese medicine, the research of green solvents has attracted the attention of researchers at home and abroad. Because of the advantages of high extraction efficiency, stable chemical properties and easy preparation, green solvents play an important role in the extraction of active ingredients of traditional Chinese medicine. At present, new green solvent instead of traditional solvent extraction has become a hot spot of modern extraction technology research. In this paper, the definition, preparation and application of new green solvents in extraction of active components of traditional Chinese medicine were summarized and sorted out by referring to relevant literature in database. The green extraction of active components such as flavonoids, saponins and alkaloids was mainly introduced. The aim of this study was to provide reference for the development and application of green extraction solvent of traditional Chinese medicine.]]></description>
<pubDate>2023/4/21 10:23:02</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Jinrong<sup>1,2,3</sup>, LI Baoxin<sup>2</sup>, XUE Xiaoxia<sup>2</sup>, SUN Jian<sup>3</sup>, LIU Jiaxin<sup>1</sup>, YANG Shubin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Jinrong<sup>1,2,3</sup>, LI Baoxin<sup>2</sup>, XUE Xiaoxia<sup>2</sup>, SUN Jian<sup>3</sup>, LIU Jiaxin<sup>1</sup>, YANG Shubin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302012&flag=1]]></guid><cfi:id>191</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on biological functions and analytical methods of dipeptide metabolites]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A dipeptide is composed of two amino acid residues and categorized as an oligopeptide. It has been known that dipeptides play crucial roles in nutrition and the regulation of various physiological and pathological processes, and can serve as potential biomarkers in multiple diseases. As one of the main forms of the absorption of digestive proteins, dipeptides are highly diverse in structure and chemical property. Endogenous dipeptides are characteristic of wide concentration range spanning several orders of magnitude, the existence of many isomers, and limited availability on commercial standards. The current quantification methods for dipeptides have the drawbacks of low sensitivity and limited coverage. This review summarizes the recent research progress on dipeptides including their transport and absorption, physiological functions, as well as qualitative and quantitative analysis methods.]]></description>
<pubDate>2023/2/27 10:11:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TANG Shaoran<sup>1</sup>, ZHOU Xuting<sup>1</sup>, HOU Xiaoying<sup>2</sup>, YANG Liu<sup>1,3</sup>, XU Fengguo<sup>1</sup>, ZHANG Pei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TANG Shaoran<sup>1</sup>, ZHOU Xuting<sup>1</sup>, HOU Xiaoying<sup>2</sup>, YANG Liu<sup>1,3</sup>, XU Fengguo<sup>1</sup>, ZHANG Pei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301008&flag=1]]></guid><cfi:id>190</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on the mechanism of Leech preparation in the treatment of Stroke]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Leech is one of the traditional Chinese medicines for promoting blood circulation and removing blood stasis. In order to provide clues and reference of leech for the clinical application in the prevention and treatment of stroke and further for the development of new drugs, this paper which is based on the understanding of stroke in traditional Chinese medicine starts from ameliorative effect of leech preparation on stroke mediated brain injury at present and the intervention mechanism include anti-immune inflammatory response, anti-free radical oxidation damage, anti-excitatory amino acid toxicity, anti-apoptosis, anti-inhibit platelet aggregation and thrombotic, and anti-atherosclerotic plaque formation to expound its action mechanism and other related research progress in basic and clinical aspects.]]></description>
<pubDate>2023/2/27 10:11:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FAN Jiaxin<sup>1,2</sup>, LIU Jinying<sup>3</sup>, GAO Ying<sup>1,2</sup>, LIU Shucha<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FAN Jiaxin<sup>1,2</sup>, LIU Jinying<sup>3</sup>, GAO Ying<sup>1,2</sup>, LIU Shucha<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301009&flag=1]]></guid><cfi:id>189</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of protein tyrosine phosphatase SHP2 and its allosteric inhibitors in tumor-targeted therapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Src homology 2 region-containing protein tyrosine phosphatase 2 (SHP2) is an intracellular non-receptor protein tyrosine phosphatase encoded by PTPN11. It has been confirmed to be involved in the occurrence and development of a variety of cancers, mainly regulating tumor cell growth, proliferation, invasion, apoptosis and immune escape through RAS/MAPK, PI3K/AKT, JAK/STAT, PD-L1/PD-1 and other signaling pathways.  Since Novartis discovered the allosteric site of SHP2 in 2016, the research on its inhibitors has shifted from catalytic site inhibitors to novel allosteric site inhibitors, overcoming the disadvantages of high polarity and poor specificity of catalytic site inhibitors. Currently, many small molecule compounds have been reported.  Moreover, SHP2 allosteric inhibitors with potential as patent drugs have been developed and entered into clinical trials.  In this review, we will focus on the structure and function of SHP2 targets, their value in tumor targeted therapy and the progress of allosteric inhibitors reported in recent five years.]]></description>
<pubDate>2023/2/27 10:11:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Yuan<sup>1,2</sup>, LI Xue<sup>2</sup>, CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yuan<sup>1,2</sup>, LI Xue<sup>2</sup>, CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301010&flag=1]]></guid><cfi:id>188</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of polysaccharide from different plant tissues of <i>Trichosanthes</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Polysaccharides from traditional Chinese medicine (TCM) revealed many pharmacologic effects, including antioxidation, antiviral, antitumor, antiaging, hyperglycemic, and immuno-enhancement. <i>Trichosanthes fructus</i>, peel, seed and <i>radix</i> are rich in polysaccharides. However, the extraction method, structural feature and pharmacologic effect of them are different from each other since the different tissues. Thus, we summarized the research progress of extraction method, structural feature and pharmacologic effect of the polysaccharides from <i>Trichosanthes Fructus</i>, <i>Trichosanthes</i> peel, <i>Trichosanthes</i> seed and <i>Trichosanthes Radix</i> in this paper. We hope to provide a useful reference for the development and utilization of polysaccharides from Trichosanthes.]]></description>
<pubDate>2023/2/27 10:11:24</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Jing<sup>1</sup>, ZHANG Bo<sup>2</sup>, LI Xinpeng<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jing<sup>1</sup>, ZHANG Bo<sup>2</sup>, LI Xinpeng<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301011&flag=1]]></guid><cfi:id>187</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[L-精氨酸补充疗法在部分疾病治疗中的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[鞠越凡，何朝勇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>鞠越凡，何朝勇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312010&flag=1]]></guid><cfi:id>186</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[巨噬细胞极化在糖尿病性创面愈合中的作用及药物研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李杰辉<sup>1</sup>，梁彬<sup>2</sup>，王丽<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李杰辉<sup>1</sup>，梁彬<sup>2</sup>，王丽<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312011&flag=1]]></guid><cfi:id>185</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[选择性剪接在肿瘤化疗耐药中的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[苗春萌<sup>1</sup>，吴启鹏<sup>1</sup>，江振洲<sup>1</sup>，张陆勇<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>苗春萌<sup>1</sup>，吴启鹏<sup>1</sup>，江振洲<sup>1</sup>，张陆勇<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312012&flag=1]]></guid><cfi:id>184</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于蜂花粉质量控制现状的问题分析及研究展望]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[朱娟娟，卢琪，曲珍妮，吕畅，周巧，石典花，戴衍朋]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>朱娟娟，卢琪，曲珍妮，吕畅，周巧，石典花，戴衍朋</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312013&flag=1]]></guid><cfi:id>183</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[丹参活性成分治疗心血管疾病的药理作用、临床应用及不良反应研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈雨萌<sup>1</sup>，李倩<sup>1</sup>，刘维海<sup>2</sup>，史永恒<sup>1</sup>，王川<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈雨萌<sup>1</sup>，李倩<sup>1</sup>，刘维海<sup>2</sup>，史永恒<sup>1</sup>，王川<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312014&flag=1]]></guid><cfi:id>182</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Anti-tumor therapies based on macrophages’ repolarization]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The high plasticity of macrophages can influence tumor progression and treatment resistance. Various therapeutic approaches have been developed for tumor-associated macrophages (TAMs), including their repolarization. The use of compounds to block the polarization of macrophages to M2 type or to promote their polarization to M1 type, and the use of nanoparticles to target macrophages to deliver stimulatory factors are all commonly used reprogramming methods. Targeting TAMs is expected to be a potential anti-tumor therapy. This paper mainly focused on immunotherapy by reprogramming TAMs to regain anti-tumor ability.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GU Jiadan, DAI Beiying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GU Jiadan, DAI Beiying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311011&flag=1]]></guid><cfi:id>181</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role of astrocyte immune inflammatory response and abnormal glutamate metabolism in the pathogenesis of post-stroke depression]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Astrocytes are the largest number of cells in the human brain, and their structure will change significantly in the early stage of ischemia, expressing a variety of neurotrophin and injury factors. After stroke, astrocytes are activated into reactive astrocytes, which affect tissue repair and the occurrence and development of neuroinflammatory diseases through neuroprotective or neurotoxic effects. The increase of intercellular glutamate concentration and inflammatory factors induced by stroke will promote the occurrence of post-stroke depression, and the activated astrocyte after stroke will regulate the immune inflammatory response and neuronal glutamate metabolism through multiple pathways. At present, the signaling pathways of astrocyte-mediated immune-inflammatory response and glutamatergic system on the development of post-stroke depression are further analyzed. This will provide strategies for targeting astrocytes to regulate glutamate and inflammatory factor levels, and provide ideas and clues for the treatment of post-stroke depression.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Qian<sup>1</sup>, ZHANG Mingkuan<sup>1</sup>, CHEN Zhibin<sup>1</sup>, LIU Xiaoyu<sup>1</sup>, HU Minghui<sup>2</sup>, WANG Xinyu<sup>2</sup>, ZHANG Hao<sup>2</sup>, LI Zifa<sup>2</sup>, GENG Xiwen<sup>2</sup>, WEI Sheng<sup>2</sup>, WU Jibiao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Qian<sup>1</sup>, ZHANG Mingkuan<sup>1</sup>, CHEN Zhibin<sup>1</sup>, LIU Xiaoyu<sup>1</sup>, HU Minghui<sup>2</sup>, WANG Xinyu<sup>2</sup>, ZHANG Hao<sup>2</sup>, LI Zifa<sup>2</sup>, GENG Xiwen<sup>2</sup>, WEI Sheng<sup>2</sup>, WU Jibiao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311012&flag=1]]></guid><cfi:id>180</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application progress of ultrasonic cavitation technology in the preparation of Nano-emulsion]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a new type of emulsion preparation technology, ultrasonic cavitation technology has been widely used in the preparation of nano-emulsions due to its unique advantages. In this paper, the principle of ultrasonic cavitation technology was studied by classifying and sorting out the literature reports at home and abroad in recent years；The research progress of preparing nano-emulsion by ultrasonic cavitation technology in medicine, food and other fields was described；The advantages of ultrasonic cavitation technology were summarized by comparing it with other methods of preparing nano-emulsion; The future research direction of ultrasonic cavitation technology was also prospected.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Di<sup>1</sup>, ZHANG Hanwen<sup>1</sup>, XIA Jiang<sup>1</sup>, LIU Siyi<sup>1</sup>, ZHANG Wenjun<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Di<sup>1</sup>, ZHANG Hanwen<sup>1</sup>, XIA Jiang<sup>1</sup>, LIU Siyi<sup>1</sup>, ZHANG Wenjun<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311013&flag=1]]></guid><cfi:id>179</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of cell membrane chromatography in screening active components of polypeptides]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, with the continuous development of chromatography technology, cell membrane chromatography has been widely used in the study of polypeptide active substances. On the basis of summarizing the relevant literature at home and abroad, this paper introduces the principle and characteristics of cell membrane chromatography, the classification of cell membrane chromatography and the research progress of cell chromatography in polypeptide active components. The advantages and existing problems of polypeptide detection by cell membrane chromatography were summarized and put forward, and the prospect was prospected.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Tiefeng<sup>1</sup>, WANG Ping<sup>1,2</sup>, DING Xianglong<sup>3</sup>, DING Lijun<sup>4</sup>, JIANG Qibao<sup>5</sup>, WANG Jinguo<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Tiefeng<sup>1</sup>, WANG Ping<sup>1,2</sup>, DING Xianglong<sup>3</sup>, DING Lijun<sup>4</sup>, JIANG Qibao<sup>5</sup>, WANG Jinguo<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311014&flag=1]]></guid><cfi:id>178</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[General situation of research on chemical constituents, pharmacological effects and clinical application of <i>Fagopyrum dibotrys</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a medicinal plant with rich nutritional value in traditional Chinese medicine, <i>Fagopyrum dibotrys</i> has been widely used in medicines and health products. Its chemical components include flavonoids, condensed tannins, terpenoids, organic acid esters, steroids, volatile oils, trace elements and amino acids, which have important effects on multiple systems of human body. With the continuous progress of technology in the field of modern pharmacy, more and more chemical components along with pharmacological efficacy are explored, and clinical applications are gradually expanded. Based on this, the author summarizes the current situation of the chemical composition, pharmacology and clinical application of <i>Fagopyrum dibotrys</i> in recent years, in order to provide a reference for its further development.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Ting, GUO Yong, ZOU Yan, JIANG Chunyu, HOU Jincai]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Ting, GUO Yong, ZOU Yan, JIANG Chunyu, HOU Jincai</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311015&flag=1]]></guid><cfi:id>177</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the development of antitumor drugs targeting glycosylation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Catalyzed by glycosyltransferases, glycosylation is an enzymatic process that produces either saccharides or glycosidic linkages to saccharides, proteins or lipids, and is the basis of various biological processes. Aberrant glycosylation, playing crucial roles in tumor development, is a common feature of many cancers, which makes it an important target in the anti-tumor research. In this review, we first briefly introduce glycosylation, glycosyltransferases and the tumor-associated carbohydrate antigens, and mainly summarize the most recent information about the research progress on the development of antitumor drugs targeting glycosylation.]]></description>
<pubDate>2023/11/13 15:04:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Lulu, DAI Peiying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Lulu, DAI Peiying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310012&flag=1]]></guid><cfi:id>176</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on weight-loss targets and drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Obesity is a state characterized by excessive accumulation of body fat, which is closely related to other metabolic diseases. The metabolic dysfunction caused by energy intake overweighing energy expenditure is the main cause of obesity. Now obesity has become a social issue worldwide, with its incidence increasing year by year. However, the approved weight loss drugs is extremely limited and far insufficient to meet the market demand. In recent years, with the in-depth research on the physiological and pathological mechanisms of obesity, a series of innovative drugs with novel targets have been found, with promising prospects for body weight control. This review summarizes latest researches on weight loss targets and weight loss drugs, and provides an outlook on the future trends of weight loss drug development.]]></description>
<pubDate>2023/11/13 15:04:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Yi, WANG Pengyuan, LIU Xia, SUN Yang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Yi, WANG Pengyuan, LIU Xia, SUN Yang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310013&flag=1]]></guid><cfi:id>175</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploring the determination and application of humane end point in animal experiments based on 3R principles]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As the main embodiment and application of the optimization principles of 3R principles, experimental animal humane endpoint has been recognized by the international community and formed a perfect system of laws and regulations. along with the great progress made in the field of experimental animal welfare ethics, the practice of experimental animal humane endpoint is also greatly applied and developed. By discussing the determination principles and methods of animal humane end points, the authenticity, accuracy and integrity of animal experimental data are effectively guaranteed under the premise of maximizing the protection of animal welfare, which provides a certain reference for researchers engaged in animal experiments.]]></description>
<pubDate>2023/11/13 15:04:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Chunling<sup>1</sup>, LIU Zengxiang<sup>1</sup>, WEN Chengli<sup>2</sup>, LYU Shibo<sup>2</sup>, CHENG Dong<sup>2</sup>, SUN Changhua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Chunling<sup>1</sup>, LIU Zengxiang<sup>1</sup>, WEN Chengli<sup>2</sup>, LYU Shibo<sup>2</sup>, CHENG Dong<sup>2</sup>, SUN Changhua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310014&flag=1]]></guid><cfi:id>174</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in extraction, purification, structural characteristics and biological activities of <i>Epimedium</i> polysaccharides]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Epimedium brevicornum</i> Maxim. is a traditional Chinese tonic herb with the effects of liver and kidney tonic, antioxidant, anti-aging and anti-tumor. <i>Epimedium brevicornum</i> polysaccharide is one of the main components of <i>Epimedium brevicornum</i> for its clinical efficacy, which has pharmacological effects such as enhancing body immunity, anti-virus, anti-aging, anti-oxidation and anti-radiation. In this paper, we reviewed the research progress on the extraction and purification, biological activity and structural characteristics of <i>Epimedium</i> polysaccharide, in order to provide a basis for its further research and development.]]></description>
<pubDate>2023/11/13 15:04:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XING Zhongfu, YU Hui, WAN Xinhuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XING Zhongfu, YU Hui, WAN Xinhuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310015&flag=1]]></guid><cfi:id>173</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on chemical constituents and pharmacological effects of <i>Dipsaci Radix</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Dipsaci Radix</i> is a commonly used traditional Chinese medicine in clinic. It is mainly used to treat tendon injury, fracture, falling and fluttering injury, rheumatism and arthralgia, liver and kidney deficiency, waist and knee soreness, metrorrhagia and leakage, fetal leakage and other diseases. By searching and summarizing the literature, the chemical components and pharmacological effects of <i>Dipsaci Radix</i> were summarized, so as to provide research reference of this natural medicinal materia.]]></description>
<pubDate>2023/11/13 15:04:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HUANG Mengmeng<sup>1,2</sup>, ZHOU Guangtao<sup>3</sup>, ZHANG Xia<sup>1</sup>, CAO Guiyun<sup>1,2</sup>, WANG Quanjun<sup>1,2</sup>, LIN Yongqiang<sup>3</sup>, MENG Zhaoqing<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Mengmeng<sup>1,2</sup>, ZHOU Guangtao<sup>3</sup>, ZHANG Xia<sup>1</sup>, CAO Guiyun<sup>1,2</sup>, WANG Quanjun<sup>1,2</sup>, LIN Yongqiang<sup>3</sup>, MENG Zhaoqing<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310016&flag=1]]></guid><cfi:id>172</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the rodent models of frailty]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Frailty is an age-related clinical syndrome characterized by a decline in multi-system physiological functions and increased susceptibility to stressors. The underlying molecular mechanisms of frailty remain incompletely understood. Rodent frailty models can be classified into (1) gene-edited developed on basis of disease-related pathology, and (2) non-gene-edited models that include frailty phenotype or frailty index assessment models and inducible models. This review summarizes the research progress in rodent frailty models, and analyzes their advantages and disadvantages, and preliminary discussion of future development, hoping to provide a reference for frailty-related research.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WEI Cailv<sup>1</sup>, SHEN Qianhui<sup>2</sup>, GUO Haiyan<sup>3</sup>, XU Jun<sup>4</sup>, PI Rongbiao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Cailv<sup>1</sup>, SHEN Qianhui<sup>2</sup>, GUO Haiyan<sup>3</sup>, XU Jun<sup>4</sup>, PI Rongbiao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409009&flag=1]]></guid><cfi:id>171</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of in situ hydrogels as co-delivery system in tumor treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In situ hydrogels have become a hot research topic in the field of pharmaceuticals due to their biocompatibility, environmental sensitivity, high stability and injectability. Due to the unique phase transition properties of in situ hydrogels, it is possible to achieve sustained release of drugs locally at the site of administration. In addition, in situ hydrogels will also be able to combine various therapeutic means (e.g., chemotherapy, photothermal therapy, photodynamic therapy, gene therapy, and immunotherapy, etc.) to achieve the combined treatment of tumors. This review focuses recent progress and development prospects of in situ hydrogels as co-delivery system in tumor treatment.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Mengli<sup>1,2</sup>, HE Dongsheng<sup>1,2</sup>, JIANG Lei<sup>1,2</sup>, TU Jiasheng<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Mengli<sup>1,2</sup>, HE Dongsheng<sup>1,2</sup>, JIANG Lei<sup>1,2</sup>, TU Jiasheng<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409010&flag=1]]></guid><cfi:id>170</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of fluorescence labeling technique in drug component tracing]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fluorescent labeling technology is an effective means to study the distribution, metabolic pathway, target and other characteristics of effective components of drugs in vivo. Because of its advantages of simple operation, high sensitivity, strong specificity, good stability and low cost, it is widely used in drug tracing research in vivo. It is of great significance to clarify the material basis and mechanism of drug action and improve the route of drug administration. In this paper, the principle of fluorescence tracing technology and the way of combining fluorescent dyes with drug molecules are reviewed, and the future application trend of this technology is discussed, which provides reference for the in vivo tracing research of drug components.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DONG Limin<sup>1</sup>, DU Haitao<sup>2</sup>, WANG Ping<sup>2</sup>, HU Ya'nan<sup>1,3</sup>, XIE Zhongbo<sup>2</sup>, ZHANG Huimin<sup>2</sup>, LIU Shanxin<sup>2</sup>, SHI Bin<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DONG Limin<sup>1</sup>, DU Haitao<sup>2</sup>, WANG Ping<sup>2</sup>, HU Ya'nan<sup>1,3</sup>, XIE Zhongbo<sup>2</sup>, ZHANG Huimin<sup>2</sup>, LIU Shanxin<sup>2</sup>, SHI Bin<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409011&flag=1]]></guid><cfi:id>169</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent advances of lipase inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Lipase is a key enzyme involved in lipid metabolism, which can be used as a key target for the treatment of obesity. Lipase inhibitors acting on the periphery have the advantages of high efficiency, few side effects. In this paper, the mechanism of lipase and the research progress of lipase inhibitors from chemical synthesis, microorganism and plant are reviewed, which provide inspiration and ideas for the discovery of more potent natural lipase inhibitors.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HU Xinghua<sup>1,2</sup>, ZHANG Zijia<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Xinghua<sup>1,2</sup>, ZHANG Zijia<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409012&flag=1]]></guid><cfi:id>168</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the mechanisms and pharmacological effectsof puerarin on gouty arthritis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Gouty arthritis （GA) is a metabolic arthritis caused by elevated uric acid levels resulting from disruptions in purine metabolism. In recent years, an increasing number of traditional Chinese medicine monomers have been used for the treatment of GA, demonstrating satisfactory therapeutic effects with no apparent adverse reactions. Among them, puerarin is an isoflavone compound extracted and isolated from the root of Pueraria lobata. It exerts immunomodulatory effects, regulates inflammatory factors, and blocks inflammatory signaling pathways, effectively alleviating arthritis inflammation. Additionally, puerarin inhibits the activity of xanthine oxidase, promotes uric acid excretion, and lowers the body's uric acid levels. This article aims to systematically review the pharmacological actions and underlying mechanisms of puerarin in the treatment of GA, providing essential theoretical evidence for further basic research and new drug development in puerarin-based therapy for GA.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Zhuanzhuan<sup>1</sup>, MA Fang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Zhuanzhuan<sup>1</sup>, MA Fang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409013&flag=1]]></guid><cfi:id>167</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[具有防治脑缺血再灌注损伤的中药有效成分研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:16</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘莹<sup>1</sup>，祝琳琳<sup>1,2</sup>，尤诗晴<sup>1</sup>，徐畅<sup>1</sup>，褚福浩<sup>1</sup>，刘斌<sup>1,3</sup>，张薇<sup>1,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘莹<sup>1</sup>，祝琳琳<sup>1,2</sup>，尤诗晴<sup>1</sup>，徐畅<sup>1</sup>，褚福浩<sup>1</sup>，刘斌<sup>1,3</sup>，张薇<sup>1,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408011&flag=1]]></guid><cfi:id>166</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[皂苷表面活性剂在药物递送系统中的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:17</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王炯文<sup>1</sup>，季笑遥<sup>2</sup>，陈可禧<sup>1</sup>，兰素敏<sup>1</sup>，林以宁<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王炯文<sup>1</sup>，季笑遥<sup>2</sup>，陈可禧<sup>1</sup>，兰素敏<sup>1</sup>，林以宁<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408012&flag=1]]></guid><cfi:id>165</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[m6A相关蛋白抑制剂的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:17</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[刘千姿<sup>1</sup>，全怡舟<sup>2</sup>，范一苇<sup>3</sup>，朱宇<sup>3</sup>，谢小娜<sup>4</sup>，赵承光<sup>3</sup>，赵海洋<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘千姿<sup>1</sup>，全怡舟<sup>2</sup>，范一苇<sup>3</sup>，朱宇<sup>3</sup>，谢小娜<sup>4</sup>，赵承光<sup>3</sup>，赵海洋<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408013&flag=1]]></guid><cfi:id>164</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用原位凝胶的分类与基质材料]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:17</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[蒋元<sup>1</sup>，严真<sup>2</sup>，杨磊<sup>1,2</sup>，尹莉芳<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>蒋元<sup>1</sup>，严真<sup>2</sup>，杨磊<sup>1,2</sup>，尹莉芳<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408014&flag=1]]></guid><cfi:id>163</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[儿童呼吸道合胞病毒肺炎的中、西医诊断及药物治疗综述]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:17</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[陈泽琦，张桂菊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈泽琦，张桂菊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408015&flag=1]]></guid><cfi:id>162</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Formation mechanism and researth progress on the immunotherapy of castrate-resistant prostate cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Prostate cancer (PCa) is a malignant reproductive disease that afflicts men worldwide, with a favourable response to androgen deprivation therapy (ADT) in the initial stages of the disease. However, patients inevitably develop hormonal resistance, which progresses to castrate-resistant prostate cancer (CRPC) and greatly reduces patient survival. Clinical studies of CRPC are mainly centred around the androgen receptor (AR), but AR bypass pathways also exist. Therefore, this review discussed the mechanism of CRPC formation and the progress of immunotherapeutic regimens for patients with CRPC, focusing on both androgen receptor-dependent and bypass pathways.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[QIU Yanyi, ZHOU Xiaohui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIU Yanyi, ZHOU Xiaohui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407009&flag=1]]></guid><cfi:id>161</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical composition and analysis methods of Dandeng Tongnao Capsules and herbal medicines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Dandeng Tongnao Soft Capsule is originated from Yi Medicine prescription, composed of four medicines: Salvia，Erigeron breviscapus ，Chuanxiong Rhizome，kudzu, with the effects of activating blood circulation, removing wind and clearing collaterals, and is mostly used in the treatment of coronary heart disease, stroke, hypertension, angina pectoris, and other diseases in the clinic. The composition of the formula is mainly composed of flavonoids, quinones, organic acids and other chemical components, research has confirmed that the drug has the effect of expanding peripheral capillaries, promoting cardiovascular circulation, increasing coronary blood flow and alleviating myocardial ischemia, this paper summarizes the chemical composition, quality control and in vivo metabolism of Dandeng Tongnao Soft Capsule by reviewing the relevant literature in recent years, and aims to provide a more detailed description of the chemical composition, quality control and in vivo metabolism of the capsules and related formulas of Dandeng Tongbengyuan. This paper summarized the chemical composition, quality control and in vivo metabolism of Dandeng Tongnao Soft Capsule by reviewing the relevant literature in recent years, aiming to provide a reference basis for the study of the pharmacological material basis of Dandeng Tongnao Soft Capsule and related formulas.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Wenyu<sup>1,2</sup>, CHEN Hao<sup>3</sup>, JIAO Xin<sup>1,2</sup>, ZHAN Shaofeng<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Wenyu<sup>1,2</sup>, CHEN Hao<sup>3</sup>, JIAO Xin<sup>1,2</sup>, ZHAN Shaofeng<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407010&flag=1]]></guid><cfi:id>160</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research process in pathogenesis of gouty arthritis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Gouty arthritis is a disease caused by the deposition of uric acid in body, and it is usually known as gout. Joint pain and necrosis always occars to the patients. The pathogenesis of gout is complex. Only few therapeutic drugs for gout are on the market. Due to the increase in the number of patients, gout has been widely concerned by researchers. In recent years, traditional Chinese medicine has shown good effects and advantages in the treatment of gout, but the research on the treatment target and treatment mechanism is not clear. In order to further develop drugs to treat gout, the pathogenesis of gout is reviewed in order to provide guidance for follow-up research.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIA Yuhan<sup>1</sup>, GAO Tianshu<sup>1</sup>, PEI Naiqi<sup>2</sup>, ZHENG Qiaohong<sup>2</sup>, LI Jiaqi<sup>1</sup>, LIU Yijiao<sup>1</sup>, QIAN Youqiao<sup>3</sup>, MA Yang<sup>1</sup>, CHEN Hui<sup>4</sup>, YE Yuanyuan<sup>1</sup>, ZHAO Jiaxin<sup>1</sup>, ZHOU Yi<sup>1</sup>, CHEN Xiaoqing<sup>1</sup>, WANG Xing<sup>1</sup>, CHEN Zhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIA Yuhan<sup>1</sup>, GAO Tianshu<sup>1</sup>, PEI Naiqi<sup>2</sup>, ZHENG Qiaohong<sup>2</sup>, LI Jiaqi<sup>1</sup>, LIU Yijiao<sup>1</sup>, QIAN Youqiao<sup>3</sup>, MA Yang<sup>1</sup>, CHEN Hui<sup>4</sup>, YE Yuanyuan<sup>1</sup>, ZHAO Jiaxin<sup>1</sup>, ZHOU Yi<sup>1</sup>, CHEN Xiaoqing<sup>1</sup>, WANG Xing<sup>1</sup>, CHEN Zhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407011&flag=1]]></guid><cfi:id>159</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in methods for the study of percutaneous permeability of drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The percutaneous permeability of drugs in the transdermal drug delivery system is directly related to the safety and effectiveness of drugs in clinical application. In the development process of transdermal preparation, drug permeability evaluation can predict the skin permeability properties of drugs, help to understand product quality and performance, and provide an important indicator for drug development. At present, researchers have developed a variety of drug skin permeability research methods, in vitro transdermal test is the most commonly used, the mainstream method is Franz diffusion cell method; mathematical model permeability prediction, animal test and other research methods can also be used to study drug permeability, in addition to parallel artificial membrane permeability model research, spectral technology and microdialysis technology and other new methods. This paper introduces these research methods and hopes to provide some reference for researchers.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CAO Yuwei<sup>1</sup>, WANG Wenxin<sup>2</sup>, YANG Shujuan<sup>2</sup>, ZHENG Jing<sup>2</sup>, XU Yuwen<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAO Yuwei<sup>1</sup>, WANG Wenxin<sup>2</sup>, YANG Shujuan<sup>2</sup>, ZHENG Jing<sup>2</sup>, XU Yuwen<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407012&flag=1]]></guid><cfi:id>158</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of polypyridine metal anticancer drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cancer has caused great harm to human health. The targeted therapy strategy of polypyridine metal complexes has a good performance due to its special geometric structure and coordination characteristics, which can be combined with DNA, protein and other biological macromolecules through electrostatic interaction, intercalation, groove binding and other methods, showing good antibacterial and anticancer activities. In addition, by changing the ligands or modifying the ligands, the function of the complexes can be adjusted, and it can act alone on mitochondria, lysosomes and other organelles to interact with specific biomolecules. This article summarizes the research progress of polypyridine metal complex drugs for cancer treatment in recent years, in order to provide more ideas for the development of new anticancer drugs.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Ting<sup>1,2</sup>, XIE Xiaowen<sup>3</sup>, LIU Xiaoyan<sup>1,2</sup>, LI Shengjun<sup>1,2</sup>, TU Qidong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Ting<sup>1,2</sup>, XIE Xiaowen<sup>3</sup>, LIU Xiaoyan<sup>1,2</sup>, LI Shengjun<sup>1,2</sup>, TU Qidong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407013&flag=1]]></guid><cfi:id>157</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A new target for drug therapy of neurological diseases: Hv1]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Voltage-gated proton channel (Hv1) is a highly proton selective channel that is expressed and performs physiological functions in nervous system. Hv1 regulates cytosolic pH and participates in the production NOX-dependent reactive oxygen species by transporting protons across membranes, and then plays a role in the regulation of neurological diseases. This review summarized the expression and distribution of Hv1 in the nervous system and the regulation of neurological diseases.]]></description>
<pubDate>2024/7/22 17:21:22</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MIAO Lurong<sup>1</sup>, LI Guang<sup>2</sup>, ZHANG Guangqin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MIAO Lurong<sup>1</sup>, LI Guang<sup>2</sup>, ZHANG Guangqin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406010&flag=1]]></guid><cfi:id>156</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on Chinese materia medica monomers acting on multidrug resistance in lung cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese medicine plays an active role in reversing drug resistance of lung cancer, and monomer compounds extracted from traditional Chinese medicine often have a good role. In order to review the research progress on TCM monomer compounds acting on multidrug resistance in lung cancer, TCM monomer, lung cancer and drug resistance were used as keywords to search the related literature in the databases of PubMed, web of science, CNKI, VIP, and Wanfang, etc. The relevant TCM monomer compounds, such as alkaloids, terpenoids, flavonoids, saponins and other compounds were summarized. The effects and mechanisms of these compounds in reversing lung cancer drug resistance were reviewed. It will provide reference and new ideas for the further research of these compounds.]]></description>
<pubDate>2024/7/22 17:21:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LU Mei<sup>1,2</sup>, ZHANG Jinjie<sup>2</sup>, SUN Binbin<sup>2</sup>, LYU Guangyao<sup>2</sup>, LYU Wenwen<sup>2</sup>, GAO Xinfu<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Mei<sup>1,2</sup>, ZHANG Jinjie<sup>2</sup>, SUN Binbin<sup>2</sup>, LYU Guangyao<sup>2</sup>, LYU Wenwen<sup>2</sup>, GAO Xinfu<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406011&flag=1]]></guid><cfi:id>155</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the “guiding drug up” effect and dosage forms of Borneol]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Borneol has a wide range of pharmacological effects in the treatment of cardiovascular and cerebrovascular diseases due to its heat-clearing and painkilling effects. At the same time, as a "drug priming", it promotes the penetration of other drugs through the blood-brain barrier by "aromatic opening the orifice and guiding drug up" and has been widely used in the design of brain-targeted drug delivery systems. Based on this, based on the pharmacological effects of Borneol, this paper focuses on the "guiding drug up" effect related mechanism of Borneol and its application in traditional compound dosage forms and modern nano-drug delivery systems. It aims to comprehensively reflect the overall progress of Borneol in the research field of "guiding drug", so as to provide a scientific reference for further exploring the medicinal value of Borneol and its modern application development research.]]></description>
<pubDate>2024/7/22 17:21:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHENG Hongyan, TAO Wenwen, TAO Wenkang, ZHANG Yanchun, ZHANG Caiyun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Hongyan, TAO Wenwen, TAO Wenkang, ZHANG Yanchun, ZHANG Caiyun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406012&flag=1]]></guid><cfi:id>154</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacological effects of rhein derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, in order to improve the bioavailability and biological activity of rhein, researchers have modified its structure to obtain many rhein derivatives such as quaternary ammonium salts, quaternary phosphorus salts, methylation, glycosides, metal complexes, etc. In this review, the structural modification sites of rhein are taken as the main line, and the activities of anti-mosquito, free radical scavenging, anti-tuberculosis, anti-osteoporosis, anti-cholestatic liver fibrosis, anti-inflammatory, anti-stress and diabetic hypogonadism, anti-Alzheimer's disease, anti-leukemia have been reviewed. This review provides a reference for the study of structure-activity relationship of rhein and the development of rhein drugs.]]></description>
<pubDate>2024/7/22 17:21:23</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIANG Meichen<sup>1</sup>, JIANG Zhihua<sup>1,2,3</sup>, ZHANG Wenjun<sup>1,2,3</sup>, LIU Jiawen<sup>1</sup>, LI Xiaofeng<sup>1</sup>, CAO Yan, WANG Qianlin<sup>1</sup>, ZHANG Jinhua<sup>1</sup>, JIANG Jingjing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Meichen<sup>1</sup>, JIANG Zhihua<sup>1,2,3</sup>, ZHANG Wenjun<sup>1,2,3</sup>, LIU Jiawen<sup>1</sup>, LI Xiaofeng<sup>1</sup>, CAO Yan, WANG Qianlin<sup>1</sup>, ZHANG Jinhua<sup>1</sup>, JIANG Jingjing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406013&flag=1]]></guid><cfi:id>153</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on extraction, purification and characterization of <i>Gastrodia elata</i> polysaccharides]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[To provide the basis for further research and industrial production by summarizing the extraction, separation, purification and characterization of <i>Gastrodia elata</i> Polysaccharides. Relevant literatures on " Gastrodia elata Polysaccharides", " extraction and purification" and " characterization methods" were searched in domestic and foreign databases, and a comprehensive review of the related content was conducted. The commonly used method for extracting Gastrodia elata Polysaccharides is water extraction, with chromatography being used for purification and spectroscopy for characterization. New extraction and separation techniques can be applied. However, the current extraction methods are relatively traditional and the separation purity is low. Although new techniques have been utilized for structural characterization, there is still no unified standard. Therefore, further research is needed to explore its application in industrial production.]]></description>
<pubDate>2024/8/6 14:20:57</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Yiran, LIU Yuxuan, GUO Daliang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yiran, LIU Yuxuan, GUO Daliang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406014&flag=1]]></guid><cfi:id>152</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the effects and novel drug delivery strategies of curcumin in cardiovascular diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cardiovascular disease (CVD) is the first killer of human life and health, causing heavy health and economic burden. Curcumin, a polyphenol compound, is the main active compound in traditional Chinese medicine turmeric. In recent years, studies have reported that curcumin has anti-inflammatory, antioxidant, hypolipidemic, antithrombotic and other beneficial effects, and is expected to become a potential drug for clinical treatment of cardiovascular diseases. Here, we give a summary of the latest research progress on the mechanism and novel drug delivery strategies of curcumin in cardiovascular diseases in past three years, thus to provide theoretical basis for the application of curcumin in the prevention and treatment of cardiovascular diseases.]]></description>
<pubDate>2024/6/11 10:53:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HAN Tuo<sup>1</sup>, YAN Bao'e<sup>2</sup>, ZHANG Jingruo<sup>1</sup>, LI Wen<sup>1</sup>, ZHANG Yan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Tuo<sup>1</sup>, YAN Bao'e<sup>2</sup>, ZHANG Jingruo<sup>1</sup>, LI Wen<sup>1</sup>, ZHANG Yan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405009&flag=1]]></guid><cfi:id>151</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The application of FGFR inhibitors in prostate cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The abnormal expression or activation of fibroblast growth factor receptors (Fibroblast Growth Factor Receptor, FGFR) is closely related to the occurrence and development of tumors, and small molecule inhibitors targeting FGFRs have become a research hotspot in recent years. Erdafitinib, as the first FGFR small molecule inhibitor, has been approved by the US FDA for use in advanced prostate cancer with FGFR gene mutations. Multiple FGFR inhibitors in clinical trials have also shown satisfactory therapeutic effects. This article provides a review of FGFR structure, FGFR signaling pathway, FGFR inhibitors, and their drug resistance patterns, with the aim of providing reference for the clinical application of FGFR inhibitors in prostate cancer.]]></description>
<pubDate>2024/6/11 10:53:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Yunxiang<sup>1</sup>, FAN Yiwei<sup>2</sup>, ZHU Yu<sup>2</sup>, ZHAO Chengguang<sup>2</sup>, ZHAO Haiyang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Yunxiang<sup>1</sup>, FAN Yiwei<sup>2</sup>, ZHU Yu<sup>2</sup>, ZHAO Chengguang<sup>2</sup>, ZHAO Haiyang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405010&flag=1]]></guid><cfi:id>150</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on anti-inflammatory effect and mechanism of <i>Ginkgo biloba</i> extract]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In this paper, the anti-inflammatory active ingredients and their mechanisms of action of <i>Ginkgo biloba</i> were reviewed, in order to provide ideas and inspiration for the study of novel anti-inflammatory drugs related to ginkgo biloba extract. Through consulting and comparative analysis of a large number of domestic and foreign related literature, it is summarized and summarized. <i>Ginkgo biloba</i> extract has a variety of active components, and its anti-inflammatory components mainly focus on flavonoids and terpene lactones, and the mechanism of action is diverse, mainly involved in regulating oxidative stress, regulating inflammatory signaling pathways, regulating inflammatory factors and so on. At present, studies on the anti-inflammatory effects of <i>Ginkgo biloba</i> extract have been in-depth in various signaling pathways and inflammatory factors, but relatively few safe and effective anti-inflammatory drugs have been found for <i>Ginkgo biloba</i> extract. Clarifying the anti-inflammatory active ingredients of <i>Ginkgo biloba</i> extract and exploring its synergistic mechanism are one of the main tasks of the anti-inflammatory studies of ginkgo biloba extract.]]></description>
<pubDate>2024/6/11 10:53:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIA Jiang<sup>1</sup>, JIANG Jingjing<sup>1</sup>, WANG Xiaoling<sup>2</sup>, CHEN Jingfang<sup>2</sup>, YAN Hong<sup>2</sup>, ZHANG Wenjun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIA Jiang<sup>1</sup>, JIANG Jingjing<sup>1</sup>, WANG Xiaoling<sup>2</sup>, CHEN Jingfang<sup>2</sup>, YAN Hong<sup>2</sup>, ZHANG Wenjun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405011&flag=1]]></guid><cfi:id>149</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Tibetan medicine and research status in the treatment of hyperlipidemia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hyperlipidemia can cause many diseases and increasingly threaten human health. Therefore, it is urgent to research and develop effective, safe and reliable lipid-lowering drugs. Tibetan medicine is an important component of traditional Chinese medicine. Deeply exploring and studying the valuable experience of the people on the Qinghai-Tibet Plateau in preventing and treating diseases and the medicinal biological resources that grow in unique conditions is an indispensable part of the inheritance, innovation, and development of traditional Chinese medicine. After more than 2000 years of sedimentation and accumulation, Tibetan medicine has discovered or invented many Tibetan medicinal materials or Tibetan compound preparations that have the potential to prevent and treat hyperlipidemia. This article takes Tibetan medicine for preventing and treating hyperlipidemia as the starting point, This article briefly reviews the pathogenesis of hyperlipidemia and the understanding of Tibetan medicine, focusing on the application and research status of single Tibetan medicine and Tibetan compound medicine with pharmacological effects on preventing and treating hyperlipidemia, in order to provide theoretical basis for in-depth research and development of Tibetan medicine for treating hyperlipidemia.]]></description>
<pubDate>2024/6/11 10:53:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Changting<sup>1,2</sup>, CAI Zengzhuoma<sup>1,2</sup>, ZHANG Shoude<sup>1</sup>, QIE Yangrangzhong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Changting<sup>1,2</sup>, CAI Zengzhuoma<sup>1,2</sup>, ZHANG Shoude<sup>1</sup>, QIE Yangrangzhong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405012&flag=1]]></guid><cfi:id>148</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Status of New lipid-lowering Drugs PCSK9 Inhibitors in Arteriosclerosis Cardiovascular Disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Atherosclerosis is an early pathological change of many cardiovascular diseases. Lipid metabolism disorder is one of the most important risk factors of atherosclerotic cardiovascular disease (ASCVD). Proprotein conver-tase subtilisin/kexin type 9 (PCSK9) is a key protein in lipid metabolism. It can bind to low-density lipoprotein receptor (LDLR) and degrade LDLR to prevent the clearance of low-density lipoprotein, resulting in increased Low density lipoprotein cholesterol (LDL-C) levels. Increased risk of cardiovascular disease. PCSK9 is also involved in the production of inflammatory cytokines, endothelial dysfunction and the formation of atherosclerotic plaques. A number of studies have shown that PCSK9 is a promising new target for the treatment of ASCVD.PCSK9 inhibitors are currently a new type of drug for the treatment of hypercholesterolemia. This article reviews the role of PCSK9 inhibitors in atherosclerosis and the research progress of drugs, so as to provide reference for clinical medication.]]></description>
<pubDate>2024/6/11 10:53:53</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ME Guowen<sup>1,2</sup>, LIU Shichang<sup>3</sup>, WANG Hailiang<sup>2</sup>, JIANG Wenyan<sup>1</sup>, WANG Xuejian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ME Guowen<sup>1,2</sup>, LIU Shichang<sup>3</sup>, WANG Hailiang<sup>2</sup>, JIANG Wenyan<sup>1</sup>, WANG Xuejian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405013&flag=1]]></guid><cfi:id>147</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application progress of hydrogel-forming microneedle technology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hydrogel-forming microneedle is a novel type of polymeric microneedle that has gained much attention lately. When inserted into the skin, it absorbs the interstitial fluid to form continuous and unobstructed micropores that allow drugs to enter the body through the gaps in the network structure. Hydrogel-forming microneedle has high drug loading capacity, adjustable drug release rate, and lack of residual needles, making it become a research hotspot in recent years. This study aims to present a thorough review of the applications of hydrogel-forming microneedle technology in skin interstitial fluid sampling and biomarker analysis, wound treatment, antitumor, drug reservoir, and other areas in recent years while offering insights into its future research prospects.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Wenlin<sup>1</sup>, MA Chao<sup>2</sup>, ZHANG Yiwen<sup>1</sup>, YUAN Hua<sup>3</sup>, GUO Na<sup>4</sup>, ZHANG Junying<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Wenlin<sup>1</sup>, MA Chao<sup>2</sup>, ZHANG Yiwen<sup>1</sup>, YUAN Hua<sup>3</sup>, GUO Na<sup>4</sup>, ZHANG Junying<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404010&flag=1]]></guid><cfi:id>146</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the biological basis of HDL transport to liver and its application as drug carrier]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The development of biomimetic nanoparticle drug delivery systems is an emerging field with enormous potential for efficient drug delivery.High density lipoprotein (HDL), as a natural nanocarrier, possesses features such as high transport efficiency, high safety, specific targeting, and strong penetration, making it a potential drug carrier.The research on HDL-based nanoparticle drug delivery systems is increasingly gaining attention. This article will review the biological basis of HDL, including its composition, structure, metabolism, and its current status of research and application as a drug carrier of reconstituted HDL. The aim of this article is to provide new ideas for the in-depth study of HDL as drug carrier materials.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIN Xutong<sup>1</sup>, JIANG Zixian<sup>1</sup>, WANG Xinyi<sup>2</sup>, TIAN Jilai<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIN Xutong<sup>1</sup>, JIANG Zixian<sup>1</sup>, WANG Xinyi<sup>2</sup>, TIAN Jilai<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404011&flag=1]]></guid><cfi:id>145</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemicaL constituents and pharmacological effects of  Agarwood essential oil]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The main context of this review of the essential oil of Agarwood is written up in aspects of the extraction methods, chemical constituents and pharmacological activity through summarizing the overall literature reports.The main extraction methods of Agarwood essential oil includes supercritical carbon dioxide extraction, subcritical fluid extraction, steam distillation, enzyme assisted extraction and so on. The essential oil of Agarwood is mainly composed of natural chemical components such as sesquiterpene, chromones, aromatics and fatty acids, which obtain pharmacological activities such as anti-inflammatory and antioxidant.Most of related researches of the Agarwood essential oil mainly focused on discovering the extraction method and the chemical property. In the field of the the extraction method, chemical composition and pharmacological activity of the essential oil and the pharmacological activity require further explored.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LAN Baoqiang, WANG Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LAN Baoqiang, WANG Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404012&flag=1]]></guid><cfi:id>144</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the mechanism of hemorrhagic transformation caused by tPA thrombolysis and the intervention effect of small molecule compounds]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tissue type plasmin activator (tPA) is the only drug approved by the US Food and Drug Administration for the treatment of acute ischemic stroke. However, its clinical application is limited due to the narrow treatment time window and severe hemorrhagic transformation (HT). In this paper, the mechanism of HT development was reviewed from the perspectives of blood-brain barrier disruption, neuroinflammation, oxidative stress, and nitrite stress, as well as the research progress of small molecule compounds on HT protection published in domestic and foreign journals in the past seven years. This information would provide some clues and references for the new drug development and drug combination for the ischemic stroke.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HUANG Juan, ZHANG Miling, YU Junhe, GONG Shuaishuai, KOU Junping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Juan, ZHANG Miling, YU Junhe, GONG Shuaishuai, KOU Junping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404013&flag=1]]></guid><cfi:id>143</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on intestinal microorganisms regulated by licorice to improve drug-induced liver injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To summarize the mechanisms of licorice and its compound prescriptions regulating intestinal microbes to improve drug-induced liver injury (DILI) in recent years.<b>Methods</b>  In the CNKI and Pubmed databases, using licorice or licorice compound and liver injury and intestinal flora as keywords, the literature on licorice and its compound in relieving liver injury in recent years was screened, and the relationship between intestinal flora and intestinal flora was summarized. The relationship between DILI, licorice and the mechanism of DILI relief by regulating gut microbiota.<b>Results</b>  The liver induced by drugs can lead to abnormal composition of intestinal flora, intestinal barrier damage, and translocation of bacteria and their metabolites, and abnormal intestinal flora may aggravate liver injury through multiple channels. The components and compounds in licorice can improve DILI by regulating the composition of intestinal flora, restoring the intestinal barrier, anti-inflammation, and enhancing the immune mechanism.<b>Conclusion</b>  Licorice and its compound can alleviate drug DILI by regulating intestinal flora, and provide reference for expanding the research and clinical treatment of drug-induced liver injury in traditional Chinese medicine.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Biqian<sup>1</sup>, HE Yujie<sup>1</sup>, HE Huiming<sup>1</sup>, DENG Yi<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Biqian<sup>1</sup>, HE Yujie<sup>1</sup>, HE Huiming<sup>1</sup>, DENG Yi<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404014&flag=1]]></guid><cfi:id>142</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Red blood cell-nanocarrier drug delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Nanocarriers such as liposomes, polymer nanoparticles, and polymer micelles are research hotspots for drug delivery in recent years, but they are easily recognized and cleared by the human immune system after administration. Cell carrying technology can prolong the circulation of nanocarriers in vivo. Red blood cells, as endogenous cells, have the advantages of abundant sources, high biocompatibility and safety of biological elimination mechanism, thus promoting the development of red blood cell-nanocarrier composite systems. Based on this, this paper reviews the research progress of several types of red blood cell-nanocarrier drug delivery systems according to the different construction methods of red blood cells and nanocarriers.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SU Yanhui, ZHANG Wenli, SHEN Yan, ZHENG Chunli]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SU Yanhui, ZHANG Wenli, SHEN Yan, ZHENG Chunli</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403009&flag=1]]></guid><cfi:id>141</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on chemical composition and pharmacological effects and clinical application of  <i>Hedyotis hedyotidea</i> (DC.) Merr.]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Hedyotis hedyotidea</i> (DC.) Merr. is a dried whole grass of the genus Rubiaceae. It has abundant resources and is widely distributed in Guangxi, Guangdong, Fujian, Taiwan, Guizhou, Yunnan and other places in China. Modern research shows that <i>Hedyotis hedyotidea</i> (DC.) Merr. contains terpenes, steroids, coumarins, lignans and other compounds.It has analgesic, antitumor, antibacterial, anti-inflammatory, anti-leukemia effects and other effects. At present, most of the pharmacological activity studies of <i>Hedyotis hedyotidea</i> (DC.) Merr. are mainly on terpenes, but there are few studies on related pharmacological mechanisms. Therefore, this paper conducts research on the chemical composition, pharmacological effects and clinical application of <i>Hedyotis hedyotidea</i> (DC.) Merr., in order to provide a theoretical reference for the development and utilization of <i>Hedyotis hedyotidea</i> (DC.) Merr. in the future.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YIN Shenggao, CHEN Shiman, LU Hailin, CEN Haixia, CHENG Ruomin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YIN Shenggao, CHEN Shiman, LU Hailin, CEN Haixia, CHENG Ruomin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403010&flag=1]]></guid><cfi:id>140</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances of BRD4 and its inhibitors in inflammatory diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The bromodomain (BD) is a highly conserved protein structural domain that has the biological function of specifically recognizing and binding acetylated lysine residues. The bromodomain-containing protein 4 (BRD4) is a member of the bromodomain and extra-terminal domain (BET) family, which has received much attention for its powerful ability to regulate gene transcription. Currently, small molecule inhibitors targeting BRD4 have shown great potential in anti-inflammatory and anti-cancer fields. This paper describes the biological function and distribution of BRD4 in human tissues, summarizes the current status of drug development of BRD4 inhibitors, and focuses on the role of BRD4 inhibitors in inflammatory diseases.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIONG Zhenghan, YIN Li, HU Qinghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIONG Zhenghan, YIN Li, HU Qinghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403011&flag=1]]></guid><cfi:id>139</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on virus-free seedlings,chemical constituents and fingerprints of <i>Pseudostellaria heterophylla</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Pseudostellaria heterophylla</i> is a Chinese herbal medicine, which contains a variety of biological active components, including saccharide, cyclic peptides, saponins, trace elements,volatile oil and so on. Modern pharmacological studies have shown that these chemical components have many activities such as enhancing memory, immune regulation, inhibiting esophageal cancer, lowering blood sugar, and promoting angiogenesis. In recent years, artificial cultivation has been vigorously promoted in many places to build a GAP base for <i>Pseudostellaria heterophylla</i>. However, some problems have arisen, such as the aggravation of Pseudostellaria heterophylla virus disease year by year, confusion of varieties, and uneven internal quality. Scholars have carried out many researches in these aspects. This paper reviewed the research on virus-free seedlings, chemical constituents and fingerprints of <i>Pseudostellaria heterophylla</i>. It is expected to provide reference for the planting and cultivation of this resource, drug research and development, establishment of quality standards, etc.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GUO Huihui<sup>1</sup>, JIANG Yuanbin<sup>1</sup>, LIN Congfa<sup>1</sup>, XU Shaoxiang<sup>1</sup>, LIN Zeyu<sup>1</sup>, XUE Liyun<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Huihui<sup>1</sup>, JIANG Yuanbin<sup>1</sup>, LIN Congfa<sup>1</sup>, XU Shaoxiang<sup>1</sup>, LIN Zeyu<sup>1</sup>, XUE Liyun<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403012&flag=1]]></guid><cfi:id>138</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of engineered probiotic live bacteria preparation in disease treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The use of engineered probiotics as live bacteria preparation is an emerging drug delivery system design idea, which mainly uses the unique biosafety and gastrointestinal targeting of probiotics to build a new drug delivery system with active targeting function. This review focuses on the research progress of engineered probiotics in the treatment of bacterial infection, viral infection, tumor and inflammation, and looks ahead to the future development of probiotic as live bacteria preparations.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Dingyuan<sup>1,2</sup>, HE Dongsheng<sup>1,2</sup>, TU Jiasheng<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Dingyuan<sup>1,2</sup>, HE Dongsheng<sup>1,2</sup>, TU Jiasheng<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402010&flag=1]]></guid><cfi:id>137</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the clinical efficacy and mechanism of Qingchang Huashi in the treatment of ulcerative colitis based on the theory of "Damp heat causing disease"]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Based on the theoretical connotation of "dampness and heat causing disease", it is believed that the accumulation of dampness and heat in the intestine, which leads to heat accumulation and polyp decay, as well as qi and blood blockage, is the key to the formation of ulcerative colitis (UC). Traditional Chinese medicine believes that UC is locate in the intestine, characterized by dampness and heat. The main syndrome is dampness and heat in the large intestine, and the treatment principle is to clear and benefit the large intestine. In clinical application, the Qingchang Huashi Compound has a significant therapeutic effect on UC, can significantly improve patient symptoms, and has high safety and minimal adverse reactions. Modern pharmacological research has found that clearing the intestines and removing dampness can exert therapeutic effects by regulating intestinal microbiota,repairing intestinal mucosal barrier, maintaining intestinal immune balance, reducing intestinal inflammation, and alleviating oxidative stress. The author has systematically summarized and analyzed the research results and mechanism of Qingchang Huashi Compound in the treatment of UC in recent years by organizing literature, and proposed suggestions for the shortcomings. The aim is to provide scientific basis for explaining the scientific connotation of Qingchang Huashi Compound in the treatment of UC, and to provide reference for evaluating and exploring the potential of classical Chinese medicine and its compound formulas in the treatment of UC.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Na<sup>1</sup>, JING Weidong<sup>2</sup>, JING Ming<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Na<sup>1</sup>, JING Weidong<sup>2</sup>, JING Ming<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402011&flag=1]]></guid><cfi:id>136</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Quality research status of Chinese medicine Toad venom]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Toad venom is a dry secretion from the posterior auricular glands or skin glands of the Bufonidae, Bufo bufo gargarizans Cantor, or Bufo melanostictus Schneider. As a traditional Chinese medicine, Toad venom has a complex chemical composition and wide clinical application. It has many pharmacological activities, such as anti-tumor, cardiac strengthening, anti-inflammatory, local anesthesia, alleviating pain ，and so on. This paper summarizes the research status of the quality of Toad venom from the aspects of herbalogical study, quality influencing factors, and quality standards. It is expected to provide a reference for the further quality control of Toad venom medicinal materials from the current standards.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHI Li<sup>1</sup>, JIANG Yang<sup>1</sup>, XUE Fei<sup>1</sup>, CHEN Juan<sup>2</sup>, WANG Bing<sup>1</sup>, LIN Yongqiang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHI Li<sup>1</sup>, JIANG Yang<sup>1</sup>, XUE Fei<sup>1</sup>, CHEN Juan<sup>2</sup>, WANG Bing<sup>1</sup>, LIN Yongqiang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402012&flag=1]]></guid><cfi:id>135</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in studies on Opioids with abuse-deterrent formulations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Opioids have played an important role in the treatment of moderate and severe pain. But a large number of drug abuse and addiction have emerged in their application, which has caused serious social problems. The United States is one of the countries with the most serious drug abuse. Around 2011, FDA successively issued a series of guidelines and evaluation rules on the development of opioids, speeding up and promoting the innovation of drug abuse prevention technology. We analyzes various opioids on the market abroad in recent years according to several drug abuse prevention technologies proposed in the "Abuse-Deterrent Opioids — Evaluation and Labeling Guidance for Industry". It is expected to be helpful to domestic research in related fields.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DING Jiaxin<sup>1</sup>, WANG Yanli<sup>2</sup>, WANG Meng<sup>1</sup>, XUE Liyun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Jiaxin<sup>1</sup>, WANG Yanli<sup>2</sup>, WANG Meng<sup>1</sup>, XUE Liyun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402013&flag=1]]></guid><cfi:id>134</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress and safety characteristics in thrombopoietin receptor agonists against immune thrombocytopenia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Traditional ITP treatment strategies work through mitigating immune-mediated platelet destruction,such as glucocorticosteroids, immunoglobulins, immunomodulatory agents, or splenectomy. Although these strategies are usually effective, many patients have poor responsiveness to these therapies and their use is limited by treatment-related side effects and contraindications.In recent years, thrombopoietin receptor agonists (TPO-RA) ,by promoting platelet production,has become a new choice for the treatment of ITP. This article focuses on the progress and safety characteristics of TPO-RA, aiming to provide reference for the research and clinical use of TPO-RA.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Mingxia<sup>1</sup>, HAN Fengsheng<sup>2</sup>, LIU Yanzhen<sup>2</sup>, SUN Yunbei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Mingxia<sup>1</sup>, HAN Fengsheng<sup>2</sup>, LIU Yanzhen<sup>2</sup>, SUN Yunbei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402014&flag=1]]></guid><cfi:id>133</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role of cell death in sepsis-induced kidney injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sepsis is a systemic inflammatory response syndrome caused by infection, accompanied by acute injury to multiple organs. Sepsis-induced acute kidney injury (AKI) is one of the most severe complications and may turn into chronic kidney disease (CKD). The pathophysiology involves a variety of cells, including renal vascular endothelial cells, tubular epithelial cells and macrophages. The associations between these cells and cell death are strongly associated with kidney injury induced by sepsis. Endoplasmic reticulum stress, mitochondrial dynamic imbalance and oxidative stress are the main causes of cell death.]]></description>
<pubDate>2024/2/26 16:18:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Wenchen, HE Chaoyong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Wenchen, HE Chaoyong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401012&flag=1]]></guid><cfi:id>132</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of traditional Chinese medicine in improving Alzheimer's disease by regulating intestinal flora]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer's disease (AD) is a progressive neurodegenerative disease with high incidence in middle-aged and elderly people, which seriously affects the quality of life. The pathogenesis is unclear. With the rise of research in the field of microorganism-gut-brain axis, researchers have made in-depth research on the use of traditional Chinese medicine in treating AD, and the role of traditional Chinese medicine in regulating intestinal flora in the occurrence and development of AD has been paid more and more attention. In this paper, the relationship between AD and intestinal flora, and the research status of regulating intestinal flora to improve AD by traditional Chinese medicine are reviewed, so as to provide reference for the research of prevention and treatment of AD by traditional Chinese medicine.]]></description>
<pubDate>2024/2/26 16:18:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZENG Chunhui, LI Shaoyan, ZHOU Guanlin, CHI Xinyu, YANG Ke]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZENG Chunhui, LI Shaoyan, ZHOU Guanlin, CHI Xinyu, YANG Ke</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401013&flag=1]]></guid><cfi:id>131</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on caffeoylquinic acids in <i>Lonicera</i> L. and their absorption and metabolism mechanism]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Caffeoylquinic acids are very important natural products with a variety of pharmacological activities and broad research prospects. By retrieving related literature, it was reported that 24 caffeoylquinic acids have been isolated from <i>Lonicera</i> so far. Absorption and metabolism research found that the main absorption site of caffeoylquinic acids is the small intestine, with passive diffusion as the main site, and the metabolic site is mainly in the large intestine. The metabolic pathways include methylation, glucuronidation, hydrolysis, isomerization and reduction reactions. This paper summarizes the chemical structures of caffeoylquinic acids in <i>Lonicera</i> and their absorption and metabolism, in order to provide reference for the research and development of caffeoylquinic acids.]]></description>
<pubDate>2024/2/26 16:18:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Haitao<sup>1</sup>, ZHANG Zhe<sup>1</sup>, ZHAO Pan<sup>1</sup>, LI Jing<sup>1</sup>, ZHANG Sixi<sup>2</sup>, DENG Zhipeng<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Haitao<sup>1</sup>, ZHANG Zhe<sup>1</sup>, ZHAO Pan<sup>1</sup>, LI Jing<sup>1</sup>, ZHANG Sixi<sup>2</sup>, DENG Zhipeng<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401014&flag=1]]></guid><cfi:id>130</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research and development progress of anti-tumor drug targeting  transcription factors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Transcription factors control many normal cellular processes such as cell growth and proliferation, metabolism, apoptosis, immune response and differentiation by binding to DNA-regulatory sequences. TFs are often dysregulate in cancer and associate with initiation and progression of cancer. Therefore targeting TFs provides new ideas for the development of anticancer drugs. However, drug design targeting TFs faces challenges because of structural disorder and lack of binding pockets. This review focuses on the advances and successes in the development of small molecules targeting TFs and demonstrates feasibility of drug discovery targeting TFs and provides paradigms for the development of drugs targeting TFs.]]></description>
<pubDate>2024/2/26 16:18:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LU Mingying, HU Weiwei, GAO Xinghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Mingying, HU Weiwei, GAO Xinghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401015&flag=1]]></guid><cfi:id>129</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical research progress of novel antiviral RNA polymerase PA subunit inhibitor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Influenza is a respiratory infectious disease caused by influenza virus, which is more harmful to human health. At present, the main problems faced by anti influenza drugs are virus resistance and low potency for highly pathogenic influenza virus. Due to the shortcomings of influenza drugs such as M2 Ion channel inhibitor and Neuraminidase inhibitor, such as low efficacy, narrow time window and drug resistance, recent anti influenza Drug development focuses on viral RNA polymerase. Influenza virus RNA polymerase is a key enzyme for virus replication and transcription in host cells. The PA subunit provides primers for the transcription process of influenza virus through Endonuclease activity and becomes a potential anti influenza drug target. Therefore, this article summarized the research progress of anti influenza drugs targeting the activity of PA subunit Endonuclease, aiming to provide a reference for the development of new safe and effective antiviral RNA polymerase inhibitors.]]></description>
<pubDate>2024/2/26 16:18:01</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Shoufei<sup>1</sup>, ZHANG Jing<sup>2</sup>, XUE Xiaoxia<sup>2</sup>, ZHAO Jie<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Shoufei<sup>1</sup>, ZHANG Jing<sup>2</sup>, XUE Xiaoxia<sup>2</sup>, ZHAO Jie<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401016&flag=1]]></guid><cfi:id>128</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in the treatment of non-alcoholic fatty liver disease based on the long chain fatty acids and related metabolic enzymes]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Long-chain fatty acids(LCFA) are defined as fatty acids with 12-20 carbons. LCFA are the most abundant type of fatty acids in diet. LCFA are involved in maintaining the normal structure and basic function of cell membranes, which play an important role in energy metabolism of the organism, glucose and lipid metabolism, and inflammatory response. In hepatocytes, an overload of LCFA can induce liver injury in various ways such as inflammation, oxidative stress, fibrosis, autophagy, and apoptosis. This article reviews the research progress of treating non-alcoholic fatty disease based on long chain fatty acids and related metabolic enzymes, providing new ideas and strategies for the treatment of non-alcoholic fatty liver disease.]]></description>
<pubDate>2025/1/9 14:34:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Rongmi<sup>1</sup>, LU Qian<sup>1</sup>, JIN Ming<sup>1</sup>, HUANG Xiaofei<sup>1</sup>, YU Qinwei<sup>1</sup>, JIANG Zhenzhou<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Rongmi<sup>1</sup>, LU Qian<sup>1</sup>, JIN Ming<sup>1</sup>, HUANG Xiaofei<sup>1</sup>, YU Qinwei<sup>1</sup>, JIANG Zhenzhou<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412012&flag=1]]></guid><cfi:id>127</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on anti-tumor effects of coumarin and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Coumarins and their derivatives belong to a class of compounds with the core structure of benzo-α-pyrone. They have garnered significant interest from researchers due to their potent antitumor activity. This paper presents a comprehensive review of the recent research literature on coumarins and their derivatives in the context of antitumor activity, encompassing their respective mechanisms of action. The objective is to establish a scientific foundation for advancing the research and development of coumarin and its derivatives, as well as to advocate for their utilization in cancer therapy.]]></description>
<pubDate>2025/1/9 14:34:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Lu<sup>1</sup>, ZHANG Wen<sup>2</sup>, ZOU Liyi<sup>2</sup>, YIN Ting<sup>2</sup>, LIU Yi<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Lu<sup>1</sup>, ZHANG Wen<sup>2</sup>, ZOU Liyi<sup>2</sup>, YIN Ting<sup>2</sup>, LIU Yi<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412013&flag=1]]></guid><cfi:id>126</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on inhibiting ferroptosis in traditional Chinese medicine for atherosclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Atherosclerosis is a complex vascular disease characterized by endothelial dysfunction, lipid deposition, and chronic inflammation, and is the major pathological basis of cardiovascular disease. Ferroptosis is a mode of cell death caused by lipid peroxidation due to excessive accumulation of iron ions. During the development of atherosclerosis, ferroptosis significantly affects plaque stability and cardiovascular risk by exacerbating lipid peroxidation and inflammation in atheromatous plaques. In recent years, traditional Chinese medicine (TCM) has played an active role in the development of ferroptosis by regulating iron homeostasis, inhibiting reactive oxygen species generation and enhancing cellular antioxidant defense, providing new therapeutic strategy for the treatment of atherosclerosis.]]></description>
<pubDate>2025/1/9 14:34:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Mengyuan, QIU Xiao, DENG Zhipeng, YANG Ying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Mengyuan, QIU Xiao, DENG Zhipeng, YANG Ying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412014&flag=1]]></guid><cfi:id>125</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application and progress of microscopic identification techniques combined with modern analytical methods in the identification of traditional Chinese medicines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a key method to identify the authenticity and quality evaluation of herbs, the application of microscopic identification technology in the field of traditional Chinese medicine has been highly valued by researchers. However, with the progress of science and technology and the deepening of the research of traditional Chinese medicine, the traditional microscopic identification technology can no longer fully meet the development needs of modern research and practical application in some aspects, in order to meet the challenge, the present study discussed the integration and application of the microscopic identification technology with modern analytical methods. In order to meet this challenge, this study thoroughly explores the integration of microscopic identification technology and modern analytical methods. In particular, microscopic observation, chemical composition analysis and computer image recognition and other advanced technologies are combined. Through microscopic technology, the microstructure and cellular characteristics of Chinese herbs can be observed in detail; chemical composition analysis can reveal the active ingredients and their contents in the herbs, providing a scientific basis for quality evaluation; and the introduction of computer image recognition technology further enhances the efficiency of processing and analyzing the microscopic images, making the identification process more accurate and efficient. The in-depth investigation of microscopic identification technology not only opens up new perspectives and paths for accurate identification and efficient analysis of traditional Chinese medicines, but also injects new vitality and strong impetus into the international development of the traditional Chinese medicine industry, and pushes the field of traditional Chinese medicines to a higher level and a wider field.]]></description>
<pubDate>2025/1/9 14:34:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Ying<sup>1,2</sup>, XU Xingyan<sup>2</sup>, WANG Bing<sup>2</sup>, NIU Yan<sup>2</sup>, ZANG Yuanfang<sup>2</sup>, ZHOU Guangtao<sup>2</sup>, MA Shuancheng<sup>3</sup>, KANG Shuai<sup>4</sup>, LIN Yongqiang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Ying<sup>1,2</sup>, XU Xingyan<sup>2</sup>, WANG Bing<sup>2</sup>, NIU Yan<sup>2</sup>, ZANG Yuanfang<sup>2</sup>, ZHOU Guangtao<sup>2</sup>, MA Shuancheng<sup>3</sup>, KANG Shuai<sup>4</sup>, LIN Yongqiang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412015&flag=1]]></guid><cfi:id>124</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the application of capillary electrophoresis in vaccine quality control]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Capillary electrophoresis is a liquid phase separation and analysis technique that uses capillaries as separation channels and high-voltage electric fields as the driving force. It offers advantages such as high separation efficiency, low sample volume, rapid analysis speed, and versatile separation modes. It can effectively separate and detect various biological macromolecule samples, such as peptides, proteins, and nucleic acids, etc. The position in the field of vaccines quality control is becoming increasingly prominent. It has been widely recognized by enterprises and inspection agencies. This paper reviews the application progress of capillary electrophoresis in vaccine quality control.]]></description>
<pubDate>2025/1/9 14:34:37</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YOU Pengfei<sup>1,2</sup>, XIAN Ruiqing<sup>1,2</sup>, CAO Shouchun<sup>3</sup>, SHI Feng<sup>1,2</sup>, YANG Mingzheng<sup>1,2</sup>, WANG Weijian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YOU Pengfei<sup>1,2</sup>, XIAN Ruiqing<sup>1,2</sup>, CAO Shouchun<sup>3</sup>, SHI Feng<sup>1,2</sup>, YANG Mingzheng<sup>1,2</sup>, WANG Weijian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412016&flag=1]]></guid><cfi:id>123</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances in the role of microglia in multiple sclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Multiple sclerosis is an immune-mediated inflammatory disease of the central nervous system, and microglia, as important immune cells in the CNS, play an essential role in CNS development, immune surveillance and homeostatic maintenance. Also in multiple sclerosis, microglia regulate a wide range of immune responses and are key mediators of neuroinflammation, and their inflammatory activity can damage myelin and promote disease progression, but phagocytosis and tissue remodeling capacity also promote endogenous repair of myelin. This article reviewed the dual role of microglia in multiple sclerosis and its mechanisms, and further discussed the potential of microglia as biomarkers and therapeutic targets in multiple sclerosis.]]></description>
<pubDate>2024/12/5 16:48:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHAN Chun, YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHAN Chun, YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411011&flag=1]]></guid><cfi:id>122</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of opioid drugs and gene polymorphism of drug metabolism enzymes]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Opioids serve as essential medications for managing advanced cancer pain. The in vivo metabolism of opioids primarily relies on drug-metabolizing enzymes, with genetic polymorphism being the primary determinant of enzyme variability in drug metabolism. The correlation between opioids and gene polymorphisms of drug metabolism enzymes has been extensively investigated in recent years. Opioid metabolism in vivo, transport efficiency, and gene polymorphisms of drug metabolism enzymes are intricately interconnected, with allelic nucleotide sequence variations potentially leading to significant interindividual differences. Therefore, a comprehensive and in-depth investigation into the correlation between opioids and genetic polymorphisms of drug metabolism enzymes based on genomics will facilitate clinicians in achieving precision medicine.]]></description>
<pubDate>2024/12/5 16:48:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Zeyu<sup>1</sup>, YAN Juan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Zeyu<sup>1</sup>, YAN Juan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411012&flag=1]]></guid><cfi:id>121</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The development and application of lipid nanoparticle in tumor therapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The global incidence of malignant tumors is increasing year by year, and anti-tumor therapy remains a difficult problem worldwide. As new therapeutic approaches, nucleic acid drugs have opened up novel avenues for oncology treatment, but their drug ability is limited by in-vivo delivery systems. Lipid Nanoparticle (LNP) is the most advanced non-viral delivery system available. LNP encapsulates nucleic acid drugs and delivers them to target cells for effective anti-tumor actions, with the advantages of low cytotoxicity and controllable targeting, and great potential for development. This review centers on the development of LNP technology and provides detailed insights into the preclinical and clinical advancements of LNP in cancer treatment, encompassing the CRISPR/Cas9 system, mRNA vaccine, small interfering RNA (siRNA), Chimeric antigen receptor (CAR) cell therapy, and other related modalities. Simultaneously, the challenges for further application of LNP in clinical therapy are discussed, with the aim of establishing theoretical frameworks and innovative design concepts for the advancement of more effective and secure in vivo delivery strategies.]]></description>
<pubDate>2024/12/5 16:48:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DU Xiuli<sup>1</sup>, LI Xianjing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DU Xiuli<sup>1</sup>, LI Xianjing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411013&flag=1]]></guid><cfi:id>120</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in rotavirus and rotavirus vaccines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Rotavirus is an enteric virus that can cause intestinal infections leading to diarrhea and vomiting. Due to the immature immune systems of infants and young children, they are more susceptible to rotavirus infection, which is a leading cause of diarrhea-related hospitalizations among infants and young children. Rotavirus is highly contagious and spreads primarily through the fecal-oral route, with outbreaks typically occurring in autumn and winter. Currently, there is no specific antiviral drug for rotavirus, making rotavirus vaccination the most effective measure for preventing acute gastroenteritis caused by this virus. This article provides a review of the biological characteristics, epidemiological features, clinical manifestations, and the development and application of rotavirus vaccines.]]></description>
<pubDate>2024/12/5 16:48:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Jiwei<sup>1,2</sup>, WANG Weijian<sup>3</sup>, WU Zhiang<sup>1,2</sup>, SHI Feng<sup>2,3</sup>, XIAN Ruiqing<sup>2,3</sup>, LIANG Haiyan<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Jiwei<sup>1,2</sup>, WANG Weijian<sup>3</sup>, WU Zhiang<sup>1,2</sup>, SHI Feng<sup>2,3</sup>, XIAN Ruiqing<sup>2,3</sup>, LIANG Haiyan<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411014&flag=1]]></guid><cfi:id>119</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the application of intelligent dispensing robots in intravenous drug preparation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Intelligent dispensing robots have tremendous potential and broad application prospects in the future. With the continuous advancement of technology and the expansion of application scenarios, these robots will play an increasingly important role in the medical field, making significant contributions to improving the quality and efficiency of medical services. This article briefly summarizes the development of intelligent dispensing robots in domestic and international markets, as well as the current research status, particularly their advantages and disadvantages. Finally, it provides an outlook for the future development of intelligent dispensing robots.]]></description>
<pubDate>2024/12/5 16:48:42</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIE Liming<sup>1</sup>, CHEN Guanfeng<sup>1</sup>, CHEN Rizhi<sup>2</sup>, LUO Rongqiong<sup>1</sup>, QUAN Weiyan<sup>3</sup>, OUYANG Qianqian<sup>3</sup>, QIU Zhiqing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Liming<sup>1</sup>, CHEN Guanfeng<sup>1</sup>, CHEN Rizhi<sup>2</sup>, LUO Rongqiong<sup>1</sup>, QUAN Weiyan<sup>3</sup>, OUYANG Qianqian<sup>3</sup>, QIU Zhiqing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202411015&flag=1]]></guid><cfi:id>118</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of arginine metabolism in tumor development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Arginine is an essential amino acid in the human body. In recent years, the study on the mechanism of arginine in the development and progression of tumors has become a hotspot in the field of biomedical research. Research has found that arginine-mediated metabolic reprogramming plays an important role in promoting tumor growth and evading immune surveillance. In addition, arginine deprivation therapy can effectively inhibit tumor growth. This article has summarized the current understanding of the biological importance of arginine in aspects such as tumor cell growth, metastasis, and immune evasion.]]></description>
<pubDate>2024/11/18 11:12:32</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Min, DAI Beiying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Min, DAI Beiying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410010&flag=1]]></guid><cfi:id>117</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploring the theory and effect of Shenqi Fuzheng Injection in the treatment of chronic obstructive pulmonary disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Shenqi Fuzheng Injection is a traditional Chinese medicine preparation composed of <i>Codonopsis pilosula</i> and <i>Astragalus membranaceus</i> extract, which has achieved good results in the clinical study of chronic obstructive pulmonary disease（COPD）. The purpose of this paper is to further clarify the traditional Chinese medicine theory and modern pharmacological effects of Shenqi Fuzheng Injection in the treatment of chronic obstructive pulmonary disease, in order to provide a theoretical basis for the clinical rational application of Shenqi Fuzheng Injection, and to provide ideas for further clinical and experimental research. In this paper, through literature review, theoretical analysis and other methods to explore the theoretical basis of the use of ' Bufei Jianpi method ' in the treatment of COPD, analysis of Shenqi Fuzheng injection ' Bufei Jianpi ' efficacy and pharmacological effects of the relationship, clinical significance and pharmacovigilance.Through this analysis, the following conclusions are drawn: ① Lung and spleen qi deficiency is an important pathogenesis in the development of chronic obstructive pulmonary disease, which can be treated by “invigorating spleen and tonifying lung method”. ②Shenqi Fuzheng Injection has the effect of “tonifying lung and invigorating spleen”, which is suitable for patients with chronic obstructive pulmonary disease of lung and spleen qi deficiency syndrome. The scientific connotation of its traditional efficacy is related to pharmacological effects such as regulating immunity, protecting lung tissue, and improving digestion and absorption function. ③Shenqi Fuzheng Injection has clinical significance in improving clinical efficacy, clinical symptoms, lung function, inflammatory index and immune function in the application of COPD. ④The application of Shenqi Fuzheng Injection should follow the principle of syndrome differentiation and treatment of traditional Chinese medicine to avoid adverse reactions caused by misuse of syndrome types.]]></description>
<pubDate>2024/11/18 11:12:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HUANG Wuzhen<sup>1</sup>, CHEN Sining<sup>1</sup>, LI Zhanhua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Wuzhen<sup>1</sup>, CHEN Sining<sup>1</sup>, LI Zhanhua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410011&flag=1]]></guid><cfi:id>116</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the mechanism of Chinese medicine in the treatment of neuroimmune inflammatory diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Neuroimmune inflammation runs through the pathogenesis of many central nervous system diseases such as neuroautoimmune and neurodegenerative diseases. Neuroimmune inflammation has a bidirectional regulatory effect. Under normal physiological conditions, it can eliminate pathogenic factors to protect neurons from injury and promote their recovery. However, chronic inflammatory induced cytotoxicity and excessive inflammatory response will aggravate the damage of neurons. At present, there is no effective drug to treat this kind of disease in clinic, mainly to improve the symptoms, unable to eliminate the cause and side effects. In recent years, traditional Chinese medicine has been widely studied for its advantages of high safety, mild action and few side effects. This article summarizes the relevant mechanisms of traditional Chinese medicine in the treatment of such diseases.]]></description>
<pubDate>2024/11/18 11:12:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CUI Bingbing<sup>1</sup>, LI Ji<sup>1</sup>, ZHU Juanjuan<sup>2</sup>, NIE Jin'e<sup>1</sup>, SUN Dandan<sup>2</sup>, YANG Chunlin<sup>3</sup>, YANG Ying<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Bingbing<sup>1</sup>, LI Ji<sup>1</sup>, ZHU Juanjuan<sup>2</sup>, NIE Jin'e<sup>1</sup>, SUN Dandan<sup>2</sup>, YANG Chunlin<sup>3</sup>, YANG Ying<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410012&flag=1]]></guid><cfi:id>115</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of chemical composition and extraction processes and pharmacological effects of <i>Ficus hirta</i> Vahl]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Ficus hirta</i> Vahl is a popular medicinal and edible homologous plant in South China, which mainly contains volatile oil, flavonoids, coumarins, terpenoids, phenols and so on. Modern pharmacological investigations have demonstrated the anti-aging, gastric mucosa protection, myasthenia gravis treatment, and alleviation of non-alcoholic fatty liver effects of Ficus hirta Vahl. In order to serve as a reference for future study and sensible development of Ficus hirta Vahl, chemical  components and extraction method of the herb were discussed in this paper.]]></description>
<pubDate>2024/11/18 11:12:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YE Ya'na<sup>1</sup>, YAN Qing<sup>1</sup>, LI Wenxiu<sup>1</sup>, HE Junjun<sup>2</sup>, LUO Ping<sup>1</sup>, ZHANG Hualin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YE Ya'na<sup>1</sup>, YAN Qing<sup>1</sup>, LI Wenxiu<sup>1</sup>, HE Junjun<sup>2</sup>, LUO Ping<sup>1</sup>, ZHANG Hualin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410013&flag=1]]></guid><cfi:id>114</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Survey on identification techniques of Traditional Chinese medicinal materials from different regions]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the current research status and development trends of different origin identification techniques for traditional Chinese medicine materials (TCMM), and to expand the research scope for TCMM origin studies. <b>Methods</b>  Using keywords such as "TCMM", "origin", and "identification", a literature review was conducted on relevant research papers published in recent 10 years in databases such as CNKI, VIP Information, PubMed, and Web of Science. The focus of the literature review was on different origin identification techniques. <b>Results</b>  Different origin identification techniques for TCMM include a variety of methods such as morphological and microscopic identification, physical and chemical identification, fingerprint technology, DNA molecular marker identification, bioactivity evaluation, and artificial intelligence identification techniques combined with computer algorithms. Traditional identification methods such as morphological identification, microscopic identification, and general physical and chemical identification are simple and easy to perform, but rely on experience and have poor specificity. Methods such as spectroscopy, fingerprint analysis, and DNA marker technology have overcome the above shortcomings and are accurate, reliable, and easy to operate. Artificial intelligence identification techniques are more accurate and efficient, greatly reducing labor and time costs. <b>Conclusion</b>  There are certain difficulties and uncertainties in identifying the different origins of TCMM. Therefore, multiple methods can be combined for comprehensive identification, leveraging the advantages of each identification method to ensure accurate results. In the future, TCMM identification will become more intelligent and automated, utilizing artificial intelligence, machine learning, and other technologies to improve identification efficiency and accuracy.]]></description>
<pubDate>2024/11/18 11:12:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DU Yujie<sup>1,2</sup>, LIN Yongqiang<sup>2</sup>, WANG Shuqi<sup>3</sup>, LIU Qingzhi<sup>1</sup>, GUO Dingxiao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DU Yujie<sup>1,2</sup>, LIN Yongqiang<sup>2</sup>, WANG Shuqi<sup>3</sup>, LIU Qingzhi<sup>1</sup>, GUO Dingxiao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410014&flag=1]]></guid><cfi:id>113</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical constituents and pharmacological effects of <i>Cinnamomum cassia</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Cinnamon</i> is the dried bark of <i>Cinnamomum cinnamomi</i>, family Camphoraceae, and is a Chinese herb with important medicinal value. Its chemical composition mainly contains volatile oils, polysaccharides, polyphenols, flavonoids, inorganic elements and other components, research has found that it has therapeutic effects in the immune system, endocrine, cardiovascular and central nervous system, with anti-inflammatory, anti-bacterial, anti-tumor, antioxidant, hypoglycemic, inhibition of tyrosinase activity, inhibit platelet aggregation, promote angiogenesis, and improve the ability to learn and remember Alzheimer's disease, Sedation, anti-anxiety and antidepressant and other pharmacological effects. Based on the literature studies of cinnamon at home and abroad, the chemical composition and pharmacological effects of cinnamon are summarized, in order to provide theoretical basis and reference value for the further study of cinnamon's pharmacological composition and the research and development of its new medicinal value.]]></description>
<pubDate>2024/11/18 11:12:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Xue, MA Yanchun, ZHAO Jinghan, WU Xinhua, XUN Sijia]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xue, MA Yanchun, ZHAO Jinghan, WU Xinhua, XUN Sijia</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410015&flag=1]]></guid><cfi:id>112</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Multi-target mechanisms and recent advances in the anti-cancer effects of gallic acid]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cancer is a major threat to human health, with traditional treatments limited by immune evasion and drug resistance. Thus, developing new therapies is essential. Gallic acid (GA), a polyphenolic compound, inhibits tumor proliferation, induces apoptosis, regulates epigenetics, and modulates the tumor microenvironment, demonstrating significant potential in cancer therapy. Advances in Nano delivery systems, organoid technology, and gut microbiota research further support its clinical translation.This review summarized GA's anti-cancer mechanisms and recent progress, providing a foundation for its clinical development.]]></description>
<pubDate>2025/10/14 16:33:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Haibo, DAI Beiying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Haibo, DAI Beiying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509010&flag=1]]></guid><cfi:id>111</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on modern pharmacology of magnololand honokiol in chronic disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Magnolia officinalis</i> is often used clinically to treat gastrointestinal and lung diseases. Magnolol and honokiol are the main active ingredients of <i>Magnolia officinalis</i>. In recent years, a large number of studies have shown that they have various pharmacological effects such as anti-inflammatory, antioxidant and anti-tumor.Inflammation is the comorbidity basis of multiple chronic diseases, indicating that it has the potential to treat multiple diseases, and its clinical application still has room for improvement. This article reviews the research progress of magnolia officinalis and its main active ingredients magnolol and honokiol in the treatment of chronic diseases at home and abroad in the past five years. It is found that they can regulate immune disorders, inflammation and oxidative stress from multiple cellular pathways, thereby achieving anti-inflammation and anti-arthritis; In addition,magnolol and honokiol can also lowers blood sugar by stimulating the popular target of diabetes,peroxisome proliferator activated receptor gamma (PPARγ), and improves diabetic complications, cognitive impairment and lipid metabolism disorders. Even in insulin-resistant mouse models, they still have significant blood sugar lowering effect. This article will discuss in detail the role and advantages of magnolol and honokiol in the treatment of various chronic diseases, and provide basis for expanding the application of <i>Magnolia officinalis</i> and its active ingredients (magnolol and honokiol).]]></description>
<pubDate>2025/10/14 16:33:20</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YU Rongrong, DENG Yiping, LIU Ying, LIN Weiting, QIN Xiaojing, YANG Chengzi, HE Longgang, CHEN Jianyu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Rongrong, DENG Yiping, LIU Ying, LIN Weiting, QIN Xiaojing, YANG Chengzi, HE Longgang, CHEN Jianyu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509011&flag=1]]></guid><cfi:id>110</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of the safety and toxicity of mRNA-LNP drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[mRNA technology has become a revolutionary technique in the biomedical field, especially during the COVID-19 pandemic when SARS-CoV-2 mRNA vaccines were widely used and largely helped to mitigate disease burden globally. However, with continuous expansion of the clinical applications of mRNA technology, its safety issues have caused major concerns and urged management of potential toxicity risks. In this concise review, we summarize current studies on the induction of undesired inflammation by mRNA drug formulations, and further discussed potential approaches that can be utilized to tackle this challenge.]]></description>
<pubDate>2025/10/14 16:33:21</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CAI Yunjie<sup>1,2</sup>, LIN Ang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAI Yunjie<sup>1,2</sup>, LIN Ang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509012&flag=1]]></guid><cfi:id>109</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the chemical constituents and pharmacological effects of <i>Rhodiola crenulata</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Rhodiola crenulata</i>, known as the "Ginseng of the Plateau," boasts a long history of folk and clinical applications and is considered one of traditional Chinese medicines (TCMs) that are both medicinal and edible, possessing rich medicinal value and potential for application in various fields. Its chemical constituents primarily encompass flavonoids, volatile oils, phenols, phenylpropanoids, and others, conferring upon it a diverse range of pharmacological effects including anti-hypoxia, antioxidant, anti-aging, anti-tumor, prevention and treatment of cardiovascular and cerebrovascular diseases, as well as diabetes. This article summarized the research progress on the chemical constituents and pharmacological activities of <i>Rhodiola crenulata</i>, aiming to provide a reference for its further development and rational application.]]></description>
<pubDate>2025/10/14 16:33:21</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DU Baoyu<sup>1</sup>, YAO Danyang<sup>1</sup>, WANG Yuan<sup>1</sup>, XIAO Song<sup>1</sup>, LI Yiqun<sup>1</sup>, WU Zongyao<sup>2</sup>, YANG Ran<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DU Baoyu<sup>1</sup>, YAO Danyang<sup>1</sup>, WANG Yuan<sup>1</sup>, XIAO Song<sup>1</sup>, LI Yiqun<sup>1</sup>, WU Zongyao<sup>2</sup>, YANG Ran<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509013&flag=1]]></guid><cfi:id>108</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the compression technology of extended-release pellets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Extended-release pellets tablets have received widespread attention because of the advantages of fewer administration times, good patient compliance and higher drug bioavailability. However, the functional coating film is easily broken after being pressurized, resulting in faster drug release rate, which limits the application of extended-release pellets tablets. Therefore, reducing the degree of coating film damage has become a technical difficulty in the development of extended-release pellets tablets. In this paper, we summarize the latest research progress of extended-release pellets tablets, and introduce the key factors affecting the integrity of the functional coating film. Meanwhile, we also summarize the latest methods to reduce the damage of the coating film of the extended-release pellets during compressing. This paper can be used as a reference for researchers to develop extended-release pellets tablets.]]></description>
<pubDate>2025/10/14 16:33:21</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHOU Yun<sup>1</sup>, FENG Keyu<sup>1,2</sup>, YANG Huaizhi<sup>1</sup>, FAN Lizhu<sup>1</sup>, QI Lin<sup>1,2</sup>, DONG Xu<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Yun<sup>1</sup>, FENG Keyu<sup>1,2</sup>, YANG Huaizhi<sup>1</sup>, FAN Lizhu<sup>1</sup>, QI Lin<sup>1,2</sup>, DONG Xu<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509014&flag=1]]></guid><cfi:id>107</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the function of GABAergic neurons in lateral hypothalamus]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The lateral hypothalamic area (LHA) is a structurally and functionally heterogeneous central regulatory hub. Recent advancements in neurotechnological tools, particularly the application of optogenetic manipulation and trans-synaptic neural circuit tracing techniques, have enabled researchers to progressively decipher the key mechanisms of how the LHA regulates diverse physiological processes via cell type-specific neural circuits. Among its neuronal subpopulations, GABAergic neurons in the LHA serve as core inhibitory regulatory units, critically implicated in maintaining dynamic equilibrium of feeding and energy metabolism, orchestrating circadian modulation of sleep-wake cycles, and integrating emotional-motivational behaviors. Dysfunction of GABAergic neuronal populations in the LHA has been confirmed as a critical contributor to the pathogenesis and progression of multiple disorders, including obesity, sleep disorders, depression, and drug addiction.. This review synthesizes cutting-edge discoveries in the field, providing an in-depth exploration of the functional architecture of LHA GABAergic neurons and their circuit-based mechanisms, while offering novel perspectives for mechanistic research and therapeutic target identification in related neuropsychiatric disorders.]]></description>
<pubDate>2025/9/17 10:50:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Shiya, HONG Hao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Shiya, HONG Hao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508009&flag=1]]></guid><cfi:id>106</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the hepatoprotective active components and mechanisms of <i>Scutellaria baicalensis</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Scutellaria baicalensis</i>, a widely utilized traditional Chinese medicine, is recognized for its properties in clearing heat and drying dampness, as well as eliminating fire and detoxifying the body. Its primary active constituents encompass flavonoids, flavonol glycosides, volatile oils, and polysaccharides, with flavonol glycosides, particularly baicalin and wogonoside, being the most significant. Extensive researches by numerous scientists have delved into the efficacy of Scutellaria baicalensis in addressing liver diseases. Studies indicate that the flavonoid and flavonol glycoside components within <i>Scutellaria baicalensis</i> exhibit notable therapeutic benefits in managing viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma (HCC), and drug-induced liver injury. These compounds effectively lower serum transaminase levels in animal models of liver injury, mitigate hepatic pathological alterations, and diminish the intensity of inflammatory reactions, thereby contributing to liver health preservation. The underlying mechanisms are multifaceted, primarily comprising anti-oxidative, anti-inflammatory, anti-fibrotic actions, as well as lipid metabolism modulation and immune regulation. Such research outcomes furnish a robust theoretical foundation and promising prospects for the clinical application of <i>Scutellaria baicalensis</i> in liver disease treatment. This paper aims to systematically review the active components of <i>Scutellaria baicalensis</i> along with their potential mechanisms in hepatic protection to provide valuable insights for clinical applications of <i>Scutellaria baicalensis</i> in hepatoprotection and the development of novel hepatoprotective agents.]]></description>
<pubDate>2025/9/17 10:50:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Hao<sup>1,2</sup>, LIU Xiaoqian<sup>1,2</sup>, ZHU Riran<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Hao<sup>1,2</sup>, LIU Xiaoqian<sup>1,2</sup>, ZHU Riran<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508010&flag=1]]></guid><cfi:id>105</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the metabolism <i>in vivo</i> and tissue distribution of the main components of Huangqi Jianzhong Decoction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Huangqi Jianzhong Decoction (HQJZ) comprises seven medicinal herbs: Astragali Radix, Cinnamomi Ramulus, Paeoniae Radix Alba, Prepared Licorice, Zingiberis Rhizoma Recens, Jujubae Fructus, and Maltose. Clinical and pharmacological studies have demonstrated that HQJZ is effective in the prevention and treatment of gastrointestinal disorders, including gastric ulcers, duodenal ulcers, and chronic atrophic gastritis. The decoction exhibits a high cure rate coupled with a low recurrence rate. However, the pharmacological basis of its constituent substances remains inadequately unclear. Due to the complex composition of the compound, it is difficult to study the active ingredients, and in vivo metabolism and target organ distribution are the means to quickly screen potential active ingredients. However, due to different experimental conditions (administration time, dosage, sample collection methods, etc.) during the research process, the experimental results were inconsistent. Based on this, this article analyzes and summarizes the in vivo metabolism and tissue distribution of the main components of HQJZ by reviewing relevant literature on HQJZ and its single ingredient formulations, providing reference for the study of HQZJ's pharmacological substances.]]></description>
<pubDate>2025/9/17 10:50:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[REN Xianfang<sup>1,2</sup>, LI Dachen<sup>1,2</sup>, YU Shuting<sup>1,3</sup>, QIN Xuemei<sup>1,4</sup>, HU Yinghuan<sup>1,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>REN Xianfang<sup>1,2</sup>, LI Dachen<sup>1,2</sup>, YU Shuting<sup>1,3</sup>, QIN Xuemei<sup>1,4</sup>, HU Yinghuan<sup>1,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508011&flag=1]]></guid><cfi:id>104</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Advances of 53BP1 in DNA Damage Response and Cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, 53BP1 has attracted considerable attention as a key regulator of DNA double-strand break (DSB) repair, playing a crucial role in DNA damage repair and the maintenance of genomic stability. Studies have demonstrated that 53BP1 is not only involved in DNA break repair but also plays a significant regulatory role in tumorigenesis, cancer progression, and drug resistance. This review focuses on the structure and function of 53BP1, systematically summarizing recent research advancements and exploring its potential implications for future studies and clinical applications.]]></description>
<pubDate>2025/9/17 10:50:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Ling, ZHUANG Shentian, YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Ling, ZHUANG Shentian, YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508012&flag=1]]></guid><cfi:id>103</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the anti-tumor effect of Ginseng]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ginseng is known as the "King of Herbs" and is a traditional Chinese medicinal material with rich medicinal value. It is widely used in the prevention and treatment of diseases. Modern research shows that various components of Ginseng have a good inhibitory effect on the proliferation of many malignant tumor cells, among which the main components include ginsenosides, Ginseng polysaccharides, Ginseng proteins, etc. Moreover, Ginseng can be used as an adjunctive treatment method in clinical practice, in combination with surgeries, radiotherapy, chemotherapy and other treatments. In addition, Ginseng has advantages such as multi-target synergy, low toxicity, and reversal of drug resistance in anti-tumor treatment. Therefore, Ginseng has demonstrated unique value in the comprehensive treatment of tumors. Its characteristic of "supporting the body's resistance and eliminating pathogenic factors" is highly consistent with modern tumor treatment concepts. With the deepening of research, it is expected to develop more targeted adjuvant treatment plans for tumors. This article reviews the anti-tumor components of Ginseng, the anti-tumor effects of Ginseng in various cancers, and the application of Ginseng's anti-tumor effects in prescriptions by consulting a large number of literatures, hoping to provide references and basis for further research and development of Ginseng.]]></description>
<pubDate>2025/9/17 10:50:06</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BU Huinan<sup>1</sup>, MIAO Miao<sup>2</sup>, WU Lun<sup>3</sup>, CHI Wencheng<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BU Huinan<sup>1</sup>, MIAO Miao<sup>2</sup>, WU Lun<sup>3</sup>, CHI Wencheng<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508013&flag=1]]></guid><cfi:id>102</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on Sphingolipid Metabolism Enzymes in Liver Diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sphingolipids are essential for maintaining the integrity of cell membranes and functioning as bioactive lipid signaling molecules, and their various metabolites actively sustain hepatic physiological homeostasis. However, under pathological conditions, the homeostasis of sphingolipid metabolites and regulatory enzymes is disrupted, leading to dysregulation that modulates the occurrence and progression of liver diseases through multiple mechanisms. Extensive studies have shown that targeting ceramide, a central sphingolipid metabolite, and its synthetic metabolic enzymes is one of the effective strategies for treating both acute and chronic liver diseases. This review summarized the roles of several sphingolipid metabolic enzymes in liver diseases and provided an overview of the progress in related targeted therapies, aiming to offer new insights and references for elucidating the pathogenesis of liver diseases and developing clinical therapeutic approaches.]]></description>
<pubDate>2025/8/8 8:41:35</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHU Yujie, ZHOU Yaochuan, NI Jingyang, LI Tingting]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Yujie, ZHOU Yaochuan, NI Jingyang, LI Tingting</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507010&flag=1]]></guid><cfi:id>101</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in the application of microbial fermentation technology in the extraction of plant active ingredients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The application of microbial fermentation technology in the extraction of plant active ingredients is to destroy the plant cell wall with the help of enzymes produced by microorganisms during the fermentation process, which will lead to the release of plant active ingredients, or to increase the content of target ingredients through the metabolism of microbial enzymes, which will in turn improve the extraction efficiency. This paper mainly reviews the research of microbial fermentation technology in the extraction of plant active ingredients at home and abroad in recent years, and looks forward to the prospect of its application, aiming to provide a reference for the efficient extraction and research of plant active ingredients.]]></description>
<pubDate>2025/8/8 8:41:35</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Bingnan<sup>1,2</sup>, LI Xiang<sup>3</sup>, YANG Dongjie<sup>3</sup>, WAN Xinhuan<sup>1</sup>, GAO Lina<sup>1</sup>, CHU Xueyan<sup>1</sup>, SUN Xiaochi<sup>1</sup>, LIU Qingzhi<sup>1</sup>, GUO Dongxiao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Bingnan<sup>1,2</sup>, LI Xiang<sup>3</sup>, YANG Dongjie<sup>3</sup>, WAN Xinhuan<sup>1</sup>, GAO Lina<sup>1</sup>, CHU Xueyan<sup>1</sup>, SUN Xiaochi<sup>1</sup>, LIU Qingzhi<sup>1</sup>, GUO Dongxiao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507011&flag=1]]></guid><cfi:id>100</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of extracellular matrix in liver metastasis of colorectal cancer and targeted therapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Colorectal cancer (CRC) is the third largest malignant tumor in the world, and colorectal liver metastases (CRLM) are the primary cause of death in patients with middle and advanced CRC. The extracellular matrix (ECM) is a highly active component of the tumor microenvironment, which continuously influences the proliferation, migration, invasion, immune escape and therapeutic resistance of tumor cells through signal transduction. The abnormalities and dysregulation of ECM are highly correlated with the liver metastasis process of CRC and the treatment response of patients. Therefore, intervention in ECM formation may be an important strategy to block the occurrence and development of CRLM. This article focuses on the role of ECM in CRLM, and reviews the latest progress of targeting ECM in the treatment of CRLM, aiming to provide a new research idea for the prevention and comprehensive treatment of CRLM.]]></description>
<pubDate>2025/8/8 8:41:35</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DA Huijuan<sup>1</sup>, CAO Qiuhua<sup>2</sup>, GAO Xinghua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DA Huijuan<sup>1</sup>, CAO Qiuhua<sup>2</sup>, GAO Xinghua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507012&flag=1]]></guid><cfi:id>99</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research status and progress on DNA Vaccines for chronic hepatitis B]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chronic hepatitis B (CHB) is a chronic infectious disease caused by the hepatitis B virus (HBV), with a high global prevalence. Current antiviral therapies primarily rely on traditional intramuscular injection drugs, which still face limitations such as incomplete viral clearance, drug side effects, drug resistance, and the need for long-term or lifelong medication. As an emerging therapeutic strategy, DNA vaccines have garnered significant attention due to their potential to simultaneously induce humoral and cellular immune responses and their high stability. Preclinical studies in animal models have demonstrated promising results. By combining adjuvants and electroporation techniques, the uptake efficiency of plasmid DNA can be enhanced, significantly improving therapeutic efficacy. Preliminary results from related clinical trials have also been encouraging. This review summarizes the current research progress of DNA vaccines in CHB treatment, including their mechanisms of action, preclinical studies in animal models, clinical trials, distinctions from RNA vaccines, and future development directions.]]></description>
<pubDate>2025/8/8 8:41:35</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[PENG Siqi, SUN Long]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>PENG Siqi, SUN Long</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507013&flag=1]]></guid><cfi:id>98</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the antitumor mechanism of disodium cantharidinate and the clinical application of its injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Disodium cantharidinate is a derivative compound of the active ingredient cantharidin in Mylabris.  Research has demonstrated that disodium cantharidinate has demonstrated significant antitumor activity against various malignancies, including hepatocellular carcinoma, lung cancer, and breast cancer. Moreover, its toxicity and irritancy are markedly reduced compared to cantharidin. Its anticancer mechanisms are multifaceted, encompassing cell cycle arrest, inhibition proliferation, induction apoptosis, and suppression of tumor angiogenesis. Additionally, disodium cantharidinate-based formulations, such as disodium cantharidinate injection and disodium cantharidinate/vitamin B6 injection, are widely employed due to their dual role in exerting direct antitumor effects and alleviating chemotherapy-induced adverse reaction. This review aims tsummarize the anticancer mechanisms, clinical applications, and drug interactions of disodium cantharidinate, thereby providing a reference for further research and potential clinical repositioning.]]></description>
<pubDate>2025/8/8 8:41:35</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Yaxin<sup>1,2</sup>, ZHANG Fangbo<sup>1</sup>, CAI Qingqing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Yaxin<sup>1,2</sup>, ZHANG Fangbo<sup>1</sup>, CAI Qingqing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507014&flag=1]]></guid><cfi:id>97</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Targeting B7-H4:a new strategy to overcome immunosuppressionand drug resistance in breast cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Breast cancer, characterized by its high invasiveness and recurrence rate, has emerged as a major disease that severely threatens women's health. Research indicates that B7-H4 is abnormally overexpressed in the majority of human tumor tissues, particularly in breast cancer, and is closely associated with cancer progression and poor clinical prognosis. It not only binds to potential receptors on T cells to exert immunosuppressive effects but also enhances the tumor cells' own capabilities in proliferation, invasion, metastasis, stemness, and anti-apoptosis, thereby promoting tumor progression. However, the regulatory mechanisms remain unclear. This article reviews the research progress on B7-H4 in breast cancer, aiming to provide new directions for future studies.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Mengxue, ZHUANG Shentian, YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Mengxue, ZHUANG Shentian, YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506011&flag=1]]></guid><cfi:id>96</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical research progress of novel μ-receptor agonists oliceridine and tegileridine in moderate to severe postoperative pain]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pain is known as the fifth major vital sign of human beings, and postoperative pain is one of the most common types of pain. Effective management of postoperative pain can reduce the burden on patients and improve their quality of life. Opioids are the cornerstone of pain medication,but their clinical application is limited by respiratory depression and tolerance. The analgesic effects of the novel μ-receptor agonists oliceridine and tegileridine are comparable to morphine, and the incidence of opioid related adverse reactions is low.They are currently the new analgesics for the treatment of moderate to severe postoperative pain without alternative therapies, and can be safely used for postoperative pain management. This article will review the efficacy of this type of medication in clinical studies of moderate to severe postoperative pain and explore related adverse reactions,in order to provide guidance for clinical use.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YUAN Shanhui<sup>1,2</sup>, JI Hui<sup>1,2</sup>, LU Yuntao<sup>1</sup>, TANG Hui<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Shanhui<sup>1,2</sup>, JI Hui<sup>1,2</sup>, LU Yuntao<sup>1</sup>, TANG Hui<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506012&flag=1]]></guid><cfi:id>95</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical constituents and pharmacological effects of Tamaricis Cacumen]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tamaricis Cacumen the dried tender branches and leaves of the Tamaricaceae plant Tamarix chinensis Lour. possesses therapeutic effects in relieving exterior syndrome, promoting eruption, dispelling wind, and eliminating dampness. Modern research indicates that its primary chemical components include flavonoids, volatile oils, and phenolic compounds, demonstrating significant pharmacological activities such as anti-inflammatory, hepatoprotective, antibacterial, and antitumor effects. These properties exhibit multi-component, multi-target, and multi-pathway characteristics. By reviewing relevant domestic and international literature, this paper systematically summarizes the chemical composition and corresponding pharmacological actions of Tamaricis Cacumen aiming to provide references for subsequent quality evaluation and developmental applications of this medicinal herb.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CUI Xiangmei<sup>1</sup>, PANG Daoran<sup>1</sup>, ZHAO Xuan<sup>1</sup>, LI Na<sup>1</sup>, GAO Yan<sup>1</sup>, WU Chen<sup>1</sup>, ZHENG Hong<sup>2</sup>, MA Xuran<sup>1</sup>, ZHAO Bonian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Xiangmei<sup>1</sup>, PANG Daoran<sup>1</sup>, ZHAO Xuan<sup>1</sup>, LI Na<sup>1</sup>, GAO Yan<sup>1</sup>, WU Chen<sup>1</sup>, ZHENG Hong<sup>2</sup>, MA Xuran<sup>1</sup>, ZHAO Bonian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506013&flag=1]]></guid><cfi:id>94</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Ingredients,pharmacological activities and predictive analysis of Q-markers of <i>Psammosilene tunicoides</i> W. C. Wu et C. Y.Wu]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The dried root of <i>Psammosilene tunicoides</i> W.C. Wu et C.Y. Wu, is a common folk herbal medicine in southwest China, which contains triterpenoids, cyclic peptides, maltoside, alkaloids. It has a variety of pharmacological activities, such as analgesic, anti-inflammatory, immunomodulatory, antioxidant, antibacterial, and also has certain toxicity.This paper summarizes the information from current publications on the root of <i>Psammosilene tunicoides</i>, with a focus on its chemical composition, pharmacological effects, and traditional efficacy, etc., and clarifies compounds including 3-methyl-β-D-glucuronidin, triterpenoid saponins and allantoin can be used as the main Q-Marker of this folk herbal medicine. We hope that this paper will stimulate further investigation and application of <i>P. tunicoides</i>.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GU Yifan<sup>1</sup>, CHEN Yu<sup>2</sup>, LU Zhiqin<sup>1</sup>, LI Yushan<sup>1</sup>, HUANG Guodong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GU Yifan<sup>1</sup>, CHEN Yu<sup>2</sup>, LU Zhiqin<sup>1</sup>, LI Yushan<sup>1</sup>, HUANG Guodong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506014&flag=1]]></guid><cfi:id>93</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the active constituents and mechanisms of licorice in the treatment of infections caused by influenza virus, respiratory syncytial virus, and SARS-CoV-2]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Respiratory viruses are among the major pathogens responsible for respiratory tract infections, which can lead to pulmonary tissue damage, inflammatory responses, and even life-threatening conditions. In both clinical treatment and basic research, licorice has demonstrated promising antiviral activity against respiratory viruses. Given the complexity of its bioactive components and the diversity of its mechanisms of action, elucidating the active constituents and underlying mechanisms of licorice is of great significance for optimizing clinical applications, rational development of licorice-based preparations, and the discovery of novel antiviral lead compounds. In recent years, significant progress has been made in identifying the active constituents and mechanisms by which licorice combats respiratory viruses. However, further in-depth and systematic investigations are still needed. This review provides a comprehensive summary of current research on the active constituents and antiviral mechanisms of licorice against respiratory viruses, outlines the research methodologies employed, and discusses future research directions. The aim is to offer new insights for the further exploration of licorice’s antiviral constituents and mechanisms, and to provide a theoretical basis for the advanced utilization of licorice resources and their clinical application.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Xinxin<sup>1</sup>, LI Zhongyuan<sup>1</sup>, TIAN Jingzhen<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Xinxin<sup>1</sup>, LI Zhongyuan<sup>1</sup>, TIAN Jingzhen<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506015&flag=1]]></guid><cfi:id>92</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effect and mechanism of bile acid metabolism disorder on alcoholic liver disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alcoholic liver disease (ALD) is a chronic liver disease that initially presents as fatty liver and can progress to alcoholic hepatitis, liver fibrosis, and cirrhosis. The pathogenesis is not fully understood, and there are currently no FDA approved therapeutic drugs. Research has shown that bile stasis runs through the entire process of alcoholic liver disease, and alcohol feeding can alter liver bile acid metabolism, while maintaining bile acid homeostasis can prevent alcohol induced liver damage. This article focuses on the relationship between bile acid imbalance and ALD, including abnormalities in bile acid metabolism related genes, receptor changes, and gut microbiota disorders, providing a theoretical basis for clinical prevention, diagnosis, and treatment.]]></description>
<pubDate>2025/6/9 8:39:28</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[PANG Luxin<sup>1</sup>, JIANG Zhenzhou<sup>1</sup>, ZHANG Luyong<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>PANG Luxin<sup>1</sup>, JIANG Zhenzhou<sup>1</sup>, ZHANG Luyong<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505010&flag=1]]></guid><cfi:id>91</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on molecular mechanisms of Chinese materia medica targeted therapy for malignant melanoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Malignant melanoma (MM) originates from melanocytes and exhibits high aggressiveness, with increasing incidence and mortality rates in recent years. Chinese materia medica (CMM) and their bioactive constituents have demonstrated unique therapeutic characteristics in intervening or treating MM through molecular mechanisms, such as interfering with signaling pathways, cell cycle arrest, promoting apoptosis, and angiogenesis. This article surveyed domestic and international literatures, and commented on and analyzed the main molecular mechanisms of MM oncogenesis, as well as the molecular mechanisms and application of CMM-based targeted therapy for MM. The aim is to provide a scientific basis for clinical treatment of MM and improving prognosis.]]></description>
<pubDate>2025/6/9 8:39:28</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Zhuohui<sup>1,2</sup>, WU Jixu<sup>2</sup>, GAO Pengfei<sup>1</sup>, ZHANG Chenggui<sup>1</sup>, YU Rongmin<sup>2,3</sup>, HU Xuqiao<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Zhuohui<sup>1,2</sup>, WU Jixu<sup>2</sup>, GAO Pengfei<sup>1</sup>, ZHANG Chenggui<sup>1</sup>, YU Rongmin<sup>2,3</sup>, HU Xuqiao<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505011&flag=1]]></guid><cfi:id>90</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of dsRNA in anti-tumor immunity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Double-stranded RNA (dsRNA) is a nucleic acid molecule with significant biological functions, widely present in viral genomes and host immune response processes. In recent studies, dsRNA has been identified as a potent activator of immune responses, capable of triggering a series of signal transduction pathways by engaging pattern recognition receptors (PRRs). This activation leads to the induction of type I interferons (IFNs) and pro-inflammatory cytokines, ultimately eliciting robust immune responses. Consequently, dsRNA has emerged as a critical focus in cancer immunotherapy research. This review systematically summarized the latest advancements in the role of dsRNA in antitumor immunity, with a particular emphasis on its mechanisms of action, including the activation of dsRNA-sensing pathways,viral mimicry, and remodeling of the tumor microenvironment. Furthermore, the review explored the potential applications of dsRNA in cutting-edge therapeutic strategies, such as cancer vaccine development, combination therapy with immune checkpoint inhibitors, and RNA interference (RNAi)-based therapies. By synthesizing a comprehensive analysis of these mechanisms and applications, this review aims to offer clearer research directions and insights for the further utilization of dsRNA in cancer immunotherapy.]]></description>
<pubDate>2025/6/9 8:39:28</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GAO Rui<sup>1</sup>, GAO Xinghua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Rui<sup>1</sup>, GAO Xinghua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505012&flag=1]]></guid><cfi:id>89</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of biomimetic carriers based on cell membranes for brain targeted drug delivery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The incidence of brain diseases such as brain tumors, ischemic stroke, Alzheimer’s disease, and Parkinson's disease is increasing year by year, posing a serious threat to human health. However, the presence of the blood-brain barrier (BBB) and blood-tumor barrier (BTB) restricts the entry of drugs into the brain and their therapeutic effects at tumor sites. Therefore, the development of safe and effective therapeutic approaches provides new opportunities for the treatment of brain diseases. Similar to the treatment of other diseases, the translocation of drugs across anticipated biological barriers necessitates considerations to ensure non-damage to normal tissues while preserving their inherent activity. In this review, we have explored the advancements in the application of various biomimetic-modified nanocarriers for targeted delivery to the brain, including endogenous biomimetic nanocarriers, exogenous biomimetic nanocarriers, and other biomimetic nanodelivery systems such as oncolytic viruses. These findings provide new insights into the development of targeted strategies for brain diseases.]]></description>
<pubDate>2025/6/9 8:39:28</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Ling, YUAN Yanling]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Ling, YUAN Yanling</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505013&flag=1]]></guid><cfi:id>88</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Shugan Jieyu Capsules in the treatment of coronary heart disease complicated with major depressive disorder]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Depression is one of the independent risk factors for the occurrence and development of coronary heart disease (CHD). CHD combined with major depressive disorder(MDD) could not only increase the difficulty of treatment, but also seriously affect the physical and mental health of patients. Shugan Jieyu Capsule (SG) is a traditional Chinese medicine(TCM) which composed of <i>Hypericum perforatum</i> and <i>Acanthopanax</i>. SG has the effects of soothing liver and relieving depression and strengthening spleen and calming nerves. In recent years, TCM treatment of CHD combined with MDD has become a focus in the field of cardiovascular diseases. However, whether SG can provide long-term benefits for patients with CHD combined with MDD remains controversial. This article reviewed the basic and clinical research progress of SG in the treatment of CHD combined with MDD, in order to provide scientific basis for clinical therapy of CHD combined with MDD.]]></description>
<pubDate>2025/6/9 8:39:28</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Tao<sup>1</sup>, WU Yuqian<sup>2</sup>, LU Shushu<sup>2</sup>, PEI Keling<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Tao<sup>1</sup>, WU Yuqian<sup>2</sup>, LU Shushu<sup>2</sup>, PEI Keling<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202505014&flag=1]]></guid><cfi:id>87</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on relationship between dorsal raphe nucleus and neuropsychiatric diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The dorsal raphe nucleus(DRN) is located ventral to the aqueduct of the midbrain, with numerous cell types, complex neural circuits, and a wide range of functions. In recent years, studies have found that DRN may be involved in the regulation of neuropsychiatric processes such as sleep-wakefulness, anxiety, depression, and addiction. This article reviewed the role and molecular mechanism of DRN-related neural circuits in different neuropsychiatric diseases, in order to provide new ideas for subsequent treatment.]]></description>
<pubDate>2025/5/9 9:16:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FU Boli, HONG Hao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FU Boli, HONG Hao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504010&flag=1]]></guid><cfi:id>86</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Relationship between metabolic reprogramming and anti-tumor drug resistance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The progression of cancer is closely related to its unique abnormal energy metabolism. To meet the higher demands for materials, energy, and REDOX power for rapid proliferation, tumor cells undergo metabolic reprogramming of their metabolic pathways, thereby inducing drug resistance. This article aims to analyze the roles of glucose metabolism, glutamine metabolism, and lipid metabolism in the energy metabolism of tumor cells, explore the relationship between metabolic reprogramming and drug resistance in tumor therapy, and provide a summary and discussion. This holds significant importance for exploring the mechanisms of tumor drug resistance from a molecular perspective, opening up new avenues for tumor treatment and prognosis for patients.]]></description>
<pubDate>2025/5/9 9:16:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Yiwen<sup>1</sup>, ZHANG Xiongfei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Yiwen<sup>1</sup>, ZHANG Xiongfei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504011&flag=1]]></guid><cfi:id>85</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of drugs and mechanisms of action to reverse Cetuximab resistance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cetuximab is mainly used in clinical practice for the treatment of gastrointestinal tumors such as colorectal cancer and gastric cancer. However, with the continuous deepening of clinical applications, the issue of resistance to Cetuximab has become increasingly prominent, greatly limiting its widespread use. Even if patients are effectively treated with Cetuximab, the remission period lasts up to 12-18 months, after which almost all patients develop secondary resistance, leading to treatment failure. Therefore, in-depth exploration of the resistance mechanism of Cetuximab and finding effective reversal drugs are of great significance for clarifying the optimal combination therapy and targeted treatment mode, and improving the therapeutic efficacy of tumors such as colorectal cancer.]]></description>
<pubDate>2025/5/9 9:16:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MENG Jin<sup>1</sup>, ZHANG Rui<sup>2</sup>, SU Guangzhu<sup>3</sup>, WANG Lu<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MENG Jin<sup>1</sup>, ZHANG Rui<sup>2</sup>, SU Guangzhu<sup>3</sup>, WANG Lu<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504012&flag=1]]></guid><cfi:id>84</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Current situation analysis and countermeasures of illegal addition of chemical drugs in proprietary Chinese medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Proprietary Chinese medicine has the advantages of safety and root cure in the treatment of diseases,but the effect is usually mild and the effect is relatively slow. In recent years, criminals have illegally added chemical drugs to proprietary Chinese medicines for improper profit,and many safety risks will occur when patients take such drugs without their knowledge. Therefore, this paper summarized and analyzed the methods, characteristics, categories, representative ingredients and detection techniques of illegal chemical drugs in proprietary Chinese medicines, and proposed countermeasures and suggestions to provide reference for scientific supervision by drug supervision and administration departments, in order to help the continuous standardized development of proprietary Chinese medicines.]]></description>
<pubDate>2025/5/9 9:16:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Jinyue<sup>1</sup>, YANG Yidi<sup>2</sup>, QU Fanna<sup>2</sup>, BI Xueyan<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Jinyue<sup>1</sup>, YANG Yidi<sup>2</sup>, QU Fanna<sup>2</sup>, BI Xueyan<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504013&flag=1]]></guid><cfi:id>83</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Summary and evaluation of representative traditional Chinese medicine and health foods based on enhanced NK cell activity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, significant progress has been made in the research of traditional Chinese medicine and health foods that enhance the activity of natural killer cells ( NK cells ). By searching academic databases such as “CNKI”, “VIP”, and “Wanfang”, this article systematically reviews domestic studies on representative Chinese medicinal herbs and their formulas for boosting NK cells activity. Most tonic Chinese medicinal herbs, herbal formulas, and TCM-based health foods have been shown to effectively activate NK cells. Their mechanisms involve modulating immune responses, promoting cell proliferation and differentiation, which aligns with the TCM principle of "strengthening the body's resistance and eliminating pathogens". Health foods derived from medicinal herbs or their bioactive extracts generally exhibit NK cell-activating properties, demonstrating broad market prospects and significant research potential.]]></description>
<pubDate>2025/5/9 9:16:55</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DUAN Yangyang, WU Binxin, LI Junhan, LI Xiaodong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DUAN Yangyang, WU Binxin, LI Junhan, LI Xiaodong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504014&flag=1]]></guid><cfi:id>82</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of masitinib, an antitumor drug in the treatment of neurodegenerative diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The prevalence of neurodegenerative diseases such as alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) is increasing annually, yet effective therapeutic drugs remain elusive. Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has recently shown potential neuroprotective effects in various neurological disorders.This review summarizes the research progress of Masitinib in the treatment of AD, ALS and MS.]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHEN Qianhui<sup>1</sup>, JIA Kang<sup>1</sup>, LIU Yuan<sup>2</sup>, ZHANG Zhixian<sup>2</sup>, MAI Chengxiong<sup>3</sup>, PI Rongbiao<sup>2</sup>, ZHOU Sigui<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHEN Qianhui<sup>1</sup>, JIA Kang<sup>1</sup>, LIU Yuan<sup>2</sup>, ZHANG Zhixian<sup>2</sup>, MAI Chengxiong<sup>3</sup>, PI Rongbiao<sup>2</sup>, ZHOU Sigui<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503008&flag=1]]></guid><cfi:id>81</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of de novo synthesis reprogramming of fatty acids in lung cancer drug resistance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Lung cancer is one of the most lethal and common cancers in the world. Tyrosine kinase inhibitors (TKIs) can target epidermal growth factor receptor (EGFR) to treat lung cancer, but patients often develop drug resistance after treatment. De novo metabolic reprogramming of fatty acids is considered to be an important reason for drug resistance in lung cancer. Therefore, targeting fatty acid synthesis related enzymes may provide a new direction for the development of anti drug resistance schemes in lung cancer. This article reviews the relationship between de novo fatty acid synthesis and drug resistance in lung cancer, and discusses the functions and roles of important enzymes and key proteins in it, providing references for the development of new strategies and potential targeted drugs for the treatment of drug resistance in lung cancer.]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LAI Yating<sup>1,2</sup>, CHEN Caixin<sup>2</sup>, ZHAO Zhongxiang<sup>2</sup>, JIN Jing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LAI Yating<sup>1,2</sup>, CHEN Caixin<sup>2</sup>, ZHAO Zhongxiang<sup>2</sup>, JIN Jing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503009&flag=1]]></guid><cfi:id>80</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the regulation of gut microbiota by <i>Radix Scutellariae</i> in the treatment of ulcerative colitis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Radix Scutellariae</i>, a Chinese herb with a long history of medical usage, is commonly employed to treat various ailments. <i>Radix Scutellariae</i> has gained considerable attention due to its effectiveness in treating ulcerative colitis, as well as its well-established pharmacological properties including antimicrobial, detoxifying, anti-inflammatory, and anticancer effects. Ulcerative colitis is a chronic inflammatory disease of the digestive tract characterized by a complex etiology associated with an imbalance in intestinal microecology. Restoring the equilibrium of intestinal microecology is crucial for the treatment of ulcerative colitis. A comprehensive investigation on the association between <i>Radix Scutellariae</i> and gut microbiota is currently lacking. Therefor,this article aims to comprehensively review the regulatory effects of <i>Radix Scutellariae</i> and its active ingredients on the intestinal microbiota in the treatment of ulcerative colitis, with the objective of unveiling its potential mechanism for the management of this disease.]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Jingmei<sup>1</sup>, ZOU Ying<sup>2,3,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Jingmei<sup>1</sup>, ZOU Ying<sup>2,3,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503010&flag=1]]></guid><cfi:id>79</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on processing methods,pharmacological effects and predictive analysis of quality markers of earth-worm]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Earth-worm is a commonly used animal medicine in clinic, which has the effects of clearing heat, relieving asthma, dredging collaterals and diuresis. It was recorded that it was processed by salt in the Wei and Jin Dynasties.Subsequently, there are a lot of processing methods, including stir-frying, roasting. Modern pharm- acological studies shows that earthworm has the effects of anti-cancer,inhibiting pyro- ptosis of human umbilical vein endothelial cells, reducing pulmonary hypertension in rats, improving diabetic erectile dysfunction in rats, inhibiting myocardial fibrosis in H9c2 cells, and anti-thrombosis.In this paper, the reported processing methods and  pharmacological mechanisms of earth-worm is systematically reviewed. According to the concept of quality markers (Q-marker), the Q-marker of earth-worm is predicted and analyzed from the aspects of quality attribute transfer change, chemical composit- ion specificity, measurability,effectiveness and blood components, in order to provide reference for the follow-up study of earth-worm.]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Fanmin<sup>1</sup>, YIN Jia<sup>2</sup>, LYU Mingyue<sup>2</sup>, WANG Liyuan<sup>1</sup>, WANG Shujing<sup>2</sup>, TAO Yaru<sup>1</sup>, FU Chunsheng<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Fanmin<sup>1</sup>, YIN Jia<sup>2</sup>, LYU Mingyue<sup>2</sup>, WANG Liyuan<sup>1</sup>, WANG Shujing<sup>2</sup>, TAO Yaru<sup>1</sup>, FU Chunsheng<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503011&flag=1]]></guid><cfi:id>78</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanisms of wolfberry and its active components for improving neurodegenerative diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Neurodegenerative diseases (ND) are a class of diseases that lead to neurological dysfunction due to degeneration and loss of central neurons, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), etc. These diseases are directly related to age and progressively worsen over time. The pathogenesis of ND is complex and difficult to elucidate, and drug development is difficult and challenging. With the acceleration of the aging process of the global population, the number of patients with ND is increasing rapidly. There are more than 55 million people suffering from AD in the world, and it is estimated that the number of patients will increase to 78 million by 2030. The number of PD patients exceeds 3 million in China, and it is expected to surge to about 5 million in 2030. This has caused a heavy social burden. Traditional Chinese medicine and its natural products are a huge treasure trove of safe and effective anti-ND. Among them, wolfberry has health care effects such as anti-oxidation, immune regulation, and neuroprotection. Therefore, it is listed as one of the tonic traditional Chinese medicines approved by the Ministry of Health of PRC and is a famous and precious Chinese medicinal material. In recent years, a large number of studies have found that wolfberry and related active substances have potential medicinal value in improving ND. This paper focuses on the active ingredients of wolfberry, such as wolfberry Polysaccharides, flavonoids and alkaloids. It reviews the progress of wolfberry in the pharmacological research of ND at home and abroad, and summarizes and discusses the anti-ND mechanism and potential targets of the active ingredients of wolfberry, providing a scientific basis for the development and application of wolfberry as an anti-ND drug or functional health product.]]></description>
<pubDate>2025/3/12 11:34:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHI Yali<sup>1,2,3</sup>, SUN Jie<sup>2</sup>, HUANG Feng<sup>1</sup>, SUN Yun<sup>1</sup>, DUAN Wenjun<sup>2,4</sup>, HE Rongrong<sup>1,2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHI Yali<sup>1,2,3</sup>, SUN Jie<sup>2</sup>, HUANG Feng<sup>1</sup>, SUN Yun<sup>1</sup>, DUAN Wenjun<sup>2,4</sup>, HE Rongrong<sup>1,2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502012&flag=1]]></guid><cfi:id>77</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the anti-tumor effect and mechanism of Bufonis Venenum]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bufonis Venenum is the dry secretion of the Bufo bufo gargarizans Cantor or Bufo melanostictus Schneider, which belongs to the toad family. Its main components include bufadienolides, fotenines, sterols and so on. Recent studies have shown that Bufonis Venenum has a good anti-tumor effect, mainly through inhibiting tumor cell proliferation, inducing tumor cell apoptosis, blocking tumor cell cycle, inhibiting tumor cell invasion and metastasis, inhibiting tumor angiogenesis, enhancing immunity, regulating immune microenvironment, reversing drug resistance and other mechanisms. This review summarizes the chemical composition,  structure and preparation of Bufonis Venenum, the anti-tumor effect and mechanism of its main active ingredients, as well as clinical trial, to provide reference for the drug development and clinical application of Bufonis Venenum.]]></description>
<pubDate>2025/3/12 11:34:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Luyao<sup>1</sup>, YE Yihan<sup>1</sup>, XU Yini<sup>1</sup>, ZHAO Chengguang<sup>2</sup>, YANG Lehe<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Luyao<sup>1</sup>, YE Yihan<sup>1</sup>, XU Yini<sup>1</sup>, ZHAO Chengguang<sup>2</sup>, YANG Lehe<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502013&flag=1]]></guid><cfi:id>76</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of nanomaterials for the diagnosis and treatment of Alzheimer's disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a neurodegenerative disease, the incidence of Alzheimer's disease (AD) is increasing year by year, and there is no effective cure around the world. Therefore, it is particularly urgent to develop new technologies to achieve early diagnosis and effective treatment of AD. Nanomaterials have shown great potential in the medical field with their unique advantages. These materials have been carefully designed and modified so that they can be used for early intervention in AD patients, including diagnosis and treatment. This article discusses the main nanomaterials used in the diagnosis and treatment of AD and their potential roles and prospects in the diagnosis and treatment of AD, hoping to provide a reference for the application of nanomaterials in the early diagnosis and treatment of AD.]]></description>
<pubDate>2025/3/12 11:34:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HAN Jiahui, CUI Jiaming, MA Zhenfeng, LIANG Yijun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Jiahui, CUI Jiaming, MA Zhenfeng, LIANG Yijun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502014&flag=1]]></guid><cfi:id>75</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on medical transdermal patches]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, transdermal patches have become an important research topic in healthcare technology. It delivers drugs directly through the skin, which has the advantages of stable efficacy, convenient use and reduced patient burden. With the progress of science and technology and the deepening of research, many important results have been achieved in related research at home and abroad, such as smart patches, degradable patches, high release patches, etc. The application areas involve vaccines, gene therapy, insulin delivery, hormone deficiency, cardiovascular diseases, etc. Which provide new choices for clinical treatment. The aim of this paper is to introduce the basic components and types of transdermal patches, to describe their important role in the field of drug delivery, and to discuss the current status and problems of related research.]]></description>
<pubDate>2025/3/12 11:34:40</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Jiayan, ZHU Qinghua, WU Aiqun, SHEN Liqun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Jiayan, ZHU Qinghua, WU Aiqun, SHEN Liqun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502015&flag=1]]></guid><cfi:id>74</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Reaserch progress on food allergic and its anti-allergy immunotherapeutics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Allergic disease is one type of chronic and pathogenic disease that can potentially be life-threatening. The prevalence of allergic diseases has significantly increased during the past decades. Effective prophylactic and therapeutic strategies to combat allergic conditions are still lacking except for intentional avoidance and timely treatment upon allergen exposure. Food allergy (FA) is a major type of allergic disease. There is a growing number of studies on the development of novel therapeutics against FA and in-depth investigations into the mechanism of action. In this article, we have summarized several key aspects of FA with particular focus on the recent advances in the development of anti-FA immunotherapeutics.]]></description>
<pubDate>2025/2/13 15:37:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WENG Changzhen<sup>1,2</sup>, LIU Lijing<sup>1,2</sup>, LIN Ang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WENG Changzhen<sup>1,2</sup>, LIU Lijing<sup>1,2</sup>, LIN Ang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501009&flag=1]]></guid><cfi:id>73</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on biological activity of 1,2,4-benzothiadiazine-1,1-dioxide]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The representative drug of 1,2,4-benzothiadiazine-1,1-dioxide chlorthiazide is widely used in clinical treatment and has diuretic and antihypertensive effects. In recent years, compounds with 1,2,4-benzothiadiazine-1,1-dioxide as the parent nucleus have shown various pharmacological activities such as improvement of cognitive function, anti-tumour, antibacterial and antiviral activities, so this class of compounds has become a hot topic of current research. In this paper, the research achievements of 1,2,4-benzothiadiazine-1,1-dioxide derivatives at home and abroad in recent years were systematically reviewed, with emphasis on the progress of structural modification and activity research. It was concluded that 1,2,4-benzothiadiazine-1,1-dioxide can be used as positive allosteric modulators (PAMs) of AMPA and KA receptors to improve nerve function; it has good inhibitory activity against cancer-related targets such as PI3K; it can inhibit HCV NS5B polymerase to exert antiviral activity; and it has high inhibition activity against diabetes-related disease targets such as aldose reductase and pyruvate dehydrogenase； in addition, the compounds have made new progress in antibacterial, anti-insect and anti-oxidation, this paper summarized these research results and analyzed the structure-activity relationship to provide research basis and ideas for the majority of researchers.]]></description>
<pubDate>2025/2/13 15:37:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Zhaolong, ZOU Yu, CHEN Xia, ZHAO Wenhao, HU Wen, XU Shiqiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Zhaolong, ZOU Yu, CHEN Xia, ZHAO Wenhao, HU Wen, XU Shiqiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501010&flag=1]]></guid><cfi:id>72</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The mechanism of antitumor action of gambogic acid and its research progress in cancer treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Garcinia hanburyi</i> is a traditional herbal medicine with anti-inflammatory and hemostatic effects, and gambogic acid is the main active ingredient extracted from <i>Garcinia hanburyi</i> with a variety of biological activities, such as anticancer, anti-inflammatory, antioxidant, antibacterial, etc.Modern studies have shown that gambogic acid has unique advantages over traditional single-target chemotherapy drugs in targeting, chemosensitization, and reversal of drug resistance.It can exert significant anti-tumor effects through a variety of molecular mechanisms.However, its shortcomings such as high toxicity, low solubility, short half-life and other disadvantages limit its clinical application.In order to improve the efficacy of cancer treatment, researchers have used many new nanotechnology to combine other drugs with gambogic acid, and developed many nano-drug delivery systems to overcome these deficiencies of gambogic acid.Therefore, this article summarizes the latest research results of gambic acid in the treatment of various tumors in recent years, and reviews the anti-tumor mechanism of gambic acid and its nano-drug delivery system for multi-pathway combination therapy,in the hopes of providing a reference for promoting the development and clinical application of gambogic acid nano drug delivery system.]]></description>
<pubDate>2025/2/13 15:37:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIANG Jiawen, YANG Heran, LI Shizhuang, YI Qikun, YUAN Hui, CHEN Haoliang, WANG Yukun, YAN Xueying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIANG Jiawen, YANG Heran, LI Shizhuang, YI Qikun, YUAN Hui, CHEN Haoliang, WANG Yukun, YAN Xueying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501011&flag=1]]></guid><cfi:id>71</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on factors affecting the quality of <i>Eucommia ulmoides</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Eucommia ulmoides</i> is a commonly used traditional Chinese medicine in clinical practice, with a high market demand. At present, there is a shortage of wild resources, and most of the <i>Eucommia ulmoides</i> products circulating in the market are artificially cultivated. Drug quality is the foundation and guarantee of safe and effective clinical medication, but there are significant differences in the quality of <i>Eucommia ulmoides</i> in the market. Therefore, the systematic exposition of the factors that affect the quality changes of <i>Eucommia ulmoides</i> is extremely important for ensuring the yield and quality of <i>Eucommia ulmoides</i> and formulating quality standards for Eucommia ulmoides. This article reviews the research results on germplasm resources, differences in origin, harvesting time, processing methods in origin, and processing methods, providing a basis for controlling the quality of <i>Eucommia ulmoides</i> and formulating grading standards.]]></description>
<pubDate>2025/2/13 15:37:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Tong, ZHANG Zijia]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Tong, ZHANG Zijia</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501012&flag=1]]></guid><cfi:id>70</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmacological action and clinical research progress of hemostatic traditional Chinese medicine for treating upper gastrointestinal bleeding]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the pharmacological action and clinical research status of hemostatic traditional Chinese medicine for treating upper gastrointestinal bleeding. <b>Methods</b>  To summarize and analyze the pharmacological action and clinical application research of hemostatic traditional Chinese medicine in the treatment of upper gastrointestinal bleeding by searching and organizing relevant literature collected from CNKI, Wanfang, and CQVIP databases in the past two decades. <b>Results</b>  Most of the hemostatic traditional Chinese medicine has a certain role in affecting the coagulation system, platelet aggregation rate, and fibrinolysis system. Platelet function is also influenced by protein signals in some of them. Clinical applications are mainly focused on single herbs, traditional Chinese medicine extracts, and traditional Chinese medicine formulas. The hemostatic effects of most hemostatic traditional Chinese medicine are significantly better than those of the Western medicine. <b>Conclusion</b>  There are various types of hemostatic traditional Chinese medicine. Active discovery of their effective ingredients and exploration of new drugs for hemostatic effects will provide reference for clinical prescription selection and development of new drugs.]]></description>
<pubDate>2025/2/13 15:37:19</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YAN Yanwei<sup>1,2</sup>, XUE Zhongfeng<sup>1,2</sup>, LI Qi<sup>1</sup>, GUO Yalei<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Yanwei<sup>1,2</sup>, XUE Zhongfeng<sup>1,2</sup>, LI Qi<sup>1</sup>, GUO Yalei<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501013&flag=1]]></guid><cfi:id>69</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pertussis and current status of pertussis vaccine development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pertussis, an acute respiratory infectious disease caused by Bordetella pertussis, has re-emerged in recent years, exposing critical public health challenges in vaccination and treatment strategies. This review comprehensively summarizes the epidemiology, pathogenesis, intervention strategies, and vaccine development. We evaluate the advantages and limitations of licensed vaccines (whole-cell and acellular pertussis vaccines) and analyze novel vaccine candidates under development (genetically attenuated vaccines, outer membrane vesicle vaccines, mRNA vaccines, etc.). Furthermore, we compare two different immunization strategies, maternal vaccination and the cocooning strategy, and analyze the impact of vaccine pressure on bacterial mutation dynamics, disease resurgence, and herd immunity. Finally, we propose recommendations for improved control of pertussis.]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[KONG Ruifang <sup>1,2</sup>, LIN Ang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KONG Ruifang <sup>1,2</sup>, LIN Ang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512009&flag=1]]></guid><cfi:id>68</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of traditional Chinese medicine intervention in liver injury induced by valproic acid and its salts]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Valproic acid and its salts (VPAs) are first-line broad-spectrum antiepileptic drugs, which can be used in the treatment of a variety of neurological diseases. However, their clinical application is limited due to the severe liver injury they can induce. Traditional Chinese medicine (TCM), mainly from the plant kingdom, most of them are rich in polyphenolic compounds, which have significant antioxidant properties. In recent years, scientific literature has shown that a variety of TCM and their active ingredients can alleviate liver damage caused by VPAs, which has attracted extensive attention from scholars at home and abroad. In this paper, the protective effects of single herbs, compound herbs and active ingredients on the induction of liver injury by VPAs and underling mechanisms were reviewed. It provides a basis for the clinical application of VPAs and the development of drugs for the treatment of liver injury.]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[BAI Wanquan, DILIREBA·Aimaier, MAIERZIYA·Maimaitituxun, ZHANG Le]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BAI Wanquan, DILIREBA·Aimaier, MAIERZIYA·Maimaitituxun, ZHANG Le</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512010&flag=1]]></guid><cfi:id>67</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[依拉环素联合用药对抗碳青霉烯类耐药革兰阴性菌的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[FENG Anlong<sup>1</sup>, WANG Shuang<sup>2</sup>, FENG Rui<sup>3</sup>, WANG Ting<sup>3</sup>, CAO Yan<sup>3</sup>, WU Jiyong<sup>1,3</sup>, CAI Meichao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FENG Anlong<sup>1</sup>, WANG Shuang<sup>2</sup>, FENG Rui<sup>3</sup>, WANG Ting<sup>3</sup>, CAO Yan<sup>3</sup>, WU Jiyong<sup>1,3</sup>, CAI Meichao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512011&flag=1]]></guid><cfi:id>66</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on nanomedicines release testing methods]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Like most pharmaceutical formulations,the performance of nanopharmaceuticals can be evaluated through a variety of in vitro and in vivo experiments. Among these,drug release serves as a critical parameter that provides essential insights into the in vitro and in vivo behavior of nanopharmaceuticals, and is key to assessing their safety and efficacy. Due to the high cost, time consumption, labor intensity, and ethical concerns associated with in vivo drug release kinetic studies (which involve human or animal experimentation), in vitro drug release testing has gained increasing attention as a surrogate and complementary approach for evaluating nanopharmaceutical performance during drug development. <b>Methods</b>  This review summarizes the commonly used in vitro drug release testing methods for nanodrug delivery systems. Given the absence of a universally standardized in vitro drug release assay for nanopharmaceuticals, a variety of techniques have been employed, including ​sample-and-separation methods, continuous flow methods, dialysis membrane-based methods, as well as combinations of these three. Additionally, emerging approaches such as the Franz diffusion cell method and tangential flow filtration (TFF) method are also discussed. For each method, the underlying principles, experimental setups, and key advantages and disadvantages are described and compared.<b>Results</b>  The sample-and-separation method allows for direct measurement of drug release, with relatively simple equipment requirements, but it involves tedious sampling procedures and carries a risk of drug loss or leakage. The continuous flow method offers more convenient sampling and higher levels of automation and standardization, but the technique is relatively complex and costly. The dialysis membrane method is simple in both setup and sampling, yet it is limited by the potential barrier effect of the dialysis membrane on drug diffusion and may not be suitable for drugs that bind to the membrane.Emerging methods, such as real-time monitoring techniques, show promise but may be applicable only to certain types of drugs or formulations. Each method presents distinct strengths and weaknesses in terms of accuracy, reproducibility, practicality, and suitability for different nanopharmaceutical systems. <b>Conclusion</b>  There is currently no one-size-fits-all in vitro drug release method for nanopharmaceuticals, and the choice of method should be carefully tailored based on the properties of the drug, the delivery system, and the intended application. Looking ahead, the development of in vitro drug release assays that better correlate with in vivo release behavior represents a crucial direction for future research. Establishing standardized protocols, improving method robustness, and integrating advanced technologies will enhance the reliability of in vitro testing and support the rational design, quality control, and clinical translation of nanopharmaceuticals.]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Jiabei<sup>1</sup>, PENG Bo<sup>2</sup>, LIN Xiaoyang<sup>3</sup>, WU Jun<sup>2</sup>, HUANG Haiwei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Jiabei<sup>1</sup>, PENG Bo<sup>2</sup>, LIN Xiaoyang<sup>3</sup>, WU Jun<sup>2</sup>, HUANG Haiwei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512012&flag=1]]></guid><cfi:id>65</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in hydrogel matrix tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper reviewed the technological advancements in hydrogel matrix tablets over the past two decades, focusing on research hotspots and recent breakthroughs in drug release mechanisms, material innovations, and process optimization. In terms of release mechanisms, it elaborates on the evolution from traditional models to multi-factor coupled models, as well as the dynamic analysis of the release process through advanced characterization techniques. Regarding material systems, it not only covers classical materials but also provides an in-depth discussion of the latest developments in natural gums, stimuli-responsive smart materials, nanocomposite gels, and biodegradable materials. The production process section focuses on 3D printing, continuous manufacturing, and process analytical technologies.]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XI Chenchen, LIU Mengsi, ZHANG Zhongheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XI Chenchen, LIU Mengsi, ZHANG Zhongheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512013&flag=1]]></guid><cfi:id>64</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of osteoarthritis therapy based on RNA technology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Osteoarthritis (OA) is a chronic degenerative bone disease, mainly manifested by joint pain and swelling that , seriously affect the quality of life. At present, the clinical medication options are limited. The first-line drugs are non-steroidal anti-inflammatory drugs (NSAIDs) and cortisol-based drugs, but they can only provide short-term relief effects and cannot change the progression of the disease. Engineered RNA-based therapies developed using synthetic chemistry and biological tools offer hope for future osteoarthritis treatments. These therapies have long-lasting and effective mechanisms of action and can specifically target the underlying drivers of pathology. In this brief review, we focus on emerging RNA-based technologies with therapeutic potential for OA, including siRNA for gene silencing, microRNA for polygenic regulation, and mRNA for gene supplementation. In conclusion, the purpose of this article is to reveal that RNA-related technologies can provide new treatment methods for osteoarthritis.]]></description>
<pubDate>2025/12/9 13:53:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GUO Yixuan<sup>1,2</sup>, LIN Ang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Yixuan<sup>1,2</sup>, LIN Ang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511009&flag=1]]></guid><cfi:id>63</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on synthesis and anti-lung cancer effects of thiophene derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Thiophene, a kind of aromatic five-membered sulfur heterocycle, has wide range of pharmacological activities. Drugs synthesized by thiophene backbone, or designed and developed by introducing or replacing thiophene moiety in the existing drugs, often exhibit anticancer activities. Thiophene derivatives demonstrate favorable antiproliferative activity and selectivity against various lung cancer cells, including A549 and NCI-H460, and have emerged in the research and development of targeted anti-lung cancer drugs as excellent inhibitors of the epidermal growth factor receptor (EGFR) and the signaling factor NF-κB. This review systematically illustrates the synthetic methods and the progress on anti-lung cancer of thiophene derivatives, providing a theoretical basis for further development of anti-lung cancer drugs.]]></description>
<pubDate>2025/12/9 13:53:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[MA Yuanfeng, ZHANG Xingze, QI Xuejie, DUAN Lili]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Yuanfeng, ZHANG Xingze, QI Xuejie, DUAN Lili</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511010&flag=1]]></guid><cfi:id>62</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the mechanism of inflammation response mediated by cGAS-STING signaling pathway in immune and inflammation related diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The cyclic GMP-AMP synthase(cGAS)-stimulator of interferon genes(STING) signaling pathway plays a pivotal role in the body's recognition of cytosolic DNA, triggering innate immune responses. By detecting aberrant DNA, cGAS synthesizes cGAMP, which activates STING and subsequently induces the expression of type I interferon(IFN-I) and pro-inflammatory cytokines, thus contributing to antiviral, antibacterial, and antitumor immunity. However, dysregulation of this pathway can lead to chronic inflammation and autoimmune diseases. This review explores the composition and biological functions of the cGAS-STING pathway, including the structure and function of cGAS, the signaling mechanisms of STING, and the activation process upon the binding of cGAMP to STING. We examine the dual roles of this pathway in inflammatory responses and analyze its complex involvement in autoimmune diseases, inflammatory conditions, infectious diseases, and cancer immunity. Furthermore, the review highlights the multi-layered regulatory mechanisms of the cGAS-STING pathway, encompassing transcriptional regulation, post-translational modifications, and modulation of organelle microenvironments. Potential therapeutic approaches targeting this pathway, including cGAS antagonists and STING inhibitors, are also discussed. Finally, we outline future research directions, emphasizing the refinement of regulatory mechanisms, the functional expansion of STING, its interaction with the immune microenvironment, and the optimization of targeted therapeutic strategies. A deeper understanding of the regulatory mechanisms governing the cGAS-STING pathway and its role in disease is poised to offer novel insights and therapeutic targets for the precision treatment of related diseases.]]></description>
<pubDate>2025/12/9 13:53:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Shanpeng<sup>1,2</sup>, YANG Fengming<sup>1,2</sup>, ZHANG Xiaohan<sup>1,2</sup>, FENG Tingting<sup>1,2</sup>, YUAN Xizhe<sup>1,2</sup>, LI Shangbin<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Shanpeng<sup>1,2</sup>, YANG Fengming<sup>1,2</sup>, ZHANG Xiaohan<sup>1,2</sup>, FENG Tingting<sup>1,2</sup>, YUAN Xizhe<sup>1,2</sup>, LI Shangbin<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511011&flag=1]]></guid><cfi:id>61</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Inflammatory mechanisms of hyperuricemia and strategies for drug development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hyperuricemia (HUA) is an independent risk factor for gout, metabolic syndrome, and cardiovascular diseases, with a global adult prevalence rate of 16%-20%. Recent studies have revealed that the inflammatory plays a central role in the pathological process of HUA. It triggers the release of IL-1β by activating the NLRP3 inflammasome, initiating the innate immune response; dendritic cells (DCs) further mediate the Th17/Treg imbalance, amplifying the adaptive immune inflammatory cascade. Meanwhile, inflammatory cytokines (such as IL-1β, TNF-α) up-regulate the activity of xanthine oxidase and inhibit uricosuria, forming a vicious cycle of "urate-inflammation", which exacerbates organ damage. Although traditional urate-lowering drugs can control serum uric acid levels, they cannot block the inflammatory pathway. Targeted NLRP3 pathway inhibitors, drugs with dual anti-inflammatory/uricosuric functions (such as modified NSAIDs), and metabolic regulation strategies provide new directions for treatment. Analyzing the inflammation-metabolism interaction network is key to developing precise therapies for HUA.]]></description>
<pubDate>2025/12/9 13:53:33</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LUO Yu, YIN Xiangnan, XU Qiang, WANG Tao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LUO Yu, YIN Xiangnan, XU Qiang, WANG Tao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511012&flag=1]]></guid><cfi:id>60</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the regulatory roles of retinoblastoma protein-binding protein family members in tumorigenesis and development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The retinoblastoma protein (pRb)-associated RBBP family, serving as core hubs linking pRb pathway with epigenetic regulatory networks, plays pivotal roles in cell cycle control through mediating chromatin remodeling complex assembly and gene transcription regulation. Emerging evidence reveals context-dependent dual functions of RBBP members in tumorigenesis: while promoting cancer stemness maintenance and metastasis via epigenetic silencing in most malignancies, they exhibit tumor-suppressive activities in specific tissue microenvironments. Structure-based inhibitor development targeting RBBP functional domains, coupled with combinatorial strategies against epigenetic regulatory circuits, has demonstrated significant anti-tumor therapeutic potential. This review systematically summarizes recent advances in understanding RBBP family's regulatory roles in tumor initiation and progression, aiming to explore novel paradigms for precision oncology targeting epigenetic dysregulation.]]></description>
<pubDate>2025/11/10 14:18:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[PAN Mengqi, HU Weiwei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>PAN Mengqi, HU Weiwei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510009&flag=1]]></guid><cfi:id>59</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Metabolic activation mediated genotoxicity of specific traditional Chinese medicine components]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Toxicity of traditional Chinese medicine (TCM) is a key issue restricting the modernization and internationalization of TCM.The adverse events represented by nephrotoxicity and genotoxicity of Aristolochia sinensis have sounded the alarm for the safety of Chinese medicines.Genotoxicity of Chinese medicines is characterized difficulty in detection and identification.Drug metabolism closely regulates the transformation and toxicity of TCM components.This review compiled the knowledge about metabolic activation in the genotoxicity of certain specific TCM components and natural products,summarized the pathways and patterns of metabolism-induced genotoxicity of TCM components,and highlighted the recent findings on genotoxicity biomarkers and genotoxicity mechanisms.Based on the existing literature,we found that metabolic activation is the key to the toxicity of TCM components,and genotoxic substances is not the prototypes of TCM ingredients,but the reactive metabolites produced after metabolic activation.Reactive metabolites are essentially terminal carcinogens that covalently bind to and damage DNA,causing mutations in proto-oncogenes or oncogenes,blocking the repair of DNA damage,and inducing tumorigenesis.In addition,this review also described the herbal components-DNA adducts and DNA mutational fingerprints,which provide biological biomarker references for risk control and translational studies of genotoxicity of herbal medicines and contribute to monitor and prevent the genotoxic effects of these components in further clinical practice.]]></description>
<pubDate>2025/11/10 14:18:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Kai<sup>1</sup>, WANG Xiaojuan<sup>1</sup>, GE Guangbo<sup>2</sup>, XIAO Xiaohe<sup>3</sup>, WANG Yikun<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Kai<sup>1</sup>, WANG Xiaojuan<sup>1</sup>, GE Guangbo<sup>2</sup>, XIAO Xiaohe<sup>3</sup>, WANG Yikun<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510010&flag=1]]></guid><cfi:id>58</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the anti-breast cancer mechanisms of caffeic acid and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Caffeic acid (CA) is a naturally occurring phenolic acid compound widely found in coffee beans, tea, fruits, and propolis. It exhibits various biological activities, including antioxidant, anti-inflammatory, cytotoxic, and anti-tumor effects. In recent years, research on CA and its structurally diverse derivatives in the field of breast cancer has attracted significant attention. Research indicates that CA exerts anti-tumor effects through multiple mechanisms, including inhibiting cell proliferation, inducing apoptosis, suppressing metastasis and invasion, and enhancing chemosensitivity, with these effects validated in multiple in vitro and in vivo studies. Notably, CA modulates multiple critical molecular pathways—including nuclear factor-kappa B (NF-κB), phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), epithelial-mesenchymal transition (EMT), and vascular endothelial growth factor (VEGF)—thereby intervening in the development and progression of breast cancer. Furthermore, reactive oxygen species (ROS) exhibit a dual role in CA-mediated tumor regulation: they not only alleviate oxidative damage via antioxidant effects but can also promote ROS accumulation under specific conditions to induce apoptosis, demonstrating a concurrent "antioxidant-prooxidant" mechanism. This review comprehensively summarizes recent advances in the study of CA and its key derivatives in breast cancer, with a focused analysis of their molecular mechanisms and structure-activity relationship optimization strategies. The synthesis aims to provide theoretical foundations for further research and drug development of these compounds as potential therapeutic candidates for breast cancer.]]></description>
<pubDate>2025/11/10 14:18:30</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIE Chufei<sup>1</sup>, WANG Wenjing<sup>2</sup>, ZHAO Lichun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Chufei<sup>1</sup>, WANG Wenjing<sup>2</sup>, ZHAO Lichun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510011&flag=1]]></guid><cfi:id>57</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on antiarrhythmic effects and mechanisms of SGLT2 inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel oral hypoglycemic agents with good cardiovascular protective effect. Multiple studies have evidenced that SGLT2i can significantly reduce the risk of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. Recent studies have found that SGLT2i can reduce the occurrence and progression of arrhythmia. However, the role of SGLT-2i against arrhythmias and its exact mechanism are not fully elucidated. This paper aims to summarize the existing evidence from basic studies and clinical reports, in order to further explore the anti-arrhythmic mechanism of SGLT2i and provide a new direction for the prevention and treatment of arrhythmias.]]></description>
<pubDate>2025/11/10 14:18:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHONG Peng, ZHANG Chenghu, CAO Xiancun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHONG Peng, ZHANG Chenghu, CAO Xiancun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510012&flag=1]]></guid><cfi:id>56</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the protective effeet of drug containing nanoenzymes onacute lung injury and nanoenzyme toxicity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Acute lung injury (ALI) is a clinical critical disease characterized by lung inflammation and tissue injury. The main causes include direct lung injury factors such as severe lung infection, as well as indirect lung injury factors such as sepsis. ALI can rapidly develop into acute respiratory distress syndrome with high morbidity and mortality. Nanomaterials are catalysts based on nanomaterials with enzymatic simulation properties, which have higher catalytic activity than common biological enzymes. However, due to their smaller size, they may cause a series of biological safety issues. This article reviewed the protective effect and toxicity research of nanomaterials on acute lung injury.]]></description>
<pubDate>2025/11/10 14:18:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Ke, YAN Chaohui, ZENG Chunhui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Ke, YAN Chaohui, ZENG Chunhui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510013&flag=1]]></guid><cfi:id>55</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bidirectional roles of neutrophils in the tumor microenvironment: mechanisms, heterogeneity, and therapeutic strategies]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Neutrophils are core effector cells of the innate immune system, playing critical roles in host defense and the regulation of inflammation. Recent studies have revealed that neutrophils exhibit significant functional plasticity within the tumor microenvironment (TME), displaying dual anti-tumor and pro-tumor effects. This review systematically elaborates on the mechanisms of neutrophil myelopoiesis, release, and chemokine-directed tumor recruitment, with a focus on their functional duality in the TME and their involvement in a regulatory network influencing tumor initiation, progression, metastasis, and angiogenesis. On this basis, we summarize their heterogeneity. Additionally, we discuss emerging cancer immunotherapies targeting neutrophil infiltration, polarization, and functional modulation, and discuss their clinical translation potential in combination with existing therapeutic strategies.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Junhui, DAI Beiying, GAO Xinghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Junhui, DAI Beiying, GAO Xinghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609010&flag=1]]></guid><cfi:id>54</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of surface plasmon resonance technology in traditional chinese medicine research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As an integral component of traditional medicine systems, the screening of active ingredients of traditional Chinese medicine (TCM) is crucial for elucidating their underlying mechanisms of action and developing novel herbal-derived therapeutics. Surface plasmon resonance (SPR) technology, which capitalizes on physical optical phenomena, enables real-time insights into the kinetics and affinity of biomolecular interactions. Featuring real-time detection and quantitative analysis, SPR holds great potential in TCM research. This article presents a systematic review of the progress achieved in the application of SPR technology in TCM research focusing on four major disease categories: viral infections, tumors, metabolic disorders, and cardiovascular diseases. We elaborated on the SPR-based research strategies, representative cases and technological advantages for each disease type, and synthesized the key challenges and future directions in this field. The aim of this review is to provide a valuable reference for advancing the modernization of traditional Chinese medicine.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Linfeng, FENG Lin, GOU Xinyun, LI Zeyao, LYU Diya, CAO Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Linfeng, FENG Lin, GOU Xinyun, LI Zeyao, LYU Diya, CAO Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609011&flag=1]]></guid><cfi:id>53</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on effects of skin inflammation with natural autophagy modulators]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Skin inflammation is a type of skin disease caused by abnormal immune regulation, environmental physical stimulation, and other factors, with its incidence closely related to environmental factors and genetic susceptibility. Autophagy participates in the pathogenesis of various skin inflammations through many mechanisms, such as regulating inflammation-related signaling pathways. Many natural products can enhance autophagy by regulating the expression of autophagy-related proteins or activating the mTOR pathway, and they show a potential therapeutic value in inflammatory skin diseases. This article reviewed the current research progress on the therapeutic effects of natural autophagy modulators in common skin inflammations, aiming to provide a reference for further research and development of natural autophagy modulators in skin inflammation.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Yamin<sup>1</sup>, LIU Yunyao<sup>2</sup>, QIANG Lei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Yamin<sup>1</sup>, LIU Yunyao<sup>2</sup>, QIANG Lei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609012&flag=1]]></guid><cfi:id>52</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of the application systems of X-ray diffraction technology in different pharmacopoeias]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper systematically reveals the core value and standard development logic of X-ray diffraction technology in pharmaceutical quality control by comparing the application systems of the Chinese, U.S., and European pharmacopoeias. All three pharmacopoeias include the powder X-ray diffraction method and explicitly define its fundamental role in qualitative and quantitative analysis of crystalline substances, establishing unified foundational norms for XRD applications in pharmaceutical quality control. International consensus has been formed in areas such as crystal form identification of drugs, asbestos testing in mineral medicines, and functional property control of pharmaceutical excipients, demonstrating the core value of XRD in pharmaceutical quality control. It is recommended that pharmacopoeias continue to strengthen the theoretical leadership of the single-crystal method, enhance the industrial applicability of the powder method, promote technological integration and data empowerment, accelerate the standardization of mature applications and the precise layout of monograph varieties, and improve the digitalized, intelligent, and comprehensive X-ray diffraction standard system.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Guangzhen<sup>1</sup>, ZHANG Lei<sup>1</sup>, LIU Qi<sup>1</sup>, XIAO Jing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Guangzhen<sup>1</sup>, ZHANG Lei<sup>1</sup>, LIU Qi<sup>1</sup>, XIAO Jing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609013&flag=1]]></guid><cfi:id>51</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploration on the research progress of traditional Chinese medicine in the treatment of cerebral infarction based on TXNIP/NLRP3/caspase-1 signaling pathways]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cerebral infarction, also known as ischemic stroke (IS), is a common major neurological disease in clinical practice, which is characterized by difficult treatment, high disability and mortality. The pathological and physiological process of IS involves multiple mechanisms such as oxidative stress response, inflammatory response and pyroptosis, which can cause blood supply disorder in local brain tissue, ischemia/hypoxia death of brain cells, and thus damage nerve function of patients. The thioredoxin interacting protein/NOD-like receptor family protein 3/cysteine aspartase-1 (TXNIP/NLRP3/caspase-1) signaling pathways are important pathways mediating pyroptosis and inflammatory response, which play key roles in IS occurrence, development and reperfusion injury. In recent years, with the development of TCM diagnosis and treatment technology, TCM has shown a good prospect in the clinical treatment of IS, which can alleviate brain tissue injury and repair nerve injury by regulating TXNIP/NLRP3/caspase-1 signaling pathways. This article will discuss the research progress of traditional Chinese medicine in the treatment of IS based on TXNIP/NLRP3/caspase-1 signaling pathways, which provides theoretical basis for pre-clinical study and Future clinical translation of traditional Chinese medicine in the treatment of IS.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Zhijie<sup>1</sup>, WANG Xiaoshan<sup>2</sup>, LI Yamin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Zhijie<sup>1</sup>, WANG Xiaoshan<sup>2</sup>, LI Yamin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609014&flag=1]]></guid><cfi:id>50</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the differentiation and risk attribution of traditional Chinese medicine induced hepatotoxicity and related liver injury]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese medicine (TCM) is a core component of China's traditional medical system and serves as a crucial material foundation for disease prevention and treatment in clinical practice. With the widespread application of TCM in clinical settings, drug safety has become a central concern for both the industry and the public, particularly regarding the mechanisms and risk prevention of drug-induced liver injury (DILI) associated with TCM. Currently, academic circles face challenges such as confusion between intrinsic hepatic toxicity and liver damage caused by inappropriate medication use, as well as inconsistent criteria for classifying hepatotoxic herbs—issues that can lead to public misunderstanding about TCM safety. Therefore, based on authoritative data from the System Toxicology Database of Traditional Chinese Medicine and the 2025 edition of the Chinese Pharmacopoeia＇s classification standards for toxic herbs, and incorporating recent key literature, this article clearly defines the fundamental differences between intrinsic hepatic toxicity and drug-related liver injury in TCM. It systematically organizes the classification of intrinsically hepatotoxic herbs, their key toxic components, and underlying mechanisms of liver injury, establishes diagnostic criteria for attributing liver injury caused by non-intrinsically toxic herbs, and identifies their core risk factors.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Lin<sup>1</sup>, DUAN Xiuran<sup>1</sup>, LIU Wei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Lin<sup>1</sup>, DUAN Xiuran<sup>1</sup>, LIU Wei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609015&flag=1]]></guid><cfi:id>49</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[GLP-1受体激动剂长效制剂的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张圣雯，何东升，涂家生]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张圣雯，何东升，涂家生</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608009&flag=1]]></guid><cfi:id>48</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[人参皂苷的药理活性及合成生物学研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:51</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李嘉懿<sup>1</sup>，郭庆梅<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李嘉懿<sup>1</sup>，郭庆梅<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608010&flag=1]]></guid><cfi:id>47</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[靶向cJun的抗癌策略：从小分子到多肽]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[易学军，乔泽宇，庄申甜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>易学军，乔泽宇，庄申甜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608011&flag=1]]></guid><cfi:id>46</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[BACH1抑制剂研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[李宁宁，常笑，于升平，赵海云，张娟，祝清芬，马超]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李宁宁，常笑，于升平，赵海云，张娟，祝清芬，马超</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608012&flag=1]]></guid><cfi:id>45</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[塑料药品包装材料的应用概况和研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[黄红，刘荷英，郑洋滨，谢迎，刘宁，洪燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>黄红，刘荷英，郑洋滨，谢迎，刘宁，洪燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608013&flag=1]]></guid><cfi:id>44</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[经典名方六君子汤的历史沿革、药理作用和现代临床应用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:52</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[田嫄<sup>1</sup>，李晓亮<sup>2</sup>，刘杉<sup>3</sup>，庄馨瑛<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>田嫄<sup>1</sup>，李晓亮<sup>2</sup>，刘杉<sup>3</sup>，庄馨瑛<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608014&flag=1]]></guid><cfi:id>43</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanisms and intervention of chronic stress in remodeling tumor immunity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, chronic stress has been confirmed as a critical factor influencing tumor development and therapeutic response. The tumor microenvironment (TME), a dynamic ecosystem composed of immune cells, stromal cells, cytokines, vascular networks, and extracellular matrix within the tumor tissue, is increasingly recognized as being remodeled by chronic stress. Chronic stress may induce tumor immune escape through the establishment of multi-level immunosuppression. To provide new insights and directions for antitumor immunotherapy, this review systematically examines the various mechanisms and recent research advances in how chronic stress reshapes tumor immunity, focusing on its effects on the neuroendocrine system, direct impacts on the TME, as well as metabolic reprogramming and the role of the host microbiota.]]></description>
<pubDate>2026/8/12 14:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Siyu<sup>1</sup>, GAO Xinghua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Siyu<sup>1</sup>, GAO Xinghua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607010&flag=1]]></guid><cfi:id>42</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of ulva polysaccharide in cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ulva polysaccharide, a sulfated polysaccharide derived from the green alga Ulva, is characterized by its structural complexity, good biocompatibility, and low toxicity. Research has demonstrated its significant anti-tumor activity through various molecular mechanisms. Notably, Ulva polysaccharide exhibits synergistic effects when combined with conventional chemotherapeutic agents and can help alleviate their associated side effects, highlighting its potential as a novel anti-tumor adjuvant or therapeutic agent. Future research should focus on elucidating its precise mechanisms of action and promoting standardized clinical translation, which offers important direction for developing new, efficient, and low-toxicity strategies for cancer therapy.]]></description>
<pubDate>2026/8/12 14:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHENG Jiamin<sup>1</sup>, GUO Long<sup>1</sup>, DING Hongyan<sup>1</sup>, ZOU Liyi<sup>2</sup>, LIU Yi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Jiamin<sup>1</sup>, GUO Long<sup>1</sup>, DING Hongyan<sup>1</sup>, ZOU Liyi<sup>2</sup>, LIU Yi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607011&flag=1]]></guid><cfi:id>41</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Microenvironmental regulation of macrophage metabolic reprogramming in liver disease and targeted therapeutic strategies]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Liver diseases closely link to immune dysregulation and metabolic dysfunction. Macrophages, serving as central immune effector cells, dynamically adjust their metabolic programs to control functional responses, thereby propelling pathological progression through sequential stages of acute injury, chronic inflammation, fibrosis, and hepatocellular carcinoma. However, a systematic understanding of how stage-specific microenvironment regulates macrophage phenotypes and clinical outcome via metabolic reprogramming remains incomplete. Therefore, this review systematically examined how the pathological microenvironment at different disease stages influences macrophage metabolism, thereby modulating the balance between pro-inflammatory and anti-inflammatory phenotypes and ultimately shaping disease progression or repair. Furthermore, current therapeutic strategies targeting macrophage metabolic reprogramming were summarized, to provide a theoretical basis for developing metabolism-guided treatments for liver diseases.]]></description>
<pubDate>2026/8/12 14:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YANG Qingjuan, WU Hongxi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Qingjuan, WU Hongxi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607012&flag=1]]></guid><cfi:id>40</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on pharmacological effects of <i>Salvia miltiorrhiza</i> in orthopedic diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Salvia miltiorrhiza</i> is a valuable traditional Chinese medicine with abundant active ingredients and important
medicinal value in the treatment of orthopedic diseases. This paper systematically reviews the research progress of <i>Salvia miltiorrhiza</i> and its main active components (tanshinones, danshensu, salvianolic acids, ete.) in skeletal and articulartepair, neuroprotection, and prevention and treatnent of postoperative complications. Its pharmacological mechanisms involvemulti-target and muli-pathway regulation.Specifically,it activates PI3K/Akt, TGF-B/Smad and other signaling pathways topromote osteogenesis and inhibit osteoclastogenesis, thereby improving bone mineral density and accelerating fracturehealing.It also suppreses inflammatory responses by inhibiting the NF-kB signaling pathway to alleviate joint inflammation.In addition,it improves microcirculation, exerts anti-oxidative and anti-apoptotic effects to facilitate neurological functionareconstruction, and effectively prevents tendon adhesion and deep vein thrombosis. Although <i>Salvia miltiorhiza</i> posessesbroad application prospects, several problems remain to be resolved, including its complex composition and the lowbioavailability of lipophilic components. Future studies should focus on clarifying its synergistic mechanisms, developing
novel drug delivery systems, and conducting high-quality clinical evidence-based research to promote its precise clinical
application in orthopedics.]]></description>
<pubDate>2026/8/12 14:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Weiqiang<sup>1</sup>, XU Limin<sup>1</sup>, WEN Dianmin<sup>2</sup>, BI Xiaojie<sup>1</sup>, RONG Lingyan<sup>1</sup>, MU Shaoxia<sup>1</sup>, YU Dapeng<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Weiqiang<sup>1</sup>, XU Limin<sup>1</sup>, WEN Dianmin<sup>2</sup>, BI Xiaojie<sup>1</sup>, RONG Lingyan<sup>1</sup>, MU Shaoxia<sup>1</sup>, YU Dapeng<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607013&flag=1]]></guid><cfi:id>39</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the main chemical constituents and
pharmacological effects of medicinal insects in the <i>Vespa</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Vespa</i> represent a diverse group of medicinal insects with a long history of application in traditional ethnicmedicine, possessing both nutritional and biological control value. Their bodies are rich in various bioactive substances,including volatile compounds, esters, amino acids, peptides, proteins, enzymes, and trace elements. Research indicates thatthese components confer significant pharmacological activities to wasps, such as antibacterial, anti-inflammatory,analgesic,and antitumor effects. This paper systematically reviewed research progress on the major chemical constituents andpharmacological effects of <i>Vespa</i>, aiming to provide theoretical references for the in-depth development and utilization of this
insect resource.]]></description>
<pubDate>2026/8/12 14:14:03</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WANG Liping<sup>1</sup>, YAN Runwen<sup>2</sup>, HUANG Yanmin<sup>3</sup>, LUO Yanqiu<sup>4</sup>, XU Shikui<sup>2</sup>, YANG Yonghua<sup>5</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Liping<sup>1</sup>, YAN Runwen<sup>2</sup>, HUANG Yanmin<sup>3</sup>, LUO Yanqiu<sup>4</sup>, XU Shikui<sup>2</sup>, YANG Yonghua<sup>5</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607014&flag=1]]></guid><cfi:id>38</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the mechanism of action of P2X receptors in liver diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The global incidence of liver diseases continues to rise, encompassing various types including acute liver injury induced by acetaminophen overdose, ischemiareperfusion injury, and hepatotropic viral infections, as well as chronic hepatitis, alcoholic liver disease (ALD), metabolic dysfunctionassociated steatotic liver disease (MASLD). Currently, therapeutic strategies for most liver disorders remain inadequate, highlighting the urgent need to identify novel therapeutic targets. P2X receptors, extracellular ATP gated cation channels widely expressed in hepatocytes stellate cells, and immune cells, play pivotal roles in regulating multiple pathological processes including hepatic metabolism, inflammation, fibrosis, and tumorigenesis. This review systematically summarized the mechanisms of P2X receptors in diverse liver diseases, including druginduced liver injury, autoimmune hepatitis, viral hepatitis, alcohol related and metabolic liver diseases, hepatic fibrosis, and liver cancer. By analyzing mRNA expression profiles of P2X receptors in patient liver tissues from the []GEO database and integrating preclinical evidence, we further discussed the potential and challenges of targeting P2X receptors for the treatment of liver diseases. This work aimed to deepen the understanding of the regulatory functions of P2X receptors in liver pathology and to provide a theoretical foundation for developing novel therapeutic strategies against liver disorders.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHEN Xin, YAN Li, WANG Wenhui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHEN Xin, YAN Li, WANG Wenhui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606008&flag=1]]></guid><cfi:id>37</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Molecular mechanisms and targets of vitiligo induced by emotional stress]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Emotional stress is an emotional response generated by the body due to the impact of life events, social failures, anxiety, tension, and psychological pressure. Clinically, the onset and recurrence of vitiligo are often accompanied by emotional stress, and the pathogenesis of vitiligo induced by emotional stress remains unclear. This review introduced the immune-dependent and immune-independent mechanisms of emotional stress-induced vitiligo, respectively, and summarized the therapeutic targets and the related therapies for ameliorating emotional stress-induced vitiligo, so as to provide a reference for research on the pathogenic mechanism, prevention, and treatment of the emotional stress-induced vitiligo.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Qiwen<sup>1</sup>, LIU Xiaoting<sup>1</sup>, CHEN Yanfen<sup>1</sup>, TANG Nan<sup>2</sup>, WANG Guo'en<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Qiwen<sup>1</sup>, LIU Xiaoting<sup>1</sup>, CHEN Yanfen<sup>1</sup>, TANG Nan<sup>2</sup>, WANG Guo'en<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606009&flag=1]]></guid><cfi:id>36</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Targeting CDC20 for cancer therapy: therapeutic strategies and molecular mechanisms]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cell division cycle 20 homolog (CDC20) plays a crucial role in regulating the cell cycle, ensuring proper separation of chromosomes during mitosis. Recent evidence highlights that CDC20 is overexpressed in various human solid tumors, suggesting its potential as a therapeutic target to treat cancer. In this review, we explore the important role of CDC20 as an activator of APC/C and a key component of the spindle assembly checkpoint during mitosis. We further summarize the therapeutic strategies targeting CDC20 and discuss potential combination therapies for human malignancies treatment, aiming to discover novel roles of CDC20 and develop targeted strategies against human malignancies.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[JIN Yuqing, TANG Xinying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIN Yuqing, TANG Xinying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606010&flag=1]]></guid><cfi:id>35</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in aspirin-based therapies for peripheral arterial disease: Monotherapy and combination strategies]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Aspirin serves as the cornerstone of antithrombotic therapy for symptomatic peripheral arterial disease (PAD). However, its monotherapy demonstrates limited efficacy in high-risk patients, making combination therapy a crucial strategy supported by substantial clinical evidence. Existing reviews predominantly focus on various PAD combination regimens, lacking systematic reviews centered on aspirin. This paper centers on aspirin to summarize research progress in its monotherapy and combination therapy, with a focus on analyzing key clinical trial evidence. The COMPASS and VOYAGER PAD studies confirmed that rivaroxaban combined with aspirin represents the optimal combination strategy for specific PAD patients, further solidifying aspirin's central role in combined antithrombotic therapy. Currently, no studies exist on fixed dose combination formulations of rivaroxaban and aspirin. Developing such formulations holds promise for improving clinical adherence and advancing the widespread adoption of antithrombotic strategies.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WEI Xianming<sup>1</sup>, WANG Lei<sup>2</sup>, CHENG Ze'neng<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Xianming<sup>1</sup>, WANG Lei<sup>2</sup>, CHENG Ze'neng<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606011&flag=1]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on intraoperative tracers for tumor surgery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Malignant tumors represent a severe threat to human health, and surgical resection remains the first-line curative treatment of choice for early-stage malignancies. During resection procedures, intraoperative tracers enable real-time visualization of tumor tissue, which can improve the gross total resection (GTR) rate and reduce postoperative recurrence rates, establishing them as a core technical pillar of precision surgery. This review comprehensively summarizes representative commercially available and investigational intraoperative tracers, providing a solid foundation for the research and development of more such agents.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LI Zongtao, YANG Xueqian, GE Yongxi, ZHANG Jianyong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Zongtao, YANG Xueqian, GE Yongxi, ZHANG Jianyong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606012&flag=1]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of curcumin and its derivatives in treatment of acute myeloid leukemia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Its complex pathological mechanisms and high recurrence rate pose significant challenges to clinical treatment. Curcumin, a polyphenolic compound derived from the natural plant Curcuma longa, has attracted widespread attention in AML treatment in recent years due to its multi-targeted and multi-mechanistic anticancer properties. This article systematically reviews the research progress of curcumin and its derivatives in AML, focusing on elaborating their mechanisms of action, including inducing apoptosis, triggering pyroptosis, regulating autophagy, reversing multidrug resistance, inhibiting immune escape, mediating epigenetic regulation, and inducing ferroptosis. Meanwhile, it discusses the synergistic efficacy-enhancing effects of curcumin with traditional chemotherapeutic drugs and the application of its derivatives in improving therapeutic efficacy. Additionally, it analyzes the challenges for clinical translation based on the limitations of current research, emphasizing the necessity of drug combination for sensitization and toxicity reduction, as well as the conduction of large-scale clinical trials. This review aims to provide a theoretical basis and reference for in-depth research and clinical application of curcumin-related anti-AML therapeutic strategies.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Zhenhui, WU Min, GAO Yao, LIANG Zhenyao, WU Xinping, ZHOU Lu, YUAN Qiuping, LIU Fan, ZENG Yingjian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Zhenhui, WU Min, GAO Yao, LIANG Zhenyao, WU Xinping, ZHOU Lu, YUAN Qiuping, LIU Fan, ZENG Yingjian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605010&flag=1]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on triterpenoids from rare and endangered plants of the Pineceae family and their biological activities]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The Pinaceae family is one of the major taxonomic groups of medicinal plants, distinguished by a highly diverse and structurally complex repertoire of chemical constituents. Numerous studies have previously reviewed the phytochemistry and bioactivities of Pinaceae species, among which triterpenoids have attracted significant interest owing to their structural diversity and prominent bioactivities. Existing evidence suggests that rare and endangered plants exhibit a relatively high degree of medicinal potential. Although China harbors abundant Pinaceae resources, a considerable proportion of species have already been listed in national and international conservation catalogues as rare and endangered plants, indicating that they are facing substantial threat. This article focuses on the recent five years (2020—2025) of research progress on triterpenoids from rare and endangered Pinaceae species, with particular emphasis on the structural diversity of these compounds and their major biological activities. The aim is to offer a scientific basis for discovering the medicinal value of these precious plant resources and for promoting their conservation and sustainable utilization.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHEN Jiaqi<sup>1</sup>, ZHOU Pengjun<sup>2,3,4</sup>, YAN Lihong<sup>2</sup>, YANG Zhongduo<sup>1</sup>, SUN Peng<sup>5</sup>, HU Jinfeng<sup>2,3,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Jiaqi<sup>1</sup>, ZHOU Pengjun<sup>2,3,4</sup>, YAN Lihong<sup>2</sup>, YANG Zhongduo<sup>1</sup>, SUN Peng<sup>5</sup>, HU Jinfeng<sup>2,3,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605011&flag=1]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in the application of transcriptomics and metabolomics in the study of traditional Chinese medicine prevention and treatment of liver fibrosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Liver fibrosis is a critical reversible stage in the progression of chronic liver disease to cirrhosis and liver cancer, yet current clinical treatment options remain highly limited. Traditional Chinese medicine (TCM), with its multi-component, multi-target, and holistic regulatory characteristics, has demonstrated significant potential in preventing and treating liver fibrosis. However, its complex mechanisms of action are still not fully understood. In recent years, advances in transcriptomics and metabolomics have provided new perspectives for elucidating the multi-target mechanisms of TCM. The comprehensive, holistic, and systematic nature of these omics technologies aligns with the “holistic philosophy” and “treatment based on syndrome differentiation” principles of TCM, thereby overcoming the limitations of single-target or single-pathway explanations for the “overall regulation” of TCM. This review summarizes the applications of transcriptomics, metabolomics, and their integrated use in TCM for the prevention and treatment of liver fibrosis, aiming to provide a theoretical basis and novel strategies for research and drug development in this field.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DENG Yanting<sup>1</sup>, XIE Zhuohua<sup>1</sup>, DENG Jiasheng<sup>1</sup>, FANG Yibin<sup>2</sup>, ZHANG Xinru<sup>2</sup>, CHEN Jeiyi<sup>2</sup>, YE Xiaoxue<sup>3</sup>, ZHOU Zhipin<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DENG Yanting<sup>1</sup>, XIE Zhuohua<sup>1</sup>, DENG Jiasheng<sup>1</sup>, FANG Yibin<sup>2</sup>, ZHANG Xinru<sup>2</sup>, CHEN Jeiyi<sup>2</sup>, YE Xiaoxue<sup>3</sup>, ZHOU Zhipin<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605012&flag=1]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Thoughts on the application of functional nucleic acid sensing strategies in the rapid analysis of pesticide residues]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Functional nucleic acid-based sensing strategies have emerged as efficient solutions for the on-site rapid detection of pesticide residues in traditional Chinese medicine (TCM), owing to their high specificity in molecular recognition, flexible and diverse structural design, and excellent compatibility with various signal output modes such as fluorescence, electrochemistry, and colorimetry. In recent years, these strategies have been progressively developed in the field of TCM pesticide residue detection and can be broadly categorized into three main technical routes. Firstly, aptamer-mediated strategies represent the most mature and widely applied route, capable of detecting approximately 20 common pesticides with limits of detection (LODs) as low as the ng/mL level. Secondly, enzyme activity inhibition-based strategies feature simple system construction and allow for visual judgment; however, their current application is limited to organophosphorus and carbamate pesticides, and their accuracy can be compromised by interference from complex TCM matrices. Lastly, signal amplification-based strategies offer the highest sensitivity, achieving LODs ranging from pg/mL to ng/mL levels, making them suitable for trace pesticide detection. Nonetheless, challenges remain regarding the stability of their core components within complex TCM matrices. This article systematically reviews the detection mechanisms, performance characteristics, and application status of these three sensing strategies, and discusses their optimization directions and application prospects for quality control in TCM.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[WU Yuxin<sup>1</sup>, DING Yue<sup>2</sup>, LIU Yue<sup>3</sup>, JIANG Dafeng<sup>4</sup>, GAO Xibao<sup>1</sup>, LI Qiyan<sup>5</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Yuxin<sup>1</sup>, DING Yue<sup>2</sup>, LIU Yue<sup>3</sup>, JIANG Dafeng<sup>4</sup>, GAO Xibao<sup>1</sup>, LI Qiyan<sup>5</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605013&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on new drug combinations and personalized treatment for clinical cure of chronic hepatitis B]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This review focused on the field of clinical cure of chronic hepatitis B, with an emphasis on exploring the great potential of novel drug combinations in personalized treatment. With the deepening of the understanding of the pathogenesis of chronic hepatitis B, significant progress has been made in the research and development of new drugs. The ingenious combination of drugs with different mechanisms of action, such as the combination of drugs targeting key links of viral replication and drugs regulating the host immune response, has opened up a new path for achieving clinical cure. Considering the individual differences among patients in terms of genetic polymorphism, immune status, and disease progression stage, the personalized treatment strategy of precisely matching drug combinations based on patient characteristics has become a current research hotspot. This article comprehensively combs through relevant research achievements, and conducts a detailed analysis of the efficacy and safety of novel drug combinations, as well as the implementation paths and challenges faced in the selection and application of drugs in personalized treatment. It aims to provide a solid theoretical basis and practical reference for drug application for the further exploration of clinical cure of chronic hepatitis B, facilitate the optimization of drug-based treatment regimens, and effectively improve the possibility of clinical cure for patients.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yuhai<sup>1</sup>, ZHANG Jiachen<sup>1</sup>, LIU Jinyi<sup>1</sup>, XIAO Yan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yuhai<sup>1</sup>, ZHANG Jiachen<sup>1</sup>, LIU Jinyi<sup>1</sup>, XIAO Yan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605014&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pathogenesis and drug selection in ankylosing spondylitis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ankylosing spondylitis (AS) involves the sacroiliac joints and spine, and is more common in young men. Symptoms include lower back pain, morning stiffness, and limited mobility. The etiology is driven by multiple factors including genetics, immune imbalance, and gut microbiota. The current drug therapy mainly uses NSAIDs and TNF -αinhibitors, supplemented by DMARDs and glucocorticoids, but the efficacy and tolerability are limited. This article provides an overview of the pathogenesis and includes a machine chart, with a focus on the efficacy and safety of IL-17, IL-23/IL-12, JAK inhibitors, osteogenic pathway inhibitors, intestinal modulators, and small molecule drugs, for reference in new strategies and clinical applications.]]></description>
<pubDate>2026/5/12 15:58:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[CHENG Wenjing<sup>1</sup>, LIU Yi<sup>1</sup>, XU Bilian<sup>1</sup>, LI Wende<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Wenjing<sup>1</sup>, LIU Yi<sup>1</sup>, XU Bilian<sup>1</sup>, LI Wende<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604009&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Translation of three-dimensional fluorescence technology in pharmaceutical research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Three-dimensional fluorescence spectroscopy, a novel spectral analysis technique that has rapidly developed in recent years, demonstrates unique application value in modern pharmaceutical research due to its capability of multidimensional spectral information acquisition and high-sensitive detection. By constructing excitation-emission matrix spectra, this technology enables synchronous acquisition of fluorescence emission characteristics under multiple excitation wavelengths, thus achieving component analysis of complex drug systems. With its advantages of accuracy, rapidity, and non-destructiveness, three-dimensional fluorescence spectroscopy shows promising application potential in fields such as drug identification, quantitative analysis, detection of exogenous harmful substances, and pharmacological mechanism research. This paper reviewed the latest application advances of three-dimensional fluorescence technology in pharmaceutical research, deeply analyzed its advantageous characteristics, and forecasted its future development potential, aiming to provide theoretical references and technical guidance for the innovative application of this technology in the pharmaceutical field.]]></description>
<pubDate>2026/5/12 15:58:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIE Lingyun<sup>1,2</sup>, WANG Bing<sup>2</sup>, YU Yameng<sup>2</sup>, XU Xingyan<sup>2</sup>, NIU Yan<sup>2</sup>, YIN Xue<sup>2</sup>, XUE Fei<sup>2</sup>, LI Shiwen<sup>3</sup>, LIN Yongqiang<sup>1,4</sup>, JIAO Yang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Lingyun<sup>1,2</sup>, WANG Bing<sup>2</sup>, YU Yameng<sup>2</sup>, XU Xingyan<sup>2</sup>, NIU Yan<sup>2</sup>, YIN Xue<sup>2</sup>, XUE Fei<sup>2</sup>, LI Shiwen<sup>3</sup>, LIN Yongqiang<sup>1,4</sup>, JIAO Yang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604010&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of <i>Tripterygium wilfordii</i> hepatotoxicity and its attenuation strategy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Tripterygium wilfordii</i> Hook. f. is the dried root or root xylem of <i>Tripterygium wilfordii</i>. It is widely used in the treatment of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and kidney disease, with the functions of dispelling wind and removing dampness, promoting blood circulation and dredging collaterals, reducing swelling and pain. However, the significant hepatotoxicity of <i>Tripterygium wilfordii</i> is an important safety hazard in its clinical application. In this paper, the related literature reports of <i>Tripterygium wilfordii</i> hepatotoxicity at home and abroad in recent years were retrieved, and the incidence of liver injury, clinical manifestations and prognosis characteristics of <i>Tripterygium wilfordii</i> and its preparations in clinical use were systematically described. The causes of liver toxicity were analyzed from multiple dimensions such as material basis, quality of traditional Chinese medicine, body factors and clinical medication. In addition, the attenuation strategies of <i>Tripterygium wilfordii</i> hepatotoxicity were summarized from the aspects of source control of medicinal materials, processing, compatibility of traditional Chinese medicine, improvement of new dosage forms, and clinical rational drug use, so as to provide reference for the clinical safety, rational use of <i>Tripterygium wilfordii</i> and further research on its hepatotoxicity.]]></description>
<pubDate>2026/5/12 15:58:31</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHANG Conghui, ZHANG Hui, ZHU Zongmin, CAO Guangshang, JU Jianfeng, MA Chuanjiang, ZHU Ruran]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Conghui, ZHANG Hui, ZHU Zongmin, CAO Guangshang, JU Jianfeng, MA Chuanjiang, ZHU Ruran</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604011&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of microdialysis technology in biomedical field]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Microdialysis technology, a membrane separation technique that emerged in the 1970s, is based on the principle of diffusion. It involves implanting a semipermeable membrane probe into tissue, allowing for continuous sampling and analysis of substances in the interstitial fluid without disturbing the internal environment of the organism. This enables realtime monitoring of dynamic changes in substances within the body, providing support for the study of disease mechanisms, drug metabolism assessment, and organ function detection. This article reviewed the application progress of this technology in the field of biomedicine, highlighted its value in promoting scientific research development, optimizing clinical monitoring, and driving technological innovation, analyzed current issues and challenges, and looks forward to future development directions while offering suggestions. It aims to provide a reference for subsequent research in the field.]]></description>
<pubDate>2026/5/12 0:00:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Zhirong<sup>1</sup>, NING Xia<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Zhirong<sup>1</sup>, NING Xia<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604012&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research and application progress of star anise essential oil]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As one of China's eight principal flavouring spices, star anise has been extensively utilised in traditional cuisines. Its essential oil, a light-yellow transparent liquid, can be extracted from tender foliage and ripe fruits. Chromatographic analyses reveal a complex chemical profile dominated by three major categories: terpenoids such as limonene, aromatic compounds such as trans-anethole, and non-terpenoid aliphatic constituents such as shikimic acid. This essential oil demonstrates remarkable biological activities, including antimicrobial, antioxidant, and insecticidal properties, which underpin its commercial potential in food preservation, livestock management, and pharmaceutical applications. This study presented a comparative evaluation of contemporary extraction methodologies for star anise essential oil, analysing their technical efficiencies and limitations. Through structural elucidation of bioactive components, we clarify the structure-activity relationships governing their functional mechanisms. A comprehensive review of international research trends confirms the oil's widespread applications and promising prospects in postharvest produce conservation, healthy livestock farming, and medical biotechnology. Finally, this work proposes strategic directions for deepening resource development research, aiming to furnish scientific foundations and practical guidelines for industrial-scale utilisation of star anise essential oil.]]></description>
<pubDate>2026/5/12 0:00:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[HE Jingjin, ZHU Ziqi, YU Kunying, ZHONG Haiyi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Jingjin, ZHU Ziqi, YU Kunying, ZHONG Haiyi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604013&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the toxicology, processing methods and quality control of aconite]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a traditional Chinese medicine, Aconite exhibits both pharmacological activities and toxicity due to its alkaloid constituents, particularly diester-diterpenoid alkaloids(DDAs). These DDAs can induce cardiotoxicity, neurotoxicity, and hepatorenal toxicity by interfering with ion channels. To mitigate toxicity risks, processed Fuzi is commonly used in clinical practice, where DDAs are converted into less toxic monoester-diterpenoid alkaloids and lipo-alkaloids through processing techniques, achieving both toxicity reduction and efficacy enhancement. Furthermore, establishing a scientific quality control system is crucial for ensuring clinical safety. This review summarizes recent advances in three key aspects: toxicological mechanisms, processing methods, and quality control, aiming to provide valuable references for future research.]]></description>
<pubDate>2026/5/12 0:00:00</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[ZHAO Xiaohui, LI Wenwei, LI Yucui, LIU Zhirong, XIE Nan, MA Xiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Xiaohui, LI Wenwei, LI Yucui, LIU Zhirong, XIE Nan, MA Xiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604014&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the "gut-kidney" axis and its correlation with the mechanism of Chinese medicines with strengthening the spleen and nourishing the kidneys]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Abstract</b>:As the largest immune organ in the human body, the intestine serves as an important barrier to protect the body from harm. The proposal of the "gut-kidney" axis theory has established a close two-way connection between the intestine and the kidney.The occurrence of kidney diseases is closely related to the disorder of the intestinal microecology,and its mechanism of action is complex,which can exert effects through metabolic, immune and barrier pathways, among others. The spleen and the kidney support each other, and the separation and conduction functions of the intestine are closely related to the transportation and transformation functions of the spleen. Good therapeutic effects can be achieved in both strengthening the spleen for kidney diseases and nourishing the kidneys for gastrointestinal disorders. This  article reviewed the research on the "gut-kidney" axis, and in combination with Chinese medicine theory, expounds on the correlation between the mechanism of action of Chinese medicines for invigorating the spleen and nourishing the kidney and the "gut-kidney" axis, providing an new ideas and a basis for the clinical treatment of intestinal and kidney diseases.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Keqin<sup>1</sup>, HUANG Chuanbing<sup>2</sup>, CHEN Xi<sup>2</sup>, ZONG Ruikai<sup>2</sup>, LI Ming<sup>2</sup>, SUN Yue<sup>1</sup>, TIAN Dandan<sup>2</sup>, LIU Tianyang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Keqin<sup>1</sup>, HUANG Chuanbing<sup>2</sup>, CHEN Xi<sup>2</sup>, ZONG Ruikai<sup>2</sup>, LI Ming<sup>2</sup>, SUN Yue<sup>1</sup>, TIAN Dandan<sup>2</sup>, LIU Tianyang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603008&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on anti-tumor oligopeptides derived from marine organisms]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Abstract</b>:Cancer remains one of the leading causes of mortality worldwide, making the development of antineoplastic drugs a critical focus in medical research. In recent years, the unique and complex characteristics of marine organisms have attracted increasing attention, prompting extensive exploration of their bioactive compounds. Numerous studies have demonstrated that oligopeptides derived from marine organisms can exert anti-tumor effects through the induction of apoptosis. Small molecular peptides offer advantages such as rapid absorption and efficient cellular and tissue penetration, making them promising candidates for targeted anti-cancer therapies. However, the identification and underlying mechanisms of action of marine-derived oligopeptides are still under investigation. This article provides a comprehensive review of anti-tumor oligopeptides isolated from various marine species, categorized by their biological sources.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Junyu<sup>1</sup>, DING Hongyan<sup>2</sup>, ZHUANG Manjiao<sup>/1</sup>, LIU Yi<sup>2</sup>, ZOU Liyi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Junyu<sup>1</sup>, DING Hongyan<sup>2</sup>, ZHUANG Manjiao<sup>/1</sup>, LIU Yi<sup>2</sup>, ZOU Liyi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603009&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanism of action and prediction and analysis of quality markers of <i>Lomatogonium rotatum</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Abstract</i>:The Mongolian medicine Lomatogonium rotatum is the dried whole herb of <i>Lomatogonium rotatum</i> (L.) Fries ex Nyman, a plant belonging to the Gentianaceae family. It possesses the effects of clearing "Xila" heat, promoting wound healing, and invigorating the stomach. Based on the core concept of traditional Chinese medicine (TCM) quality marker (Q-marker), this study summarized the chemical components, traditional efficacy, and pharmacological effects of Mongolian medicine <i>Lomatogonium</i> to preliminarily predict its Q-markers. Furthermore, it predicts the active components of Mongolian medicine <i>Lomatogonium</i> using network pharmacology, constructs a "component-target-pathway" network diagram, and verifies the results through molecular docking and molecular dynamics simulation. This research aims to provide a theoretical basis for the development and utilization of Mongolian medicine <i>Lomatogonium</i> and obtain better practical value.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[Junjun, BAO Sachurula, Laxinamujila]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Junjun, BAO Sachurula, Laxinamujila</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603010&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on chemical composition and pharmacological effects of <i>Sambucus adnata</i> Wall.]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Abstract</b>:<i>Sambucus adnata</i> Wall. is a commonly used herbal medicine among ethnic minorities, which is often used for the treatment of rheumatic arthralgia, traumatic injuries, skin itching, edema, and other conditions. Modern pharmaceutical research has found that <i>Sambucus adnata</i> Wall. mainly contains various chemical components such as terpenoids, flavonoids, steroids, phenolic acids, lignans, and fatty acids, and possesses pharmacological effects including anti-inflammatory and analgesic effects, anti-tumor activity, antioxidant properties, and immunomodulatory effects. This article reviews the research progress on the chemical components and pharmacological effects of <i>Sambucus adnata</i> Wall., aiming to provide a reference for its in-depth research, development, utilization, and clinical application, and to promote its rational application and development in the medical field.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TIAN Shuxing, ZOU Lan, YANG Qiaoyan, ZI Fayun, YANG Yue, ZHANG Pan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TIAN Shuxing, ZOU Lan, YANG Qiaoyan, ZI Fayun, YANG Yue, ZHANG Pan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603011&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on natural saponins for anti-influenza virus action]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Abstract</i>:Influenza virus is a virus that causes acute respiratory infectious diseases, which is highly infectious, fast spreading and highly mutable, seriously threatening human health. Studies have shown that saponins can exert anti-influenza virus effects through multiple pathways, including inhibition of virus adsorption and replication, modulation of signaling pathways, inhibition of inflammatory factor production, and modulation of the immune system. As a naturally occurring substance, saponin generally exhibits good biocompatibility and low toxicity. Its structural diversity allows for the possibility of controllable structural changes, which can increase the target point of action, reduce toxicity and side effects, and facilitate large-scale production and application. Consequently, saponin is a promising candidate for research and development as a new anti-influenza drug.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[YE Yu<sup>1</sup>, WAN Xinhuan<sup>1</sup>, ZHANG Li<sup>2</sup>, ZHOU Changzheng<sup>1</sup>, LIU Qingzhi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YE Yu<sup>1</sup>, WAN Xinhuan<sup>1</sup>, ZHANG Li<sup>2</sup>, ZHOU Changzheng<sup>1</sup>, LIU Qingzhi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603012&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the pharmacological effects and nano drug delivery systems of osthole]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Cnidium monnieri</i> (L.) Cuss is the mature and dried fruit of the umbelliferae medicinal plant cnidium monnieri, which has various effects such as warming the kidney, assisting yang, and killing insects. It is extensively utilized in TCM clinical practice to treat diseases such as eczema, scabies, and infertility. Osthole is a natural coumarin compound mainly derived from <i>Cnidium monnieri</i> (L.) Cuss. Modern pharmacological investigations have demonstrated that it endows various pharmacological activities, including anti-inflammatory, anti-tumor, cardiovascular protection, bronchial protection, organ protection, analgesic, anti-microbial infection, and resistance to pests, which the pharmacological effects involve multiple molecular signaling pathways and targets. However, the low aqueous solubility and poor bioavailability seriously restricts the application in basic research and clinical setting. Combining osthole with nanodrug delivery technology could effectively ameliorate the above shortcomings. Therefore, this review systematically retrospects and summarizes the pharmacological effects and nano drug delivery systems of osthole, to provide ideas and basis for its clinical application and agent development.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[GONG Hui<sup>1,2</sup>, ZHAO Xinke<sup>1,2,3</sup>, JIANG Hugang<sup>1,2,3</sup>, ZHI Xiaodong<sup>1,2,3</sup>, WU Xue<sup>1,3,4,5</sup>, LI Yingdong<sup>1,2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GONG Hui<sup>1,2</sup>, ZHAO Xinke<sup>1,2,3</sup>, JIANG Hugang<sup>1,2,3</sup>, ZHI Xiaodong<sup>1,2,3</sup>, WU Xue<sup>1,3,4,5</sup>, LI Yingdong<sup>1,2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602012&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on hair growth-promoting agents: Optimization of traditional medications and exploration of novel therapeutic approaches]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To systematically review the progress in the optimization of traditional drugs and the research on new therapies in hair loss treatment, providing a basis for hair loss treatment.<b>Methods</b>  Comprehensive computer-based searches of relevant domestic and international databases were performed to systematically summarize the current status of existing drug treatments and emerging therapies for alopecia.<b>Results</b>  Traditional drugs such as minoxidil and finasteride have significantly improved efficacy through optimization strategies including nanocarrier technology or combination therapy. Meanwhile, novel therapeutic approaches—such as prostaglandin analogs, small nucleic acid drugs, JAK inhibitors, and biological therapies—have shown promising potential for treating alopecia via different mechanisms. <b>Conclusion</b>  The research on formulation optimization and novel therapeutic strategies provides more ideas for hair loss treatment, holding significant clinical implications and research value.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TENG Yanping<sup>1,2</sup>, SHAO Junhui<sup>2</sup>, ZHANG Ce<sup>2</sup>, XIE Xin<sup>2,3</sup>, GU Shimeng<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TENG Yanping<sup>1,2</sup>, SHAO Junhui<sup>2</sup>, ZHANG Ce<sup>2</sup>, XIE Xin<sup>2,3</sup>, GU Shimeng<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602013&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the extraction of alkaloid compounds using deep eutectic solvents]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alkaloids, as nitrogen-containing natural compounds characterized by complex cyclic structures and significant pharmacological activities, present a fundamental challenge for their efficient and precise extraction in natural drug development. Conventional methods, including acid extraction followed by alkaline precipitation and organic solvent extraction, are often associated with high toxicity, poor selectivity, and interference from impurities, rendering them less compatible with green chemistry principles. Deep eutectic solvents (DES), distinguished by their tunable properties, low toxicity, and high solvation capacity, provide a novel strategy for sustainable alkaloid extraction. This review systematically summarizes recent advances in DES-based extraction methodologies for alkaloids, with the aim of establishing a reference framework for the advancement of green extraction and separation systems.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[XIE Junhui, LUO Feng, ZHONG Haiyi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Junhui, LUO Feng, ZHONG Haiyi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602014&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on effective ingredients, pharmacological mechanisms, and product development of "Lu Shi Wei" traditional Chinese medicine honeysuckle]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Honeysuckle as a Chinese medicinal herb with both edible and medicinal value, contains various effective ingredients such as volatile oils, flavonoids, organic acids, triterpenoid saponins, etc. It has many pharmacological effects such as antibacterial and antiviral, anti-inflammatory and antipyretic, antioxidant, and immune regulation, and has broad development prospects and high economic value.The research focuses on three aspects: the active ingredients, main pharmacological mechanisms, and current industrial development status of honeysuckle. A systematic review and summary of relevant studies are conducted, aiming to provide scientific basis for the deep development and utilization of honeysuckle and the high-quality development of the industry.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TAN Qian<sup>1</sup>, DONG Xiaodong, ZHU Ruijuan<sup>1</sup>, ZHANG Na<sup>1</sup>, LI Dexin<sup>1</sup>, WANG Lili<sup>3</sup>, WANG Youpeng<sup>4</sup>, WEI Pei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TAN Qian<sup>1</sup>, DONG Xiaodong, ZHU Ruijuan<sup>1</sup>, ZHANG Na<sup>1</sup>, LI Dexin<sup>1</sup>, WANG Lili<sup>3</sup>, WANG Youpeng<sup>4</sup>, WEI Pei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602015&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the anti-tumor mechanism of indirubin and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Indirubin, a kind of bis-indole alkaloid, is derived from the traditional Chinese medicine Indigofera tinctoria L, and exhibits anti-tumor activities against various cancers, especially chronic myelocytic leukemia. This paper describes the structural modification of Indirubin and relative anti-tumor mechanisms from the cellular level, cancer-related proteins, targets, and signaling pathways, providing a basis for the development of novel Indirubin derivatives with excellent anti-tumor activity.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SONG Gaoping, CHEN Wenmin, YU Pengxin, DUAN Lili]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Gaoping, CHEN Wenmin, YU Pengxin, DUAN Lili</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602016&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The role and regulatory mechanism of oxidative stress system in drug hepatotoxicity]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Drug-induced liver injury (DILI) is a core issue that leads to the interruption of drug development and clinical treatment risks, and its pathological mechanism is closely related to the imbalance of the oxidative stress system.This article first clarifies the generation and toxicity of reactive oxygen species (ROS) and the hierarchical regulatory mechanism of the antioxidant defense system. Further, it deeply explores the correlation between oxidative stress and DILI. Finally, it summarizes the regulatory mechanisms and intervention strategies for targeting the oxidative stress system to alleviate DILI. This review integrates the multi-dimensional correlations between the oxidative stress system and the pathological process of DILI, providing theoretical support for the prevention and treatment of DILI.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SHEN Weishuang<sup>1</sup>, JIANG Zhenzhou<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHEN Weishuang<sup>1</sup>, JIANG Zhenzhou<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601009&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the role of natural compounds in regulating ferroptosis in metabolic associated fatty liver disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ferroptosis is an iron-dependent programmed cell death form driven by lipid peroxidation, plays a pivotal role in the pathogenesis of metabolic associated fatty liver disease(MAFLD). MAFLD is characterized by hepatic lipid metabolism disorder, with disease progression strongly associated with iron overload, lipid peroxidation, and oxidative stress—where the imbalance in ferroptosis regulation could additionally exacerbate hepatic injury and inflammatory responses. Although there are no clinical drugs specifically targeting ferroptosis approved for market currently, natural compounds demonstrate significant potential in intervening ferroptosis to alleviate MAFLD due to their multi-target regulatory properties. This review focuses on precisely regulating key ferroptosis pathways by natural compounds, integrating multiple experimental studies to propose innovative strategies for targeted MAFLD therapy.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[TANG Yi, YAN Chulin, DAI Xinli, ZENG Yizhen, QU Bangchen, TAO Liang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TANG Yi, YAN Chulin, DAI Xinli, ZENG Yizhen, QU Bangchen, TAO Liang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601010&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of RNA delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, RNA structural modification and delivery technologies have driven the vigorous development of RNA-based therapeutic drugs. RNA-based therapies have the ability to regulate gene expression, produce therapeutic proteins or antigens that trigger immune responses, and have shown great potential in combating infectious diseases, cancers, immune diseases, neurodegenerative diseases, and other conditions. However, the instability and negative charge of RNA seriously hinder its application. RNA has difficulty passing through the numerous barriers both inside and outside cells on its own. Therefore, an efficient delivery system is the key to RNA therapies. This review summarized the RNA drug delivery systems that were currently widely studied, discussed the strategies for targeted delivery of RNA drugs, and prospects the future development of drug delivery systems in RNA drugs.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[LIU Yanqing, HE Dongsheng, YANG Mengyun, WANG Jiamin, TU Jiasheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yanqing, HE Dongsheng, YANG Mengyun, WANG Jiamin, TU Jiasheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601011&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application and research progress of Amphotericin B for the treatment of mucormycosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Mucormycosis is an invasive fungal infection with high mortality. Amphotericin B (AmB), as the cornerstone therapeutic drug, demonstrates potent in vitro antifungal activity against Mucorales. The efficacy and safety as monotherapy have been confirmed by multiple clinical trials and retrospective studies. Emerging studies suggest potential synergistic effects between AmB and azoles or echinocandins, as well as enhanced therapeutic outcomes through combined local and intravenous administration. However, these findings are currently limited to case reports or small-scale retrospective studies, lacking high-level evidence-based support. This article reviews the epidemiological characteristics of mucormycosis, the in vitro antifungal activity of AmB, and the progress of its clinical applications, aiming to provide insights and future directions for optimizing AmB-based treatment strategies.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[KAN Min, WU Yuanyuan, SHAO Hua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KAN Min, WU Yuanyuan, SHAO Hua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601012&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on preparation of chondroitin sulfate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chondroitin sulfate is an acidic mucopolysaccharide widely distributed in animal tissues such as cartilage, tendons, ligaments, and blood vessel walls in the form of proteoglycans. It demonstrates outstanding physiological functions, including immune-modulating, hypolipidemic, antiviral, and antitumor activities. Additionally, its inherent properties of water retention, colloidal stability, and high viscosity endow it with extensive applications in pharmaceutical, cosmetic industries, thus rendering significant commercial value. This review systematically summarized the historical development of chondroitin sulfate preparation methods, evaluated advanced detection techniques, and discussed future application prospects in medicine, nutraceuticals, cosmeceuticals, and related fields.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[SUN Mengmeng, ZHAO Shuwen, CHEN Weiyi, LIU Yuxuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Mengmeng, ZHAO Shuwen, CHEN Weiyi, LIU Yuxuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601013&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于合成致死策略的肿瘤治疗研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:25</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[崔珣<sup>1</sup>，高兴华<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>崔珣<sup>1</sup>，高兴华<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610009&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药活性成分及复方调节软骨细胞线粒体自噬在骨关节炎治疗中的作用机制研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:25</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[何艳凤<sup>1</sup>，王江波<sup>2</sup>，庞政<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>何艳凤<sup>1</sup>，王江波<sup>2</sup>，庞政<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610010&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[胰腺星状细胞及其通讯在慢性胰腺炎纤维化中的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:25</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[纪岑<sup>1</sup>，刘春晓<sup>2</sup>，胡庆华<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>纪岑<sup>1</sup>，刘春晓<sup>2</sup>，胡庆华<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610011&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中氮茚C-3位C-H官能团化研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:25</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[张天佑，胡敬峰，明奕，宋凯，刘荣，苏学浩，刘飞，冯巧巧]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张天佑，胡敬峰，明奕，宋凯，刘荣，苏学浩，刘飞，冯巧巧</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610012&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[药食同源中药材功能性成分提取技术及其食品开发应用进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:25</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[王仪，张艳，王萌，孙铁锋]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王仪，张艳，王萌，孙铁锋</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610013&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The mechanism of isatin’s anti-atherosclerosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper introduced the mechanism of isatin’s (indole-2,3-two isatin ketone) anti-atherosclerosis effect by decreasing the level of Oxidized LDL,improving the lipid metabolism,anti-inflammatory and anti-oxidant.The compounds has a positive effect on prevention and treatment of atherosclerosis which provides a new research direction for the treatment of atherosclerosis.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Review]]></category>
<author><![CDATA[DING Bo<sup>1</sup>, QIU Bo<sup>2</sup>, REN Ailing<sup>1</sup>, SUN Yanfei<sup>3</sup>, ZHOU Baokun<sup>3</sup> and ZHANG Jian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Bo<sup>1</sup>, QIU Bo<sup>2</sup>, REN Ailing<sup>1</sup>, SUN Yanfei<sup>3</sup>, ZHOU Baokun<sup>3</sup> and ZHANG Jian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706013&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>